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cost-effectiveness of duplex ultrasound (DUS),
magnetic resonance angiography (MRA), and computed
tomography angiography (CTA), as alternatives to
contrast angiography (CA), for the assessment of lower
limb peripheral arterial disease (PAD).
Data sources: Ten electronic databases were searched
in April 2004, with an update in May 2005. Six key
journals and bibliographies of included studies were
also searched and experts in the field were consulted.
Review methods: Data extraction and quality
assessment were performed in duplicate. Data were
analysed according to test type and diagnostic
threshold. For the economic analysis, a decision tree
was developed and a probabilistic sensitivity analysis
performed to incorporate statistical uncertainty into
the cost-effectiveness analysis.
Results: A total of 113 studies met the inclusion
criteria (including six economic evaluations).
For the detection of stenosis greater than 50% in the
whole leg, contrast-enhanced (CE) MRA (14 studies)
had the highest diagnostic accuracy, with sensitivity
ranging from 92 to 99.5% and specificity from 64 to
99%. Two-dimensional (2D) time-of-flight (TOF) MRA
(11 studies) was less accurate, with sensitivity ranging
from 79 to 94% and specificity from 74 to 92%. 2D
phase-contrast (PC) MRA (one study) had a sensitivity
of 98% and specificity of 74%. CTA (seven studies)
also appeared slightly inferior to CE MRA, with a
sensitivity ranging from 89 to 99% and specificity from
83 to 97%, but better than DUS (28 studies), which
had a sensitivity ranging from 80 to 98% and specificity
from 89 to 99%. There was some indication that CE
MRA and DUS were more accurate for detecting
stenoses/occlusions above the knee than below the
knee or in the pedal artery. The four studies of patient
attitudes strongly suggested that patients preferred CE
MRA to CA. CA was considered the most
uncomfortable test, followed by CE MRA, with CTA
being the least uncomfortable. Half of the patients
(from a sample who did not suffer from claustrophobia
and had no metallic implants) expressed no preference
between undergoing TOF MRA or DUS; most of those
who did express a preference favoured TOF MRA. In
the 55 studies identified for adverse events, MRA was
associated with the highest reported proportion.
However, the most severe adverse events were more
common in patients undergoing CA; although these
were rare for both tests. The economic evaluation
showed DUS dominated the other alternatives when
the whole leg was assessed, by presenting higher
effectiveness at a lower cost per quality-adjusted 
life-year (QALY; i.e. £13,646 per QALY). When the
assessment was limited to a section of the leg, either
above the knee or below the knee, 2D TOF MRA was
the most cost-effective preoperative diagnostic
strategy. The incremental cost per QALY for below-
the-knee comparisons was equal to £37,024 when 2D
TOF MRA was compared with DUS. For above-the-
knee comparisons, 2D TOF MRA presented the lowest
cost and slightly lower effectiveness compared with CE
MRA, with a cost per QALY equal to £13,442.
Conclusions: The results of the review suggest that
CE MRA has a better overall diagnostic accuracy than
CTA or DUS, and that CE MRA is generally preferred
by patients over CA. Where available, CE MRA may be
a viable alternative to CA. The only controlled trial
suggested that the results of DUS were comparable to
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Abstract
A systematic review of duplex ultrasound, magnetic resonance
angiography and computed tomography angiography for the
diagnosis and assessment of symptomatic, lower limb peripheral
arterial disease
R Collins,1* G Cranny,1 J Burch,1 R Aguiar-Ibáñez,1 D Craig,1 K Wright,1 E Berry,2
M Gough,3 J Kleijnen1 and M Westwood1
1 Centre for Reviews and Dissemination, University of York, UK
2 Academic Unit of Medical Physics, University of Leeds, UK
3 Leeds Teaching Hospitals NHS Trust, UK
* Corresponding authoriv
those of CA, in terms of surgical planning and outcome.
This finding conflicts with the results of diagnostic
accuracy studies, which reported poor estimates of
accuracy for DUS in comparison with CA. There was
insufficient evidence to evaluate the usefulness of CTA
for the assessment of PAD, particularly newer
techniques. The results of the economic modelling
suggest that for PAD patients for whom the whole leg
is evaluated by a preoperative diagnostic test, DUS
dominates the other alternatives by presenting higher
effectiveness at a lower cost per QALY. However,
when the analysis of stenosis is limited to a section of
the leg, either above the knee or below the knee, 
2D TOF MRA appears to be the most cost-effective
preoperative diagnostic strategy. Further research is
needed into a number of areas including the relative
clinical effectiveness of the available imaging tests, in
terms of surgical planning and postoperative outcome. 
AbstractHealth Technology Assessment 2007; Vol. 11: No. 20
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Technical terms and abbreviations are used throughout this report. The meaning is usually clear from
the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the
literature, but the term has a constant meaning throughout this review.
This section summarises the measures of
diagnostic test performance used in the review,
and how these are calculated.
Stenosis above positive threshold/occlusion
Present Absent
Test result + ab
– cd
True positive (TP) Correct positive test
result: a – number of diseased persons with a
positive test result
True negative (TN) Correct negative test
result: d – number of non-diseased persons
with a negative test result
False positive (FP) Incorrect positive test
result: b – number of non-diseased persons
with a positive test result
False negative (FN) Incorrect negative test
result: c – number of diseased persons with a
negative test result
Sensitivity a/(a + c) – Proportion of people
with the target disorder who have a positive
test result
Specificity d/(b + d) – Proportion of people
without the target disorder who have a negative
test result.
Likelihood ratio (LR) – positive (LR +) –
negative (LR –) Describes how many times a 
person with disease is more likely to receive a
particular test result than a person without 
disease. A likelihood ratio of a positive test
result is usually a number greater than 1; a
likelihood ratio of a negative test result usually
lies between 0 and 1.
LR+=  [ a/(a + c)]/[b/(b + d)] 
= Sensitivity/(1 – Specificity)
LR–=  [ c/(a + c)]/[d/(b + d)]
= (1 – Sensitivity)/Specificity
Diagnostic odds ratio (DOR) Used as an
overall (single indicator) measure of the
diagnostic accuracy of a diagnostic test. It is
calculated as the odds of a positive test result
among diseased persons, divided by the odds
of a positive test result among non-diseased
persons. When a test provides no diagnostic
evidence then the DOR is 1.0. 
DOR = [a/c]/[b/d]
= [Sensitivity/(1 – Specificity)]/
[(1 – Sensitivity)/Specificity]
= LR+ /LR– = ad/bc
Predictive value Positive predictive value: the
probability of disease among all persons with a
positive test result 
Positive predictive value (PPV) = a/(a + b)
Negative predictive value: the probability of
non-disease among all persons with a negative
test result
Negative predictive value (NPV) = d/(c + d)
Predictive values depend on disease
prevalence; the more common a disease is, the
more likely it is that a positive test result is
right and a negative result is wrong.
continued
Measures of diagnostic test performanceReceiver operating curve (ROC curve) An
ROC curve represents the relationship between
the ‘true-positive rate’ (Sensitivity) and ‘false-
positive rate’ (1 – Specificity). It displays the
trade-offs between sensitivity and specificity as
a result of varying the threshold for positivity
in the case of a continuous test result.
Summary ROC curve (sROC curve) The
sROC curve models test accuracy, defined by
the log of the diagnostic odds ratio 
(D = logit(Sensitivity) – logit(1 – Specificity)),
as a function of test threshold (S =
logit(Sensitivity) + logit(1 – Specificity)). 
S relates to the positivity threshold: it is 0 in
studies where sensitivity equals specificity, it is
positive in studies where sensitivity is higher
than specificity, and negative in studies where
specificity is higher than sensitivity. For a set of
primary studies, the following linear regression
model is fitted:
D =  + S
where D (the log odds ratio) and S (the positivity
threshold) are calculated for each study from the
sensitivity and specificity;  is the estimated
intercept (the expected log odds ratio when 
S = 0); and  is the estimated coefficient of S
(which indicates whether the log diagnostic odds
ratio varies across different thresholds). The
estimates of  and  are used to plot the ROC
curve by calculating the sensitivity for each value
of (1 – Specificity) across the range of observed
values. This is calculated using the following
equation:
Sensitivity = [1+e–/(1–)V(1+)/(1–)]–1
where V = Specificity/(1 – Specificity).
List of abbreviations
2D two-dimensional
3D three-dimensional
AUC area under the curve
CA contrast angiography/
arteriography
CDPwATP correctly diagnosed patient with
accurate treatment plan
CDS colour duplex sonography 
CE MRA contrast-enhanced magnetic
resonance angiography
CEAC cost-effectiveness acceptability
curve
CER cost-effectiveness ratio
CI confidence interval
CRD Centre for Reviews and
Dissemination
CTA computed tomography 
angiography
DOR diagnostic odds ratio
DSA digital subtraction
angiography/arteriography
DUS duplex ultrasound scanning
FN false negative
FP false positive
ICER incremental cost-effectiveness ratio
ICUR incremental cost–utility ratio
LR+ positive likelihood ratio
continued
Measures of diagnostic test performance and list of abbreviations
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List of abbreviations continued
LR– negative likelihood ratio
MM medical management
MR magnetic resonance
MRA magnetic resonance 
angiography
NA not applicable
NHS EED NHS Economic Evaluation
Database
NPV negative predictive value
NR not reported
PAD peripheral arterial disease
PC MRA phase-contrast magnetic resonance
angiography
PPP purchasing power parity
PSA probabilistic sensitivity analysis
PSVR peak systolic velocity ratio
PTA percutaneous transluminal
angioplasty
PVD peripheral vascular disease
QALY quality-adjusted life-year
RCT randomised controlled trial
ROC receiver operating characteristic
SD standard deviation
SE standard error
sROC summary receiver operating
characteristic
STARD Standards for Reporting of
Diagnostic Accuracy
TN true negative
TOF time-of-flight
TOF MRA time-of-flight magnetic resonance
angiography
TP true positive
All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or 
it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case 
the abbreviation is defined in the figure legend or at the end of the table.Health Technology Assessment 2007; Vol. 11: No. 20
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Background
Lower limb peripheral arterial disease (PAD) is
characterised by atheromatous narrowing or
occlusion of one or more of the arteries of the leg.
Symptoms include intermittent claudication (pain
on walking), ischaemic rest pain, ulceration and
gangrene. This review concerns the assessment 
of symptomatic PAD. Intervention decisions 
utilise information regarding the degree, 
length and location of stenoses or occlusions. 
This review summarises the evidence on the 
role of duplex ultrasound (DUS), magnetic
resonance angiography (MRA), and computed
tomography angiography (CTA), as alternatives 
to contrast angiography (CA), for the assessment 
of PAD.
Objectives
The objectives of this review were:
● to determine the diagnostic accuracy of DUS,
MRA and CTA, alone or in combination, for the
assessment of lower limb PAD
● to evaluate the impact of these assessment
methods on patient management/outcome
● to evaluate the evidence regarding patient
attitudes to these technologies
● to summarise available adverse event data
associated with these technologies
● to analyse the cost-effectiveness of these
technologies using a review of existing cost-
effectiveness literature, and decision analysis.
Methods
Data sources
Studies were identified through extensive 
searches of electronic databases (carried out in
April 2004, with update searches in May 2005),
handsearching of journals, scanning reference lists
of included papers and consultation with experts
in the field.
Study selection
Two reviewers independently screened titles and
abstracts for relevance. Full papers of potentially
relevant studies were assessed for inclusion by one
reviewer and checked by a second. Published and
unpublished studies in any language were eligible
for inclusion.
Inclusion criteria
Separate inclusion criteria, relating to study
design, participant characteristics and outcome
measures, were derived for each objective.
Data extraction
Data extraction and quality assessment were
performed using standardised forms. The quality
of the included studies was evaluated using
published checklists and criteria. All data
extraction was checked by a second reviewer.
Data synthesis
Assessment of stenosis/occlusion
Results were analysed according to test type (MRA,
DUS, CTA) and diagnostic threshold (e.g. 50%
stenosis, occlusion). Data for different MRA
techniques [e.g. time-of-flight (TOF), phase-
contrast (PC), contrast-enhanced (CE)] were
grouped separately. Data were further grouped
according to the area of the leg assessed (whole
leg, above knee, below knee, foot). Sensitivity,
specificity, positive and negative likelihood ratios
and diagnostic odds ratios were calculated for each
data set. Individual study results were presented
graphically in receiver operating characteristic
(ROC) space. Heterogeneity was investigated using
the Q statistic and through visual examination of
study results. Pooled estimates of diagnostic test
performance were calculated where statistically and
clinically meaningful; otherwise, median likelihood
ratios and ranges were presented. Insufficient data
were available to facilitate the use of subgroup or
regression analyses to investigate potential sources
of between study heterogeneity (e.g. aspects of
methodological quality, presence of co-morbidities
or risk factors, image postprocessing techniques,
personnel involved in test interpretation). 
Impact of assessment method on patient
management/outcome
A narrative synthesis was presented.
Studies of patient attitudes
A narrative synthesis was presented.
Executive summaryxii
Adverse events
Results were tabulated and, where more than one
study reported a particular adverse event, the
range of the proportion of patients experiencing
that adverse event was presented.
Economic evaluations
Economic evaluations were described and critically
appraised in a narrative summary. 
Economic modelling
The objective of the economic analysis was to
assess the relative cost-effectiveness of MRA, DUS
and CTA compared with CA, from the UK NHS
perspective, in order to identify the type and level
of stenosis and subsequently formulate a treatment
plan for patients with PAD. A decision tree was
developed and a probabilistic sensitivity analysis
performed to incorporate statistical uncertainty
into the cost-effectiveness analysis.
Results
The searches identified 650 potentially relevant
studies, of which 113 met the inclusion criteria
(including six economic evaluations).
Assessment of stenosis/occlusion (58 studies)
For the detection of stenosis greater than 50% in
the whole leg, CE MRA (14 studies) had the
highest diagnostic accuracy, with sensitivity
ranging from 92 to 99.5% and specificity from 
64 to 99%. Two-dimensional (2D) TOF MRA 
(11 studies) was less accurate, with sensitivity
ranging from 79 to 94% and specificity from 74 to
92%. 2D PC MRA (one study) had a sensitivity of
98% and specificity of 74%. CTA (seven studies)
also appeared slightly inferior to CE MRA, with a
sensitivity ranging from 89 to 99% and specificity
from 83 to 97%, but better than DUS (28 studies),
which had a sensitivity ranging from 80 to 98%
and specificity from 89 to 99%. There was some
indication that CE MRA and DUS were more
accurate for detecting stenoses/occlusions above
the knee than below the knee or in the pedal
artery. 
Impact of assessment method on patient
management/outcome (one study)
This historically controlled trial reported no
statistically significant differences in immediate or
intermediate-term patient outcomes, following
treatment plans based on DUS alone or based on
conventional CA alone. However, in a subgroup of
22% of patients having DUS supplementary CA
was needed to form a treatment plan.
Studies of patient attitudes (four studies)
These studies strongly suggested that patients
preferred CE MRA to CA. CA was considered the
most uncomfortable test, followed by CE MRA,
with CTA being the least uncomfortable. Half of
the patients (from a sample who did not suffer
from claustrophobia and had no metallic implants)
expressed no preference between undergoing TOF
MRA or DUS, while the majority of those who did
express a preference favoured TOF MRA.
Adverse events (55 studies)
MRA was associated with the highest proportion of
adverse events reported in the studies. However, the
most severe adverse events were more common in
patients undergoing CA than MRA; although these
only occurred in a very small proportion of patients
undergoing either test. The most commonly
reported adverse events were acute digestive system
symptoms associated with CE MRA, unspecified
contrast agent-related adverse events associated
with CE MRA, minor pain/discomfort during or
immediately after DUS, 2D TOF MRA or CE MRA,
anxiety associated with 2D TOF MRA, and acute
central and peripheral nervous system adverse
events associated with CE MRA.
Economic evaluations/modelling
When the whole leg was assessed by a preoperative
diagnostic test, DUS dominated the other
alternatives by presenting higher effectiveness at a
lower cost per quality-adjusted life-year (QALY; 
i.e. £13,646 per QALY). When the assessment was
limited to a section of the leg, either above the
knee or below the knee, 2D TOF MRA was the
most cost-effective preoperative diagnostic
strategy. The incremental cost per QALY for
below-the-knee comparisons was equal to £37,024
when 2D TOF MRA was compared with DUS. For
above-the-knee comparisons, 2D TOF MRA
presented the lowest cost and slightly lower
effectiveness compared with the most effective
diagnostic strategy (i.e. CE MRA), with a cost per
QALY equal to £13,442.
Conclusions
The results of the review suggest that CE MRA has
a better overall diagnostic accuracy than CTA or
DUS, and that CE MRA is generally preferred by
patients over CA. Where available, CE MRA may
be a viable alternative to CA. 
The only controlled trial of the effectiveness of
imaging procedures suggested that the results of
DUS were comparable to those of CA, in terms of
Executive summarysurgical planning and outcome. This finding
conflicts with the results of diagnostic accuracy
studies, which reported poor estimates of accuracy
for DUS in comparison with CA.
There was insufficient evidence to evaluate the
usefulness of CTA for the assessment of PAD,
particularly newer techniques.
The results of the economic modelling suggest
that for PAD patients for whom the whole leg is
evaluated by a preoperative diagnostic test DUS
dominates the other alternatives by presenting
higher effectiveness at a lower cost per QALY.
However, when the analysis of stenosis is limited to
a section of the leg, either above the knee or
below the knee, 2D TOF MRA appears to be the
most cost-effective preoperative diagnostic
strategy.
Recommendations for future
research
The following specific questions requiring further
research were identified:
● What is the relative clinical effectiveness of the
available imaging tests, in terms of surgical
planning and postoperative outcome?
● What adverse events occur as a consequence of
testing, and what is the relative incidence for
the available tests? 
● Which tests do patients prefer?
● What is the true diagnostic accuracy of DUS for
the detection of 50% or greater stenoses and
occlusions and how is this affected by timing of
the test and operator skill?
● What are the effects of operator
skill/training/experience on measures of test
accuracy for all the imaging modalities of
interest?
● What is the diagnostic accuracy and clinical
effectiveness of tests to image arteries in
different areas of the leg, particularly the 
foot?
● What is the diagnostic accuracy and clinical
effectiveness of tests in particular patient
subgroups, for example diabetes mellitus?
● Are the prognosis and quality of life of PAD
patients different according to whether they
have an accurate or an inaccurate treatment
plan?
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disease?
Lower limb peripheral arterial disease (PAD) is
characterised by atheromatous narrowing or
occlusion of one or more of the arteries of the leg.
Narrowing (stenosis) of the arteries reduces blood
flow through the affected artery and hence to distal
tissues and may lead to the development of
symptoms. Complete occlusion usually results from
superimposed thrombosis within a narrowed artery.
The most common symptom of lower limb PAD is
calf pain when walking or, if more proximal
arteries such as the common/external iliac arteries
or the aorta are narrowed, then pain may develop
in the thighs or buttocks. This results in the
patient needing to pause during walking, in order
to relieve pain. The condition is known as
intermittent claudication. Less specific symptoms
of lower limb PAD include poor hair and toenail
growth and cool feet. When lower limb blood flow
is more severely compromised rest pain may
develop. Any further deterioration in limb
perfusion may result in ulceration or gangrene,
both of which may be precipitated by minor
trauma.1 The severity of lower limb PAD can be
described using the classification developed by
Leriche and Fontaine in the 1920s: stage I,
asymptomatic; stage II, intermittent claudication;
stage III, ischaemic rest pain; stage IV, focal tissue
necrosis with or without ischaemic rest pain.
Risk factors for PAD include advanced age,
smoking, hypertension, hyperlipidaemia, diabetes,
obesity, physical inactivity and family history.2 The
most important of these risk factors is smoking.
The relative risk for a person smoking more than
15 cigarettes a day of developing PAD, compared
with a non-smoker, is approximately 9.2 PAD is
also common in diabetes, which is present in
around 20% of PAD patients.
Epidemiology of PAD in England
and Wales
The prevalence of PAD increases with age. It is
estimated that around one in five people over the
age of 65 has evidence of PAD on clinical
examination, although only around one in four of
these will have symptoms.3 Patients with PAD have
an increased risk of other cardiovascular
conditions. Patients with symptomatic PAD have a
30% risk of death within 5 years of diagnosis and
almost 50% after 10 years.4 These risks are highest
in patients with more severe disease requiring
surgery. Approximately half of the deaths at
5 years will be from cardiac causes, with the
remainder being due to cerebrovascular events,
other vascular causes or non-vascular disease.3
Further, 5–10% of these patients will suffer a non-
fatal cardiovascular event. Patients with
asymptomatic disease also have an increased risk
of mortality.4
It has been estimated that, of every 100 patients
presenting to their GP with intermittent
claudication, over the next 5 years symptoms will
improve in 50, remain stable in 25 and deteriorate
in 25. Of the 25 legs that worsen five will need
intervention and two to five will need a major
amputation.
Management
Management strategies for patients with
symptomatic lower limb PAD can be conveniently
divided into two categories: those for patients with
intermittent claudication (Fontaine stage II) and
those for patients with limb-threatening ischaemia
(Fontaine stages III and IV).5 Because of the
relatively benign course associated with
intermittent claudication, and the risks incurred
during and after reconstructive surgery, most
patients are managed conservatively, with
intervention being reserved for patients in whom
there is a significant impact upon quality of life.
Although angioplasty (with or without a stent) is a
less invasive procedure, similar considerations
apply to the use of these techniques.
The choice between angioplasty (with or without a
stent) and surgical revascularisation is governed by
the extent and severity of the vascular disease.
Some patients require primary amputation when
the pattern of disease is such that revascularisation
is not technically possible. Thus, patients with
limb-threatening ischaemia require a detailed
Health Technology Assessment 2007; Vol. 11: No. 20
1
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Chapter 1
Backgroundassessment of their vascular disease to allow a
suitable treatment plan to be developed.
The most important factors in intervention
planning are the distribution of disease and the
length and severity of stenoses or occlusions.
Thus, while high-grade stenoses (50%
narrowing) and occlusions of an artery are more
likely to exert a significant haemodynamic effect,
lesser stenoses can usually be ignored. The length
and location of the diseased segment are also
important predictors of the success of angioplasty,
which is usually reserved for stenoses or occlusions
less than 10 cm in length. For any intervention to
be successful, diagnostic imaging must also
confirm that the vessels proximal to the artery to
be treated are relatively disease free, so that there
is good inflow of blood as far as the diseased
segment. For this reason, when intervention is
planned the most proximal lesions are treated
first, as these tend to restrict flow to the greatest
extent.6 In addition to confirming that the inflow
from proximal vessels is satisfactory, imaging must
be capable of demonstrating the patency of the
distal arteries below the site of maximum disease.
If there is no adequate outflow to the ischaemic
limb then proximal intervention will be of limited
benefit. Given the importance of a clear
demonstration of the proximal inflow, the site of
maximum disease and the outflow or run-off, it is
important to evaluate the performance of
diagnostic imaging techniques within the various
arterial segments.
Diagnostic tests
A diagnosis of intermittent claudication can
usually be made using the Edinburgh claudication
questionnaire, which has a reported specificity of
91% and sensitivity of 99%.7 Examination of
patients with PAD usually reveals weak or absent
pulses and a crude numerical measure of disease
severity is readily obtained with the ankle/brachial
pressure index (ABPI). Further investigations are
normally only carried out in patients for whom
invasive intervention is considered.3 A number of
imaging techniques may be used to evaluate the
lower limb vasculature before intervention. These
can be broadly grouped as follows.
Contrast angiography
Contrast angiography (CA) entails the
intravascular injection of contrast agent during
planar X-ray imaging. Images can be enhanced by
background subtraction of a precontrast frame,
leaving an image of only the opacified arterial
tree. Digital subtraction arteriography (DSA)
requires a lower dose of contrast agent (typically
30% versus 76% for screen-film arteriography)
owing to superior contrast resolution, which is
more comfortable for the patients, so reducing
artefacts,8 and also permits further views if
necessary without using an excessive total contrast
load. Contrast agent may be injected intra-
arterially or intravenously. However, the
intravenous technique has serious limitations in
terms of image quality, resulting from dilution of
the contrast medium, and is not considered in this
review. Intra-arterial CA is regarded as the
reference standard for the imaging of PAD, and
will be treated as the preferred reference standard
for those elements of this project that consider
diagnostic accuracy. The drawbacks of contrast
angiography are those associated with arterial
puncture and ionising radiation, the potential
nephrotoxicity of iodinated contrast agents,
particularly in patients with pre-existing renal
impairment, and allergic reactions to the contrast
agent. While developments in contrast agents may
overcome some of these issues, DSA will continue
to carry a small risk. 
Magnetic resonance angiography
Magnetic resonance angiography (MRA) is a less
invasive alternative to CA. Both time-of-flight
(TOF) and phase-contrast (PC) MRA are non-
contrast techniques with intravascular blood
detected by virtue of its movement compared with
static surrounding tissues. Contrast-enhanced (CE)
MRA relies on the T1 shortening effect of
intravenously administered contrast media
circulating in the blood.9
TOF techniques use a gradient echo pulse
sequence in which protons entering the slice (such
as those in flowing blood) are unsaturated
compared with static protons and so return a
higher signal which forms the basis of the
contrast. Compared with the two-dimensional (2D)
method, three-dimensional (3D) TOF provides a
higher signal-to-noise ratio and shorter imaging
times; however, it is more susceptible to saturation
effects.10 Phase-contrast methods rely on phase
shifts imparted to protons moving through a
gradient magnetic field, whereas stationary
protons show no phase change. Technical
problems with the use of TOF and PC MRA in
peripheral arterial disease include motion
artefacts, long acquisition times, low spatial
resolution, unreliable visualisation of lesions with
high flow and turbulence (excessive signal loss at
regions of high grade stenosis), and non-
visualisation of patent vessels with reversed blood
Background
2flow. All magnetic resonance (MR) studies have the
problem of the exclusion of patients with
pacemakers and some other metallic implants or
who suffer from severe claustrophobia.
Some of the problems described above have been
addressed by contrast-enhanced techniques, the
most commonly used MRA method for assessment
of PAD.11 CE MRA is flow independent, therefore
most of the artefacts due to flow turbulence and
slow flow that are problematic in TOF and PC
MRA are eliminated, reducing acquisition times
and increasing the quality of images.12 Flow
independence also allows in-plane imaging of
vessels, reducing the number of image slices
needed to cover an extended vascular territory and
thereby allowing faster high-resolution imaging. In
combination with a moving table this allows the
whole of the lower limb vascular tree to be covered
in three steps after a single contrast injection.
CE MRA may also visualise patent distal segments
not seen with TOF techniques or CA. The
potential for adverse events relating to the use of
contrast agents is a consideration; however, since
contrast media used in MRA are delivered
intravenously, the potential complications
associated with arterial puncture are avoided.
Computed tomography angiography
Helical computed tomography angiography (CTA)
has been widely used for the evaluation of
abdominal aortic aneurysms, but has only recently
begun to be used in PAD, as newer multidetector
row machines have enabled fine collimation to be
combined with rapid (arterial phase) contrast-
enhanced scanning of the extended ranges
needed to cover the lower limb vascular tree.
Although CTA avoids the potential complications
associated with arterial puncture, in common with
CA it still requires exposure to ionising radiation
and the injection of relatively large volumes of
contrast material.
Duplex ultrasound
Duplex sonography (strictly meaning the
combination of pulsed Doppler sonography with
real time B mode ultrasound imaging, but in
current practice usually also including colour
Doppler scanning) allows the interrogation of
Doppler flow patterns in a precisely defined area
within the vessel lumen, facilitating the
localisation of arterial stenoses. Stenosis is graded
by the ratio between the peak systolic velocity of
the target/stenosed vessel and adjacent or
contralateral non-stenosed vessels: the peak
systolic velocity ratio (PSVR). Unlike MRA, 
CTA and CA, duplex ultrasound (DUS) does 
not directly provide the familiar ‘roadmap’
overview of the circulation which facilitates
treatment planning. However, a diagram 
drawn by the ultrasound operator can fulfil a
similar role, particularly in distinguishing patients
who are candidates for angioplasty from those
requiring surgical reconstruction. A further
technical drawback of DUS which may limit its
utility is the technical difficulty in assessing
aortoiliac disease owing to the potential
interference by bowel gas and the depth of the
vessels. However, the benefits of DUS are 
that it avoids the possible complications 
associated with more invasive procedures, it 
does not involve ionising radiation or the hazards
and contraindications associated with strong
magnetic fields, and it is relatively cheap and
mobile.
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The aim of the review was to determine the best
method, or combination of methods, for the
diagnosis and assessment of lower limb PAD.
Objectives
The review had several objectives:
● to determine the diagnostic accuracy of DUS,
MRA and CTA, alone or in combination, for the
assessment of lower limb PAD
● to evaluate the impact of these technologies on
patient management/outcome
● to evaluate the evidence on the attitudes of
patients to these assessment methods
● to summarise the available data on the adverse
events associated with these technologies
● to analyse the cost-effectiveness of the available
methods of assessment for PAD using a critical
review of the existing cost-effectiveness
literature, and decision analysis. 
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Research questionsA
n advisory panel was established. In addition 
to providing subject-specific input during the
review, members of the panel were invited to offer
comment on the protocol and draft report. Details
of advisory panel members can be found in
Appendix 1. The systematic review was undertaken
in accordance with the Centre for Reviews and
Dissemination (CRD) guidelines for undertaking
systematic reviews13 and published guidelines on
the meta-analysis of diagnostic tests.14,15 Details of
protocol changes are presented in Appendix 2.
Search strategy
A database of published and unpublished
literature was assembled from systematic searches
of electronic sources, handsearching and
consultation with experts in the field.
Studies were identified by searching major medical
databases such as MEDLINE, EMBASE, BIOSIS
Previews, Science Citation Index, LILACS and
Pascal from 1996 to April 2004. Update searches
were undertaken in May 2005 (see Appendix 3 for
detailed search strategies).
In addition, information on studies in progress,
unpublished research and research reported in the
grey literature was sought from a range of relevant
databases, including Inside Conferences, System for
Information on Grey Literature in Europe (SIGLE),
Dissertation Abstracts Online and the National
Technical Information Service (NTIS) database. Six
key journals were handsearched: Radiology (1965 to
January 2005), Journal of Vascular Intervention and
Radiology (1990 to January 2005), European Journal of
Vascular and Endovascular Surgery (1999 to February
2005), American Journal of Roentgenology (2000 to
March 2005), Journal of Vascular Surgery (2000 to
December 2004 and articles in press) and
Cardiovascular and Interventional Radiology (2000 to
December 2004 and articles in press).
Attempts to identify further studies were made by
contacting clinical experts and examining the
reference lists of all included articles.
There was no restriction by country of origin or
language of publication. The results of the searches
were imported into Endnote6 bibliographic
management software and deduplicated.
In addition to the literature searches to identify
studies of effectiveness, searches were undertaken
to inform the economic modelling. These searches
were undertaken in MEDLINE, EMBASE and the
Cochrane Database of Systematic Reviews.
Detailed search strategies are reported in
Appendix 3.
Inclusion criteria
Effectiveness studies
Two reviewers screened titles and abstracts for
relevance independently, and any disagreements
were resolved by consensus. Full papers of
potentially relevant studies were obtained and
assessed for inclusion by one reviewer and checked
by a second. Disagreements were resolved by
consensus or referral to a third reviewer when
necessary. There were separate inclusion criteria
for each section of the review, as shown in Table 1. 
Economic evaluations
Studies were included in the review if they met the
criteria of being full economic evaluations, namely
that they included an explicit analysis of both costs
and effects for an intervention and at least one
comparator16 and were considered to be useful in
answering the research questions relating to cost-
effectiveness.
Data extraction
Data extraction was performed by one reviewer
and checked by a second. Disagreements were
resolved by consensus or referral to a third
reviewer when necessary. Non-English-language
papers were extracted by one reviewer,
accompanied by a speaker of that language. Data
extraction from non-English-language studies were
not checked by a second reviewer. 
Assessment of stenosis/occlusion
Data extraction forms were developed using
Microsoft Access. These were piloted on a small
sample of studies. The following information was
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Review methodsextracted: study details [identifier, aim, study
design, country, setting (teaching hospital/non-
teaching hospital)], participant details (number of
participants, age, gender, whether from a patient
subgroup and Fontaine classification, where
provided), test details [test(s) evaluated, reference
standard, definition of a positive test result, area of
the leg assessed, how the results were reported in
the studies (leg, artery, arterial segment), time
elapsed between index test and reference
standard, details of dropouts and exclusions] and
results (data to construct a 2 × 2 table).
Impact of assessment method on
patient management/outcome
Data were extracted into Microsoft Word. Data
were extracted on the test being evaluated, study
methodology, management decisions/outcomes
reported and results.
Studies of patient attitudes
Data were extracted into Microsoft Word. Data
were extracted on the test being evaluated, study
methodology and results.
Adverse events
Data were extracted into Microsoft Access. The
following information was extracted: study details
[identifier, aim, study design, country, setting
(teaching hospital/non-teaching hospital)],
participant details (number of participants, age,
gender, whether from a patient subgroup and
Fontaine classification, where provided), test
details [test(s) evaluated, reference standard] and
type and frequency of adverse events.
Quality assessment
Quality assessment was carried out by one reviewer
and checked by a second. Disagreements were
resolved by consensus or referral to a third
reviewer when necessary. Data specific to the type
of study were extracted.
Diagnostic accuracy studies
Quality assessment forms were developed using
Microsoft Access. Included diagnostic accuracy
studies were assessed for methodological quality
using the QUADAS tool.17 The 14 items of the
QUADAS tool check the appropriateness of the
patient spectrum composition, whether selection
criteria for patients have been described, the
appropriateness of the reference standard,
whether disease progression bias has been avoided
(time lapsed between index test and reference
standard was sufficiently short to make a change in
disease status unlikely), whether partial and/or
Review methods
8
TABLE 1 Inclusion criteria for each of the four sections of the review
Diagnostic accuracy of  Impact on patient  Patient  Adverse events
DUS/MRA/CTA management/outcome acceptability
Study design Diagnostic cohort or  RCT/CCT Studies of any design. 
case–control Case reports were excluded
Population Studies that include 20 or more adults (18 years) with  Studies of adults 
symptoms suggestive of lower limb PAD  with symptoms
suggestive of lower
limb PAD 
Index tests/ DUS, MRA or CTA, alone or in combination
interventions
Reference standard Conventional angiography  NA
(CA) or findings at surgery/
follow-up. Studies that 
reported the use of 
intravenous CA were 
excluded
Outcome measures Sufficient information to  Any treatment decision or  Any reported  Adverse events 
construct 2 × 2 tables of  long-term outcome  criteria relating to  relating to the 
test performance measure (e.g. graft/vessel  patient index test or to 
patency following  acceptability  currently used 
intervention, morbidity,  contrast agents 
mortality)
NA, not applicable.differential verification bias have been avoided (all
participants received verification using the same
reference standard of diagnosis) and whether
incorporation bias has been avoided (the index
test did not form part of the reference standard).
The checklist also addresses the question of
whether the reference standard and index tests
have been reported in sufficient detail to permit
replication, and whether test review bias,
diagnostic review bias and clinical review bias have
been avoided (the results of tests have been
interpreted independently of each other and with
appropriate clinical information available). Finally,
the studies were checked with regard to the
reporting of uninterpretable results and whether
all withdrawals had been accounted for. Item 3 of
the QUADAS tool (appropriateness of reference
standard) was omitted from this review as the use
of a specified, adequate reference standard formed
part of the inclusion criteria. Those elements of
the QUADAS tool that require specification for
individual projects were defined a priori by
discussion among the authors. The QUADAS tool,
together with details on how studies were scored,
is reported in Appendix 4.
Controlled trials and other study
designs
The quality of each study was assessed using the
appropriate checklist from the CRD guidelines for
undertaking systematic reviews.13
Economic evaluations
The quality assessment of each included study was
undertaken using two methods. First, the quality
of economic evaluations was assessed using a
modified version of the 35-point checklist
developed for authors of economic evaluation
submissions to the British Medical Journal, to which
an additional item was added (item 36) in order to
report whether or not the authors had addressed
the issue of the generalisability of the results. Each
item in the checklist was given one of four
responses: (a) yes, (b) no, (c) not clear and (d) not
applicable. The checklists were completed
independently by two health economists, with
discrepancies being discussed and a final
agreement reached (see Appendix 5).
Secondly, for each study a critical review (textual)
summary was completed following the approach
adopted by the NHS Economic Evaluation
Database (NHS EED). This includes an appraisal
of the validity of the choice of comparator(s), 
the validity of the analysis of effectiveness 
results, the validity of the benefit measure used in
the economic analysis, the validity of the cost
results, and a variety of other important issues,
including whether or not the authors compared
their results with those of other (similar) studies,
whether generalisability was addressed by the
authors, and the principal limitations and
strengths of the study, and finally the implications
of the study in terms of clinical practice and 
future research. 
Data synthesis
Assessment of stenosis/occlusion
Results were analysed according to the imaging
tests assessed (DUS, MRA or CTA). Within these
groups, tests were further grouped by specific
technique where appropriate (e.g. 2D, 3D TOF
and CE MRA techniques were analysed
separately). Analyses were conducted using 
Meta-DiSc.18
For each individual data set the sensitivity,
specificity, positive and negative likelihood ratios
and diagnostic odds ratio (DOR) were calculated
from the 2 × 2 tables. These are presented in
tables, grouped by anatomy assessed (whole leg,
above or below knee, and foot) and the threshold
used in the definition of stenosis/occlusion (50%,
70% or 100%). To account for cells with a value
of zero in the 2 × 2 tables when calculating
likelihood ratios and DOR, 0.5 was added to all
cells of every 2 × 2 table, as recommended by
Moses and colleagues.19
Pooling was only considered where 2 × 2 data were
reported in the same way (e.g. arterial segment,
artery or limb) and for the same anatomy and
threshold used in the definition of
stenosis/occlusion. As some studies presented
results for more than one anatomy or threshold,
this method avoids the issue of multiple data sets
being obtained from the same patients. Within
data sets that were considered for pooling,
heterogeneity was assessed using statistical tests
and also graphically with forest plots of individual
study results. Heterogeneity between sensitivities
and specificities was assessed using a 2 test, and
Cochran’s Q test was used for likelihood ratios and
diagnostic odds ratios. Statistically significant
heterogeneity was assumed if p < 0.1. When there
was evidence of significant statistical or clinical
heterogeneity the range was presented for
sensitivity and specificity, and the median value
(and range) for likelihood ratios. Individual study
results were presented plotted in receiver
operating characteristic (ROC) space (without a
summary curve).
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heterogeneity, pooled estimates of sensitivity,
specificity and likelihood ratios were calculated
using a random effects model and presented with
their corresponding 95% confidence intervals (CI).
In addition, summary ROC (sROC) curves were
fitted, estimated by calculating the sensitivity at
each value of (1 – Specificity) using the following
equation:
Sensitivity = [(1+e–/(1–)) × (V(1+)/(1–))]–1
where V = Specificity/(1 – Specificity).
 and  were calculated using the following
regression equation:
D =  + S
with D and S being calculated from the
sensitivities and specificities of each study:
D = [logit (Sensitivity) – logit (1 – Specificity)]
= ln (DOR)
S = [logit (Sensitivity) + logit (1 – Specificity)]
logit (Sensitivity) = ln[Sensitivity/(1 – Sensitivity)] 
logit (1 – Specificity) = ln[(1 – Specificity)/
Specificity]
This was estimated by fitting a regression model
containing S to the outcome D, which was
weighted by the sample size of each study. Beta ()
provides an estimate of the effect upon the DOR
of the choice of threshold for a positive test result.
If  is 0 (when the line is symmetrical with respect
to the line True-positive rate = 1 – False-positive
rate), or not statistically significantly different from
0, then the DOR is not affected by the threshold
used. 
Impact of assessment method on
patient management/outcome
A narrative synthesis was presented.
Studies of patient attitudes
A narrative synthesis was presented.
Adverse events
Results were tabulated and when more than one
study reported a particular adverse event, the
range of the proportions of patients experiencing
that adverse event was presented.
Economic evaluations
The identified economic evaluations were
described and evaluated in a narrative summary.
Review methods
10Assessment of stenosis/occlusion
Fifty-eight diagnostic accuracy studies provided
data on tests to diagnose stenosis/occlusion
(Table 2). A more detailed description of the
included diagnostic accuracy studies is presented
in Appendix 6. Twenty-six studies evaluated DUS,
seven evaluated CTA and 23 evaluated MRA; of
which nine evaluated 2D TOF MRA, one
evaluated 2D PC MRA and 13 evaluated CE MRA.
In addition, one study evaluated both DUS and
2D TOF MRA, and one study evaluated DUS, 2D
TOF MRA and CE MRA. Conventional
angiography was the reference standard in all
studies.
Impact of assessment method on
patient management/outcome
One controlled trial provided data on the impact
of the assessment method on patient management
and/or patient outcomes. The study evaluated
DUS in comparison with CA.77
Studies of patient attitudes
Four studies reported results relating to patient
attitudes. Two studies evaluated MRA and CA,78,79
one evaluated DUS and MRA,80 and one evaluated
CTA, MRA and CA.81
Adverse events
Nine of the diagnostic accuracy studies that met
the inclusion criteria for the review provided data
on adverse events.29,30,32,40,41,54,57,60,61 In addition,
46 studies that did not meet the inclusion criteria
for the review of diagnostic accuracy reported
results relating to adverse events.78,80,82–125
Economic evaluations
Six economic evaluations met the inclusion criteria
for the review.126–131 However, one was published
in German and the results could not be translated
in time to be included.127 Detailed data extraction,
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Details of studies included in the review
TABLE 2 Studies evaluating tests to diagnose stenosis/occlusion
Study Index test
Aly, 199820 DUS
Ashleigh, 199321 DUS
Baum, 199522 2D TOF MRA
Baxter, 199323 DUS
Bergamini, 199524 DUS
Bostrom, 200125 DUS
Catalano, 200426 CTA
Cortell, 199627 2D TOF MRA
Cronberg, 200328 CE MRA
Currie, 199529 (1) 2D TOF MRA
(2) DUS
Davies, 199230 DUS
Eiberg, 200131 DUS
Eklof, 199832 2D TOF MRA
El-Kayali, 200433 DUS
Fletcher, 199034 DUS
Grassbaugh, 200335 DUS
Hany, 199736 CE MRA
Hatsukami, 199237 DUS
Heuschmid, 200338 CTA
Hirai, 199839 DUS
Hoch, 199640 2D TOF MRA
Hoch, 199941 2D TOF MRA
Hofmann, 200442 DUS
Karacagil, 199643 DUS
Koelemay, 199744 DUS
Koelemay, 199845 DUS
Kreitner, 200046 CE MRA
Lai, 199547 DUS
Lai, 199648 DUS
Laissy, 199849 CE MRA
Legemate, 199150 DUS
Lenhart, 200051 CE MRA
Linke, 199452 DUS
Lundin, 200053 (1) DUS
(2) 2D TOF MRA
(3) CE MRA
Martin, 200354 CTA
McDermott, 199555 2D TOF MRA
Meaney, 19999 CE MRA
Mergelsberg, 198656 DUS
Portugaller, 200457 CTA
Puls, 200258 CTA
Rieker, 199659 CTA
Rieker, 199760 CTA
Schafer, 200361 CE MRA
Sensier, 199662 DUS
Shaalan, 200363 DUS
Snidow, 199564 2D TOF MRA
Snidow, 199665 CE MRA
continuedin the form of NHS EED abstracts, is provided for
the five English language studies in Appendix 7.
Details about the results of the quality assessment
of the economic evaluations using a modified
version of the 35-point checklist are reported in
Appendix 5. 
Details of studies included in the review
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TABLE 2 Studies evaluating tests to diagnose stenosis/occlusion
(cont’d)
Study Index test
Steffens, 199766 2D PC MRA
Steffens, 200367 CE MRA
Sueyoshi, 199968 CE MRA
Timonina, 199969 2D TOF MRA
Vavrik, 200470 CE MRA
Whyman, 199271 DUS
Wilson, 199772 DUS
Winterer, 199973 CE MRA
Yucel, 199374 2D TOF MRA
Zeuchner, 199475 DUS
Zhang, 200576 CE MRAI
n total, 534 of the 647 articles ordered and
screened did not meet the inclusion criteria for
the review. Eight were duplicate records. The
reasons for exclusion of the remaining 526
(Table 3) articles are listed below.
1 Study included fewer than 20 participants
2 The results for adult patients could not be
extracted separately from those of children
3 Study of patients with aneurysms only
4 Assessment of the complications of CA only
5 Discussion paper; no data
6 Duplicate publication
7 Study included patients with aortic aneurysms,
and results for PAD patients could not be
extracted separately
8 Study of intravascular ultrasound
9 Letter/editorial
10 Study did not report sufficient data to allow
construction of a 2 × 2 contingency table
11 Study did not include a reference standard
12 Reference standard was not conventional
angiography
13 Not a study of MRA, DUS or CTA
14 Not a study of patients with PAD
15 The study included asymptomatic patients and
results for symptomatic patients could not be
extracted separately, or the symptomatic status
of the participants was not reported
16 All patients were hospitalised for
reconstruction failure or thrombosis of artery
reconstruction
17 Some patients received intravenous rather
than intra-arterial catheter angiography
18 The study was a randomised controlled trial
(RCT) with no patient outcomes reported. 
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TABLE 3 Studies excluded from the review and reasons for exclusion 
AbuRahma, 1980132 12
AbuRahma, 1993133 4
Adriaensen, 2002134 6
Adriaensen, 2004135 18
Agadzhanova, 1986136 10
Alexander, 1987137 15
Alexander, 2002138 10
Allard, 1994139 15
Allard, 1996140 5
Allard, 1999141 5
Alson, 1997142 5
Aly, 1998143 6
Aly, 1998144 6
Aly, 1999145 6
Amano, 1998146 1
Amendt, 1992147 8
Andres, 2003148 14
Andrew, 1989149 14
Archie, 1982150 12
Aronow, 2005151 5
Ascher, 1999152 1
Ascher, 2002153 0
Ascher, 2003154 10
Auerbach, 2004155 5
Avenarius, 2002156 10
Bagi, 1990157 10
Baker, 1978158 14
Baker, 1986159 10
Balas, 1989160 5
Balas, 1990161 14
Balas, 1990162 5
Balbarini, 1995163 8
Balzer, 2000164 5
Balzer, 2000165 10
Balzer, 2000166 10
Barnes, 1977167 4
Barnes, 1979168 5
Barrett, 1992169 14
Barretto, 2003170 13
Bashir, 2003171 5
Battino, 1996172 10
Baum, 1992173 10
Baum, 1992174 6
Baum, 1994175 10
Baum, 1998176 5
Baumgartner, 1993177 1
Baumgartner, 2005178 5
Baun, 2004179 5
Becker, 2003180 5
Belch, 2003181 5
Bendib, 1997182 1
Bendib, 1997183 10
Bendick, 2003184 12
Benhamou, 1997185 5
Beregi, 1997186 1
Bertschinger, 1999187 15
Bertschinger, 2001188 15
Bettmann, 1997189 14
Binkert, 2004190 10
Bizzini Pezzetta, 1999191 5
Bluemke, 1995192 5
Boos, 1995193 10
Borrello, 1993194 5
Bostrom, 2002195 10
Bostrom-Ardin, 2002196 10
Bostrom-Ardin, 2002197 10
Bourlet, 2000198 1
Brillet, 2001199 1
Brillet, 2003200 10
Brismar, 1991201 14
Brummett, 1988202 14
Bruninx, 2002203 14
Bulynin, 1989204 11
Busch, 1999205 15
Busch, 2001206 15
Cairols, 2003207 10
Calligaro, 1996208 15
Cambria, 1993209 1
Cambria, 1997210 10
Campbell, 1986211 15
Cappelli, 1999212 11
Caputo, 1992213 14
Caputo, 1992214 5
Carpenter, 1992215 10
Carpenter, 1994216 10
Carpenter, 1994217 7
Carpenter, 2000218 5
Carriero, 1998219 15
Carriero, 2002220 15
Caster, 1992221 7
Catalano, 2001222 10
Catalano, 2003223 5
Cherro, 2004224 1
Cochran, 2001225 14
Coenegrachts, 2003226 3
Coffi, 2002227 12
Coffi, 2004228 1
Collier, 1990229 10
Comel, 2004230 5
Correas, 1999231 5
Cossman, 1989232 15
Cotroneo, 1997233 5
Cramer, 1990234 1
Cruz, 1986235 4
Currie, 1995236 12
Currie, 1995237 11
Davis, 1997238 1
De Backer, 2000239 5
De Benito-Fernandez, 
2004240 7
De Cobelli, 1999241 10
Dehaut, 2000,242 14
Demolis, 1990,243 15
De Morais Filho, 2004244 10
Depairon, 1998245 5
DeSouza, 1991246 15
continuedDetails of studies excluded from the review
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TABLE 3 Studies excluded from the review and reasons for exclusion (cont’d)
De Vries, 1996247 5
Di Cesare, 2001248 10
Diaz, 2000249 4
Dorenbeck, 2002250 1
Dorweiler, 2002251 10
Douek, 1995252 14
Drugova, 1981253 15
Duncan, 1990254 11
Dunne, 1984255 1
Dyet, 2000256 5
Earls, 1998257 1
Earls, 1998258 1
Ebner, 1992259 10
Edwards, 1991260 7
Edwards, 2005261 10
Eiberg, 2001262 5
Eiberg, 2002263 5
Eiberg, 2002264 10
Eiberg, 2003265 1
Ekelund, 1996266 5
Eklof, 1997267 6
Eklof, 1998268 6
Elsharawy, 2002269 10
Elsman, 1995270 10
Elsman, 1996271 10
Elson, 1994272 5
Engeler, 1991273 1
Engelmann, 1997274 1
Ernst, 1998275 10
Fauvel, 1996276 15
Fellner, 1999277 9
Fischer-Colbrie, 1997278 10
Forster, 1999279 1
Froelich, 1997280 14
Fronek, 1976281 15
Fushimi, 1998282 13
Fussl, 2001283 5
Gaylis, 2002284 9
Georgiou, 1993285 5
Gerritsen, 1993286 8
Giannini, 2004287 1
Goldberg, 1997288 10
Goldstein, 1990289 14
Gooding, 1980290 1
Gooding, 1991291 15
Gosling, 1971292 11
Goyen, 2000293 5
Goyen, 2000294 11
Goyen, 2002295 1
Goyen, 2002296 5
Goyen, 2004297 5
Gregor, 2002298 10
Hany, 1998299 7
Hartnell, 2000300 9
Haslam, 1999301 10
Hendrickx, 1997302 15
Hentsch, 2003303 10
Hentsch, 2004304 5
Herborn, 2004305 1
Herborn, 2004306 10
Herrington, 1994307 13
Hertz, 1993308 1
Hessel, 1981309 4
Hiatt, 1992310 5
Hingorani, 2004311 10
Hingorani, 2004312 10
Hirai, 2002313 10
Ho, 1996314 10
Ho, 1997315 10
Ho, 1998316 10
Ho, 1998317 10
Ho, 2003318 5
Ho, 2004319 15
Hobson, 1981320 10
Hofmann, 2002321 10
Holder, 1978322 4
Huber, 1999323 15
Huber, 2000324 6
Huber, 2003325 10
Hudon, 1979326 15
Huljev, 1994327 15
Humphries, 1980328 10
Huppert, 1994329 8
Hussain, 1996330 15
Hynynen, 1996331 14
Illescas, 1986332 1
Inoue, 1994333 5
Ito, 1996334 1
Jacobovicz, 2004335 7
Jacobs, 1998336 14
Jager, 1985337 15
Jager, 1989338 5
Janka, 2001339 1
Janka, 2005340 10
Jezic, 1982341 5
Johnson, 1984342 15
Kaiser, 1995343 15
Kalden, 2000344 1
Kanal, 1990345 14
Karacagil, 1994346 10
Karacagil, 1995347 15
Karagacil, 1996348 6
Karacagil, 1998349 10
Karasch, 1991350 10
Karasch, 1992351 6
Katayama, 1990352 14
Katsamouris, 2001353 10
Katz, 2001354 5
Kaufman, 1982355 10
Kelekis, 1999356 10
Khilnani, 2002357 10
Kita, 1999358 1
Klein, 2003359 10
Koelemay, 1996360 5
Koelemay, 2001361 11
Koelemay, 2001362 5
Koelemay, 2001363 10
Koennecke, 1989364 15
Kohler, 1987365 14
Kohler, 1990366 6
Kojima, 1995367 1
Konkus, 2002368 11
Korogi, 1996369 5
Korst, 1999370 1
Korst, 1999371 15
Krajina, 2001372 5
Kramer, 1998373 1
Kreissig, 2000374 10
Kreitner, 1998375 6
Krombach, 2000376 10
Krug, 1995377 10
Krug, 1995378 10
Laissy, 1995379 1
Laissy, 1995380 1
Lalli, 1980381 14
Lang, 1981382 14
Langholz, 1993383 10
Langholz, 1998384 5
Langsfeld, 1988385 7
Larch, 1997386 15
Lasser, 1997387 14
Lawler, 2003388 5
Lawrence, 1995389 1
Lee, 1998390 10
Legemate, 1989391 6
Legemate, 1991392 7
Leiner, 2004393 5
Leiner, 2005394 10
Leng, 1993395 15
Leng, 2000396 5
Lenhart, 1999397 1
Lenhart, 2001398 6
Lenhart, 2002399 11
Leon, 2002400 10
Levy, 1998401 10
Lewis, 1986402 14
Lewis, 1997403 9
Leyendecker, 1997404 10
Leyendecker, 1998405 10
Ligush, 1998406 10
Limpert, 1987407 15
Link, 1999408 15
Loewe, 2000409 10
Loewe, 2002410 15
Loewe, 2003411 15
Loewe, 2003412 5
Lofberg, 2001413 10
Lossef, 1992414 1
Lujan, 2002415 10
Mackaay, 1995416 11
Maeda, 1996417 1
Makita, 1997418 10
Marcus, 2000419 10
Markovic, 1996420 10
Marshall, 1988421 5
Marti, 2004422 10
Mast, 2001423 14
Masui, 1995424 1
Matsubara, 1984425 11
Matsumura, 2001426 15
Mazzariol, 2000427 10
McCarthy, 1999428 10
McCauley, 1994429 10
McClennan, 1987430 14
Meaney, 1998431 10
Meaney, 2003432 5
Meissner, 2004433 1
Melke, 1983434 10
Mesurolle, 1999435 10
Meuli, 1986436 1
Mills, 1982437 4
Mitsuzaki, 2000438 1
Mohler, 2003439 10
Moneta, 1987440 15
Moneta, 1992441 7
Moneta, 1993442 10
Morasch, 2003443 10
Muller-Buhl, 2003444 13
Mulligan, 1993445 1
Murphy, 2000446 5
Nagashima, 1979447 12
Naidich, 1992448 4
Nau, 2002449 5
Nchimi, 2002450 15
Nelemans, 2000451 5
Nelemans, 2000452 5
Nemcek, 1996453 5
Nicolaides, 1976454 10
Nikolenko, 1987455 11
Nyamekye, 1996456 10
Nzeh, 1998457 10
Oberholzer, 1999458 1
Ofer, 2003459 1
Ohi, 1987460 1
Oliva, 1999461 4
Oser, 1995462 13
Ota, 2004463 2
Owen, 1992464 10
Owen, 1992465 10
Owen, 1993466 10
Pandharipande, 2000467 1
Pandharipande, 2002468 1
Pasterkamp, 1996469 12
Pellerin, 2001470 15
Pellerito, 1993471 5
Pemberton, 1996472 10
Pemberton, 1996473 10
Pemberton, 1997474 5
Perrier, 1998475 10
Phillips, 1980476 5
Phillips, 1993477 5
Pinto, 1996478 15
Pividal, 2001479 5
Pocek, 1999480 1
Polak, 1991481 14
Polak, 1993482 5
Poletti, 2004483 1
Poon, 1993484 9
Poon, 1997485 1
Portig, 2004486 5
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TABLE 3 Studies excluded from the review and reasons for exclusion (cont’d)
Portugaller, 1998487 15
Portugaller, 2003488 15
Postiglione, 1992489 13
Powe, 1988490 4
Proia, 2001491 10
Prokop, 1997492 5
Quinn, 1993493 10
Quinn, 1997494 10
Quinn, 1998495 10
Radak, 1998496 11
Radak, 1999497 12
Rajagopalan, 2002498 5
Raman, 2002499 1
Ramaswami, 1999500 17
Ranke, 1992501 10
Raptopoulos, 1996502 1
Raptopoulos, 1995503 1
Rathenborg, 2003504 16
Reid, 2001505 1
Reimer, 1997506 15
Reimer, 1998507 15
Reimer, 1998508 5
Rezzo, 1982509 11
Ricco, 1983510 10
Richter, 1994511 15
Rieker, 1995512 6
Rieker, 1997513 15
Rizzo, 1990514 14
Rofsky, 1997515 1
Rofsky, 1999516 11
Rofsky, 2000517 5
Rose, 2000518 5
Rose, 2000519 5
Rose, 2001520 5
Rosenfield, 1989521 1
Rosfors, 1993522 15
Rubin, 1999523 1
Rubin, 1999524 1
Rubin, 2000525 3
Rubin, 2001526 7
Ruehm, 2000527 15
Ruehm, 2001528 15
Ruehm, 1999529 5
Ruthlein, 1988530 5
Sacks, 1990531 11
Sacks, 1992532 15
Sacks, 1994533 11
Saito, 1989534 14
Saito, 2004535 7
Savader, 2001536 13
Sawchuk, 1990537 11
Sawchuk, 1997538 15
Schiebler, 1992539 10
Scheibler, 1993540 5
Schindler, 2001541 13
Schmeller, 1993542 14
Schmiedl, 1996543 5
Schneider, 1999544 10
Schoenberg, 2001545 1
Seifert, 1988546 14
Seifert, 1989547 15
Sensier, 1996548 6
Sensier, 1996549 9
Sensier, 1998550 15
Shannon, 1997551 1
Sharafuddin, 2000552 10
Sharafuddin, 2002553 1
Shearman, 19867 10
Shehadi, 1980554 14
Shehadi, 1982555 14
Sheikh, 1991556 1
Shetty, 1995557 1
Shetty, 1998558 1
Sigstedt, 1978559 4
Sivananthan, 1993560 1
Snidow, 1995561 10
Snidow, 1996562 10
Solomon, 1995563 14
Sorensen, 2003564 6
Sostman, 1996565 5
Soule, 2003566 10
Spinosa, 2000567 4
Spinosa, 2000568 5
Spring, 1997569 14
Spring, 1997570 14
Steffens, 1996571 6
Steffens, 1997572 15
Steffens, 1998573 10
Steffens, 1999574 10
Stoffers, 1997575 5
Strandness, 1978576 5
Sueyoshi, 2000577 1
Sugihara, 2002578 10
Swan, 2002579 10
Szendro, 2001580 10
Tabuchi, 2000581 1
Tala, 1968582 1
Ternovoy, 1999583 1
Tesauro, 1991584 13
Thiele, 1983585 5
Tielbeek, 1996586 8
Tielbeek, 1997587 1
Tomihira, 2002588 1
Torreggiani, 2002589 14
Trusen, 2003590 5
Ubbink, 2001591 11
Uberoi, 2002592 15
Unger, 1995593 1
Van Asten, 1991594 12
Van der Heijden, 
1993595 15
Van der Lugt, 1996596 10
Van Lankeren, 1998597 8
Van Rij, 1989598 14
Vashisht, 1992599 1
Velazquez, 1998600 5
Venkataraman, 2003601 15
Vergara, 1996602 14
Verrel, 2002603 15
Visser, 1999604 6
Visser, 2000605 5
Vodnansky, 2001606 6
Vodnansky, 2002607 14
Von Kalle, 2004608 11
Vosshenrich, 1993609 15
Vosshenrich, 1996610 7
Vosshenrich, 1998611 10
Wain, 1999612 10
Walter, 2000613 14
Walton, 1984614 15
Wang, 2001615 11
Wasser, 1999616 5
Watanabe, 1998617 1
Watts, 2001618 11
Weishaupt, 1999619 6
Wendt, 1990620 14
Wesbey, 1985621 15
Westenberg, 2000622 1
Wetzner, 1984623 14
Whelan, 1992624 15
Whiteley, 1996625 9
Whiteley, 1999626 13
Whiting, 200317 14
Widrich, 1982627 4
Widrich, 1983628 4
Wikstrom, 2000629 15
Wikstrom, 2001630 6
Wilhelm, 2000631 10
Willmann, 2002632 6
Willmann, 2003633 15
Winchester, 1998634 15
Winterer, 2002635 10
Winter-Warnars, 1996636 10
Wixon, 2000637 10
Wolf, 2003638 13
Wolff, 2002639 6
Wright, 1983640 3
Yamaguchi, 1991641 6
Yamashita, 1997642 10
Yamashita, 1998643 10
Yeon Hyeon, 2001644 14
Yilmaz, 2002645 14
Yoshikawa, 1992646 14
Yucel, 1992647 5
Yucel, 1992648 1
Yucel, 1992649 1
Yucel, 1994650 9
Yucel, 1994651 5
Zagoria, 1988652 1
Zakharova, 1990653 12
Zhao, 2003654 14
Zubarev, 1990655 10Results of the literature searches
The literature searches identified 8590 references.
These were screened for relevance and 650 were
considered to be potentially relevant. Copies of
three of these articles could not be obtained
during the review.656–658 A total of 647 articles was
assessed for inclusion in the review. Figure 1 shows
the flow of studies through the review process and
the number of studies excluded according to each
of the inclusion criteria. Chapter 5 summarises the
studies excluded from the review.
A total of 113 studies met the review inclusion
criteria. Fifty-eight studies provided data on the
diagnostic accuracy of tests to diagnose
stenosis/occlusion, nine of which also provided
data on adverse events. One controlled trial
provided data on the impact of the assessment
method on patient management and/or patient
outcomes. Four studies that did not meet the
inclusion criteria for the review of diagnostic
accuracy reported results relating to patient
attitudes, two of which also provided data on
adverse events. An additional 44 studies that did
not meet the inclusion criteria for the review of
diagnostic accuracy reported results relating to
adverse events. Six economic evaluations met the
inclusion criteria for the review.
Seven non-English-language papers were included
in the review: five German,51,56,58,61,90 one
French120 and one Russian.69 One German-
language paper met the inclusion criteria for the
review, but could not be translated in time to be
included.127
Where studies were only published as an abstract
and insufficient details were reported to screen
studies for inclusion or extract the relevant data,
authors were contacted to provide further
information. In total, 37 authors were contacted.
Four authors replied, providing further
information about their study. All four studies
were found to fail the inclusion criteria.
Assessment of stenosis/occlusion
A total of 25 studies provided diagnostic accuracy
results for MRA: one evaluated 2D PC MRA, ten
evaluated 2D TOF MRA (one of these studies
investigated both 2D TOF MRA and DUS), 13
evaluated CE MRA, and one evaluated both 2D
TOF and CE MRA (in addition to DUS). Seven
studies provided diagnostic accuracy results for
CTA and 28 studies provided diagnostic accuracy
results for DUS. 
Most of the studies reported results by arterial
segment. The number of arterial segments
assessed per patient and their anatomical
distribution varied between studies and were
incompletely reported. The majority of 
studies provided accuracy data for more 
than one anatomical area (e.g. above knee, 
below knee) and/or more than one stenosis
threshold. Pooling of studies was considered 
only where 2 × 2 accuracy data were reported 
in the same way (e.g. arterial segment, 
artery or limb), for the same anatomy (above 
knee, below knee or whole leg) and using the
same stenosis threshold. Thus, the number 
and, to some extent, distribution of arterial
segments could vary between studies within a
grouping considered for pooling. Each study
contributed a maximum of one data set to each
pooled group.
Differences between studies regarding quality
items, test specific details (e.g. the type of coil
used and field strength for MRA; PSVR, type of
probe, and use of colour for DUS; and the
instrument used for CTA), the use of digital
subtraction (DSA) as part of the reference
standard, sample size, Fontaine classification, date
of publication (as a surrogate for technological
advances), the inclusion/exclusion of the foot in
the scans of the whole leg or below knee, and
restriction of the population to a subgroup 
(e.g. people with diabetes mellitus) were
considered as potential explanatory factors for the
variability seen between study findings. These
issues are discussed in detail below; data were
insufficient to allow valid statistical exploration of
hypothesised sources of heterogeneity. There was
insufficient information regarding the proportion
of patients included in the studies with diabetes
mellitus, or who were smokers (or had smoked), to
consider subgroup analyses for these patient
groups.
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Chapter 6
Results of the reviewMRA
One study evaluated 2D PC MRA,66 11 evaluated
2D TOF MRA,22,27,29,32,40,41,53,55,64,69,74 and 14
evaluated CE MRA.9,28,36,46,49,51,53,61,65,67,68,70,73,76
There were no studies providing results for the
assessment of 3D TOF MRA. The full results of
the quality assessment using the QUADAS tool for
the 25 studies evaluating MRA are presented in
Table 4. Eighteen studies (72%) did not include an
appropriate patient spectrum or failed to provide
sufficient details of the patient population for this
to be judged, and 12 (48%) did not provide
adequate details of the patient selection criteria.
The tests themselves were generally well
Results of the review
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Titles and abstracts identified and 
screened n = 8590
Not relevant
n = 7940
Potentially relevant papers ordered
n = 650
Could not be obtained
n = 3
Full copies retrieved and screened for
inclusion n = 647
Total number of studies included in the 
review n = 113
Duplicate record (due to foreign-language 
translation/spelling differences between different 
sources of evidence)
n = 8
Excluded n = 526
Study included fewer than 20 patients n = 80
Results for adults could not be extracted separately n = 1
Study of patients with aneurysms only n = 3
Assessment of the complications of CA only n = 14
Discussion paper, no data n = 90
Duplicate publication of an included article n = 25
Study includes patients with aortic aneurysms n = 13
Study of intravascular ultrasound n = 6
Letter/editorial n = 8
Insufficient data to construct a 2  2 contingency 
  table n = 127
No reference standard n = 22
Reference standard was not CA n = 10
Not a study of MRA, DUS or CTA n = 11
Not a study of patients with PAD n = 48
No evidence that participants were symptomatic n = 65
Patients hospitalised for reconstruction failure/thrombosis 
  of artery reconstruction n = 1
Intravenous rather than intra-arterial angiography n = 1
Controlled trial with no patient outcomes reported n = 1
Diagnostic accuracy n = 58 
  (nine also provided data on adverse events)
Patient management n = 1
Patient attitudes n = 4 
  (two also provided data on adverse events)
Adverse events only n = 44
Economic evaluations n = 6 
FIGURE 1 Flowchart of studies through review processHealth Technology Assessment 2007; Vol. 11: No. 20
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mconducted. Twenty studies (80%) reported having
less than a 1-month interval between the index
test and reference standard; 1 month was the
maximum time interval judged appropriate to
minimise the potential impact of disease
progression on test results. All patients received
the reference standard in 21 studies (84%) and in
24 studies (96%) patients received the same
reference standard test. The decision to use the
reference test was independent of the MRA results
in all the studies. The MRA results were
interpreted without knowledge of the reference
test results (and vice versa) in 21 studies (84%).
Whether or not clinical data were available at the
time the results were interpreted was poorly
reported, with only one study reporting that
clinical data were available.
Further details of the diagnostic accuracy results
for the individual MRA techniques are presented
below by technique.
2D PC MRA
One study66 assessed the accuracy of 2D PC MRA
for grading lesions, already identified using intra-
arterial DSA, at the diagnostic thresholds of 50%
stenosis and occlusion. The study assessed grading
of stenoses in the whole leg. The sensitivity was
98% and the specificity was 74%. The positive
likelihood ratio (LR+) was 3.6 and the negative
likelihood ratio (LR–) was 0.03 (Table 5).
2D TOF MRA
The 11 studies evaluating 2D TOF
MRA22,27,29,32,40,41,53,55,64,69,74 provided a total of 22
data sets. The results are reported by the anatomy
assessed and the full set of diagnostic accuracy
results is presented in Table 5.
Whole leg
Results for the detection of a stenosis of at least
50% or occlusion were reported by five
studies.22,40,41,64,74 The sensitivity of 2D TOF MRA
ranged from 79% (specificity 89%) to 94%
(specificity 92%). The specificity ranged from 74%
(sensitivity 92%) to 92% (sensitivity 94%). There
was evidence of significant statistical heterogeneity
between the study results (p < 0.001) for all the
diagnostic accuracy measures, hence no pooling
was undertaken. The sensitivities and specificities
have been plotted in ROC space (Figure 2). The
median LR+ was 7.1, with a range from 3.5 (LR–
of 0.12) to 11.7 (LR– of 0.07). The median LR–
was 0.12, with a range from 0.07 (LR+ of 11.7) to
0.24 (LR+ of 7.1).
The study in this group that reported the highest
sensitivity (94%), specificity (92%) and LR+ (11.7)
and the lowest LR– (0.07)40 was one of only two
that reported Fontaine classification; 62% of the
patients had stage IV PAD. More severe pathology
in the diseased patients included in a study
implies that they are more different from the
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T
ABLE 5
Results of studies assessing 2D PC, or 2D TOF MRA
, reported by area of leg assessed
Study
Stenosis
R
esults 
TP
FP
FN
TN
Sensitivity (%) 
Specificity (%) 
LR+ (95% CI)
LR– (95% CI)
DOR
threshold
reported by
(95% CI)
(95% CI)
2D PC MRA
: whole leg
Steffens 1997
66
50–100%
Area of stenosis/
229
5
5
14
97.9 (95.1, 99.1)
73.7 (51.2, 88.2)
3.6 (1.7,7.2)
0.03 (0.01, 0.08)
110.0
occlusion
2D TOF MRA
: whole leg, 


50% stenosis 
Baum, 1995
22
50–100%
Segment
527
101
100
460
84.1 (81.0, 86.7)
82.0 (78.6, 85.0)
4.7 (3.9, 5.6)
0.20 (0.16, 0.23)
23.8
Hoch, 1999
41
50–100%
Segment
161
37
44
302
78.5 (72.4, 83.6)
89.1 (85.3, 92.0)
7.1 (5.2, 9.7)
0.24 (0.19, 0.32)
29.3
Hoch, 1996
40
50–100%
Segment
172
13
12
155
93.5 (88.9, 96.2)
92.3 (87.2, 95.4)
11.7 (7.0, 19.5)
0.07 (0.04, 0.13)
159.0
Snidow
, 1995
64
50–100%
Segment
80
76
7
215
92.0 (84.3, 96.0)
73.9 (68.5, 78.6)
3.5 (2.9, 4.3)
0.12 (0.06, 0.23)
30.2
Y
ucel, 1993
74
50–100%
Segment
65
16
6
119
91.5 (82.8, 96.1)
88.1 (81.6, 92.6)
7.5 (4.7, 11.9)
0.10 (0.05, 0.21)
73.0
2D TOF MRA
: whole leg, 


70% stenosis
Y
ucel, 1993
74
70–100%
Segment
53
5
6
142
89.8 (79.5, 95.3)
96.6 (92.3, 98.5)
24.0 (10.5, 54.7)
0.11 (0.05, 0.23)
213.3
2D TOF MRA
: whole leg, occlusion
Baum, 1995
22
100%
Segment
322
118
76
672
80.9 (76.8, 84.5)
85.1 (82.4, 87.4)
5.4 (4.5, 6.4)
0.23 (0.18, 0.28)
23.9
Hoch, 1999
41
100%
Segment
103
17
31
393
76.9 (69.0 ,83.2)
95.9 (93.5, 97.4)
18.0 (11.3, 28.7)
0.24 (0.18, 0.33)
73.9
Hoch, 1996
40
100%
Segment
101
4
1
1
236
90.2 (83.3, 94.4)
98.3 (95.8, 99.4)
48.1 (19.2, 120.4)
0.10 (0.06, 0.18)
463.9
Y
ucel, 1993
74
100%
Segment
40
4
0
162
100
(91.2, 100)
97.6 (94.0, 99.1)
36.7 (14.7, 91.3)
0.01 (0.00, 0.20)
2925.0
2D TOF MRA
: above knee
Lundin, 2000
53
50–100%
Segment
35
20
8
197
81.4 (67.4, 90.3)
90.8 (86.2, 94.0)
8.6 (5.5, 13.3)
0.21 (0.12, 0.39)
40.2
100%
Segment
13
7
2
238
86.7 (62.1, 96.3)
97.1 (94.2, 98.6)
27.7 (13.3, 57.7)
0.16 (0.05, 0.50)
171.7
Currie, 1995
29
50–99%
Segment
25
7
1
0
3
8
71.4 (54.9, 83.7)
84.4 (71.2, 92.3)
4.3 (2.2, 8.6)
0.35 (0.21, 0.59)
12.5
Timonina, 1999
69
100%
Artery
36
0
1
163
97.3 (86.2, 99.5)
100
(97.7, 100)
315.1 (19.8, 5020)
0.04 (0.01, 0.19)
7957.0
2D TOF MRA
: below knee
Cortell, 1996
27
50–100%
Segment
172
10
3
208
98.3 (95.1, 99.4)
95.4 (91.8, 97.5)
20.4 (11.3, 36.9)
0.02 (0.01, 0.06)
978.7
75–100%
Segment
155
10
3
225
98.1 (94.6, 99.4)
95.7 (92.3, 97.7)
22.0 (12.2, 39.7)
0.02 (0.01, 0.06)
954.2
100%
Segment
125
7
3
258
97.7 (93.3, 99.2)
97.4 (94.6, 98.7)
34.5 (17.0, 69.9)
0.03 (0.01, 0.08)
1235.9
McDermott, 1995
55
100%
Segment
95
1
2
1
9
9
81.9 (73.9, 87.8)
99.0 (94.6, 99.8)
55.0 (11.2, 269.7)
0.19 (0.13, 0.27)
294.6
Diseased or 
Segment
124
7
1
5
7
0
89.2 (83.0, 93.4)
90.9 (82.4,95.5)
9.2 (4.7,18.3)
0.12 (0.08, 0.20)
75.5
occluded
Eklof
, 1998
32
50–100%
Artery
59
2
1
4
3
1
80.8 (70.3,88.2)
93.9 (80.4, 98.3)
10.9 (3.3, 36.3)
0.21 (0.13, 0.34)
51.7
100%
Artery
40
10
7
4
9
85.1 (72.3,92.6)
83.1 (71.5, 90.5)
4.8 (2.7, 8.5)
0.19 (0.10, 0.37)
25.5
2D TOF MRA
: foot
Eklof
, 1998
32
100%
Artery
19
8
3
3
86.4 (66.7,95.3)
27.3 (9.7, 56.6)
1.2 (0.8, 1.8)
0.52 (0.14, 1.93)
2.3
0.5 was added to all values for the calculation of LR+, LR– and DOR.
FN, false negative; FP
, false positive; TN, true negative; TP
, true positive.‘normal’ than would be a less severely diseased
population, and hence more easily distinguished.
This can give rise to an apparent increase in the
performance of diagnostic tests. However, the
other study reporting Fontaine classification had
only 16% stage IV patients, and this reported
similar diagnostic performance: sensitivity of 92%,
specificity of 88%, LR+ of 7.5 and LR– of 0.10.74
One study74 provided results for the detection of a
stenosis of 70% or greater; the sensitivity was 90%
and the specificity was 97% (Table 5).
Results for the detection of an occlusion were
reported by four studies.22,40,41,74 The sensitivity
ranged from 77% (specificity 96%) to 100%
(specificity 98%). The specificity ranged from 85%
(sensitivity 81%) to 98% (for two studies with
sensitivities of 90% and 100%). Again, there was
evidence of significant statistical heterogeneity
between the study results (p = 0.004 for LR–,
p < 0.001 for all other measures). The sensitivities
and specificities have been plotted in ROC space
(Figure 3). The median LR+ was 27.4, with a
range from 5.4 (LR– of 0.23) to 48.1 (LR– of 0.1).
The median LR– was 0.17, with a range from 0.01
(LR+ of 36.7) to 0.24 (LR+ of 18).
Above the knee
Three studies provided results for assessment
above the knee, but these did not use similar
thresholds and did not report the results in the
same way (e.g. arterial segment, artery or
limb).29,53,69 Further details are presented in 
Table 5.
Below the knee
Three studies provided results for assessment
below the knee or of the foot;27,32,55 further details
are presented in Table 5. Only one study32
reported separate results for arteries in the foot;
for detecting an occlusion the sensitivity was 86%
and the specificity was 27%.
CE MRA
Fourteen studies evaluated CE MRA and provided
a total of 34 data sets.9,28,36,46,49,51,53,61,65,67,68,70,73,76
The results are reported by the anatomy assessed
and the full set of diagnostic accuracy results is
presented in Table 6.
Whole leg
Results for the detection of a stenosis of 50% or
greater were reported by seven
studies.28,49,51,61,67,68,73 The sensitivity of CE MRA
ranged from 92% (for two studies with specificities
of 64% and 97%) to 99.5% (specificity 99%). The
specificity ranged from 64% (sensitivity 92%) to
99% (for two studies with sensitivities of 97% and
99.5%). There was evidence of significant
statistical heterogeneity between the study results
(p = 0.002 for sensitivity, p < 0.001 for all other
Results of the review
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T
ABLE 6
Results of studies assessing CE MRA
, reported by area of leg assessed
Study
Stenosis
R
esults 
TP
FP
FN
TN
Sensitivity (%) 
Specificity (%) 
LR+ (95% CI)
LR– (95% CI)
DOR
threshold
reported by
(95% CI)
(95% CI)
Whole leg, 


50% stenosis
Cronberg, 2003
28
50–100%
Segment
227
62
20
109
91.9 (87.8, 94.7)
63.7 (56.3, 70.6)
2.5 (2.1, 3.1)
0.13 (0.08, 0.20)
19.4
Laissy
, 1998
49
50–100%
Segment
104
14
9
393
92.0 (85.6, 95.8)
96.6 (94.3, 97.9)
25.8 (15.5, 42.9)
0.09 (0.05, 0.16)
298.5
Lenhart, 2000
51
50–100%
Segment
79
8
4
129
95.2 (88.3, 98.1)
94.2 (88.9, 97.0)
15.4 (8.0, 29.5)
0.06 (0.02, 0.14)
269.2
Schafer
, 2003
61
51–100%
Segment
138
13
9
416
93.9 (88.8, 96.7)
97.0 (94.9, 98.2)
29.8 (17.6, 50.5)
0.07 (0.04, 0.12)
449.8
Steffens, 2003
67
51–100%
Segment
185
8
1
706
99.5 (97.0, 99.9)
98.9 (97.8, 99.4)
83.4 (42.8, 162.8)
0.01 (0.00, 0.04)
10278.9
Sueyoshi, 1999
68
50–100%
Segment
67
3
2
351
97.1 (90.0, 99.2)
99.2 (97.5, 99.7)
97.8 (34.5, 277.7)
0.04 (0.01, 0.12)
2711.6
Winterer
, 1999
73
51–100%
Segment
362
43
14
1361
96.3 (93.8, 97.8)
96.9 (95.9, 97.7)
31.1 (23.2, 41.6)
0.04 (0.02, 0.07)
782.5
Whole leg, 


70% stenosis
Schafer
, 2003
61
76–100%
Segment
110
3
4
459
96.5 (91.3, 98.6)
99.4 (98.1, 99.8)
127.1 (44.7, 361.2)
0.04 (0.02, 0.10)
3223.8
Steffens, 2003
67
76–100%
Segment
147
11
4
738
97.4 (93.4, 99.0)
98.5 (97.4, 99.2)
63.3 (35.6, 112.4)
0.03 (0.01, 0.07)
2104.9
Sueyoshi, 1999
68
75–100%
Segment
53
4
0
366
100 (93.2, 100)
98.9 (97.3, 99.6)
81.7 (32.6, 204.7)
0.01 (0.00, 0.15)
8714.6
V
avrik, 2004
70
70–100%
Segment
170
26
17
661
90.9 (85.9, 94.2)
96.2 (94.5, 97.4)
23.5 (16.2, 34.3)
0.10 (0.06, 0.15)
243.2
Whole leg, occlusion
Lenhart, 2000
51
100%
Segment
54
2
4
160
93.1 (83.6, 97.3)
98.8 (95.6, 99.7)
60.2 (17.6, 206.5)
0.08 (0.03, 0.19)
777.5
Meaney
, 1999
9
100%
Segment
83
16
15
516
84.7 (76.3, 90.5)
97.0 (95.2, 98.1)
27.2 (16.8, 44.1)
0.16 (0.10, 0.26)
168.6
Schafer
, 2003
61
100%
Segment
72
1
5
498
93.5 (85.7, 97.2)
99.8 (98.9, 100)
309.8 (62.6, 1533)
0.07 (0.03, 0.16)
4380.8
Steffens, 2003
67
100%
Segment
85
7
4
804
95.5 (89.0, 98.2)
99.1 (98.2, 99.6)
102.9 (50.4, 210.0)
0.05 (0.02, 0.12)
2038.1
Sueyoshi, 1999
68
100%
Segment
39
1
0
383
100 (91.0, 100)
99.7 (98.5, 100)
253.5 (51.3, 1252)
0.01 (0.00, 0.20)
20197.7
Winterer
, 1999
73
100%
Segment
255
11
13
1502
95.1 (91.9, 97.1)
99.3 (98.7, 99.6)
125.0 (70.3, 222.5)
0.05 (0.03, 0.09)
2472.7
Above knee, 


50% stenosis
Lenhart, 2000
51
50–100%
Segment
24
6
2
83
92.3 (75.9, 97.9)
93.3 (86.1, 96.9)
12.6 (5.9, 26.6)
0.10 (0.03, 0.33)
125.9
Lundin, 2000
53
50–100%
Segment
35
18
8
204
81.4 (67.4, 90.3)
91.9 (87.5, 94.8)
9.7 (6.1, 15.4)
0.21 (0.12, 0.39)
46.2
Hany
, 1997
36
50–100%
Artery
62
7
2
163
96.9 (89.3, 99.1)
95.9 (91.7, 98.0)
21.9 (10.9, 44.2)
0.04 (0.01, 0.14)
545.0
Snidow
, 1996
65
50–100%
Artery
26
6
0
96
100 (87.1, 100)
94.1 (87.8, 97.3)
15.6 (7.4, 32.8)
0.02 (0.00, 0.31)
786.8
Above knee,


70% stenosis
V
avrik, 2004
70
70–100%
Segment
86
13
9
468
90.5 (83.0, 94.9)
97.3 (95.4, 98.4)
32.2 (18.9, 54.7)
0.10 (0.06, 0.19)
316.0
Above knee, occlusion
Lenhart, 2000
51
100%
Segment
14
0
2
99
87.5 (64.0, 96.5)
100 (96.3, 100)
170.6 (10.7, 2728)
0.15 (0.05, 0.46)
1154.2
Lundin, 2000
53
100%
Segment
13
0
2
250
86.7 (62.1, 96.3)
100 (98.5, 100)
423.6 (26.4, 6808)
0.16 (0.05, 0.49)
2705.4
Hany
, 1997
36
100%
Artery
19
1
0
214
100 (83.2, 100)
99.5 (97.4, 99.9)
140.4 (28.5, 692.8)
0.03 (0.00, 0.39)
5577.0
Snidow
, 1996
65
100%
Artery
18
0
0
110
100 (82.4, 100)
100 (96.6, 100)
216.2 (13.6, 3438)
0.03 (0.00, 0.41)
8177.0
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ABLE 6
Results of studies assessing CE MRA
, reported by area of leg assessed (cont’d)
Study
Stenosis
R
esults 
TP
FP
FN
TN
Sensitivity (%) 
Specificity (%) 
LR+ (95% CI)
LR– (95% CI)
DOR
threshold
reported by
(95% CI)
(95% CI)
Below knee,


50% stenosis
Kreitner
, 2000
46
50–100%
Segment
27
3
1
1
3
3
71.1 (55.2, 83.0)
91.7 (78.2, 97.1)
7.5 (2.7, 20.6)
0.33 (0.20, 0.54)
22.9
Lenhart, 2000
51
50–100%
Segment
55
2
2
46
96.5 (88.1, 99.0)
95.8 (86.0, 98.8)
18.8 (5.6, 62.8)
0.05 (0.01, 0.15)
412.9
Zhang, 2005
76
51–100%
Segment
252
31
52
207
82.9 (78.3, 86.7)
87.0 (82.1, 90.7)
6.3 (4.5, 8.7)
0.20 (0.15, 0.25)
31.7
Below knee,


70% stenosis
V
avrik, 2004
70
70–100%
Segment
84
13
8
193
91.3 (83.8, 95.5)
93.7 (89.5, 96.3)
13.9 (8.3, 23.4)
0.10 (0.05, 0.19)
142.5
Below knee, occlusion
Lenhart, 2000
51
100%
Segment
40
2
2
61
95.2 (84.2, 98.7)
96.8 (89.1, 99.1)
24.1 (7.1, 81.5)
0.06 (0.02, 0.20)
398.5
Zhang, 2005
76
100%
Segment
200
22
32
288
86.2 (81.2, 90.1)
92.9 (89.5, 95.3)
11.9 (8.0, 17.8)
0.15 (0.11, 0.21)
79.1
Foot
Zhang, 2005
76
51–100%
Segment
59
20
16
48
78.7 (68.1, 86.4)
70.6 (58.9, 80.1)
2.6 (1.8, 3.9)
0.31 (0.20, 0.49)
8.5
100%
Segment
50
11
13
69
79.4 (67.8, 87.5)
86.3 (77.0, 92.1)
5.6 (3.2, 9.6)
0.25 (0.15, 0.40)
22.6
0.5 was added to all values for the calculation of LR+, LR– and DOR.measures), hence no pooling was undertaken. One
study had a low specificity in comparison with the
others;28 however, there was still statistically
significant heterogeneity when the analysis was
repeated without this study. The sensitivities and
specificities have been plotted in ROC space
(Figure 4). The median LR+ was 29.8, with a
range from 2.5 (LR– of 0.13) to 97.8 (LR– of
0.04). The median LR– was 0.06, with a range
from 0.01 (LR+ of 83.4) to 0.13 (LR+ of 2.5).
The study that had a low specificity in comparison
with the others28 was the only study to include the
foot in the scan. The diagnostic accuracy of MRA
is thought to be lower in the foot than in other
areas of the leg and this may have been a factor in
this difference.
Results for the detection of a stenosis of 70% or
greater were reported by four studies.61,67,68,70 The
sensitivity of CE MRA ranged from 91%
(specificity 96%) to 100% (specificity 99%). The
specificity ranged from 96% (sensitivity 91%) to
99% (for three studies with sensitivities of 97%,
97% and 100%). There was evidence of significant
statistical heterogeneity between the study results
(p = 0.004 for sensitivity, p = 0.012 for LR–,
p < 0.001 for all other measures), hence no
pooling was undertaken. The sensitivities and
specificities have been plotted in ROC space
(Figure 5). The median LR+ was 72.5, with a
range from 23.5 (LR– of 0.1) to 127.1 (LR– of
0.04). The median LR– was 0.04, with a range
from 0.01 (LR+ of 81.7) to 0.1 (LR+ of 23.5).
Results for the detection of an occlusion were
reported by six studies.9,51,61,67,68,73 The sensitivity
of CE MRA ranged from 85% (specificity 97%) to
100% (specificity 99.7%). The specificity ranged
from 97% (sensitivity 85%) to 99.8% (sensitivity
94%). There was evidence of significant statistical
heterogeneity between the study results (p = 0.006
for sensitivity, p = 0.005 for LR–, p < 0.001 for all
other measures), hence no pooling was
undertaken. The sensitivities and specificities have
been plotted in ROC space (Figure 6). The median
LR+ was 114, with a range from 27.2 (LR– of
0.16) to 309.8 (LR– of 0.07). The median LR– was
0.06, with a range from 0.01 (LR+ of 253.5) to
0.16 (LR+ of 27.2).
Above the knee
Five studies provided results for assessment above
the knee, but not all reported results on an
arterial segment basis.36,51,53,65,70 Further details
are presented in Table 6.
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FIGURE 4 ROC plot for CE MRA: whole leg, 50% stenosisResults of the review
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FIGURE 5 ROC plot for CE MRA: whole leg, 70% stenosis
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FIGURE 6 ROC plot for CE MRA: whole leg, occlusion Below the knee
Four studies provided results for assessment below
the knee or of the foot.46,51,70,76 Further details are
presented in Table 6.
Three studies provided results for assessment of
stenosis of 50% or greater below the knee using
CE MRA. One study in this group was restricted to
patients with diabetes mellitus.46 This study had
the lowest sensitivity (71%).
One study76 assessed the ability of CE MRA to
detect stenoses in the foot. For the detection of a
stenosis greater than 50%, the sensitivity was 79%
and the specificity was 71%; and for the detection
of an occlusion, the sensitivity was 79% and the
specificity was 86%.
CTA
The full results of the quality assessment using 
the QUADAS tool, for the seven studies 
evaluating CTA, are presented in Table 7. 
Five studies (71%) did not include an appropriate
patient spectrum, or failed to provide sufficient
details of the patient population for this to be
judged, and two (29%) did not provide adequate
details of the patient selection criteria. The tests
themselves were generally well conducted. Five
studies (71%) reported having less than a 
1-month interval between the index test and
reference standard and all patients received the
reference standard in all seven studies. All studies
reported that the decision to use the reference 
test was independent of the CTA results. 
The CTA results were interpreted without
knowledge of the reference test results (and vice
versa) in five studies (71%). Whether or not
clinical data were available at the time the results
were interpreted was again poorly reported, with
no studies reporting that clinical data were
available.
The seven studies evaluating CTA provided a total
of 22 data sets.26,38,54,57–60 The full set of
diagnostic accuracy results is presented in Table 8.
All the studies presented the results on an arterial
segment basis.
Whole leg
Results for the detection of a stenosis of 50% or
greater were reported by six studies.26,38,54,57–59
The sensitivity of CTA ranged from 89% (for two
studies with specificities of 86% and 91%) to 99%
(specificity 97%). The specificity ranged from 83%
(sensitivity 92%) to 97% (sensitivity 99%). There
was evidence of significant statistical heterogeneity
between the study results (p < 0.001), hence no
pooling was undertaken. The sensitivities and
specificities have been plotted in ROC space
(Figure 7). The median LR+ was 12, with a range
from 5.5 (LR– of 0.1) to 37.1 (LR– of 0.01). The
median LR– was 0.11, with a range from 0.01
(LR+ of 37.1) to 0.14 (LR+ of 6.3).
The study in this group that reported the highest
sensitivity (99%), specificity (97%) and LR+ (37.1)
and the lowest LR– (0.01)26 was one of two studies
that scored 12 out of 13 on the quality assessment,
and reported recruiting an appropriate patient
spectrum. The other high-quality study reported
the next highest sensitivity (97%).59
Results for the detection of a stenosis of 70% or
greater were reported by three studies.38,54,59
There was no evidence of statistical heterogeneity
between the study results (p > 0.1 for all accuracy
measures). The pooled sensitivity was 89% 
(95% CI 86 to 92%), the pooled specificity 
was 98% (95% CI 97 to 99%), the pooled LR+ 
was 44 (95% CI 31.5 to 61.3) and the pooled LR–
was 0.12 (95% CI 0.09 to 0.16). The sensitivities
and specificities have been plotted with the 
sROC curve (Figure 8). The area under the curve
(AUC) was 0.987 and the Q* index (the point at
which sensitivity and specificity are equal) was
0.951. 
Results for the detection of an occlusion were
reported by five studies.26,38,54,58,59 There was no
evidence of statistical heterogeneity between the
study results for specificity, LR+ and LR–
(p > 0.09), although there was for sensitivity
(p = 0.001). The sensitivity ranged from 89%
(specificity 99.8%) to 100% (specificity 100%). The
pooled specificity was 99.5% (95% CI 99.2 to
99.7%), the pooled LR+ was 160.2 (95% CI 76.7
to 334.3), and the pooled LR– was 0.06 (95% CI
0.03 to 0.13). The sensitivities and specificities
have been plotted in ROC space (Figure 9). There
were no obvious differences between the studies to
explain the heterogeneity seen. 
Above the knee
Two studies reported results for above the
knee.57,60 The study by Rieker60 gave results for
maximum intensity projections and cine axial
images separately. Further details are provided in
Table 8.
Below the knee
Only one study provided data evaluating the
accuracy of CTA below the knee.57 This found a
sensitivity of 90% and a specificity of 74% for
detecting a stenosis of 50% or greater (Table 8).
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T
ABLE 8
Results of studies assessing CT
A
, reported by area of leg assessed
Study
Stenosis
R
esults 
TP
FP
FN
TN
Sensitivity (%) 
Specificity (%) 
LR+ (95% CI)
LR– (95% CI)
DOR
threshold
reported by
(95% CI)
(95% CI)
Whole leg, 


50% stenosis
Heuschmid, 2003
38
51–100%
Segment
133
40
16
379
89.3 (83.3, 93.3)
90.5 (87.3, 92.9)
9.2 (6.9, 12.4)
0.12 (0.08, 0.19)
75.8
Martin, 2003
54
50–100%
Segment
327
61
38
886
89.6 (86.0, 92.3)
93.6 (91.8, 95.0)
13.8 (10.8, 17.6)
0.11 (0.08, 0.15)
122.6
Puls, 2002
58
51–100%
Segment
56
17
7
106
88.9 (78.8, 94.5)
86.2 (79.0, 91.2)
6.3 (4.0, 9.7)
0.14 (0.07, 0.27)
45.8
Rieker
, 1996
59
50–100%
Segment
111
20
3
193
97.4 (92.5, 99.1)
90.6 (85.9, 93.8)
10.1 (6.7, 15.3)
0.03 (0.01, 0.09)
300.7
Catalano, 2004
26
51–100%
Segment
251
23
3
860
98.8 (96.6, 99.6)
97.4 (96.1, 98.3)
37.1 (24.9, 55.3)
0.01 (0.00, 0.04)
2631.2
P
ortugaller
, 2004
57
50–100%
Segment
240
80
21
399
92.0 (88.0, 94.7)
83.3 (79.7, 86.4)
5.5 (4.5, 6.7)
0.10 (0.07, 0.15)
55.5
Whole leg, 


70% stenosis
Heuschmid, 2003
38
76–100%
Segment
88
7
1
2
461
88.0 (80.2, 93.0)
98.5 (96.9, 99.3)
54.8 (26.8, 111.9)
0.13 (0.07, 0.21)
435.7
Martin, 2003
54
75–100%
Segment
236
20
34
1022
87.4 (82.9, 90.8)
98.1 (97.1, 98.8)
44.4 (28.9, 68.3)
0.13 (0.10, 0.18)
341.9
Rieker
, 1996
59
75–100%
Segment
91
6
6
224
93.8 (87.2, 97.1)
97.4 (94.4, 98.8)
33.2 (15.5, 70.9)
0.07 (0.03, 0.14)
486.2
Whole leg, occlusion
Heuschmid, 2003
38
100%
Segment
49
6
5
508
90.7 (80.1, 96.0)
98.8 (97.5, 99.5)
71.3 (33.1, 153.8)
0.10 (0.05, 0.22)
704.1
Martin, 2003
54
100%
Segment
202
2
2
6
1082
88.6 (83.8, 92.1)
99.8 (99.3, 99.9)
383.8 (111.2, 1325)
0.12 (0.08, 0.17)
3308.8
Puls, 2002
58
100%
Segment
13
0
0
173
100
(77.2, 100)
100
(97.8, 100)
335.6 (21.0, 5354)
0.04 (0.00, 0.54)
9369.0
Rieker
, 1996
59
100%
Segment
61
1
1
264
98.4 (91.4, 99.7)
99.6 (97.9, 99.9)
173.1 (35.1, 854.2)
0.02 (0.00, 0.12)
7229.7
Catalano, 2004
26
100%
Segment
170
5
5
957
97.1 (93.5, 98.8)
99.5 (98.8, 99.8)
169.6 (73.7, 390.5)
0.03 (0.01, 0.07)
5396.8
Above knee, 


50% stenosis 
Rieker
, 1997
60
50–100%
Segment (1)
49
2
3
101
94.2 (84.4, 98.0)
98.1 (93.2, 99.5)
38.9 (11.4, 132.5)
0.07 (0.02, 0.19)
574.2
Rieker
, 1997
60
50–100%
Segment (2)
63
4
2
114
96.9 (89.5, 99.2)
96.6 (91.6, 98.7)
25.4 (10.3, 63.1)
0.04 (0.01, 0.13)
646.3
P
ortugaller
, 2004
57
50–100%
Segment
86
23
3
238
96.6 (90.6, 98.8)
91.2 (87.1, 94.1)
10.7 (7.3, 15.8)
0.04 (0.02, 0.12)
250.8
Above knee, 


70% stenosis
Rieker
, 1997
60
75–100%
Segment (1)
28
0
0
127
100
(87.9, 100)
100
(97.1, 100)
251.6 (15.8, 4002)
0.02 (0.00, 0.27)
14535.0
Rieker
, 1997
60
75–100%
Segment (2)
30
0
0
153
100
(88.6, 100)
100
(97.6, 100)
303.0 (19.0, 4825)
0.02 (0.00, 0.25)
18727.0
Above knee, occlusion
Rieker
, 1997
60
100%
Segment (1)
39
0
2
114
95.1 (83.9, 98.7)
100
(96.7, 100)
216.3 (13.6, 3441)
0.06 (0.02, 0.20)
3618.2
Rieker
, 1997
60
100%
Segment (2)
48
1
2
132
96.0 (86.5, 98.9)
99.2 (95.9, 99.9)
85.0 (17.3, 417.7)
0.05 (0.01, 0.17)
1713.7
Below knee, 


50% stenosis
P
ortugaller
, 2004
57
50–100%
Segment
154
57
18
161
89.5 (84.1, 93.3)
73.9 (67.6, 79.2)
3.4 (2.7, 4.3)
0.15 (0.09, 0.22)
23.5
0.5 was added to all values for the calculation of LR+, LR– and DOR.
The study by Rieker
60
reported separate results for different CT
A images: (1) maximum intensity projections and (2) cine axial images.Results of the review
30
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 0.2 0.4 0.6 0.8 1.0
1 – Specificity
Sensitivity
ROC plane
FIGURE 7 ROC plot for CTA: whole leg, 50% stenosis
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 0.2 0.4 0.6 0.8 1.0
1 – Specificity
Sensitivity
SROC curve
Symmetric sROC
AUC = 0.9869
SE (AUC) = 0.0024
Q* = 0.9513
SE (Q*) = 0.0052
FIGURE 8 ROC plot for CTA: whole leg, 70% stenosisDUS
The full results of the quality assessment using the
QUADAS tool for the 28 studies evaluating DUS
are presented in Table 9. Twenty studies (71%) did
not include an appropriate patient spectrum or
failed to provide sufficient details of the patient
population for this to be judged. Sixteen studies
(57%) did not provide sufficient details of the
patient selection criteria. Only 18 studies (64%)
reported having less than a 1-month interval
between the index test and reference standard. In
all 28 studies, all patients received the same
reference standard test and the decision to use the
reference test was independent of the DUS results
in 27 (96%) of these. The DUS results were
interpreted without knowledge of the reference
test results in 20 studies (71%) and the reference
test results were interpreted without knowledge of
the DUS results in 23 studies (82%). Whether or
not clinical data were available at the time the
results were interpreted was again poorly reported,
with only one study reporting that clinical data
were available.
The 28 studies evaluating DUS provided a total of
56 data sets.20,21,23–25,29–31,33–35,37,39,42–45,47,48,50,52,53,
56,62,63,71,72,75 The full set of diagnostic accuracy
results is presented in Table 10. Seven studies
presented results by limb21,23,30,31,47,56,63 and 
one presented results by artery;35 the rest were
presented on an arterial segment basis. 
Whole leg
Results for the detection of a stenosis of 50% or
greater, with results reported by arterial segment,
were reported by seven studies.20,24,33,37,50,52,62 The
sensitivity of DUS ranged from 80% (specificity
96%) to 98% (specificity 94%). The specificity
ranged from 89% (sensitivity 88%) to 99%
(sensitivity 92%). There was evidence of significant
statistical heterogeneity between the study results
(p < 0.001 for all measures), hence no pooling was
undertaken. The sensitivities and specificities have
been plotted in ROC space (Figure 10). The
median LR+ was 19.3, with a range from 7.6 (LR–
of 0.13) to 89.5 (LR– of 0.08). The median LR–
was 0.13, with a range from 0.03 (LR+ of 14.6) to
0.22 (LR+ of 16.9). A study with a particularly low
sensitivity (79.7%) was the only study in this group
with an unacceptable delay between conducting
the index test and reference standard.24
Results for the detection of an occlusion, on an
arterial segment basis, were reported by seven
Health Technology Assessment 2007; Vol. 11: No. 20
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T
ABLE 10
Results of studies assessing DUS, reported by area of leg assessed
Study
Stenosis
R
esults 
TP
FP
FN
TN
Sensitivity (%) 
Specificity (%) 
LR+ (95% CI)
LR– (95% CI)
DOR
threshold
reported by
(95% CI)
(95% CI)
Whole leg, 


50% stenosis 
Aly
, 1998
20
50–100%
Segment
404
27
34
2643
92.2 (89.3, 94.4)
99.0 (98.5, 99.3)
89.5 (61.6, 129.9)
0.08 (0.06, 0.11)
1127.1
Bergamini, 1995
24
50–100%
Segment
94
13
24
273
79.7 (71.5, 85.9)
95.5 (92.4, 97.3)
16.9 (9.9, 28.6)
0.22 (0.15, 0.31)
78.1
Hatsukami, 1992
37
50–100%
Segment
73
6
1
2
152
85.9 (76.9, 91.7)
96.2 (92.0, 98.2)
20.9 (9.8, 44.6)
0.15 (0.09, 0.25)
138.0
Linke, 1994
52
50–100%
Segment
41
4
2
87
95.3 (84.5, 98.7)
95.6 (89.2, 98.3)
19.3 (7.8, 47.6)
0.06 (0.02, 0.20)
322.8
Sensier
, 1996
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50–100%
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214
26
28
201
88.4 (83.8, 91.9)
88.5 (83.7, 92.1)
7.6 (5.3, 10.9)
0.13 (0.09, 0.19)
57.2
El-K
ayali, 2004
33
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3
216
97.6 (93.2, 99.2)
93.5 (89.6, 96.0)
14.6 (9.0, 23.6)
0.03 (0.01, 0.08)
492.9
Legemate, 1991
50
50–100%
Segment
179
30
33
676
84.4 (78.9, 88.7)
95.8 (94.0, 97.0)
19.5 (13.7, 27.8)
0.16 (0.12, 0.22)
118.8
Ashleigh, 1993
21
50–100%
Limb
69
2
0
5
100
(94.7, 100)
71.4 (35.9, 91.8)
3.2 (1.1, 8.9)
0.01 (0.00, 0.17)
305.8
Baxter
, 1993
23
50–100%
Limb
32
1
3
4
91.4 (77.6, 97.0)
80.0 (37.6, 96.4)
3.6 (0.9, 14.5)
0.13 (0.04, 0.39)
27.9
Whole leg, occlusion
Aly
, 1998
20
100%
Segment
272
18
25
2793
91.6 (87.9, 94.2)
99.4 (99.0, 99.6)
139.0 (88.1, 219.2)
0.09 (0.06, 0.12)
1613.6
Bergamini, 1995
24
100%
Segment
76
10
13
305
85.4 (76.6, 91.3)
96.8 (94.3, 98.3)
25.6 (14.0, 46.7)
0.16 (0.09, 0.25)
164.9
Hatsukami, 1992
37
100%
Segment
51
3
6
173
89.5 (78.9, 95.1)
98.3 (95.1, 99.4)
44.9 (15.9, 127.2)
0.11 (0.06, 0.24)
392.8
Linke, 1994
52
100%
Segment
14
0
5
115
73.7 (51.2, 88.2)
100
(96.8, 100)
168.2 (10.4, 2709)
0.28 (0.14, 0.56)
609.0
Sensier
, 1996
62
100%
Segment
166
11
21
271
88.8 (83.4, 92.5)
96.1 (93.2, 97.8)
21.8 (12.3, 38.5)
0.12 (0.08, 0.18)
182.8
Zeuchner
, 1994
75
100%
Segment
50
3
3
266
94.3 (84.6, 98.1)
98.9 (96.8, 99.6)
72.1 (25.4, 204.8)
0.07 (0.02, 0.18)
1098.6
Legemate, 1991
50
100%
Segment
103
6
9
800
92.0 (85.4, 95.7)
99.3 (98.4, 99.7)
113.7 (52.8, 245.0)
0.08 (0.05, 0.16)
1341.7
Ashleigh, 1993
21
100%
Limb
36
7
6
27
85.7 (72.2, 93.3)
79.4 (63.2, 89.7)
4.0 (2.1, 7.6)
0.19 (0.09, 0.40)
20.6
Whole leg, other stenosis thresholds
Zeuchner
, 1994
75
50–99%
Segment
12
1
4
305
75.0 (50.5, 89.8)
99.7 (98.2, 99.9)
150.5 (29.7, 761.7)
0.27 (0.12, 0.59)
565.7
Ashleigh, 1993
21
Suitability for 
Limb
25
7
4
42
86.2 (69.4, 94.5)
85.7 (73.3, 92.9)
5.7 (2.9, 11.1)
0.18 (0.07, 0.42)
32.1
angioplasty
Lai, 1995
47
Selection for 
Limb
14
9
9
54
60.9 (40.8, 77.8)
85.7 (75.0, 92.3)
4.1 (2.1, 8.0)
0.46 (0.28, 0.77)
8.8
angioplasty
Above knee, 


50% stenosis
Bergamini, 1995
24
50–100%
Segment
83
12
8
194
91.2 (83.6, 95.5)
94.2 (90.1, 96.6)
15.0 (8.7, 25.8)
0.10 (0.05, 0.19)
152.9
Fletcher
, 1990
34
50–100%
Segment
59
12
8
8
9
88.1 (78.2, 93.8)
88.1 (80.4, 93.1)
7.1 (4.2, 12.1)
0.14 (0.08, 0.27)
50.1
Hatsukami, 1992
37
50–100%
Segment
34
2
6
73
85.0 (70.9, 92.9)
97.3 (90.8, 99.3)
25.6 (7.5, 87.2)
0.16 (0.08, 0.33)
156.0
Lai, 1996
48
50–100%
Segment
124
12
42
354
74.7 (67.6, 80.7)
96.7 (94.4, 98.1)
21.9 (12.6, 38.0)
0.26 (0.20, 0.34)
83.1
Lundin, 2000
53
50–100%
Segment
27
7
1
1
207
71.1 (55.2, 83.0)
96.7 (93.4, 98.4)
20.2 (9.7, 42.0)
0.31 (0.19, 0.50)
66.2
El-K
ayali, 2004
33
50–100%
Segment
74
9
1
171
98.7 (92.8, 99.8)
95.0 (90.8, 97.3)
18.7 (10.0, 34.7)
0.02 (0.00, 0.10)
896.6
Whyman, 1992
71
51–100%
Segment
41
1
0
1
100
(91.4, 100)
50.0 ( 9.5, 90.5)
2.0 (0.6, 6.1)
0.02 (0.00, 0.47)
83.0
Eiberg, 2001
31
50–100%
Limb
50
8
1
35
98.0 (89.7, 99.7)
81.4 (67.4, 90.3)
5.0 (2.7, 9.2)
0.04 (0.01, 0.17)
140.6
Shaalan, 2003
63
50–100%
Limb
97
12
5
100
95.1 (89.0, 97.9)
89.3 (82.2, 93.8)
8.6 (5.1, 14.5)
0.06 (0.03, 0.14)
142.5
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Results of studies assessing DUS, reported by area of leg assessed (cont’d)
Study
Stenosis
R
esults 
TP
FP
FN
TN
Sensitivity (%) 
Specificity (%) 
LR+ (95% CI)
LR– (95% CI)
DOR
threshold
reported by
(95% CI)
(95% CI)
Above knee, 


70% stenosis
Fletcher
, 1990
34
75–100%
Segment
14
2
0
40
100
(78.5, 100)
95.2 (84.2, 98.7)
16.6 (5.0, 55.6)
0.04 (0.00, 0.54)
469.8
Lai, 1996
48
76–100%
Segment
83
8
4
4
397
65.4 (56.7, 73.1)
98.0 (96.2, 99.0)
31.2 (15.8, 61.3)
0.36 (0.28, 0.45)
87.7
Above knee, occlusion
Currie, 1995
29
100%
Segment
25
4
5
146
83.3 (66.4, 92.7)
97.3 (93.3, 99.0)
27.6 (10.9, 69.6)
0.18 (0.09, 0.39)
150.9
Fletcher
, 1990
34
100%
Segment
45
7
5
111
90.0 (78.6, 95.7)
94.1 (88.3, 97.1)
14.2 (7.0, 28.5)
0.12 (0.05, 0.25)
123.0
Hatsukami, 1992
37
100%
Segment
29
0
1
85
96.7 (83.3, 99.4)
100
(95.7, 100)
163.7 (10.3, 2599)
0.05 (0.01, 0.23)
3363.0
Hirai, 1998
39
100%
Segment
64
0
1
454
98.5 (91.8, 99.7)
100
(99.2, 100)
889.3 (55.7, 14201)
0.02 (0.00, 0.11)
39087.0
Lai, 1996
48
100%
Segment
50
0
1
2
470
80.6 (69.1, 88.6)
100
(99.2, 100)
755.1 (47.2, 12088)
0.20 (0.12, 0.33)
3801.6
Lundin, 2000
53
100%
Segment
13
1
1
237
92.9 (68.5, 98.7)
99.6 (97.7, 99.9)
143.4 (28.8, 713.3)
0.10 (0.02, 0.46)
1425.0
Whyman, 1992
71
100%
Segment
26
1
0
16
100
(87.1, 100)
94.1 (73.0, 99.0)
11.8 (2.5, 54.6)
0.02 (0.00, 0.32)
583.0
Davies, 1992
30
100%
Limb
27
1
1
36
96.4 (82.3, 99.4)
97.3 (86.2, 99.5)
24.0 (5.0, 115.6)
0.05 (0.01, 0.26)
446.1
Mergelsberg, 1986
56
100%
Limb
25
6
1
17
96.2 (81.1, 99.3)
73.9 (53.5, 87.5)
3.5 (1.8, 6.8)
0.08 (0.02, 0.37)
45.8
Above knee, other stenosis thresholds
Bostrom, 2001
25
Suitable for 
Segment
93
11
6
5
3
93.9 (87.4, 97.2)
82.8 (71.8, 90.1)
5.3 (3.1, 9.0)
0.08 (0.04, 0.17)
66.9
endovascular 
intervention
Hirai, 1998
39
50–99%
Segment
43
3
9
399
82.7 (70.3, 90.6)
99.3 (97.8, 99.7)
94.5 (33.0, 270.2)
0.18 (0.10, 0.32)
522.7
Davies, 1992
30
50–99%
Limb
16
1
1
47
94.1 (73.0, 99.0)
97.9 (89.1, 99.6)
29.9 (6.2, 145.6)
0.09 (0.02, 0.40)
348.3
Below knee, 


50% stenosis
Bergamini, 1995
24
50–100%
Segment
11
1
1
6
7
9
40.7 (24.5, 59.3)
98.8 (93.3, 99.8)
22.2 (4.3, 115.1)
0.60 (0.44, 0.82)
36.9
Hatsukami, 1992
37
50–100%
Segment
27
1
6
44
81.8 (65.6, 91.4)
97.8 (88.4, 99.6)
24.8 (5.1, 120.7)
0.20 (0.10, 0.40)
125.5
K
aracagil, 1996
43
51–100%
Segment
211
47
36
186
85.4 (80.5, 89.3)
79.8 (74.2, 84.5)
4.2 (3.2, 5.4)
0.18 (0.14, 0.25)
22.8
El-K
ayali, 2004
33
50–100%
Segment
49
6
2
45
96.1 (86.8, 98.9)
88.2 (76.6, 94.5)
7.6 (3.7, 15.7)
0.05 (0.02, 0.18)
138.6
Below knee, occlusion
Hatsukami, 1992
37
100%
Segment
25
0
5
48
83.3 (66.4, 92.7)
100
(92.6, 100)
80.6 (5.1, 1277)
0.18 (0.08, 0.38)
449.7
K
aracagil, 1996
43
100%
Segment
199
44
34
203
85.4 (80.3, 89.4)
82.2 (76.9, 86.5)
4.8 (3.6, 6.2)
0.18 (0.13, 0.25)
26.4
K
oelemay
, 1998
45
100%
Segment
457
77
324
655
58.5 (55.0, 61.9)
89.5 (87.0, 91.5)
5.5 (4.4, 6.9)
0.46 (0.43, 0.51)
11.9
K
oelemay
, 1997
44
100%
Segment
84
21
33
121
71.8 (63.0, 79.2)
85.2 (78.4, 90.1)
4.8 (3.2, 7.1)
0.33 (0.25, 0.45)
14.3
Wilson, 1997
72
100%
Segment
80
1
5
36
94.1 (87.0, 97.5)
97.3 (86.2, 99.5)
23.7 (4.9, 113.9)
0.07 (0.03, 0.15)
356.2
Grassbaugh, 2003
35
100%
Artery
36
6
1
2
5
6
75.0 (61.2, 85.1)
90.3 (80.5, 95.5)
7.2 (3.4, 15.2)
0.28 (0.18, 0.46)
25.4
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Results of studies assessing DUS, reported by area of leg assessed (cont’d)
Study
Stenosis
R
esults 
TP
FP
FN
TN
Sensitivity (%) 
Specificity (%) 
LR+ (95% CI)
LR– (95% CI)
DOR
threshold
reported by
(95% CI)
(95% CI)
Below knee, other stenosis thresholds
K
oelemay
, 1998
45
Severe 
Segment
813
99
257
344
76.0 (73.3, 78.4)
77.7 (73.5, 81.3)
3.4 (2.8, 4.0)
0.31 (0.28, 0.35)
10.9
stenosis
K
oelemay
, 1997
44
Severe and 
Segment
136
23
52
48
72.3 (65.5, 78.2)
67.6 (56.1, 77.3)
2.2 (1.6, 3.1)
0.41 (0.31, 0.55)
5.4
occluded
Foot
Hofmann, 2004
42
T
arget vessels 
Segment
54
11
30
45
64.3 (53.6, 73.7)
80.4 (68.2, 88.7)
3.2 (1.9, 5.5)
0.45 (0.33, 0.61)
7.1
suitable for 
surgery
0.5 was added to all values for the calculation of LR+, LR– and DOR.studies.20,24,37,50,52,62,75 There was evidence of
significant statistical heterogeneity between the
study results (p < 0.001) for all accuracy measures
apart from sensitivity (p = 0.18), therefore only
results for sensitivity were pooled. The pooled
sensitivity was 90% (95% CI 88 to 92%). The
specificity ranged from 96% (sensitivity 89%) to
100% (sensitivity 74%). The sensitivities and
specificities have been plotted in ROC space
(Figure 11). The median LR+ was 72.1, with a
range from 21.8 (LR– of 0.12) to 168.2 (LR– of
0.28). The median LR– was 0.11, with a range
from 0.07 (LR+ of 72.1) to 0.28 (LR+ of 168.2).
Although there was no evidence of statistically
significant between-study heterogeneity in
sensitivity values, one study reported a notably 
low sensitivity (74%).52 Of the three studies that
reported Fontaine classification, this was the 
only study restricted to people with Fontaine 
stage II PAD. A possible explanation for the
observed lower sensitivity may therefore be the
theoretically greater difficulty in distinguishing
patients at the milder end of the disease spectrum
from the ‘normal’ population. The statistically
significant heterogeneity for LR– disappeared
when this study was removed from the analysis
(p = 0.35).
Above the knee
Results for the detection of a stenosis of 50% or
greater, on an arterial segment basis, were
reported by seven studies.24,33,34,37,48,53,71 The
sensitivity of DUS ranged from 71% (specificity
97%) to 100% (specificity 50%). The specificity
ranged from 50% (sensitivity 100%) to 97% (for
three studies with sensitivities of 71%, 75% and
85%). There was evidence of significant statistical
heterogeneity between the study results (p < 0.001
for all measures), hence no pooling was
undertaken. The sensitivities and specificities have
been plotted in ROC space (Figure 12). The
median LR+ was 18.7, with a range from 2.0 (LR–
of 0.02) to 25.6 (LR– of 0.16). The median LR–
was 0.14, with a range from 0.02 (two studies:
LR+ of 2.0 and 18.7) to 0.31 (LR+ of 20.2).
One study had an outlying value for specificity of
50%.71 None of the variables considered appeared
to offer an explanation for this result, and when
this study was removed from the analysis
heterogeneity between the studies was still
statistically significant (p < 0.05). The study that
reported the lowest sensitivity (71%),53 was the
only study to use a PSVR of 2.5 as the cut-off for
50% stenosis (one study did not report PSVR and
all the others used 2.0).
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FIGURE 12 ROC plot for DUS: above knee, 50% stenosisTwo studies provided results for the accuracy of
DUS in detecting a stenosis of 75% or greater.34,48
The two studies had very different sensitivities,
one reporting a sensitivity of 100%34 and the other
of 65.4%,48 with corresponding specificities of 95%
and 98%, respectively (Table 10). The study with
the higher sensitivity had an acceptable time
between the index test and reference standard,
whereas the other study did not. 
Results for the detection of an occlusion, on an
arterial segment basis, were reported by seven
studies.29,34,37,39,48,53,71 The sensitivity of DUS
ranged from 81% (specificity 100%) to 100%
(specificity 94%). The specificity ranged from 94%
(for two studies with sensitivities of 90% and
100%) to 100% (for three studies with sensitivities
of 81%, 97% and 99%). There was evidence of
significant statistical heterogeneity between the
study results (p = 0.002 for sensitivity, p = 0.03 for
LR–, p < 0.001 for specificity and LR+), hence no
pooling was undertaken. The sensitivities and
specificities have been plotted in ROC space
(Figure 13). The median LR+ was 143.4, with a
range from 11.8 (LR– of 0.02) to 889.3 (LR– of
0.02). The median LR– was 0.1, with a range from
0.02 (two studies: LR+ of 11.8 and 889.3) to 0.2
(LR+ of 755.1).
One study reported the highest sensitivity (100%),
and the lowest specificity (94%), LR+ (11.8) and
LR– (0.02).71 Another study reported the lowest
sensitivity (81%), the highest specificity (100%)
and LR– (0.2), and second highest LR+ (755.1).48
When comparing these two studies, as the
extremes of the data set, one had an acceptable
time between the index test and reference
standard,71 whereas the other did not.
Below the knee
Results for the detection of a stenosis of 50% or
greater, on an arterial segment basis, were
reported by four studies.24,33,37,43 The sensitivity of
DUS ranged from 41% (specificity 99%) to 96%
(specificity 88%). The specificity ranged from 80%
(sensitivity 85%) to 99% (sensitivity 41%). There
was evidence of significant statistical heterogeneity
between the study results (p = 0.01 for LR+,
p < 0.001 for all others), hence no pooling was
undertaken. One study had an outlying value for
sensitivity of 41%.24 None of the variables
considered appeared to offer an explanation for
this result, and when this study was removed from
the analysis heterogeneity between the studies was
still statistically significant. The sensitivities and
specificities have been plotted in ROC space
(Figure 14). The median LR+ was 14.9, with a
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FIGURE 13 ROC plot for DUS: above knee, occlusionrange from 4.2 (LR– of 0.18) to 24.8 (LR– of 0.2).
The median LR– was 0.19, with a range from 0.05
(LR+ of 7.6) to 0.6 (LR+ of 22.2).
Results for the detection of an occlusion, on an
arterial segment basis, were reported by five
studies.37,44–46,72 The sensitivity of DUS ranged
from 59% (specificity 90%) to 94% (specificity
97%). The specificity ranged from 82% 
(sensitivity 85%) to 100% (sensitivity 83%). 
There was evidence of significant statistical
heterogeneity between the study results (p = 0.06
for LR+, p < 0.001 for all others), hence no
pooling was undertaken. The sensitivities and
specificities have been plotted in ROC space
(Figure 15). The median LR+ was 5.5, with a 
range from 4.8 (two studies: LR– of 0.18 and 0.33)
to 80.6 (LR– of 0.18). The median LR– was 0.18
with a range from 0.07 (LR+ of 23.7) to 0.46
(LR+ of 5.5).
One study reported a particularly low sensitivity
(59%) compared with the other studies in this
group.45 This study was the highest quality study,
responding positively to 12 of the 13 quality
criteria. It was also one of only two studies to
include the foot in the scan, with the other study
reporting the next lowest sensitivity (72%).44
Only one study assessed the ability of DUS to
detect stenoses in the foot separately.42 For the
detection of target vessels suitable for surgery the
sensitivity was 64% and the specificity was 80%. 
Impact of assessment method on
patient management and outcome
One controlled trial was identified that met the
inclusion criteria for the review in relation to the
impact of the assessment method on patient
management and outcomes.77 The study was a
prospective assessment of DUS involving 114
consecutive patients with lower leg ischaemia who
underwent DUS alone (unless CA was indicated)
between April 1997 and September 1998. The
DUS results served as the basis for the treatment
plan, which was decided jointly by the vascular
surgeons and interventional radiologist, and
comprised conservative treatment, percutaneous
transluminal angioplasty or surgical
revascularisation. These patients were compared
with a historical control group, herein referred to
as the CA group, of 113 consecutive patients with
lower leg ischaemia who had participated in an
earlier study between February 1995 and March
1997, with the same inclusion criteria. All patients
Health Technology Assessment 2007; Vol. 11: No. 20
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FIGURE 14 ROC plot for DUS: below knee, 50% stenosisin the CA group had undergone intra-arterial
DSA, which had served as the basis for the
treatment plan, formulated by the same vascular
surgeons and interventional radiologist.
Complications occurring within 30 days, 12-month
and 24-month patency rates, survival rates and
limb salvage rates were recorded and compared
between the two groups. There were no significant
differences between the DUS group and the CA
group in terms of patient characteristics (such as
co-morbidities and prior interventions),
indications for specific treatment or the type of
treatment that the patients underwent. 
Using DUS, 125 limbs were assessed in the 114
included patients and 119 limbs were assessed
using CA in the 113 patients in the historical
control group. For 97 of the 125 limbs (78%) the
management plan was based on DUS without the
need for CA. However, additional CA was
necessary before a femorocrural bypass graft when
DUS detected multiple patent or partially patent
crural arteries (18 patients), although DUS
suggested an identical treatment to CA in 14 of
these patients. In four patients DUS could not
visualise all popliteal or crural arteries, making CA
necessary. The management plan was conservative
treatment for 33 limbs in the DUS group and 21
in the CA group, percutaneous transluminal
angioplasty for 25 limbs in the DUS group and 31
in the CA group, femoropopliteal bypass graft for
29 limbs in each group, femorocrural bypass graft
for 29 limbs in the DUS group and 37 limbs in the
CA group, and other surgical procedures for eight
limbs in the DUS group and one limb in the CA
group. One patient in the DUS group died of
acute myocardial infarction before their operation.
Follow-up was available for 113 patients in the
DUS group (99%) and 111 patients in the CA
group (98%).
Five patients (4%) in the DUS group and eight
patients (7%) in the CA group died within 30 days;
2-year survival was 83% in the DUS group and
74% in the CA group. After a femoropopliteal
bypass graft, the 2-year primary patency rate was
75% in the DUS group and 58% in the CA group,
the 2-year secondary patency rate was 93% in the
DUS group and 80% in the CA group, and the
limb salvage rate was 93% in the DUS group and
92% in the CA group. After a femorocrural bypass
graft the 1-year primary patency rate was 35% in
the DUS group and 54% in the CA group, the 
1-year secondary patency rate was 73% in the DUS
group and 85% in the CA group, and the limb
salvage rate was 74% in the DUS group and 82%
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FIGURE 15 ROC plot for DUS: below knee, occlusionin the CA group. There were no statistically
significant differences between the DUS group
and the CA group in terms of immediate and
intermediate-term outcomes.
The authors concluded that in a vascular unit with
wide expertise in DUS of the lower leg arteries,
management of patients with severe lower leg
ischaemia can be based on DUS in most patients
without negative effects on clinical outcome within
30 days and at 2-years’ follow-up.
The lack of randomisation and inability to blind
either the patients or clinicians to the
investigation being performed increases the
potential for bias. As this trial used a historical
control group it is possible that other factors
occurring within the time-frame of the trial might
have affected the results. The use of the same
inclusion criteria for both groups helps to reduce
differences between the groups; the authors
present details of the characteristics of the two
groups and found no statistically significant
differences between them. There were also no
significant differences between the type of
treatment that the patients underwent. However,
the authors do not comment on other factors that
could have had a major influence upon outcomes,
particularly graft patency, such as the nature of the
graft material, whether smoking patients
continued to smoke and the use of antiplatelet
drugs. Follow-up was high in both groups. This
trial appears to have been well conducted and the
results are likely to be reliable. However, no data
were collected relating to patient acceptability or
adverse events of the investigations, other than
mortality within 30 days.
Studies of patient attitudes
Four studies reported results relating to patient
attitudes.78–81 The results of the studies strongly
suggest that CE MRA is preferred by patients over
CA;78,79,81 statistically significantly more patients
preferred CE MRA if having to undergo testing
again in the future (p = 0.01)78 and CE MRA
scored statistically significantly better on a rating
scale, compared with CA (p = 0.0001 and
p = 0.0002).78,79 In terms of level of discomfort,
CA was found to be the most uncomfortable,
followed by CE MRA, with CTA being the least
uncomfortable; again, this result was statistically
significant (p = 0.016).81 The majority of patients
(from a sample who did not suffer from
claustrophobia and had no metallic implants) had
no preference between undergoing TOF MRA or
DUS, while the majority of those who did express
a preference preferred TOF MRA.80 Within the
same population there was no significant
difference between TOF MRA and DUS on a scale
that rated how bothersome the tests were.80 Each
of the studies assessing patient attitudes is
described below.
One study surveyed 98 of 117 patients who had
undergone both TOF MRA and DUS in the
pretreatment work-up of PAD, as part of a clinical
study.80 The reasons the other 19 patients who
underwent TOF MRA and DUS did not
participate were communication problems between
the institutions conducting the study (n = 12),
participant refusal (n = 5), hearing problem
making telephone interview impossible (n =1 )
and patient missed DUS appointment (n = 1).
Fifty-one per cent of patients had undergone DUS
before TOF MRA and 49% had undergone TOF
MRA before DUS. The time between the two tests
was on average 4.2 days.
Patients were sent a questionnaire that asked
which imaging test they would prefer if they were
to require testing in the future, with a rating 
scale with scores ranging from 0 (not bothersome
at all) to 10 (extremely bothersome) and specific
questions on whether patients experienced
discomfort due to the imaging test (the results 
of this part of the survey are presented in the
section ‘Adverse events’, p. 44). Patients were
interviewed by telephone after receiving the
questionnaire. On average, the interviews took
place approximately 10 days after the test, at
which time 34% of patients knew the result for
both tests, 22% knew only the DUS result, 4%
knew only the TOF MRA result and 40% did not
know either test result.
Fifty per cent of respondents had no preference
for either TOF MRA or DUS, 41% expressed a
preference for TOF MRA and 9% expressed a
preference for DUS. The average rating scale
scores were not significantly different between the
two procedures [1.6 for TOF MRA (SD 2.1) and
1.7 (SD 2.2) for DUS; p = 0.53]. There was a
slight, but statistically significant correlation
between the rating scale scores of TOF MRA and
DUS (Spearman’s correlation coefficient 0.52, 
p < 0.01) and a statistically significant inverse
association between the rating scale score for TOF
MRA and the age of the patient (Spearman’s
correlation coefficient –0.21, p = 0.04). Knowledge
of the test result, gender, time between test and
interview and the order of performance of the
MRA and DUS did not influence the rating scale
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to the imaging test gave higher rating scale 
scores (i.e. more bothersome), as might be
expected. The authors concluded that their results
suggest that the majority of patients have no
preference between TOF MRA and DUS in the
diagnostic work-up of PAD. Among those patients
who do have a preference, TOF MRA was
preferred over DUS.
Although the authors state that the section of 
the questionnaire regarding adverse events was
piloted before this study, they do not mention
whether the other sections of the questionnaire
were also piloted. There was a high response rate
to the questionnaire and reasons for non-
participation were presented. The proportion of
participants undergoing TOF MRA first was
approximately the same as the proportion
undergoing DUS first. Both the time between the
two tests and the time between the tests and
interviews was short, thus reducing the potential
for recall bias. The authors assessed whether there
was any correlation between the rating scale scores
and certain study and patient characteristics. This
survey appears to have been well conducted and
the results are likely to be reliable. However, as the
authors point out, this survey may not be
representative of all patients undergoing
pretreatment work-up of PAD, as 18% (25
patients) of the initial patient population did not
participate in the clinical study, from which this
sample was drawn, 4% of whom (one patient) did
not participate because of an implanted cardiac
pacemaker, 8% (two patients) because the scanner
was not available and 8% (two patients) because
they were claustrophobic.
Another study surveyed 30 patients who had
undergone both CE MRA and CA for the
assessment of PAD as part of a diagnostic accuracy
study.78 Patients were interviewed in person
(n = 2) or via the telephone (n = 28). Seventeen
patients underwent CA first and 13 underwent CE
MRA first. Patients were interviewed a mean of
30 weeks after the last test they had undergone.
Patients were asked the strength of their
agreement (on a scale of 1 to 5) with a statement
that they would consent to have the test done
again, which test they would prefer if they were to
require testing in the future and their experience
of the test on a scale from 0 (neutral experience)
to –10 (extremely unpleasant experience). Patients
were also assessed using a willingness-to-pay
approach, where they were asked what percentage
of their income they would pay to avoid
undergoing the test in future (without
compromising their healthcare), and a time trade-
off approach, where they were asked whether they
would undergo the test if they could be
guaranteed an extra 2 years of healthy life in
addition to the (5 or 10) years they already have.
Patients were also surveyed in relation to adverse
events (the results of this part of the survey are
presented in the ‘Adverse events’ section, p. 44).
Twenty-nine patients were willing to respond to
the willingness-to-pay questions, 28 responded to
the time trade-off questions and all 30 patients
responded to the other questions.
More patients agreed that they would consent to
have CE MRA done again than CA, and the
difference was statistically significant (p = 0.01).
One patient expressed no preference as to which
test they would prefer if they required testing in
the future, 28 patients stated a preference for CE
MRA and one patient stated a preference for CA.
The mean score relating to their experience of the
tests was –1.1 for CE MRA and –3.8 for CA, and
the difference was statistically significant
(p = 0.0002). Using the willingness-to-pay
approach, patients were willing to pay a mean of
2.12% of their annual income to avoid CE MRA
and a mean of 7.41% of their annual income to
avoid CA, and the difference was statistically
significant (p = 0.01). However, 16 of the 29
patients who responded to this question were
unwilling to pay an amount above zero to avoid
either CE MRA or CA. The median required
survival gain to undergo CE MRA was 10.5 days
(range 0–547) and for CA was 52.5 days (range
0–1095) (given a 10-year life expectancy); the
difference was not statistically significant. The
authors concluded that their findings indicate a
strong preference for CE MRA over CA.
The authors state that their utilities questionnaires
were piloted before use. The proportion of
participants undergoing CE MRA first was
approximately the same as the proportion
undergoing CA first. The authors did not state the
time interval between patients undergoing CE
MRA and CA. The potential for recall bias is very
high in this study, owing to the delay between the
last test and the interview. However, the authors
state that they read a short paragraph
summarising each procedure to the patient to help
them to remember the details of the procedure,
and that patients showed no difficulties in
remembering the particulars of their procedures.
Given the consistently, and statistically
significantly, better score for CE MRA over CA,
the authors’ conclusion is likely to be reliable.
Results of the review
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undergone both CE MRA and CA for the
assessment of PAD as part of a diagnostic accuracy
study.79 The original sample size was 40, but two
patients refused to participate at the time of
interview as they were not comfortable with the
questionnaire format. Patients were interviewed via
telephone. Twenty-eight patients underwent CA
first and 12 underwent CE MRA first. The time
between the two tests was a mean of 28 days.
Patients were interviewed a mean of 8 weeks after
the last test they had undergone. Half of the
patients were asked about their preferences for CE
MRA before CA and half were asked about their
preferences for CA before CE MRA.
Patients were asked to keep in mind a typical week
with their symptoms before the performance of
MRA or CA. They were then given the option of
(1) having the test they had received (e.g. CA),
with the associated pain, discomfort and other
adverse effects, with the physician having
immediate access to the results and immediate
treatment, or (2) having a hypothetical ‘ideal’ test,
which takes very little time to perform and where
there is no associated pain or other adverse
effects, but where the results require a certain
amount of time to analyse. The patient is initially
given the hypothetical waiting time of 4 weeks for
the ideal test results and subsequent treatment and
a bisection method was used to work towards the
patient’s point of indifference to which test they
received. Patients were also asked to rate their
experience of the test from 0 (neutral experience)
to –10 (extremely unpleasant experience).
Patients were willing to wait a mean of 42.1 days
after the ideal test for results and treatment,
rather than having to undergo CA, and a mean of
16.1 days to avoid having to undergo CE MRA;
the difference was 26.0 days and was statistically
significant (p = 0.0001). The mean score relating
to their experience of the tests was –3.73 for CA
and –1.05 for CE MRA, and the difference was
statistically significant (p = 0.0001). The authors
concluded that their findings indicate a clear
preference for CE MRA, in agreement with known
literature.
The main aim of this study was to validate the
‘wait trade-off ’ method. More patients underwent
CA before CE MRA, which increases the potential
for order/sequential bias. The time interval
between the two tests was relatively short, as was
the average time between the last test and the
interview, reducing the potential for recall bias.
Although this study has some limitations, the
potential biases are unlikely to have had a major
impact on the overall conclusions.
Another diagnostic accuracy study that compared
CE MRA and CTA with CA in 46 consecutive
patients also measured patient acceptance for each
modality, although this was not a stated objective of
the study.81 All patients underwent CA, CE MRA
and CTA within 1 week, CA was always performed
first and half of the patients underwent CE MRA
before CTA, while half underwent CTA before CE
MRA. After all three examinations had been
performed, patients were asked to give a subjective
score of discomfort using a 10-cm visual analogue
scale, the left end of the scale representing ‘no
discomfort, excellently tolerated’ and the right end
of the scale representing ‘very uncomfortable,
hardly tolerable’. The distance between the left end
of the scale and the patient’s mark was measured
and the patient acceptance for each modality was
expressed in millimetres. After completing the
visual analogue scale, patients were asked which of
the following factors provided the most discomfort
during all three procedures: confinement, keeping
still, noise, puncture of a vessel, application of a
pressure bandage, nothing, or other. 
CA was the most uncomfortable procedure, with a
mean discomfort score of 41.0 mm (SD 33.0),
followed by CE MRA, with a mean discomfort
score of 27.9 mm (SD 25.7). CTA was the least
uncomfortable, with a mean discomfort score of
15.5 mm (SD 19.8). The difference was statistically
significant between CA and CTA (p < 0.001),
between CE MRA and CTA (p = 0.016), and
between CA and CE MRA (p = 0.037). The most
disturbing factors were noise and having to keep
still for CE MRA, and puncture of a vessel and
application of a pressure bandage for CA. The
authors conclude that CTA was better accepted by
patients.
The authors do not state whether their
questionnaire was piloted before use. The
proportion of participants undergoing CE MRA
before CTA was the same as the proportion
undergoing CTA before CE MRA. However, all
patients underwent CA first, which increases the
potential for order/sequential bias. The time
between the three tests was short; however, the
authors do not state the length of time between
patients undergoing the tests and completing the
visual analogue scale or questionnaire, and
therefore the potential for recall bias cannot be
assessed. Although this study has some limitations,
the potential biases mentioned above are unlikely to
have had a major impact on the overall conclusions.
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Only nine of the diagnostic accuracy studies that
met the inclusion criteria for the review provided
data on adverse events. In addition, 46 studies
that did not meet the inclusion criteria for the
review of diagnostic accuracy reported results
relating to adverse events. Therefore, a total of 55
studies contributed adverse event data. The lack of
adverse event data reported by diagnostic accuracy
studies cannot be interpreted as no adverse events
having occurred. The criteria used to determine
whether adverse events were procedure related
(e.g. temporal relation to procedure) and the
methods by which adverse event data were 
sought and recorded varied by study and were not
always reported. This section should therefore
only be regarded as a guide to the spectrum of
adverse events reported, and not an accurate
assessment of their actual or relative frequency.
Table 11 shows the number of studies reporting
each adverse event, with the total number of
patients in the studies, and the proportion of
patients suffering the adverse event, for 53 of the
55 studies. The other two studies reported adverse
event data, but did not report the number of
patients affected; these data are presented at the
end of this section.
As shown in Table 11, MRA was associated with the
highest proportion of adverse events reported in
the studies. However, the two major adverse events
(death and severe vascular adverse events) were
reported in a higher proportion of patients who
underwent CA than MRA, although the
proportion of patients undergoing CA that
suffered these adverse events was still very low 
[2% death (one patient) compared with 0.5% 
(one patient) for CE MRA and up to 5% severe
vascular adverse events compared with 0.5% for
CE MRA]. However, it should be noted that only
two studies reported that a patient had died;
therefore, a figure of 2% is an unrealistic
overestimate of the death rate in the total
population undergoing CA.
Contrast agents were responsible for some of the
reported adverse events, although generally the
proportion of patients suffering significant
contrast agent-related adverse events was low.
However, studies reported up to 25% of patients
suffering from unspecified contrast agent-related
adverse events associated with CE MRA, although
the study that reported the highest proportion of
contrast agent-related adverse events was designed
to evaluate the dose response and safety of the
contrast agent.101
The most commonly reported adverse events were
minor pain/discomfort during or immediately
after DUS (22% of patients), minor
pain/discomfort during or immediately after 2D
TOF MRA (17% of patients), minor
pain/discomfort during or immediately after CE
MRA (up to 10% of patients), acute digestive
system symptoms associated with CE MRA (up to
10% of patients), anxiety associated with 2D TOF
MRA (up to 10% of patients), and acute central
and peripheral nervous system adverse events
associated with CE MRA (up to 10% of patients).
The two studies that reported adverse event data,
but did not report the number of patients affected,
reported acute change in renal function after
administration of contrast agent, anxiety, minor
pain/discomfort during or immediately
postprocedure and unspecified adverse events, all
related to CA.
Economic evaluations
Of the five included English-language studies,
none was conducted in the UK; one was
conducted in the USA,131 one in Sweden,126 two in
The Netherlands,128,130 and one failed to state
where it had been carried out.129 Given the setting
of the studies, the cost data are likely to have only
limited generalisability to the UK framework. Four
out of the five studies were modelling studies and
derived their effectiveness data from reviews of
published literature, while the fifth derived its
effectiveness data from a single clinical trial.126
The perspective adopted in the modelling studies
was that of society; the single study was
undertaken from the perspective of the hospital.
None of the published models compared the four
imaging techniques and treatment strategies at the
same time (i.e. MRA, DUS, CTA and CA).
However, where appropriate, effectiveness data,
cost/resource information and health outcome
data were used to inform the decision-analytical
modelling undertaken for this review. The
structured abstracts for each of the studies are
shown in Appendix 7.
Geitung and colleagues126 assessed the use of DUS
as a preoperative tool for examination of the
aorta, pelvic and lower limb vessels compared with
CA (which was considered to be the gold
standard). The aim of the study was to establish
whether it would be cost-effective to replace the
current practice of preoperative CA with
preoperative DUS. The economic analysis
evaluated diagnostic results on consecutive
Results of the review
44patients examined with both DUS and CA, then
compared the outcomes obtained.
The study was conducted in Sweden from the
perspective of the hospital. The direct costs were
obtained from the study hospital and included a
mixture of both costs and prices. The effectiveness
data were derived from a cohort of 53
consecutively referred patients who underwent
both diagnostic procedures. The results obtained
showed a number of diagnostic discrepancies
between the two techniques, which could
potentially lead to reoperations, delayed
operations and overtreatment. No summary
measure of benefit was derived so, in effect, a
cost–consequence approach was adopted. The
observational nature of the study design is subject
to a number of limitations.
The cost analyses found that the cost savings
obtained from using DUS (due to avoidance of
hospitalisation and lower costs for the test) would
be outweighed by the cost of reoperations, delayed
operations and overtreatment. The authors
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TABLE 11 Adverse events reported
Adverse event Test No. of studies % of patients affected
Acute cardiac signs and symptoms CE MRA 2 (n = 879) 0.00–0.42
Acute central and peripheral nervous system adverse events  CE MRA 3 (n = 591) 1.48–10.00
(weakness/paralysis/dizziness)
Acute change in biochemical measures of renal function after  CE MRA 1 (n = 136) 1.48 
gadolinium infusion
Acute digestive system adverse events (nausea/diarrhoea/taste  CE MRA 3 (n = 591) 0.74–10.00
perversion)
Acute renal failure after gadolinium infusion CA 1 (n = 42) 9.52
(patients had baseline chronic renal insufficiency)
Acute renal failure after gadolinium infusion CE MRA 1 (n = 218) 1.38
(patients had baseline chronic renal insufficiency)
Anxiety 2D TOF MRA 1 (n = 40) 10.00
Anxiety CA 1 (n = 23) 4.35 
Anxiety CE MRA 1 (n = 98) 8.16 
Anxiety DUS 1 (n = 98) 1.02
Death (from haemorrhage due to dissection of an external  CA 1 (n = 52) 1.92 
iliac artery following CA)
Death (deemed as possibly related to the study drug by the  CE MRA 1 (n = 238) 0.42 
principal investigator. Immediate cause of death was 
atherosclerotic cardiovascular disease)
Minor pain/discomfort during or immediately after procedure 2D TOF MRA 1 (n = 12) 16.67
Minor pain/discomfort during or immediately after procedure CA 1 (n = 35) 8.57
Minor pain/discomfort during or immediately after procedure CE MRA 5 (n = 719) 0.23–10.20
Minor pain/discomfort during or immediately after procedure DUS 1 (n = 98) 22.45 
Minor vascular adverse events CA 2 (n = 133) 2.17–7.32
Minor vascular adverse events CE MRA 2 (n = 571) 0.74–2.30
Severe unspecified adverse events CE MRA 1 (n = 274) 1.09 
Severe unspecified contrast agent-related adverse events CE MRA 3 (n = 740) 0.00–0.78
Severe vascular adverse events CA 2 (n = 111) 1.09–5.26
Severe vascular adverse events CE MRA 1 (n = 435) 0.46 
Skin adverse events (irritation/rash) CE MRA 2 (n = 673) 0.23–0.42
Skin adverse events (irritation/rash) CTA 1 (n = 49) 2.04 
Unspecified adverse events 2D TOF MRA 3 (n = 62) 0.00a
Unspecified adverse events 3D TOF MRA 1 (n = 49) 0.00a
Unspecified adverse events CA 11 (n = 355) 0.00a
Unspecified adverse events CE MRA 9 (n = 618) 0.00–6.67
Unspecified adverse events CTA 5 (n = 179) 0.00a
Unspecified adverse events DUS 4 (n = 181) 0.00a
Unspecified adverse events PC-MRA 1 (n = 19) 0.00a
Unspecified contrast agent-related adverse events CA 4 (n = 125) 0.00a
Unspecified contrast agent-related adverse events CE MRA 10 (n > 1334) 0.00–24.79
Unspecified contrast agent-related adverse events DUS 1 (n = 14) 0.00a
a Study stated that no adverse events/contrast agent-related adverse events occurred.concluded that DUS of the aorta and arteries of
the pelvis and lower limb is not a cost-effective
option for preoperative examination. 
Yin and colleagues131 developed a decision tree to
evaluate the use of MRA in the preoperative
evaluation of patients with limb-threatening PAD,
but the degree of stenosis was not reported. The
main objective of the economic analysis was to
evaluate MRA compared with CA. However, a
secondary aim was to determine a diagnostic
accuracy threshold that MRA was required to
reach before it would become a cost-effective
alternative to CA. 
The study population comprised a hypothetical
cohort of patients undergoing angiography. The
model inputs (effectiveness data, utility data and
costs) were derived from published literature and,
when necessary, were augmented by expert/author
opinion. Full details of the review were not
reported; consequently, it is not possible to
establish whether the best available evidence 
was used to populate the decision tree. Full 
details of the structure of the decision tree were
reported. The measure of benefit used was the
number of quality-adjusted life-years (QALYs).
These were not directly measured, but were 
based on assumed quality-of-life values which, in
turn, were based upon the Quality of Well-Being
Scale. Benefits were discounted at an annual rate
of 5%.
The study was conducted from a societal
perspective, and included both the direct costs to
the hospital, which were derived from Medicare
sources, and indirect costs, in the form of
productivity losses, which were derived from US
national average daily earnings. All costs were
subjected to discounting at an annual rate of 5%.
An incremental cost–utility ratio was calculated to
combine costs and QALYs; the base case showed
that the incremental cost per QALY saved with
MRA over CA was US$25,895. Univariate
sensitivity analysis showed that the results were
sensitive to variations in some of the sensitivity
parameters used in the model.
In addition, the authors assessed MRA in
combination with CA compared with CA alone.
The results obtained showed that the combined
approach produced an incremental cost per QALY
saved of $29,305 relative to CA alone.
The threshold analysis showed that, when the
sensitivity and specificity of CA were 95%, MRA
would have to have at least 90% sensitivity and
85% specificity for it to be a cost-effective option
at a threshold of $30,000 per QALY.
The authors highlighted several limitations to their
analysis and concluded that their results indicate
that MRA could prove to be a cost-effective
alternative to CA as a preoperative diagnostic tool
in patients with limb-threatening PAD. In addition,
they stressed that further research is required to
address many of the data limitations found and to
corroborate the findings of their study. It is also
worth noting that, given the publication date of
this paper, techniques used and treatment
pathways are likely to have changed significantly.
Visser and colleagues129 aimed to evaluate
alternative pretreatment imaging work-up
procedures followed by treatment. The imaging
techniques included MRA, DUS and DSA. A
Markov model was developed to compare the
alternative strategies over a lifetime horizon. The
main objective of the evaluation was to assess the
cost-effectiveness of MRA, DSA and DUS for the
pretreatment imaging work-up of patients with
lifestyle-limiting intermittent claudication. The
comparator chosen was exercise therapy without
imaging work-up. The analysis was conducted for
two different treatment scenarios, namely
minimally invasive (i.e. where treatment was
limited to angioplasty or an exercise programme
for those patients not suitable for angioplasty) and
invasive (where bypass was performed if patients
were not suitable for angioplasty).
The study population comprised a hypothetical
cohort of 60-year-old men with a 1-year history of
severe unilateral claudication, an initial ankle
brachial index of 0.70 and no history of coronary
artery disease. The model parameters were
derived from published literature and augmented
by authors’ assumptions. It is not clear whether a
systematic review of the literature was conducted
to identify the best available evidence with which
to populate the model, although the authors did
identify and use several meta-analyses of RCTs.
The measure of benefit used in the economic
analysis was QALYs; these were also obtained from
the literature review. QALYs were discounted at an
annual rate of 3%.
The direct costs included in the analysis were
those of both the health service and the patient.
The costs, including technical and professional
fees, for the three alternative imaging techniques
were derived from Medicare reimbursement rates.
All other costs were derived from the literature.
Results of the review
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conducted from a societal perspective, indirect
costs were not discussed. Costs were discounted at
an annual rate of 3%.
Cost-effectiveness was determined by excluding
dominated and extended dominated strategies
(i.e. strategies that were less effective and more
costly), then calculating the incremental
cost–utility ratio (ICUR). For the minimally
invasive scenario the ICUR for MRA yielded
$35,000 per QALY compared with no diagnostic
work-up; DSA had an ICUR of $471 per QALY
compared with MRA. DUS was dominated by
MRA. For the invasive scenario, DSA had an ICUR
of $179,000 per QALY compared with no imaging
work-up. MRA and DUS were both dominated by
DSA. The model was also evaluated for relevant
subpopulations, namely 40-year-old men and 
70-year-old men, with results showing ICURs
lower than for the base-case analysis. In addition,
several sensitivity analyses were conducted, which
showed that the results obtained were not sensitive
to changes in the diagnostic test characteristics.
The authors highlight a number of limitations to
the study; these are mainly concerned with the
model assumptions made to develop fully a
tractable model. 
The authors concluded that the differences in
costs and effectiveness among diagnostic imaging
strategies for the baseline patient population were
slight. MRA or DUS could replace intra-arterial
DSA without substantial loss in effectiveness and
with a slight cost reduction. They also state that
their results suggest that a clinical study should
focus on the decision-making process and
workflow in clinical practice.
Visser and colleagues128 undertook an analysis to
determine the societal cost-effectiveness of a
variety of management strategies including the
imaging work-up and treatment for patients with
intermittent claudication. (See abstract in
Appendix 7 for full details of the strategies
compared.) A previously developed Markov model
was enhanced to evaluate appropriately the
relevant strategies. The population was modelled
over a lifetime from the time the initial diagnostic
work-up was performed. The comparator chosen
was conservative treatment in which all patients
entered a supervised exercise programme.
The study population comprised a hypothetical
cohort of previously untreated 60-year-old patients
presenting with severe unilateral claudication of at
least 1 year’s duration, who had at least one
significant lesion that was located predominantly
suprainguinal or infrainguinal, an ankle brachial
index of 0.70 and no history of coronary artery
disease. The model parameters were obtained
from published sources; it is not apparent whether
a systematic review of the literature was performed
and as such it is not possible to assess whether the
best available evidence was used to populate the
decision model. The measure of benefit used in
the economic evaluation was QALYs; these were
mainly derived using time trade-off values
obtained from the literature. All benefits were
discounted at an annual rate of 3%.
The direct costs included those incurred by both
the hospital and patients; these were obtained
directly from the hospital and the literature and,
when necessary, augmented by the authors’
assumptions. Productivity costs (indirect costs)
were excluded from the analysis as most patients
with PAD would be retired. Given that the
population being modelled comprised 60-year-old
patients, this justification for excluding
productivity losses may be flawed. Costs were
discounted at an annual rate of 3%.
Cost-effectiveness was determined by excluding
dominated and extended dominated strategies,
then calculating the incremental ICUR. The
strategy of MRA plus percutaneous transluminal
angioplasty (PTA)/supervised exercise had an
ICUR of €20,138 per QALY compared with no test
plus exercise strategy. The strategy of DSA plus
PTA/bypass surgery/supervised exercise had an
ICUR of €130,557 per QALY compared with MRA
plus PTA/supervised exercise. All other strategies
were inferior by either dominance or extended
dominance. The analysis was also undertaken for a
subpopulation of 40-year-old and 70-year-old
men. Several parameters were varied in sensitivity
analyses, which suggests that the results are very
sensitive to changes in the costs of MRA.
The authors concluded that for the population
modelled, non-invasive imaging modalities could
replace intra-arterial DSA without an important
loss in effectiveness and at a minimal cost
reduction. In addition, management strategies
that include bypass surgery were more effective,
but their incremental costs were very high.
Visser and colleagues130 evaluated the cost-
effectiveness of a new imaging modality,
multidetector row CTA, compared with that of
gadolinium-enhanced MRA. The objective of the
study was to determine the costs, sensitivity for
detection of stenoses and proportion of equivocal
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examination cost-effective compared with
gadolinium-enhanced MRA. The analysis was
conducted for two treatment scenarios: minimally
invasive and invasive (as defined above). A Markov
model was used to simulate the lifetime cost-
effectiveness of the comparative strategies.
The population comprised a hypothetical cohort
of 60-year-old men with symptoms of severe
unilateral claudication for 1 year, an ankle
brachial index of 0.70 and no history of coronary
artery disease. The model parameters were
obtained from a review of published literature and
when necessary augmented by the authors’
assumptions. Full details of the review process
were not reported, although the authors selected
and used a number of published meta-analyses.
The measure of benefit used in the analysis was
QALYs. Estimated health values were obtained
from the literature review and discounted at an
annual rate of 3%.
Although the authors state that the analysis was
conducted from a societal perspective, no indirect
costs (productivity losses) were included. The
direct costs included were those of the healthcare
system and were derived from the literature.
Healthcare resource utilisation data were based on
the authors’ assumptions. All costs were
discounted at an annual rate of 3%.
The analyses showed that for the minimally
invasive treatment scenario, with the use of a
societal willingness-to-pay threshold of $100,000
per QALY, CTA was equivalent to MRA in terms of
cost-effectiveness if the cost of the modality was
$420, the sensitivity for detection of significant
stenosis was 90%, and 20% of patients required
additional work-up owing to equivocal CTA
results. For the invasive treatment scenario, with
the use of the same willingness-to-pay threshold,
CTA was equivalent to MRA in terms of cost-
effectiveness if the cost of the modality was $673,
the sensitivity for detection of significant stenosis
was 95%, and 20% of patients required additional
work-up owing to equivocal CTA results.
Sensitivity analyses showed that these results did
not change substantially when the societal
willingness-to-pay threshold was varied. 
The authors concluded that multidetector row
CTA, as compared with currently used imaging
modalities such as MRA, has the potential to be
cost-effective in the evaluation of patients with
intermittent claudication. They also suggested that
the role of new imaging modalities that have fairly
good preliminary results could be assessed by
performing a pragmatic RCT in which the new
modality could be compared with the imaging
modality currently in use.
One further study was identified that met the
inclusion criteria for the review, but a full
translation was not obtained in time for it to be
included.127
Results of the review
48The choice of modelling questions
The objective of the economic analysis was the
assessment of the relative cost-effectiveness of
MRA, DUS and CTA compared with CA (which
was considered to be the gold-standard
preoperative diagnostic test) for the assessment
and treatment planning of PAD patients.
Both a short-term and a long-term model were
developed to evaluate the costs and outcomes of
the different preoperative diagnostic strategies
considered at analysis over different time-
horizons.
● The short-term model focused on the period of
diagnosis and formulation of the treatment
plans. It aimed to estimate the cost per
correctly diagnosed patient for whom an
accurate treatment plan was formulated; an
accurate treatment plan was defined as one that
did not require modification during the
procedure. 
● The long-term model considered not only the
diagnosis and formulation of treatment plans,
but also follow-up of the patients, including
community care (i.e. 1 year time-horizon). In
this case, the objective was to estimate the cost
per QALY related to each of the diagnostic
tests.
The perspective adopted was that of the UK NHS.
A wider societal perspective may have been more
appropriate, but given that the prevalence of PAD
is low among people younger than 65,659 it is
unlikely that productivity losses would have a
major impact on the results obtained. 
The data that were obtained from the systematic
review have enabled comparisons of the accuracy
of the tests not only for the whole leg, but also for
above-the-knee and below-the-knee comparisons,
analysed by arterial segment. Table 12 highlights
the potential comparisons to be performed across
the alternative diagnostic imaging techniques in
terms of the available diagnostic accuracy data
obtained from the systematic review, according to
the type of test, how the results were reported (e.g.
arterial segment, artery or limb) and the degree of
stenosis.
The boundary of 50–100% stenosis was considered
for the base-case analysis to diagnose and plan
treatment for PAD patients. There are two
additional diagnostic thresholds that are
considered relevant for the diagnosis and
treatment planning of PAD patients: 0–49% or
100% versus 50–99%, and 0–99% versus 100%.660
However, it was not possible to consider these
latter thresholds in the economic analysis, since
data were mainly reported for the former
threshold (i.e. 0–49% versus 50–100%).
The fact that some relevant data required to
populate the decision models were not available
for CTA led to the exclusion of this test from the
economic evaluation (see below).
In line with the inclusion criteria for the study
population that were used in the systematic review,
the type of patients considered in the model was
those with symptoms suggestive of lower limb
PAD, either with intermittent claudication
(Fontaine stage II) or with limb-threatening
ischaemia (Fontaine stage III or IV), who needed
to undergo lower limb vascular imaging to
formulate an appropriate treatment plan for their
condition.
Methods
Structure of the model and choice of
the input parameters
A decision tree was developed, using the software
package Data Professional (TreeAge Software), to
synthesise experimental data about sensitivity and
specificity of the tests with resource use, survival
and utility values associated with the alternative
preoperative diagnostic tests and consequent
treatment plans (Figures 16–19). The initial aim of
the model was to estimate the costs and
consequences of performing preoperative vascular
tests (MRA, CTA or DUS), compared with the gold
standard (i.e. CA). Since only limited data were
available for CTA, it was decided to exclude this
diagnostic test from the economic analysis.
The input parameters and strategies were
primarily based on the clinical studies and
economic evaluations that were identified in the
Health Technology Assessment 2007; Vol. 11: No. 20
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Chapter 7
Economic modellingsystematic review. In addition, other studies
identified by screening the references of the
included economic evaluations were reviewed to
retrieve additional data that were required.
The structure of the decision tree was principally
based on a previously developed model,660 which
evaluated the cost-effectiveness of MRA compared
with CA in the diagnosis and management of
patients with PAD. This model reflected the
relevant features related to the preoperative
diagnosis and subsequent treatment for PAD
patients, although some aspects of the model were
simplified (mainly those related to the possible
treatments for PAD patients, following the results
obtained from the diagnostic test). 
Several issues were investigated to progress the
structure and accuracy of this previous model. One
issue was the concern that some patients may
obtain an inconclusive test result and, therefore,
may need to undergo an additional diagnostic test.
Moreover, there are some contraindications to
undergoing MRA (e.g. experiencing
claustrophobia or having a pacemaker128). These
issues are commented on in the following
subsections.
Comparators
The model starts by comparing the ability of
several preoperative diagnostic tests to accurately
determine the severity of lesions and formulate an
appropriate interventional treatment plan for
Economic modelling
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TABLE 12 Potential test comparisons to be performed in terms of how the results were reported and the degree of stenosis considered
for the diagnosis of PAD
MRA CTA DUS
Whole leg 50–100% Segment Yes Yes Yes
Lesion Yes – –
Artery – – –
100% Segment Yes Yes Yes
Lesion – – –
Artery – – –
Above knee 50–100% Segment Yes Yes Yes
Lesion – – –
Artery Yes – –
100% Segment Yes Yes Yes
Lesion – – –
Artery Yes – –
Below knee 50–100% Segment Yes Yes Yes
Lesion – – –
Artery Yes – –
100% Segment Yes – Yes
Lesion – – –
Artery Yes – Yes
Foot 50–100% Segment – – –
Lesion – – –
Artery – – –
100% Segment Yes – –
Lesion – –
Artery Yes – –
Patient with
PAD
2D TOF MRA
CE MRA
DUS
CA
Diagnostic test result, Figure 17
Diagnostic test result, Figure 17
Diagnostic test result, Figure 17
Diagnostic test result, Figure 17
FIGURE 16 Decision tree I: preoperative diagnostic tests comparedHealth Technology Assessment 2007; Vol. 11: No. 20
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Plan incorrect
Plan correct
Plan incorrect
Plan correct
Plan incorrect
Plan correct
Plan amputation
Plan bypass
Plan PTA
True-negative stenosis,
medical management correct
False-negative stenosis,
medical management incorrect
50–100% stenosis,
plan surgery
0–49% stenosis, plan 
medical management
Conclusive results
Equivocal result:
Perform CA
Diagnostic
test results
Incorrect plan, Figure 18
Outcomes, Figure 19
Surgery, Figure 18
Outcomes, Figure 19
Surgery, Figure 18
Outcomes, Figure 19
Outcomes, Figure 19
Outcomes, Figure 19
CA, Figure 16
FIGURE 17 Decision tree II: diagnostic results after initial testing
Amputation plan incorrect
Modify amputation
Change to bypass
Change to PTA
Change to medical management
Outcomes, Figure 19
Outcomes, Figure 19
Outcomes, Figure 19
Outcomes, Figure 19
Bypass plan incorrect
Change to amputation
Modify bypass
Change to PTA
Change to medical management
Outcomes, Figure 19
Outcomes, Figure 19
Outcomes, Figure 19
Outcomes, Figure 19
PTA plan incorrect
Change to amputation
Change to bypass
Modify PTA
Change to medical management
Outcomes, Figure 19
Outcomes, Figure 19
Outcomes, Figure 19
Outcomes, Figure 19
FIGURE 18 Decision tree III: incorrect treatment planspatients with symptomatic PAD. The choice of the
diagnostic tests to be included in the analysis was
initially based on those tests assessed in the
systematic review (i.e. DUS, MRA, or CTA).
Nevertheless, as indicated above, owing to the
unavailability of relevant data related to the use of
CTA (none of the included or excluded studies
reported information about how patients would be
managed according to the results of a preoperative
CTA test), and in consultation with the expert
panel, the decision was taken to exclude this
diagnostic test from the economic analysis. The
model structure considered two MRA techniques,
2D TOF MRA and CE MRA, as separate
diagnostic techniques, while CA was included as
the reference standard for the imaging of PAD. In
total, there were four preoperative diagnostic
techniques evaluated in the economic analysis
(Figure 16): 
● 2D TOF MRA 
● CE MRA
● DUS
● CA.
Contraindications for the diagnostic tests or
inconclusive test results
The economic literature review suggested that
preoperative diagnostic tests might not be
appropriate for all PAD patients, or may not
always provide a definite result.126,128–130 For the
case purpose of the model, it was considered that
an equivocal test result could be obtained if there
was a contraindication for the patient to undergo
the test, if there was a technical failure of the test,
or if a treatment plan could not be formulated
from the test results.128
Overall, for those patients with inconclusive test
results, any diagnostic test could be subsequently
performed, as a secondary test, to determine the
severity of lesion and derive the appropriate
treatment plan for the patient (with the exception
of those patients with contraindications, for whom
only some specific tests could be performed). The
initial intention was to consider that any of the
diagnostic tests could have been performed as the
secondary test. However, data about accuracy of
the diagnostic tests being serially performed owing
Economic modelling
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Dead, 1 year
Confined to bed, 1 year
Confined to wheelchair, 1 year
Limited ambulance, dependent, 1 year
Limited ambulance, independent, 1 year
Fully ambulant, 1 year
Dead, 1 year
Confined to bed, 1 year
Confined to wheelchair, 1 year
Limited ambulance, dependent, 1 year
Limited ambulance, independent, 1 year
Fully ambulant, 1 year
Surgery within 1 year
of initial treatment
No surgery within 1 year
of initial treatment
Survive initial 
treatment
Do not survive
initial treatment
After amputation, 
bypass, PTA or 
medical management
FIGURE 19 Decision tree IV: outcome at 1 yearto initial inconclusive results were not available in
any of the included studies. As a solution to this
problem, it was assumed that after an inconclusive
test result (or for those patients with
contraindications for MRA), CA would be
undergone to obtain a final conclusive result that
would allow the formulation of the appropriate
treatment plans. In this situation, CA was assumed
to be 100% sensitive and specific. It was further
assumed that after performing CA as a secondary
test to obtain definite results, all the data
associated with this branch were similar to those in
the main branch of CA.
Three of the economic evaluations reviewed
reported the probabilities that MRA and DUS
would lead to equivocal test results.128–130 The
baseline values for these probabilities were chosen
from one of these studies.128 Based on the
information reported by Geitung and
colleagues,126 it was assumed that 5% of patients
would require repeated CA because of inconclusive
findings (Table 13).
Accuracy of the tests
For the base-case analysis, a conclusive test result
would indicate that the patient has no stenoses of
50% or higher in the limb under investigation
(test negative) or stenoses between 50 and 100%
(test positive) in that limb, i.e. the unit of analysis
is the limb.
Regarding the accuracy of the diagnostic tests, the
baseline data included in the model were the
probabilities that the test indicated a degree of
stenosis of less than 50% versus 50% or higher
(p[T(+)]), and the negative predictive values
(NPVs) for stenosis of 0–49% versus 50–100%.
These probabilities were obtained from the studies
included in the systematic review (Table 14).
Sample sizes were used to weight the studies in
order to obtain pooled estimates of the means and
standard errors (SEs) for calculating these
probabilities. As CA was considered the reference
standard, it was assumed to have 100% sensitivity
and specificity. Therefore, the average probability
of having a positive test with CA was equal to the
prevalence of PAD obtained by pooling the results
of the studies included in the systematic review.
The model considers the patient as the focus of
analysis. However, in the studies included in the
systematic review results were mostly reported by
arterial segment, although some studies presented
results by artery32,36,65 or limb21,23,31,63 as the unit
of analysis. Consequently, the units of analysis
tested were not independent of each other because
one patient could have several segments or
arteries evaluated, and either one or both legs. No
information was reported in the studies about the
accuracy of the test results on a patient basis. As
such, it was necessary to assume that the estimates
of sensitivity and specificity were equivalent,
independent of how the results were reported (e.g.
arterial segment, artery or limb). This was an
appropriate assumption given that it has been
shown that this issue affects only the precision of
sensitivity and specificity estimates.661 It has been
further assumed that each patient entering the
model has one leg evaluated. While the authors
acknowledge that it may be possible with certain
techniques to image more that one limb at a time,
it was considered impractical to evaluate both legs
in one session with 2D TOF MRA, according to
expert opinion. Therefore, outcomes have been
reported per patient, per leg.
The probability of having a positive test result with
CA was estimated as the prevalence of stenosis
50% or greater among the total number of
patients in the included studies that evaluated 2D
TOF MRA, CE MRA or DUS versus CA.
Treatment plans
Based on the result obtained with the diagnostic
test a treatment plan will be formulated for each
patient. Following the model structure, patients
diagnosed with 50% or more stenosis could be
treated with PTA, bypass or amputation, according
to the choice of the surgeon, depending on the
technical options and the clinical state of the
patient, while patients diagnosed with less than
50% stenosis would be treated with medical
management. This is a simplification of the reality,
Health Technology Assessment 2007; Vol. 11: No. 20
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TABLE 13 Estimated probabilities of having inconclusive test results with the imaging modalities
Base case Range Sources
Additional work-up with CA for equivocal 2D-MRA results 0 – Eklof, 199832
Additional work-up with CA for equivocal CE MRA results 0.09 0.06–0.14 Visser, 2003128
Additional work-up with CA for equivocal DUS results 0.23 0.08–0.37 Visser, 2003128
Additional work-up with CA for equivocal CA results 0.05 – Geitung, 1996126since other options are available for the treatment
of patients with PAD. For example, endovascular
stents have been used after PTA to improve health
outcomes for specific subgroups of patients with
intermittent claudication. However, a systematic
review comparing the use of stents after PTA with
PTA alone found no significant differences in the
outcomes when studies were combined, and
concluded that there is no clear evidence that
stent following angioplasty should be
recommended.662 This supports the decision of
choosing PTA alone for the model. Patients with
intermittent claudication could also be
recommended to undergo exercise programmes,
which may improve maximal walking distance,663
but a lack of clear evidence led to the exclusion of
this alternative from the model. 
In this sense, the alternative treatments considered
for patients diagnosed with less than 50% stenosis
could be not only medical management but also
angioplasty, which has shown short-term clinical
benefits for patients. In the present model, only
medical management was finally considered, since
there is doubt about the value of angioplasty in
the long-term for this type of patient.664 When
formulating a treatment plan the surgeon would,
in practice, consider a number of factors in
addition to the degree of stenosis, such as the
length and position of stenosis, and the presence
of co-morbidities affecting suitability for surgery.
Literature suggests that both MRA and DUS may
not correctly identify the degree of stenosis in all
patients; in which case, an inaccurate plan may be
formulated.33,40,41,126 In addition, although CA is
assumed to be 100% sensitive and specific, the
treatment plan chosen will depend to some extent
on the interpretation of the test results (i.e. images
obtained) by the radiologist and the surgeon (i.e.
it is subject to inter-observer variability), which
may also lead to the formulation of an inaccurate
treatment plan.40,41
For those patients for whom an inaccurate surgical
intervention is chosen, there is the possibility of
identifying the error and changing the type of
treatment during the procedure.33,40,41,126
The probabilities associated with the treatment
plans chosen by surgeons according to the results
of each of the imaging tests were obtained from
four studies included in the systematic review. Two
of these studies provided information about how
patients would be managed using the results of the
MRA test compared with those of CA,40,41 while
two other studies provided information about
treatment plans for patients undergoing DUS.33,126
The types of data to be identified from these
papers were:
● the treatment plans initially formulated
according to each diagnostic test
● the number and type of inaccurate treatment
plans formulated using each test
● the treatments that were actually performed
according to the intraoperative findings
Economic modelling
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TABLE 14 Pooled estimates associated with the accuracy of the diagnostic tests (0–49% versus 50–100% stenosis for the whole leg)
derived from the systematic review
p[T(+)] SE (p[T(+)]) NPV SE (NPV) Sources
2D TOF MRA 0.468 0.0097 0.881 0.0087 Baum, 1995,22 Hoch, 1996,40 Hoch, 1999,41
Snidow, 1995,64 Yucel, 199374
CE MRA 0.271 0.0064 0.983 0.0023 Cronberg, 2003,28 Laissy, 1998,49
Lenhart, 2000,51 Schafer, 2003,61 Steffens, 2003,67
Sueyoshi,1999,68 Winterer, 199973
DUS 0.222 0.0055 0.969 0.0028 Aly, 1998,20 Ashleigh, 1993,21 Baxter, 1993,23
Bergamini, 1995,24 El-Kayali, 2004,33
Hatsukami, 199237 Legemate, 1991,50
Linke, 1994,52 Sensier, 199662
CA 0.279 0.0039 1 – Aly, 1998,20 Ashleigh, 1993,21 Baum, 1995,22
Baxter, 1993,23 Bergamini, 1995,24
Cronberg, 2003,28 El-Kayali, 2004,33
Hatsukami, 1992,37 Hoch, 1996,40
Hoch, 1999,41 Laissy, 1998,49 Legemate, 1991,50
Lenhart, 2000,51 Linke, 1994,52 Schafer, 2003,61
Sensier, 1996,62 Snidow, 1995,64 Steffens, 2003,67
Sueyoshi, 1999,68 Winterer, 1999,73 Yucel, 199374Health Technology Assessment 2007; Vol. 11: No. 20
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TABLE 15 Estimated probabilities of having PTA, bypass or amputation as the initially formulated treatment plan according to
diagnostic test result
CA MRA DUS
Amputation
El-Kayali, 200433 – – 0.11
Hoch, 199640 0.06 0.06 –
Hoch, 199941 0.04 0.00 –
Pooled estimate 0.05 0.03 0.11
Bypass
El-Kayali, 200433 – – 0.49
Hoch, 199640 0.56 0.58 –
Hoch, 199941 0.67 0.78 –
Pooled estimate 0.62 0.68 0.49
PTA
El-Kayali, 200433 – – 0.41
Hoch, 199640 0.38 0.36 –
Hoch, 199941 0.29 0.22 –
Pooled estimate 0.33 0.29 0.41
● the type of change made for each inaccurate
treatment plan to manage the patient
appropriately.
The aim was to identify:
● the probabilities that a patient would be initially
managed with PTA, bypass or amputation
according to the results of the preoperative test
● the probability that the initial plan was
inaccurate
● the probability that an inaccurate plan would be
managed by modifying the intervention or
changing the management plan.
However, some of these studies failed to report all
the information in a homogeneous way. Moreover,
results were reported in different units of analysis
(i.e. by arterial segment, leg or patient), or in
some instances the unit of analysis was not clearly
specified. To interpret and extract data that could
be used for the estimation of these probabilities,
several assumptions had to be made based on the
conjecture of the researchers dealing with the
papers.
Related to the interpretation of these studies was
the fact that some of them included patients who
had undergone endarterectomy. Endarterectomy is
a surgical procedure which, like bypass grafting,
generally requires either a regional (epidural or
spinal) or a general anaesthetic. For some
peripheral stenoses or occlusions, usually of the
common/external iliac or superficial femoral
arteries, a remote endarterectomy may be
performed. This is a less invasive procedure, which
involves passing an instrument along the artery
from an incision in the groin. Nevertheless,
endarterectomy carries risks that are similar to
both bypass grafting (i.e. perioperative
complications such as haemorrhage, vessel
occlusion by thrombolysis of embolism, infection
and risk from general anaesthesia) and PTA
(vessel rupture, thrombolysis or embolism). For
this reason, two sets of parameters were obtained
to populate the model; for the base-case analysis
endarterectomy was grouped with bypass grafting,
although a sensitivity analysis was performed to
quantify the effect of including people with
endarterectomy in the PTA group. 
To obtain pooled estimates for the probabilities
related to the accuracy of the treatment plans
formulated (i.e. the probabilities of having PTA,
bypass or amputation after the diagnostic test
results, the probabilities of having an inaccurate
treatment plan given the type of treatment
formulated, and the probabilities of changing
from an inaccurate plan to another intervention),
the estimates from the studies were weighted by
their sample size (Tables 15–17).
A relevant issue to highlight at this point is that
the distribution of patient characteristics may not
have been similar across studies. In two of the
studies used for these estimations33,41 patients
were stated to be symptomatic, but no further
characteristics about their severity were reported.
In another study40 18% (8/45) of patients were
Fontaine II, 20% (9/45) were Fontaine III and 62%
(28/45) were Fontaine IV. This seems to be a
disproportionate number with severe disease,which will almost certainly have led to a relatively
high number of amputations in this study. The last
of these studies126 did not report relevant
characteristics for the patients evaluated (only age
and gender). Consequently, the samples in these
studies may not have been representative of the
general population of symptomatic PAD patients. 
Effectiveness of treatments undergone after
diagnosis
The model considers that, after a specific
treatment plan has been followed, intervention-
related mortality may occur. Otherwise, the patient
survives and may or may not require further
surgery within the first year.
Following bypass, 6% of patients would die within
30 days from causes related to the intervention,
while for PTA none of the patients would
experience intervention-related mortality.396 The
probability of amputation-related mortality was
assumed to be the same as that after bypass.665
Once an intervention has been undergone, a
patient may require a secondary procedure within
1 year (Table 18). Data about the percentage of
patients who would undergo secondary procedures
within 1 year, and about the type of procedure
undergone, were scarce. Some assumptions were
therefore formulated:
● Amputation was regarded as an end-point for a
given incidence of disease, and therefore the
proportion of patients with primary amputation
that required further PTA or bypass graft within
a year was assumed to be zero. 
● Similarly, the proportion of patients who had a
PTA after bypass graft was assumed to be zero
on the basis that after bypass, PTA would only
be performed at a new disease site. The use of
PTA to treat stenosis of bypass grafts was not
considered as this is outside the scope of the
current project.
Health states
Patients could end in one of six health states: 
(1) fully ambulant; (2) limited ambulance and
independent; (3) limited ambulance and
dependent; (4) non-ambulant and using a
wheelchair; (5) bedridden; or (6) dead (Table 19).
The probability that a patient ended in each one
of these health states depended on whether the
initial treatment plan was correct or not, and
whether complications such as graft failure,
amputation or death occurred.660
An adjustment was performed for the probabilities
related to the prognosis after amputation for
patients with 50–100% stenosis, medical
management for patients with 50–100% stenosis,
and amputation for patients with less than 50%
stenosis, to overcome the problem that they did
not sum up to one in the original study.660
In addition, these probabilities were adjusted to
account for the fact that some patients may
undergo further revascularisation within 1 year. In
this case the probabilities of ending in a less
favourable health state would increase (Table 20).
For example, the probability of ending in a health
state of independency and full mobility for a
patient initially treated with bypass and
Economic modelling
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TABLE 16 Estimated probabilities of having an inaccurate treatment plan
CA MRA DUS
Inaccurate amputation
El-Kayali, 200433 – – 0.00
Hoch, 199640 0.33 0.33 –
Hoch, 199941 1.00 0.00 –
Pooled estimate 0.66 0.17 0.00
Inaccurate bypass
El-Kayali, 200433 – – 0.11
Hoch, 199640 0.07 0.10 –
Hoch, 199941 0.00 0.11 –
Pooled estimate 0.04 0.10 0.11
Inaccurate PTA
El-Kayali, 200433 – – 0.07
Hoch, 199640 0.11 0.06 –
Hoch, 199941 0.07 0.00 –
Pooled estimate 0.09 0.03 0.07Health Technology Assessment 2007; Vol. 11: No. 20
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TABLE 17 Estimated probabilities of changing plan after inaccurate plan formulation
CA MRA DUS
Amputation incorrect
Modify amputation
El-Kayali, 200433 –– 0 .00
Geitung, 1996126 –– 0 .00
Hoch, 199640 1.00 0.00 –
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.51 0.00 0.00
Change to bypass
El-Kayali, 200433 –– 0 .00
Geitung, 1996126 –– 0 .00
Hoch, 199640 0.00 0.00 –
Hoch, 199941 1.00 0.00 –
Pooled estimate 0.49 0.00 0.00
Change to PTA
El-Kayali, 200433 –– 0 .00
Geitung, 1996126 –– 0 .00
Hoch, 199640 0.00 0.00 –
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.00 0.00 0.00
Change to MM
El-Kayali, 200433 –– 0 .00
Geitung, 1996126 –– 0 .00
Hoch, 199640 0.00 0.00 –
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.00 0.00 0.00
Bypass incorrect
Change to amputation
El-Kayali, 200433 0.00 0.00 –
Geitung, 1996126 –– 0 .00
Hoch, 199640 –– 0 .00
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.00 0.00 0.00
Modify bypass
El-Kayali, 200433 1.00 0.67 –
Geitung, 1996126 – – 0.82
Hoch, 199640 –– 1 .00
Hoch, 199941 0.00 0.00 –
Pooled estimate 1.00 0.34 0.91
Change to PTA
El-Kayali, 200433 0.00 0.33 –
Geitung, 1996126 – – 0.18
Hoch, 199640 –– 0 .00
Hoch, 199941 0.00 1.00 –
Pooled estimate 0.00 0.66 0.09
Change to MM
El-Kayali, 200433 0.00 0.00 –
Geitung, 1996126 –– 0 .00
Hoch, 199640 –– 0 .00
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.00 0.00 0.00
continuedsubsequently requiring further surgery within
1 year was estimated as follows:
ProbFMb_Byp_surg =
ProbByp_surgAmp*ProbFMb_Amp +
ProbByp_surgByp*ProbFMb_Byp +
ProbByp_surgPTA*ProbFMb_PTA
where ProbFMb_Byp_surg is the probability of
ending in a health state of independency and full
mobility for a patient treated initially with bypass
and requiring further surgery within 1 year,
ProbByp_surgAmp is the probability that the
revascularisation procedure performed within 1 year
was amputation, ProbFMb_Amp is the probability of
ending fully ambulant after initial amputation,
ProbByp_surgByp is the probability that the
revascularisation procedure performed within 1 year
was bypass, ProbFMb_Byp is the probability of
ending fully ambulant after initial bypass,
ProbByp_surgPTA is the probability that the
revascularisation procedure performed within 1 year
was PTA; and ProbFMb_PTA is the probability of
ending fully ambulant after initial PTA.
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TABLE 17 Estimated probabilities of changing plan after inaccurate plan formulation (cont’d)
CA MRA DUS
PTA incorrect
Change to amputation
El-Kayali, 200433 –– 0 .00
Geitung, 1996126 –– 0 .00
Hoch, 199640 0.00 0.00 –
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.00 0.00 0.00
Change to bypass
El-Kayali, 200433 –– 0 .00
Geitung, 1996126 –– 1 .00
Hoch, 199640 0.00 0.00 –
Hoch, 199941 1.00 0.00 –
Pooled estimate 0.49 0.00 0.49
Modify PTA
El-Kayali, 200433 –– 0 .00
Geitung, 1996126 –– 0 .00
Hoch, 199640 1.00 1.00 –
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.51 1.00 0.00
Change to MM
El-Kayali, 200433 –– 1 .00
Geitung, 1996126 –– 0 .00
Hoch, 199640 0.00 0.00 –
Hoch, 199941 0.00 0.00 –
Pooled estimate 0.00 0.00 0.51
MM, medical management.
TABLE 18 Probability of having a revascularisation procedure among patients undergoing surgery within 1 year after initial treatment
Amputation Bypass PTA Total probability of  Sources
surgery within 1 year
After amputation 1.00 0.00 0.00 0.56 Peters, 1998666
Assumption
After bypass 0.78 0.22 0.00 0.18 Holm, 1991667
After PTA 0.52 0.05 0.43 0.40 Holm, 1991667
After MM 0.07 0.19 0.74 0.27 Vascular Surgical Society of Great
Britain and Ireland, 2003668
Expert opinionHealth Technology Assessment 2007; Vol. 11: No. 20
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TABLE 19 Health states at 1 year after diagnosis and treatment of PAD patients
Event Probability Source
Stenosis 50–100%, amputation
Full mobility 0.04 Berry, 2002,660 Davies, 1991,669 assumption
Limited mobility, independent 0.18 Berry, 2002660
Limited mobility, dependent 0.2 Berry, 2002660
Wheelchair 0.32 Berry, 2002660
Bedridden 0.01 Berry, 2002660
Dead 0.25 Berry, 2002660
Stenosis 50–100%, bypass
Full mobility 0.05 Berry, 2002660
Limited mobility, independent 0.29 Berry, 2002660
Limited mobility, dependent 0.32 Berry, 2002660
Wheelchair 0.19 Berry, 2002660
Bedridden 0.01 Berry, 2002660
Dead 0.14 Berry, 2002660
Stenosis 50–100%, PTA
Full mobility 0.05 Berry, 2002660
Limited mobility, independent 0.26 Berry, 2002660
Limited mobility, dependent 0.29 Berry, 2002660
Wheelchair 0.28 Berry, 2002660
Bedridden 0.01 Berry, 2002660
Dead 0.11 Berry, 2002660
Stenosis 50–100%, MM
Full mobility 0.04 Berry, 2002,660 Davies, 1991,669 assumption
Limited mobility, independent 0.18 Berry, 2002660
Limited mobility, dependent 0.2 Berry, 2002660
Wheelchair 0.32 Berry, 2002660
Bedridden 0.01 Berry, 2002660
Dead 0.25 Berry, 2002660
Stenosis <50%, amputation
Full mobility 0.04 Berry, 2002,660 Davies, 1991,669 assumption
Limited mobility, independent 0.18 Berry, 2002660
Limited mobility, dependent 0.2 Berry, 2002660
Wheelchair 0.32 Berry, 2002660
Bedridden 0.01 Berry, 2002660
Dead 0.25 Berry, 2002660
Stenosis <50%, bypass
Full mobility 0.06 Berry, 2002660
Limited mobility, independent 0.33 Berry, 2002660
Limited mobility, dependent 0.36 Berry, 2002660
Wheelchair 0.14 Berry, 2002660
Bedridden 0 Berry, 2002660
Dead 0.11 Berry, 2002660
Stenosis <50%, PTA
Full mobility 0.07 Berry, 2002660
Limited mobility, independent 0.37 Berry, 2002660
Limited mobility, dependent 0.4 Berry, 2002660
Wheelchair 0.16 Berry, 2002660
Bedridden 0 Berry, 2002660
Dead 0 Berry, 2002660
Stenosis <50%, MM
Full mobility 0.07 Berry, 2002660
Limited mobility, independent 0.37 Berry, 2002660
Limited mobility, dependent 0.4 Berry, 2002660
Wheelchair 0.16 Berry, 2002660
Bedridden 0 Berry, 2002660
Dead 0 Berry, 2002660For those patients who initially underwent primary
amputation and subsequently required further
surgery within the first year of treatment, it was
assumed that the probabilities of ending in the
different health states were the same as for initial
amputation (although this was considered to be
the best case scenario in relation to these
parameters).
Life expectancy and quality of life
Life expectancy for those patients dying within the
first year was assumed to be 6 months to account
for differences in survival times through the year.
For those patients experiencing intervention-
related mortality, life expectancy was assumed to
be zero since these patients are more likely to die
during or just after the intervention. Evidence
about long-term survival according to each of the
possible health states was uncertain,660 which led
to limiting the period of analysis to 1 year for the
long-term model.
Health utility values were assigned to each of the
possible health states according to those previously
published660 (Table 21). QALYs were estimated by
multiplying the health utility values by the
estimated life expectancy.
Following expert opinion, it was assumed that
those patients undergoing a revascularisation
procedure within the first year after initial
treatment would experience a reduction in their
quality of life of 30%, 15% or 5% during the
period of recovery (which was estimated to be
2 months), depending on whether the
revascularisation procedure undergone was PTA,
bypass or amputation, respectively. To estimate the
utilities associated with the possible end health
states after revascularisation within 1 year, these
reductions in quality of life were weighted by the
probabilities that the type of procedure undergone
would be PTA, bypass or amputation. For
example, the utility associated with the health
state of a patient initially managed with medical
treatment, requiring a revascularisation procedure
during the first year of treatment and ending with
full mobility, was estimated as follows:
UMM_surg = [10/12 + 2/12 * (1 – 0.30 *
Prob_MM_surgAmp – 0.15 * Prob_MM_surgByp –
0.05 * Prob_MM_surgPTA)] * U_FMb
where UMM_surg is the utility obtained by a
patient receiving initially medical treatment 
and requiring a revascularisation procedure 
within 1 year after initial treatment,
Prob_MM_surgAmp, Prob_MM_surgByp and
Prob_MM_surgPTA are the probabilities that a
patient under initial medical management (MM)
and requiring a revascularisation procedure 
within 1 year would undergo amputation, bypass
or PTA, respectively, and U_FMb is the utility
associated with the health state of being
independent and with full mobility for those
patients not requiring further interventions within
1 year (Table 22).
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TABLE 20 Probabilities of ending in different health states for patients undergoing further revascularisation procedures within 1 year
Health state After initial  After initial  After initial  After initial MM 
amputation bypass PTA (50–100% stenosis)
Full mobility 0.040 0.042 0.045 0.049
Limited mobility, independent 0.180 0.204 0.230 0.260
Limited mobility, dependent 0.200 0.226 0.254 0.289
Wheelchair, dependent 0.320 0.291 0.268 0.266
Bedridden 0.010 0.010 0.010 0.010
Dead 0.250 0.226 0.194 0.126
TABLE 21 Utility values of health states following treatment of
PAD
Health state Utility value
Full mobility
Amputation 0.83
Critical limb ischaemia 0.83
Claudication 0.83
Limited mobility, independent:
Amputation 0.56
Critical limb ischaemia 0.73
Claudication 0.78
Limited mobility, dependent:
Amputation 0.56
Critical limb ischaemia 0.69
Claudication 0.69
Wheelchair, dependent 0.46
Bedridden 0.33
Dead 0.00
Source: Berry et al. (2002).660Costing
The perspective adopted for the economic
evaluation was that of the service provider (UK
NHS). According to this perspective, the costs
included in the economic analysis were the direct
medical costs incurred in performing the
preoperative diagnostic tests (and secondary CA
for those inconclusive tests or those patients with
contraindications), costs of treatments (i.e. PTA,
bypass, amputation, medical management, and
costs derived from intervention-related mortality)
and follow-up costs.
The costs of major complications associated with
CA128 were also included in the economic
evaluation. Other diagnostic procedure-related
costs incurred due to adverse events were excluded
as the adverse events obtained from the systematic
review were not considered representative of the
actual adverse events experienced by patients
while undergoing the preoperative diagnostic tests
(since not all the studies reported information
about adverse events). Moreover, most of the
adverse events reported in the studies did not
imply an incurrence of costs, and when they did,
the costs were considered to be negligible. 
The costs of the vascular interventions included
theatre time and the time spent in the intensive
care unit, the high-dependency unit and other
inpatient wards. The cost of the amputation was
averaged according to the percentage of patients
undergoing amputations at the below- and above-
knee level (i.e. 40% of the amputations performed
would be at the below-knee level, according to 
UK data).670
In addition, there were costs related to the
adjustment of the treatment plans that were
inaccurately formulated after the diagnostic result.
The probability that an initially formulated
amputation would be changed to medical
treatment is remote (a zero probability was
observed in the primary studies providing these
types of data).33,40,41,126 However, the possibility
exists that a patient with limb-threatening
ischaemia requiring amputation may decide not to
undergo the procedure and to receive only medical
treatment. Therefore, the costs of changing from
amputation to medical management were assumed
to be zero. In the unlikely case that a treatment
plan was changed from bypass to medical
treatment, the associated costs were assumed to be
those of a normal bypass. The costs incurred while
changing other types of inaccurately formulated
treatment plans are reported in Table 23.
A retrospective study evaluating data from the
Trent Regional Database (UK) reported data about
the rates of secondary procedures undergone by
patients with PAD within the same admission
considering a follow-up period of 2 years
(1995–1997).670 As the authors stated, these rates
were likely to be underestimated. However, they
were used in the present analysis to estimate more
accurately the costs associated with the surgical
procedures undergone. The fact that some
patients may require further surgery within the
same admission was also considered in the cost
estimation (Table 24).
The costs of outpatient visits related to the vascular
procedure undergone have been included670
(Table 25) and were estimated according to the
type of vascular procedure. In the case of either
amputation or bypass, the patient incurred a total
of three outpatient visits, whereas in the case of
PTA only two outpatient visits were required.
The costs associated with any additional surgery
required at 1 year were estimated according to the
proportion of patients that would experience
recurrent ischaemia at 1 year and, consequently,
would require further intervention (Table 18). The
costs incurred in performing the preoperative
diagnostic tests, the costs due to inconclusive test
results and those of CA complications (when this
test was performed) were also included in the cost
estimation of surgery within 1 year after initial
treatment.
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TABLE 22 Utilities for patients undergoing further revascularisation procedures within one year
Health state After  After  After  After MM  After MM 
amputation bypass PTA (50–100% stenosis) (0–49% stenosis)
Full mobility 0.789 0.793 0.800 0.818 0.818
Limited mobility, independent 0.532 0.698 0.704 0.719 0.744
Limited mobility, dependent 0.532 0.659 0.665 0.680 0.680
Wheelchair, dependent 0.437 0.440 0.443 0.453 0.453
Bedridden 0.314 0.318 0.318 0.325 0.325
Dead 0.266 0.330 0.333 0.340 0.340Economic modelling
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T
ABLE 23
Resource use and costs associated with diagnostic procedures and follow
-up
R
esource use
Unit costs (£ 2004)
Estimated costs (£ 2004)
A
verage
R
ange (95% CI)
Source
A
verage
R
ange
Source
A
verage
R
ange
P
reoperative diagnostic tests
CA
CA, including capital equipment
1
No range
Berry
, 2002
660
492.30
432.79–704.37
Berry
, 2002
660
536.80
215.56–914.04
Complications of CA
–
–
Visser
, 2003
129
–
–
Visser
, 2003
129
5740.35
3183.47–8300.33
MRA
MRA, including capital equipment
1
No range
Berry
, 2002
660
462.00
450.10–502.04
Berry
, 2002
660
462.00
450.10–502.04
DUS
DUS
1
No range
92.49
72.90–134.34
DH
, 2004
671
92.49
72.90–134.34
Amputation
Above-knee primary
Theatre time (minutes)
125
100–150
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
1081.98
907.51–1132.02
Intensive care unit (hours)
6
5–7.2
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
312.42
283.21–341.36
High-dependency unit (hours)
4
3.3–5
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
23
20.75–25.47
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
4852.66
4554.04–5151.29
6328.02
5825.36–6705.99
Above-knee plan changed to bypass
Theatre time (minutes)
312
No range
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
2700.61
2265.14–2825.51
Intensive care unit (hours)
4
3.58–5.36
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
208.28
188.80–227.58
High-dependency unit (hours)
4
2.94–4.4
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
14
13.51–25.5
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
2953.79
2772.02–3135.57
5943.65
5306.57–6269.98
Above-knee revision, readmission
Theatre time (minutes)
114
83–144
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
986.76
827.65–1032.40
Intensive care unit (hours)
6
5–7.2
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
312.42
283.21–341.36
High-dependency unit (hours)
4
3.3–5
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
23
20.75–25.47
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
4852.66
4554.04–5151.29
6232.81
5745.50–6606.38
Below knee primary
Theatre time (minutes)
156
125–187
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
1350.31
1132.57–1412.76
Intensive care unit (hours)
6
5–7.2
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
312.42
283.21–341.36
High dependency unit (hours)
4
3.3–5
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
23
20.75–25.47
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
4852.66
4554.04–5151.29
6596.35
6050.42–6986.73
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T
ABLE 23
Resource use and costs associated with diagnostic procedures and follow
-up (cont’d)
R
esource use
Unit costs (£ 2004)
Estimated costs (£ 2004)
A
verage
R
ange (95% CI)
Source
A
verage
R
ange
Source
A
verage
R
ange
Below
-knee plan changed to bypass
Theatre time (minutes)
312
No range
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
2700.61
2265.14–2825.51
Intensive care unit (hours)
4
3.58–5.36
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
208.28
188.80–227.58
High-dependency unit (hours)
4
2.94–4.4
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
14
13.51–25.5
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
2953.79
2772.02–3135.57
5943.65
5306.57–6269.98
Below
-knee revision, readmission
Theatre time (minutes)
114
83–144
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
986.76
827.65–1032.40
Intensive care unit (hours)
6
5–7.2
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
312.42
283.21–341.36
High-dependency unit (hours)
4
3.3–5
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
23
20.75–25.47
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
4852.66
4554.04–5151.29
6232.81
5745.50–6606.38
Bypass
Bypass primary
Theatre time (minutes)
199
190–318
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
1722.51
1444.75–1802.17
Intensive care unit (hours)
4
3.58–5.36
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
208.28
188.80–227.58
High-dependency unit (hours)
4
2.94–4.4
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
14
13.51–25.5
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
2953.79
2772.02–3135.57
4965.55
4486.18–5246.64
Bypass plan changed to amputation
Theatre time (minutes)
199
190–318
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
1722.51
1444.75–1802.17
Intensive care unit (hours)
4
3.58–5.36
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
208.28
188.80–227.58
High-dependency unit (hours)
4
2.94–4.4
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
14
13.51–25.5
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
2953.79
2772.02–3135.57
4965.55
4486.18–5246.64
Bypass plan changed to PT
A
Theatre time (minutes)
199
190–318
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
1722.51
1444.75–1802.17
Intensive care unit (hours)
0
No range
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
0.00
0.00–0.00
High-dependency unit (hours)
0
No range
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
0.00
0.00–0.00
Other inpatient ward (days)
3
2.29–3.18
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
632.96
594.00–671.91
2355.46
2038.76–2474.08
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T
ABLE 23
Resource use and costs associated with diagnostic procedures and follow
-up (cont’d)
R
esource use
Unit costs (£ 2004)
Estimated costs (£ 2004)
A
verage
R
ange (95% CI)
Source
A
verage
R
ange
Source
A
verage
R
ange
Bypass revision, readmission
Theatre time (minutes)
199
190–318
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
1722.51
1444.75–1802.17
Intensive care unit (hours)
4
3.58–5.36
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
208.28
188.80–227.58
High-dependency unit (hours)
4
2.94–4.4
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
14
13.51–25.5
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
2953.79
2772.02–3135.57
4965.55
4486.18–5246.64
PT
A
PT
A primary
Theatre time (minutes)
63
50–75
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
545.32
457.38–570.54
Intensive care unit (hours)
0
No range
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
0.00
0.00–0.00
High-dependency unit (hours)
0
No range
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
0.00
0.00–0.00
Other inpatient ward (days)
3
2.29–3.18
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
632.96
594.00–671.91
1178.27
1051.39–1242.44
PT
A plan changed to bypass
Theatre time (minutes)
261
No range
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
2259.16
1894.87–2363.65
Intensive care unit (hours)
4
3.58–5.36
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
208.28
188.80–227.58
High-dependency unit (hours)
4
2.94–4.4
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
14
13.51–25.5
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
2953.79
2772.02–3135.57
5502.21
4936.31–5808.12
PT
A plan changed to amputation
Theatre time (minutes)
219
No range
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
1895.62
1589.95–1983.29
Intensive care unit (hours)
6
5–7.2
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
312.42
283.21–341.36
High-dependency unit (hours)
4
3.3–5
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
80.97
80.61–81.33
Other inpatient ward (days)
23
20.75–25.47
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
4852.66
4554.04–5151.29
7141.67
6507.80–7557.27
PT
A plan changed to MM
–
–
Visser
, 2003
129
–
–
Visser
, 2003
129
245.36
122.68–368.04
PT
A revision, readmission
Theatre time (minutes)
63
50–75
Berry
, 2002
660
8.66
7.26–9.06
Berry
, 2002
660
545.32
457.38–570.54
Intensive care unit (hours)
0
No range
Berry
, 2002
660
52.07
47.20–56.89
Berry
, 2002
660
0.00
0.00–0.00
High-dependency unit (hours)
0
No range
Berry
, 2002
660
20.24
20.15–20.33
Berry
, 2002
660
0.00
0.00–0.00
Other inpatient ward (days)
3
2.29–3.18
(95% CI)
Berry
, 2002
660
210.99
198.00–223.97
Berry
, 2002
660
632.96
594.00–671.91
1178.27
1051.39–1242.44
Mortality from vascular interventions
–
–
Visser
, 2003
129
–
–
Visser
, 2003
129
9906.04
3067.01–17051.00
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T
ABLE 23
Resource use and costs associated with diagnostic procedures and follow
-up (cont’d)
R
esource use
Unit costs (£ 2004)
Estimated costs (£ 2004)
A
verage
R
ange (95% CI)
Source
A
verage
R
ange
Source
A
verage
R
ange
L
ong-term costs
F
ull mobility
1
No range
Berry
, 2002
660
0.00
–
Berry
, 2002
660
0.00
–
Limited mobility
, independent
1
No range
Berry
, 2002
660
771.45
0.00–1541.82
Berry
, 2002
660
771.45
0.00–1541.82
Limited mobility
, dependent
1
No range
Berry
, 2002
660
7290.35
1541.82–13038.89
Berry
, 2002
660
7290.35
1541.82–13038.89
Wheelchair
1
No range
Berry
, 2002
660
13169.81
11387.79–14950.74
Berry
, 2002
660
13169.81
11387.9–14950.74
Bedridden
1
No range
Berry
, 2002
660
22150.20
14950.74–29348.59
Berry
, 2002
660
22150.20
14950.74–29348.59
Medical management 
(i.e. aspirin; mg per day; 
75
No range
BNF
, 2005
672
0.04
0.01–0.06
BNF
, 2005
672
14.66
3.47–20.21
unit cost per day; estimated 
cost per year)
BNF
, British National Formulary; DH
, Department of Health.Independently of whether or not patients undergo
an invasive treatment intervention, medical
management, consisting of antiplatelet therapy
(generally aspirin),171 is recommended for all
patients with PAD. Therefore, the cost of medical
management with aspirin (300 mg per day) for all
patients was also included in the economic
analysis. Moreover, it has been stated that patients
should follow risk-factor modification therapies,
such as smoking cessation, and controlling
hyperlipidaemia, diabetes and hypertension.151,673
However, these costs were not considered in the
economic analysis since these risk-factor
modification therapies appeared to be
underused.151,670
The short-term model included only the costs of
performing the diagnostic procedures plus any
additional costs incurred while formulating and
performing an incorrect plan (Table 26). This was
estimated as the costs of performing the initially
incorrect treatment plan and changing it
subsequently during the intervention minus the
costs that would have been incurred in case the
appropriate treatment plan had been performed
initially. In the cases in which an initially incorrect
PTA, bypass or amputation were modified, there
were no data available that allowed an estimation
of these differential costs; therefore, they were
assumed to be zero (since the costs associated with
these modifications are likely to be very similar to
performing the appropriate plan initially). There
was a lack of information about the costs of
changing from bypass to medical management,
and therefore it was assumed to be equal to the
cost of changing from PTA to medical
management. This may have led to an
underestimation of these costs, since bypass is a
more invasive and more expensive procedure than
PTA. However, it is expected that the difference
would not have a significant impact on the final
cost-effectiveness results. In addition, the costs of
changing from incorrect amputation to PTA were
assumed to be equal to those of changing from
incorrect amputation to bypass. In this case, these
costs may have been overestimated for the same
reason as previously explained, although, as
before, this overestimation is not expected to affect
relevantly the results of the economic analysis.
The costs per incorrect treatment plan were
estimated as the cost average of having incorrect
amputation, bypass or PTA weighted by the
corresponding probabilities of these events
happening.
For example, the costs incurred when an incorrect
amputation was formulated after MRA and had to
be changed or modified was estimated as follows:
cIncAmp_MRA = pIncAmp_Amp_MRA *
cIncAmp_Amp + pIncAmp_Byp_MRA *
cIncAmp_Byp + pIncAmp_PTA_MRA *
cIncAmp_PTA + pIncAmp_MM_MRA *
cIncAmp_MM 
where cIncAmp_MRA was the additional costs
incurred when an incorrect amputation plan was
formulated and had to be changed or modified
after MRA results, pIncAmp_Amp_MRA,
pIncAmp_Byp_MRA, pIncAmp_PTA_MRA and
pIncAmp_MM_MRA were the probabilities of
having an initially inaccurate amputation plan
followed by an appropriate modification to
alternative amputation, bypass, PTA or medical
management, respectively, after an MRA test
result; and cIncAmp_Amp, cIncAmp_Byp,
cIncAmp_PTA and cIncAmp_MM were the
additional costs incurred when an incorrect
amputation plan had to be modified to another
amputation, bypass, PTA or medical management.
All costs were adjusted for inflation, using the Pay
and Prices Indices for Hospital and Community
Health Services (HCHS), in order to reflect 2004
costs in UK sterling pounds (£). Owing to the
limited time-horizon of the analysis, 1 year,
discounting was not relevant, and as such, has not
been conducted.
Costs were obtained from a variety of sources and,
where necessary, these have been converted to UK
Economic modelling
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TABLE 24 Probabilities of patients undergoing a secondary
procedure within the same admission
Primary procedure Amputation Bypass PTA
Amputation 0.04 0.13 0.13
Bypass 0.00 0.29 0.00
PTA 0.00 0.00 0.05
Source: Michaels et al. (2000).670
TABLE 25 Number of outpatient visits per admission according
to the vascular procedure undergone
Vascular procedure Outpatient visits
Amputation 3
Bypass 3
PTA 2
Source: Michaels et al. (2000).670costs using purchasing power parity (PPP)
indices.674 For example, the costs related to CA
complications, the mortality costs associated with
the vascular interventions and the extra costs due
to planned but not performed PTA were obtained
in an aggregate manner and from other settings129
and were converted into UK cost data using the
PPP indices.
Cost-effectiveness analysis
Incremental analysis of costs and consequences
To compare the costs and consequences of the
alternative diagnostic imaging techniques, cost-
effectiveness ratios (CERs) were estimated as the
cost per unit of health benefit gained in the
economic analysis. In the short-term model, the
CER was estimated as the cost per correctly
diagnosed patient for whom an accurate treatment
plan was formulated (CDPwATP). In the long-term
model, the CER was calculated as the cost per
QALY gained. 
Those strategies with lower effectiveness and
higher costs (i.e. dominated strategies) were
eliminated from the analysis, and incremental
cost-effectiveness ratios (ICERs) were estimated 
for the remaining strategies as the incremental
cost per correctly diagnosed patient for whom 
an accurate treatment plan was formulated 
in the case of the short-term model, and as 
the incremental cost per QALY gained in the 
case of the long-term model, when two 
alternative diagnostic imaging techniques were
compared. 
Dealing with uncertainty
A probabilistic sensitivity analysis (PSA) was
performed to incorporate statistical uncertainty
into the cost-effectiveness analysis. This allowed
assessment of the effect of varying simultaneously
different variables on the study results (on both
costs and consequences). Appropriate parameter
distributions were chosen, according to the nature
of the variables, for those input parameters for
which suitable data were available. Beta
distributions were generally used for the
probability parameters where only two categories
of events were possible (i.e. test result showing
50–100% degree of stenosis versus 0–49%;
management plan incorrect versus correct, etc.).
For those input parameters presenting more than
two categories of events, a Dirichlet distribution was
used in order to account for the polychotomous
nature of the variable. A Dirichlet distribution was
applied for the following types of events:
● After a 50–100% degree of stenosis was detected
with the test, there were three possible events:
amputation, bypass or PTA. 
● An incorrectly formulated treatment plan could
end in amputation, bypass, PTA or medical
management.
Some of these events had a zero probability
according to the data retrieved from the studies
reporting information about the formulation of
the treatment plans after the diagnostic test results
(see Tables 16 and 17). For example, the observed
probability of changing from an initially
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TABLE 26 Incremental costs incurred while formulating and performing an incorrect treatment plan
Estimated costs (£ 2004)
Average Range Source
Amputation
Modify amputation  0 – Assumption
Amputation changed to bypass 978.11 820.39–1023.34 Berry, 2002,660 Michaels, 2000670
Amputation changed to PTA 978.11 820.39–1023.34 Assumption (same as for bypass)
Amputation changed to MM 0 – Assumption
Bypass
Bypass plan changed to amputation 706.31 592.42–738.98 Assumption (based on Berry, 2002660 for PTA)
Modify bypass 0 – 
Bypass plan changed to PTA 1177.19 987.37-1231.63 Berry, 2002660
Bypass plan changed to MM 0 – Assumption (i.e. same as for bypass)
PTA
PTA plan changed to amputation 706.31 592.42–738.98 Berry, 2002660
PTA plan changed to bypass 536.66 450.12–561.48 Berry, 2002660
Modify PTA 0 – Assumption
PTA plan changed to MM 245.36 122.68–368.04 Visser, 2003129formulated incorrect bypass to amputation was
zero for all the tests considered at analysis.
However, the fact that some of the events were not
observed in these trials does not mean that they
cannot occur in clinical practice. A Bayesian
approach was adopted in order to overcome the
problem of zero counts encountered for some of
the probabilities within the multivariate
distributions. Following the method proposed by
Briggs,675 an uninformative prior distribution was
specified by assuming it as uniform (i.e. all the
possible events had the same probability of
happening). This prior distribution was combined
with the observed counts to obtain the posterior
Dirichlet distribution for these model parameters.
However, the number of observed counts in the
retrieved studies was very low and consequently
there was concern that a prior uniform
distribution combined with the observed counts
could considerably bias the likelihood of events
happening, weighting the probabilities in favour
of those events less likely to happen. To ensure
that the observed data dominated the prior
distribution, the observed counts were multiplied
by 1000, therefore making the probabilities of
those events non-observed in the clinical trials
very low, but still possible. Further analyses were
performed to assess the impact of using this
adjustment: in sensitivity analyses the observed
counts were multiplied by 100 and by 10. 
The probabilistic distributions assigned to the
event ‘formulation of an incorrect amputation
after DUS’, and all subsequent events associated
with changes of initial incorrectly formulated
amputation after DUS, were assumed to be the
same as those observed after MRA, to overcome
the problem of observing zero counts. This was
based on the fact that DUS presented a
distribution of observed counts more similar to
that presented by MRA than that of CA.
Given the type of data available for the cost
parameters (i.e. means and ranges), it was
necessary to assume that the lower and upper
values of the ranges were those corresponding to
the interquartile ranges.676 After assuming a
normal distribution for these parameters, the
standard errors of the costs were estimated. To
ensure that the cost results simulated could not
become negative, a gamma distribution was fitted
using the method of moments approach.
No information about the covariance structure
that correlates parameters was available.
Therefore, it had to be assumed that the
parameters varied independently. 
The distributions assigned to the parameters 
used in the baseline PSA for the 1-year time
horizon model have been reported in 
Appendix 8.
Cost-effectiveness acceptability curves (CEACs)
were used to summarise uncertainty. CEACs
assess what the chance is for each alternative
diagnostic test to be cost-effective according to the
willingness to pay per unit of health benefit
obtained (in the long-term model, per QALY, and
in the short-term model, per CDPwATP).
Reporting of incremental results by means of
CEACs overcomes the problem of interpreting
confidence intervals for ICERs when these are
negative.677
The accuracy of the tests for above-the-knee and
below-the-knee comparisons, separately,
considering a threshold of 50–100% stenosis, was
assessed in the sensitivity analysis. Only one
included study evaluated the results for the above-
the-knee diagnosis with 2D TOF MRA, two
included studies assessed CE MRA, and seven
studies assessed DUS. For the below-the-knee
comparisons, only one study assessed the results
with 2D TOF MRA, three studies assessed 
CE MRA and four assessed DUS. To perform the
simulation, it had to be assumed that the
distribution of the parameters after the results of
the diagnostic tests would be the same
independently of whether the whole leg or only a
section of the leg was assessed. For those
parameters obtained from a unique study, a
probabilistic distribution was not assigned and,
therefore, they were left as deterministic.
Results from the probabilistic
cost-effectiveness analysis
Short-term model
The results for the baseline short-term model
(Table 27) show that 2D TOF MRA was the least
effective and least costly strategy, achieving a
correct diagnosis followed by an accurate
formulated treatment plan in 88.9% of the cases,
at a cost of £492 per CDPwATP. CE MRA and
DUS were more effective and more costly than 2D
TOF MRA, both obtaining 96.2% of CDPwATP at
a cost of £697 and £657 per CDPwATP,
respectively. CE MRA was found to be dominated
by DUS since it obtained the same effectiveness
but at a higher average cost per diagnosed
patient. The most effective strategy, but also the
most expensive, was CA, with 97.8% of CDPwATP,
at a cost of £2558 per CDPwATP.
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in Table 28. The results show that the incremental
cost incurred by DUS to obtain an additional
CDPwATP was £2260, compared with 2D TOF
MRA. Whereas every additional CDPwATP
obtained with CA compared with DUS incurred an
additional cost of £122,171, which would appear
to be an excessive cost if compared with the
implicit ICER threshold used by the National
Institute for Health and Clinical Excellence
(NICE) to approve pharmaceutical products.678
The cost-effectiveness plane for the above results
is presented in Figure 20.
The uncertainty captured in the PSA can be seen
visually in the scatterplot (Figure 21). It is clear
that in terms of costs, CA (top right cloud) has a
wide dispersion of points, compared with 2D TOF
MRA (bottom left cloud), which presents a high
dispersion in terms of effectiveness, but shows
more tightly clustered results in terms of costs.
The similarities presented by DUS and CE MRA
(bottom right clouds) in terms of costs and
effectiveness can be observed from the plot,
although DUS tends to be have a more highly
concentrated scattering of points in a slightly
lower cost band, and therefore it would appear to
dominate CE MRA. 
A CEAC represents the probability that a health
technology falls in the right section of the cost-
effectiveness plane,677 which means that, when
compared with another health technology, it
achieves higher effectiveness (at higher, the same
or at lower cost). The interpretation of the CEACs
has been performed according to that presented
by Fenwick and colleagues,679 which described the
CEACs as a graphic transformation of the cost-
effectiveness plane, representing the joint
densities of the incremental costs and effects. 
According to this interpretation, DUS in some
cases results in cost-savings as the curve does not
cut the y-axis at zero. However, health gains are
not obtained through all of its density since the
curve does not asymptote to 1. A similar situation
is found for the CEAC of CE MRA, although the
health gains obtained are lower than with DUS.
The fact that the CEAC for DUS is the curve that
most closely approaches 1 when the willingness-to-
pay threshold increases indicates that DUS is the
alternative that most frequently shows health
benefits through its density (even if it does not
always achieve health benefits) (Figure 22).
The CEAC for 2D TOF MRA also shows some
cost-savings, although not always health gains
(again, since the curve does not asymptote to 1).
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TABLE 27 Baseline cost-effectiveness results for the short-term model
Mean SD Minimum Median Maximum
2D TOF MRA Cost (£ 2004) 492 16 444 492 544
CDPwATP 0.889 0.014 0.839 0.89 0.922
CER 554 24 492 552 647
CE MRA Cost (£ 2004) 697 56 564 689 923
CDPwATP 0.962 0.007 0.933 0.962 0.979
CER 725 59 589 717 968
DUS Cost (£ 2004) 657 138 371 639 1,250
CDPwATP 0.962 0.008 0.926 0.963 0.979
CER 682 144 387 665 1,300
CA Cost (£ 2004) 2,558 628 1,271 2,494 5,196
CDPwATP 0.978 0.008 0.944 0.979 0.996
CER 2,617 644 1,308 2,544 5,271
TABLE 28 Baseline incremental cost-effectiveness results (short-term model)
Strategy Cost Incremental Effectiveness Incremental  C/E Incremental  C/E 
cost effectiveness (ICER)
2D TOF MRA 492.0264 – 0.889271 – 553.2918 –
DUS 656.5048 164.4785 0.962042 0.072771 682.4077 2,260.223
CE MRA 696.8975 40.39268 0.961704 –0.00034 724.6486 Dominated
CA 2,557.801 1901.296 0.977604 0.015563 2616.396 122,171.4CA is the more costly alternative and, in addition,
it shows lower effectiveness. This is displayed by
the fact that its CEAC does not cut the y-axis at 0
and asymptotes to a value higher than 0 but much
lower than 1 (indicating the existence of health
benefits, but not throughout its density).
Long-term model
The results of the baseline analysis for the 1-year
time-horizon model are reported in Table 29. It
can be observed from the results that DUS and CA
are the diagnostic procedures associated with the
highest health benefit, obtaining 0.64 QALYs for
the 1-year period considered. CE MRA achieves
an insignificantly lower number of QALYs for the
first year (0.639), while 2D TOF MRA is the
diagnostic procedure with the lowest health
benefits (0.61 QALYs). In terms of costs, DUS was
the diagnostic procedure with the lowest costs.
Since DUS presented the highest effectiveness at
the lowest cost, it was the dominant strategy for
the baseline analysis. Consequently, an
incremental cost-effectiveness analysis was not
performed for the baseline analysis of the 1-year
Economic modelling
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FIGURE 20 Cost-effectiveness plane for baseline analysis (short-term model)
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FIGURE 21 Scatter plot for PSA (baseline short-term model)time-horizon model as all the other strategies
considered were dominated. The baseline results
are presented in Table 29. The findings show that
the cost incurred with DUS to obtain one QALY
was £13,646. 
Figure 23 presents the cost-effectiveness plane for
the above results. In addition, the cumulative
probabilities for the distributions of costs, health
benefits (i.e. QALYs) and cost-effectiveness ratios
(with their corresponding 10/50/90 percentiles) are
reported in Appendix 9.
The scatterplot represented in Figure 24 shows the
dispersion regarding cost-effectiveness estimators
for the different samples drawn from the PSA. CA
(top right cloud) presents the widest dispersion in
costs, being the health benefits at 1 year around
0.64 QALYs. The health benefits for DUS (bottom
right cloud) are similar to those of CA (top right
cloud), although the costs are at a lower level. 2D
TOF MRA (top left cloud) is associated with the
lowest effectiveness for all sampling. The position
of the sampling clouds shows that DUS (bottom
right cloud) appears to dominate the other
strategies.
The CEACs for the baseline long-term model
show that the densities of DUS and CE MRA
involve cost-savings at some points (since the
curves do not cut the y-axis at 0) and also health
benefits (although not for their entire densities
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FIGURE 22 CEACs of the alternative diagnostic preoperative tests for baseline short-term model. CEAC of 2D TOF MRA, CE MRA
and DUS versus CA. The lines give the probability that the relevant strategy is cost-effective for a given willingness to pay per CDPwATP .
TABLE 29 Baseline cost-effectiveness results for 1-year time-horizon model
Mean SD Minimum Median Maximum
2D TOF MRA Cost (£ 2004) 10,688 1,096 8,159.66 10,590.96 15,657.72
QALYs 0.61 0.002 0.603 0.609 0.613
CER 17,549 1,802 13,339 17,427 25,722
CE MRA Cost (£ 2004) 9,092 1,119 6,599 9,005 14,088
QALYs 0.639 0.001 0.635 0.639 0.642
CER 14,222 1,752 10,302 14,093 22,051
DUS Cost (£ 2004) 8,734 1,138 6,275 8,639 13,820
QALYs 0.64 0.002 0.632 0.64 0.644
CER 13,646 1,782 9,764 13,490 21,617
CA Cost (£ 2004) 11,509 1,409 8,232 11,385 17,732
QALYs 0.64 0.001 0.635 0.64 0.642
CER 17,990 2,205 12,854 17,784 27,678since the curves asymptote to a value lower than
1). Both 2D TOF MRA and CA CEACs show that
cost-savings are not obtained at any point of their
density curves, since they cut the y-axis at 0.
Moreover, they have the lowest effectiveness since
none of their densities appears to involve health
gains compared with the other preoperative
diagnostic imaging tests. This is reflected by the
fact that the curves for both 2D TOF MRA and CA
lie on the x-axis. Therefore, 2D TOF MRA and CA
are clearly dominated, as shown in Figure 25.
Change of assumption: endarterectomy
considered as a PTA procedure
When endarterectomy was included as a PTA
procedure, the impact on the cost-effectiveness
Economic modelling
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FIGURE 23 Cost-effectiveness plane for baseline analysis (1-year time-horizon model)
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FIGURE 24 Scatterplot for PSA (baseline 1-year time-horizon model)results was negligible. As this change of
assumption had minimal impact on the results
obtained all results of this analysis are presented
in Appendix 10. 
Impact of adjustments in Dirichlet
distributions
The adjustments performed to the Dirichlet
distributions to ensure that the observed data
dominated the prior distribution appeared to have
a negligible impact on the cost-effectiveness results
obtained. The results obtained corresponding to
the adjustment of the observed data by multiplying
it by 10 are reported in Appendix 11. (For the
baseline analysis data were adjusted by multiplying
the observed data by 1000.) It can be observed
from the simulation results that, overall, there was
a very slight increase in the average costs for 2D
TOF MRA, CE MRA and DUS, with the same or
slightly lower effectiveness results. DUS continued
as the dominant strategy, presenting the highest
health benefits and the lowest costs.
This is an expected result as the probabilities
assigned to those non-observed events by means of
the adjustments in the Dirichlet distributions were
very low. The adjustments, therefore, allowed us to
assign probabilistic distributions to some relevant
effectiveness parameters without affecting the cost-
effectiveness results.
Above-the-knee comparison
When the accuracy of the tests was considered to
assess their cost-effectiveness for stenoses above
the knee, the results were considerably different
from those obtained in the baseline analysis. As
can be observed from Table 30, there was a
reduction in the average cost per patient
undergoing either 2D TOF MRA or CE MRA, in
addition to a slight increase in the effectiveness in
terms of the number of QALYs obtained during
the first year after initial treatment. This led to a
reduction in the cost-effectiveness ratios associated
with 2D TOF MRA and CE MRA (which became
£8628 and £8761 per QALY gained, respectively).
In contrast, the average costs related to DUS
increased, while there was a slight reduction in the
number of QALYs gained after performing this
diagnostic test. DUS became more expensive and
less effective compared with 2D TOF MRA and CE
MRA, and therefore it became a dominated
strategy. In this analysis, as previously, CA
maintained its condition as a dominated strategy,
as it was found to be more expensive and of
slightly lower effectiveness than either 2D TOF
MRA or CE MRA.
MRA became the preferred strategy when the
accuracy of the tests was assessed for stenoses
above the knee. As shown in Table 31, 2D TOF
MRA obtained a slightly lower level of
effectiveness compared with CE MRA, although
the incremental costs incurred with CE MRA,
compared with 2D TOF MRA, in order to gain an
additional QALY were very high (i.e. £122,687 per
additional QALY gained). Therefore, when above-
the-knee comparisons were considered as the unit
of diagnosis for PAD patients, the preoperative
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FIGURE 25 CEACs of the alternative diagnostic preoperative tests for baseline 1-year time-horizon modeldiagnostic strategy that appeared to be more cost-
effective was 2D TOF MRA (with a cost per QALY
equal to £8628).
The cost-effectiveness plane for the above results
is presented in Figure 26.
The scatterplot represented in Figure 27 shows that
when above-the-knee comparisons are considered
as the basis of analysis, the differences in the
overall sampling of the alternative strategies
appeared less clearly defined for 2D TOF MRA,
CE MRA and CA, since all points are dispersed in
Economic modelling
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TABLE 30 Cost-effectiveness results for above-the-knee comparisons (1-year time-horizon model)
Mean SD Minimum Median Maximum
2D TOF MRA Cost (£ 2004) 8,628 1,130 6,175 8,489 14,581
QALYs 0.642 0.001 0.639 0.642 0.643
CER 13,442 1,761 9,632 13,224 22,701
CE MRA Cost (£ 2004) 8,761 1,139 6,238 8,637 14,624
QALYs 0.643 0.002 0.637 0.643 0.649
CER 13,627 1,777 9,674 13,432 22,666
DUS Cost (£ 2004) 9,104 1,143 6,485 8,969 15,056
QALYs 0.631 0.003 0.622 0.631 0.637
CER 14,424 1,816 10,264 14,188 23,712
CA Cost (£ 2004) 11,454 1,414 8,188 11,330 18,350
QALYs 0.64 0.001 0.633 0.64 0.644
CER 17,889 2,211 12,849 17,702 28,772
TABLE 31 Incremental cost-effectiveness results for above-the-knee comparisons (1-year time-horizon model)
Strategy Cost Incremental Effectiveness Incremental  C/E Incremental  C/E 
cost effectiveness (ICER)
2D TOF MRA 8,628.311 – 0.641904 – 13,441.76 –
CE MRA 8,761.333 133.0225 0.642988 0.001084 13,625.97 122,686.7
DUS 9,103.687 342.3536 0.631169 –0.01182 14,423.52 Dominated
CA 11,454.18 2692.847 0.640283 –0.0027 17,889.24 Dominated
14,000
12,000
10,000
8000
6000
4000
2000
0
Cost (£ 2004)
0.630 0.635 0.640 0.645
QALYs
2D TOF MRA
CE MRA
DUS
CA
FIGURE 26 Cost-effectiveness plane for above-the-knee comparisons (1-year time-horizon model)a concentrated, more specific area of the
scatterplot for these diagnostic strategies. DUS is
shown to be the diagnostic strategy with a more
differentiated sampling compared with the 
others. The CEAC for the above-the-knee
comparison is shown in Figure 28.
Below-the-knee comparisons
According to the data retrieved for below-the-knee
comparisons, the results of the economic analysis
show an increase in the average costs for CE MRA,
DUS and CA. The overall health benefits obtained
were lower in comparison with the health benefits
observed in the analysis assessing comparisons for
the whole leg (baseline analysis). 
As in the baseline analysis, DUS presented the
lowest costs among the diagnostic imaging
strategies considered (£10,260 per patient),
although these were higher than those obtained
from the baseline analysis (i.e. £8734) (Table 32).
CE MRA was dominated by DUS and 2D TOF
MRA since it achieved lower health benefits at a
higher cost per patient (i.e. 0.606 QALYs at 1 year
at a cost of £10,798 per patient), and therefore it
was excluded from the incremental cost-
effectiveness analysis (Table 33).
The incremental cost incurred with 2D TOF 
MRA to obtain an additional QALY, compared
with DUS, was equal to £37,024. However, 
since the difference in health benefits between 
CA and 2D TOF MRA was very low, each
additional QALY obtained with CA, compared
with 2D TOF MRA, implied an additional 
cost of £4,928,686. According to these results, 
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FIGURE 27 Scatterplot for PSA for above-the-knee comparisons (1-year time-horizon model)
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FIGURE 28 CEACs of the alternative diagnostic preoperative tests for above-the-knee comparisons (1-year time-horizon model)2D TOF MRA appears to be a cost-effective
preoperative diagnostic strategy when below-the-
knee comparisons are considered as the basis for
the analysis.
The cost-effectiveness plane for the above results
is presented in Figure 29.
In a similar manner to the findings obtained when
comparisons above the knee were considered, the
scatterplot presented in Figure 30 shows that for
below-the-knee comparisons the differences in 
the overall sampling of the alternative strategies
appear to be less clearly defined. Again,
dispersion is concentrated around a specific area
Economic modelling
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TABLE 32 Cost-effectiveness results for below-the-knee comparisons (1-year time-horizon model)
Mean SD Minimum Median Maximum
2D TOF MRA Cost (£ 2004) 10,570 1,139 7,720 10,427 15,084
QALYs 0.616 0.001 0.61 0.616 0.618
CER 17,154 1,850 12,537 16,917 24,551
CE MRA Cost (£ 2004) 10,798 1,136 7,689 10,659 15,286
QALYs 0.606 0.002 0.596 0.606 0.614
CER 17,833 1,888 12,672 17,612 25,406
DUS Cost (£ 2004) 10,260 1,148 7,267 10,119 14,762
QALYs 0.608 0.004 0.593 0.608 0.618
CER 16,882 1,903 11,943 16,678 24,164
CA Cost (£ 2004) 12,913 1,400 9,073 12,824 17,647
QALYs 0.617 0.002 0.606 0.617 0.622
CER 20,942 2,277 14,657 20,796 28,770
TABLE 33 Incremental cost-effectiveness results for below-the-knee comparisons (1-year time-horizon model)
Strategy Cost Incremental Effectiveness Incremental C/E Incremental  C/E 
cost effectiveness (ICER)
DUS 10,259.65 – 0.607802 – 16,879.92 –
2D TOF MRA 10,569.59 309.9456 0.616173 0.008371 17,153.6 37,024.29
CE MRA 10,798.4 228.8103 0.605562 –0.01061 17,832.05 Dominated
CA 12,913.43 2343.836 0.616649 0.000476 20,941.3 4,928,686
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FIGURE 29 Cost-effectiveness plane for below-the-knee comparisons (1-year time-horizon model)of the scatterplot, although differences in
effectiveness and costs are still easily observed.
DUS is the diagnostic strategy presenting 
highest dispersion, but given the wider 
standard deviations related to its average costs and
health benefits (see Table 32) this was an expected
result.
The graph represented in Figure 31 shows the
CEACs obtained from the analysis of the
alternative diagnostic preoperative tests at 1 year,
considering below-the-knee comparisons. It can be
observed that when the values for the willingness
to pay are low, DUS is the strategy with greatest
probability of being cost-effective, which may be
due to the fact that it is the imaging strategy with
the lowest costs for below-the-knee comparisons.
However, since 2D TOF MRA shows a slightly
higher effectiveness at a lower cost, compared with
DUS, the probability of 2D TOF MRA being the
cost-effective imaging strategy increases at higher
values for the willingness to pay.
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FIGURE 30 Scatterplot for PSA for below-the-knee comparisons (1-year time-horizon model)
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FIGURE 31 CEACs of the alternative diagnostic preoperative tests for below-the-knee comparisons (1-year time-horizon model)T
his chapter is divided into two main sections,
the first covering methodological issues
associated with the literature review and economic
modelling and the second covering the findings of
the review and modelling.
Methodology
Review methodology
Extensive literature searches were conducted in an
attempt to locate all relevant studies. These
included electronic searches of a variety of
resources, scanning the references of included
studies, contacting experts in the field and
handsearching. The search strategy was developed
to maximise sensitivity, at the expense of reducing
specificity. Therefore, large numbers of citations
were identified and screened, many of which did
not meet the inclusion criteria for the review.
However, owing to deficiencies in specific indexing
terms for diagnostic accuracy studies, it was felt
that a more sensitive search strategy was
necessary.680
The possibility of publication bias remains a
potential problem for all systematic reviews. The
extent to which publication bias is an issue for
diagnostic studies remains unclear. For
intervention studies there is a clear cut-off
defining a ‘positive result’; that is, whether there is
a significant difference in outcome between the
treatment and control groups, and whether this
difference favours the intervention. This is not the
case for studies of diagnostic accuracy, which are
essentially a measure of agreement between the
results of the index test and a reference standard.
It is possible, and indeed likely, that studies
reporting higher estimates of test performance will
more often be published, but the extent to which
this occurs is unclear. Similarly, it is possible that
tests will not perform as well in the clinical setting
as may be indicated by reports from research
studies. There is evidence that publication bias is a
particular problem for studies with a small sample
size, although these data are not specific to the
diagnostic literature.681,682 This review was
restricted to studies that included at least 20
patients, meaning that this type of publication bias
is less likely to be a problem.
Clear inclusion criteria were set out in the protocol
for this review. It is therefore explicit exactly which
studies were eligible for inclusion. A list of studies
has been provided that appeared initially relevant,
but which did not meet all of the inclusion criteria
for the review.
All studies contributing results to the section of
the review relating to diagnostic accuracy were
assessed for methodological quality using
QUADAS. Individual components of
methodological quality, specific to diagnostic
accuracy studies, could therefore be assessed using
criteria developed by an evidence-based
method.683 However, where studies are poorly
reported the information that may be derived
from quality assessment becomes limited. It
cannot be known whether an unreported
QUADAS item reflects a true methodological flaw
or poor reporting of a study that may be
methodologically sound. It should also be noted
that the QUADAS tool does not contain any
criteria to assess the impact of inter-observer
variability. Since the interpretation of imaging
studies is inherently subjective, the impact of
characteristics of the observers (e.g. training,
experience) upon measures of accuracy is likely to
be of particular interest. The Standards for
Reporting of Diagnostic Accuracy (STARD)
initiative has recommended reporting of 
observer characteristics, but very little evidence
was found of reporting of such information by the
studies included in this review. While poor
reporting remains a widespread problem, it is
almost impossible to assess the impact of
components of methodological quality on the
results of systematic reviews of diagnostic tests.
The STARD initiative has provided clear guidance
for the reporting of diagnostic accuracy
studies684,685 and its uptake should improve all
aspects of the evaluation of diagnostic accuracy.
The full results of the quality assessment using the
QUADAS tool were tabulated and a narrative
summary was presented.
The methodological quality of studies with other
study designs was assessed using the appropriate
checklist from the CRD guidelines for undertaking
systematic reviews,13 and a narrative summary of
study quality was presented.
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Chapter 8
DiscussionThe processes of study selection, data extraction
and quality assessment were carried out by one
reviewer and checked by a second, with
disagreements resolved by consensus or referred
to a third reviewer when necessary. This reduces
the potential for reviewer error or bias.
Sensitivity, specificity and likelihood ratios were
used to summarise estimates of test performance.
Ranges in sensitivity and specificity were reported
and results of individual studies plotted in ROC
space. ROC plots provide an easy to interpret
visual summary of all the studies included in a
review. They enable the reader quickly to assess
the variability between studies, the accuracy of the
test and whether there appears to be a threshold
effect, without the potentially misleading effect of
pooling using an sROC where there is significant
unexplained statistical heterogeneity between
study results. SROC curves were only presented
where there was no evidence of significant
heterogeneity. Likelihood ratios were also
presented, as it has been suggested that these are
the measure that physicians find easiest to
interpret.686 Pooled likelihood ratios were not
calculated, for the majority of data groupings,
owing to the presence of statistically significant
heterogeneity; instead, the median values and
ranges were presented. A general problem with
pooled likelihood ratios as summary measures is
that positive and negative likelihood ratios are
pooled individually. These measures are likely to
be correlated within an individual study and
ignoring this correlation may be problematic. This
is an area of current research in the methodology
of diagnostic meta-analysis.
Further analyses using regression methods to
investigate reasons for the observed heterogeneity
were not performed. As results for more than one
stenosis threshold and arterial segment were
reported by some studies, these studies provided
multiple sets of diagnostic accuracy results for the
same patients. The standard sROC regression
analysis is used to investigate the effects of
differing cut-off thresholds, study quality and
other study-level factors on the DOR. To perform
an sROC analysis would require the pooling of
only one data set from each study, reducing the
number of studies available for analysis and
potentially introducing bias by the choice of data
sets to include. Therefore, the reviewers chose not
to perform multiple regression modelling to
investigate QUADAS components as they were
restricted by the small numbers of similar data sets
considered for pooling; it is recommended that at
least ten outcomes are needed for each factor in
the model.687 Further research into statistical
methods accounting for multiple sets of accuracy
results within a study is ongoing, but these
methods are complex and have not yet been fully
evaluated in practice.688,689
A further consideration in this review was the way
the results were reported, as studies reported
results by arterial segment, artery, limb or area of
stenosis/occlusion. The majority of studies
reported results using arterial segment as the unit
of analysis and, for consistency, only segmental
results were considered for pooling. The
‘clustering’ of analysis units is a common feature
of diagnostic accuracy studies, for example arteries
within a patient, or segments within an artery.
This means that there is likely to be correlation
between results within each patient and this
should be accounted for in any statistical analyses.
However, estimates of sensitivity, specificity and
likelihood ratios are not affected by this issue; 
it is the calculation of their variance that needs to
take into account the clustering.661 This means
that the estimates of diagnostic accuracy in this
review are likely to be accurate, but their 95%
confidence intervals may be too narrow because
they have ignored the multiple segments within
each patient. This is less of a concern for
systematic reviews such as this one, where all 
data sets are reported individually and pooling
and statistical comparisons are limited. 
However, it should be considered where 
primary diagnostic accuracy studies or meta-
analyses make statistical comparisons between
diagnostic accuracy parameters for two or more
diagnostic methods.
Modelling methodology
The economic model developed aimed to assess
the relative cost-effectiveness of MRA, DUS and
CTA when compared with CA (which was
considered to be the gold-standard preoperative
diagnostic test) for the assessment and treatment
planning of PAD patients. It was developed
keeping in mind the intrinsic properties of good
decision-analytical models identified by the
Consensus Conference on Guidelines on
Economic Modelling in Health Technology
Assessment.690
A detailed reporting of the sources, the methods
used to perform the economic evaluation and the
assumptions formulated has been presented to
ensure the transparency of the analysis and
enhance the interpretability and the applicability
of the study results, and to allow ready
reproducibility of the analysis.
Discussion
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comparators should be included in the model,
independently of whether or not they represent
currently accepted clinical practice.691 However, in
this case a lack of data led to the exclusion of one
relevant comparator, CTA. The authors
acknowledge that this may have an effect on the
results obtained. However, the inclusion of CTA
was not viable given that no data were available to
populate the model for this diagnostic test. The
only alternative available was to use expert
opinion to obtain efficacy estimates; this was
deemed unrealistic by the clinical experts.
The structure of the decision model was based on
a previously published model,660 which was
enhanced to allow clinical practice to be better
represented. As with any decision model the
structure is a simplification of reality, the main
purpose of which is to synthesise different types of
data to inform resource allocation. A problem
inherent to modelling studies in general is that it
is often necessary to oversimplify the structure.
PAD is a very complex disease and this model
structure, like any other, has limitations compared
with clinical reality. 
Guidelines on economic modelling in health
technology assessment suggest that the time-
horizon considered for the model should be long
enough to incorporate all the relevant cost and
benefit differences between the alternatives
compared.691,692 Data were not available about the
prognosis of patients on a long-term basis
according to whether they underwent a treatment
that had initially been accurately or inaccurately
formulated, and how this may affect their quality
of life. Therefore, the time-horizon of the study
was limited to 1 year.
For this analysis, treatments postdiagnosis have
been considered as chance nodes, determined by
the clinician’s choice of appropriate treatment.
This was done to reflect clinical practice, since the
treatment path to be followed will actually depend
on the choice of the surgeon according to his
interpretation of the test results and other clinical
characteristics of the patient. However, the
structure of the model could be modified to
consider that treatments after diagnosis become
decision nodes, which would allow the best
pathway to be identified not only for diagnosis,
but also for the planning of treatments. 
The present model could be further enhanced by
incorporating serial tests, using a variety of
assumptions about the relationship between tests
(both assumptions of independency of tests and
dependency of tests could be investigated). As with
many diagnostic procedures the complexity of
testing variations that occur in clinical practice are
poorly reported in the literature, which in turn
makes modelling the scenario impossible without
the use of wild assumptions. 
For the short-term model a specific measure of
health benefit was identified according to what the
clinicians considered a relevant outcome for the
diagnostic tests in a short-term period (i.e. the
percentage of patients who would be correctly
diagnosed according to the test results and for
whom an appropriate treatment plan was
formulated according to the judgement of the
vascular surgeon). The measure of health benefits
used in the long-term model was the number of
QALYs, which is a generic measure that allows the
comparison of the results of these interventions
with those of different types of intervention.
Probabilistic sensitivity analysis was undertaken to
address the existing uncertainty surrounding the
input variables used to populate the model, which
were obtained by merging data from a variety of
sources (medical literature, expert opinion and
assumptions). Scatter plots on the cost-effectiveness
plane and cost-effectiveness acceptability curves
were reported, which are the most appropriate way
of presenting the results according to the NICE
guide to the methods of technology appraisal.692
Results of the review
The electronic literature searches were conducted
in May 2004 and updated in May 2005. The
update searches identified an additional two
studies that provided data on tests to diagnose
stenosis/occlusion that were eligible for inclusion
in the review. In addition, three studies that did
not meet the inclusion criteria for the review of
diagnostic accuracy, but which reported results
relating to adverse events, were identified by the
update searches. This indicates the rapidly
evolving nature of vascular imaging research. As
the update search represents the approximate
number of studies being indexed in electronic
medical databases per year that would have been
eligible for inclusion in this review, it can be used
to assess how rapidly this area of research is
growing and to evaluate how soon the data in this
review will be out of date.
The data obtained from studies meeting the
inclusion criteria for the review were insufficient to
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The studies identified and included in the review
focused on assessing the level of stenosis or
occlusion to assist in the formulation of a
treatment plan. Although no studies were
identified that investigated diagnostic techniques
merely to confirm the diagnosis of PAD, there is
no reason to believe that the diagnostic accuracy
of the tests would be different when used to
confirm the diagnosis of PAD in symptomatic
patients, with a similar spectrum of disease,
presenting to primary care.
The quality of the included diagnostic accuracy
studies was generally good with respect to the test
descriptions, blinding and independence of the
reference standard. However, other aspects were
poorly reported. Most studies either did not
include an appropriate patient spectrum or failed
to report sufficient details of the included patients
for this to be assessed. Around half of the MRA
and DUS studies did not describe the method
used to select patients for the study, although this
was better reported by the CTA studies, with 71%
reporting patient selection criteria. This may be
due to the impact of STARD on the more recently
reported studies. The most poorly reported quality
item, across all the tests, was the availability of
clinical data when the test results were interpreted,
with 86% of the studies being classed as unclear as
they did not discuss the availability of other data.
In around 30% of studies it was not clear whether
the test results were interpreted without
knowledge of the reference standard results, which
is a major source of potential bias. In general,
both tests were performed in a short period
(within 1 month of each other) for around 80% of
the CTA and DUS studies, reducing the potential
for disease progression bias. The test and
reference standard were performed within an
acceptable time-frame in only 64% of the DUS
studies. This may reflect a difference in the
application of DUS in clinical practice, with this
test more likely to be used as an early ‘screening’
procedure, and tests that are viewed as able to
produce the classic ‘road map’ used to assess
patients for intervention. However, the potential
for disease progression bias indicated by the
observed delay in many studies makes objective
assessment of the diagnostic performance of DUS
difficult. 
When considering the diagnostic accuracy for
detecting stenosis/occlusion, CE MRA had the best
overall performance, with nearly all the studies
reporting sensitivities and specificities of over
90%. MRA was associated with the highest
proportion of adverse events reported in the
studies. However, the most severe adverse events
(death and severe vascular adverse events) were
more common in patients undergoing CA than
MRA, although they only occurred in a very small
proportion of patients undergoing either test. The
increased likelihood of suffering a mild adverse
event does not appear to affect patients’
preferences for MRA over CA, as the results of
three patient attitude surveys strongly suggest that
MRA is preferred by patients over CA. The
contrast agent was responsible for some of the
reported adverse events, although generally the
proportion of patients suffering contrast agent-
related adverse events was very low. The most
commonly reported adverse events associated with
CE MRA were acute digestive system symptoms,
minor pain/discomfort, and acute central and
peripheral nervous system adverse events. The
most commonly reported adverse events
associated with 2D TOF MRA were minor
pain/discomfort and anxiety.
Overall, the performance of CE MRA appeared
superior to that of 2D TOF MRA, which also
showed more variation in diagnostic accuracy. This
is consistent with the findings of previous
systematic reviews.362,660 However, one study
assessing 2D TOF MRA in arteries below the knee
reported results comparable to CE MRA,27 with a
sensitivity of 98% and specificity of 95% for the
detection of stenoses of 50% or higher. It should
also be noted that a simple comparison of
accuracy for the detection of degree of stenosis,
cannot fully assess the ability of a procedure to
produce the ‘vascular road map’. Factors such as
length and grouping of stenoses are not considered.
The relative ability of procedures to provide a
complete and clinically useful picture is therefore
difficult, if not impossible, to assess using
diagnostic accuracy studies alone. It also seems
unlikely that further evidence relating to 3D TOF
MRA will become available given the overriding
enthusiasm for CE MRA among radiologists.
For CTA, there was less heterogeneity between the
results for the detection of stenoses of 70% or
greater, or an occlusion, with CTA having a higher
specificity (above 97%) than sensitivity (above
87%) for the whole leg. This indicates that CTA
may be useful for ‘ruling in’ the presence of
higher grade stenosis, but its overall performance
in detecting stenoses of 50% or above was slightly
inferior to CE MRA. However, the application of
CTA to the assessment of PAD remains a relatively
Discussion
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effective surgical planning remains to be explored.
No studies investigating the diagnostic accuracy of
the new 64-slice CTA were identified, as this is a
very new development in CTA technology. A
survey of patient attitudes towards CA, MRA and
CTA found that in terms of level of discomfort CA
was found to be the most uncomfortable, followed
by MRA, with CTA being the least uncomfortable.
Only one study reported mild adverse events
associated with CTA (skin adverse events), which
occurred in a very small proportion of the study
population.
The performance of DUS was inferior to both CE
MRA and CTA. Again, the specificity of DUS
tended to be higher than the sensitivity (specificity
above 89% and sensitivity above 74% for the whole
leg). There was more heterogeneity among the
study sensitivities for DUS and the lower overall
sensitivity means that DUS may miss some
significant stenoses. This may be of particular
concern if DUS were to be used to screen patients
before surgical planning. However, although the
sensitivity of DUS may be inadequate for the
detection of individual lesions, it is unlikely to
classify wrongly a whole limb as ‘normal’ and thus
inappropriately screen out a patient from further
investigation. Sensitivities were generally adequate
for DUS studies reporting data by limb. DUS may
be useful for broader diagnostic classification (e.g.
is this patient suitable for PTA or bypass graft?),
although data are not currently available to assess
this adequately. It should also be noted that the
long delay between the index test and reference
standard, apparent in some studies, is likely to
reduce estimates of sensitivity. The only trial of the
effectiveness of imaging procedures, in terms of
surgical planning and patient outcome, found
DUS and CA to be comparable, a result which is
seemingly at odds with poor estimates of
diagnostic accuracy. A survey of patient attitudes
found that the majority of patients (from a sample
who did not suffer from claustrophobia and had
no metallic implants) had no preference between
undergoing MRA or DUS, while the majority of
those who did express a preference preferred
MRA. There was no significant difference between
MRA and DUS on a scale rating how bothersome
the tests were. This conclusion may be open to
question, however, since patients experiencing
claustrophobia (an important reason for patient
dissatisfaction with MRA) were excluded from the
relevant study. Only two studies reported adverse
events associated with DUS: anxiety occurred in a
very small proportion of the study population in
one study, and minor pain/discomfort during or
immediately after the procedure was reported in
22% of patients in one study.
There were some differences in diagnostic
performance of individual imaging techniques with
respect to the area of leg being assessed. CE MRA
was more accurate for detecting stenoses above the
knee than below the knee. Only one CE MRA
study76 provided separate results for the foot and
these were less accurate (sensitivity of 79%,
specificity of 71% for detecting stenosis of 50% or
above). There was insufficient evidence to judge
CTA (only one study provided results below the
knee), although its accuracy above the knee was
high (sensitivity above 96% and specificity above
91%). The results were similar for DUS, with the
overall accuracy tending to be higher for the
assessment of stenoses above the knee. The one
DUS study that provided separate results for the
foot42 reported a low sensitivity of 64% and a
specificity of 80% for detecting vessels suitable for
surgery. The assessment of potential outflow vessels
in the foot appears to be a problematic area and
one that warrants further research, particularly
with respect to newer technologies such as CTA.
Only nine of the diagnostic accuracy studies that
met the inclusion criteria for the review provided
data on adverse events. The lack of adverse event
data reported by the majority of included
diagnostic accuracy studies cannot be interpreted
as no adverse events having occurred. Therefore,
the results of this review in relation to adverse
events are unlikely to be a complete picture of all
adverse events occurring in the included
diagnostic accuracy studies. In addition to this
potential source of bias, the reporting of adverse
events was subjective; therefore, an adverse event
categorised as ‘severe’ in one study may not have
been classed as ‘severe’ in another.
Heterogeneity
There are various potential sources of
heterogeneity between the studies. These include
the spectrum of patients included, the interval
between the reference standard and index test,
other quality criteria, test-specific details,
technological advancement (using the date of
publication as a surrogate) and the extent of the
scan (inclusion/exclusion of the foot). Operator bias
may also be a source of heterogeneity; however,
insufficient data were reported in the included
studies for the impact of this bias to be assessed.
Quality criteria
Spectrum bias may help to explain some of the
heterogeneity seen between studies. A study may
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test by investigating a selected population. Factors
that may affect the measures of accuracy include
the severity of disease in the population studied,
demographics and co-morbidity.17 Population-
based differences may be a factor in the
heterogeneity seen in CE MRA studies, with two
studies that reported recruiting an appropriate
patient spectrum reporting the lowest sensitivity
and specificity in their groups.9,70 One of these
studies also reported that clinical data were not
available when interpreting scans,70 which may
also be a factor in lower accuracy. The major
factor in spectrum-related heterogeneity is likely
to be the proportion of patients at each stage of
the disease process included in the studies. It may
be expected that studies recruiting a high
proportion of patients with less severe disease
(Fontaine stage II) may underestimate overall
accuracy, as identifying less severe stenosis, with
fewer symptoms, may be more difficult.
Conversely, studies recruiting a high proportion of
patients with more severe disease (Fontaine stage
IV) may overestimate overall accuracy. This
hypothesis is supported by the 2D TOF MRA
study that had the highest proportion of patients
with Fontaine stage IV in its grouping, and
reported the highest sensitivity and specificity.40 In
addition, a DUS study restricted to Fontaine stage
II reported the lowest sensitivity and highest
specificity in its group.52 However, contrary to this,
a CE MRA study with the highest proportion of
patients with Fontaine stage IV in its group
reported the lowest sensitivity and specificity.28
The delay between the index test and reference
standard is likely to affect significantly measures of
diagnostic performance where disease progression
is relatively rapid. Where the reference standard is
conducted a clinically significant time after the
index test, estimates of the sensitivity of the index
test are likely to be reduced. This is borne out by
the data presented in this review, where timing of
tests seemed to have an effect on the diagnostic
measures for all three technologies
evaluated.28,34,48,54,59,71 In the studies reporting a
delay of over 1 month between tests 33 patients
received the index test first and eight patients
received the reference standard first in one
study,54 and it was unclear which test was first in
the other.24 It is therefore possible that the
patient’s condition deteriorated during this time,
making it easier to diagnose, and therefore
underestimating the accuracy of the index test.
Similarly, the reference standard may be detecting
clinically significant disease that simply was not
present at the time of the index test.
Whether withdrawals and dropouts were reported,
and the reasons explained, appeared to have some
relation to the diagnostic measures. This may
reflect the type of patients that withdrew, with
withdrawals being unequal across the patient
spectrum and potentially resulting in an
underestimate or overestimation of diagnostic
accuracy. The 2D TOF MRA study that did not
explain withdrawals from the study had the highest
proportion of patients with Fontaine stage IV, and
reported the highest sensitivity and specificity.40
The failure to explain withdrawals and dropouts
may imply selective reporting, or that the patients
who dropped out may have been from the less
severe stages of disease; both scenarios could have
led to an overestimation of the accuracy of the
index test. In this study, however, it appears that
certain segments were not imaged in all patients,
which may imply that the scans for these segments
were uninterpretable, or were not imaged for
unspecified reasons. Omitting these results from
the analysis may have overestimated the diagnostic
accuracy of the index test.
Most studies that reported whether interpreters
were blinded to the results of the index test when
interpreting results of the reference standard (and
vice versa) stated that the interpreters were
blinded. However, for a large proportion of
studies, it was unclear whether interpreters were
blinded or not. Therefore, the impact of 
blinding the interpreters on the reported
diagnostic accuracy could not be investigated. The
vast majority of studies also did not report
whether other clinical data were available to
interpreters. 
Test-specific details
One criterion that requires defining when
undertaking DUS is the PSVR used to diagnose a
specified level of stenosis. The majority of the
studies either did not report the PSVR, or used a
PSVR of 2.0 as representing 50% stenosis. In one
analysis of 50% or more stenosis, above the knee,
one study used 2.5 for 50% stenosis, with the
others using 2.0 or not reporting the PSVR. The
study that used 2.5 reported the lowest sensitivity
and highest specificity.53 By choosing a higher
PSVR for the diagnosis of 50% or greater stenosis,
the difference in flow rate between stenosed and
non-stenosed sections of artery will need to be
greater to produce a positive result, requiring a
greater severity of stenosis. Therefore, stenosis of
lesser severity may be missed, reducing the
sensitivity. However, the number of false-positive
results would also be reduced, so increasing
specificity. There was no evidence that the type of
Discussion
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accuracy of the test. 
The only other test-specific detail identified that
may have had an impact on the diagnostic
accuracy measures was related to the reference
standard, and was seen in the group of CE MRA
studies diagnosing 50% stenosis or more in below-
the-knee scans. The study reporting the highest
sensitivity and specificity stated that the location of
the catheter during the reference standard
angiography was aortic,51 whereas the other
studies identified the puncture site, but not the
position of the catheter.46,76 However, it is more
likely that the exclusion of the foot from the
images explains the superior diagnostic accuracy
reported in this study (see below).51 There was no
clear pattern between technological advancement
(using the date of publication as a surrogate) and
diagnostic measures.
Inclusion of the foot
In general, the inclusion of the foot in the scan
seems to decrease the diagnostic accuracy of CE
MRA and DUS. The arteries in the foot are
deemed to be more difficult to visualise using CA
owing to dilution of contrast material, slow flow
and difficulties in timing of imaging relative to the
arterial injection.593 These factors may, therefore,
also be an issue during CE MRA. The small size of
the arteries and greater movement of the foot
during imaging also contribute to the problems of
imaging the arteries of the foot.76 The only CE
MRA study to include the foot in the evaluation of
50% or greater stenoses in the whole leg reported
the lowest sensitivity and specificity,28 and a CE
MRA study evaluating below the knee that did not
include the foot reported the highest sensitivity
and specificity in that group.51 Only four DUS
studies included the foot in the scan. Three of
these were grouped together evaluating occlusions
below the knee. Two reported the two lowest
sensitivities,44,45 and the other the lowest
specificity.43 The effect of including the foot when
undertaking a CTA scan was less clear, and was
based on just two studies giving contrasting
results.26,54 Both of these studies were included in
two analyses. In studies evaluating 50% stenosis or
more in the whole leg, one reported the highest
sensitivity and specificity,26 whereas the other54
reported one of the lowest sensitivities, with a
similar value to that of the study reporting the
lowest sensitivity that did not include the foot.58 In
the group evaluating occlusions in the whole leg,
one study again reported the lowest sensitivity,54
whereas the other reported the second highest
sensitivity.26 Both studies reported a specificity
over 99% in this category. It is possible that the
difference in results between these studies is
related to quality, as the study reporting the lower
diagnostic accuracy did not include an appropriate
patient spectrum, had an unacceptable delay
between the index test and reference standard,
and did not report the Fontaine classification (or
its equivalent) of the participants.54 The
performance of all imaging technologies in the
foot is an area that requires further evaluation.
Gaps in the evidence
The review was limited by the lack of high-quality,
well-reported studies. The searches located only a
single controlled trial. This used a historical
control group and could be subject to selection
and interpretation bias. The majority of the
available studies were diagnostic cohorts, with
most having small sample sizes. Data regarding
the influence of imaging technologies upon the
surgical planning and postoperative outcome for
patients with PAD are urgently needed. These
cannot be provided by diagnostic accuracy studies.
The most reliable and appropriate methodology is
the RCT. A well-designed RCT could provide
information on the influence of tests on treatment
decisions and patient outcomes in patients with
PAD. Health economic data could be collected
simultaneously. Advantages of an RCT include:
the measurement of directly relevant clinical and
economic outcomes (as opposed to the ability to
detect a specific diagnostic feature), no
requirement for a reference standard (the
diagnostic accuracy study design is dependent 
on the assumption that the result of a reference
standard test is always correct, whereas the RCT
design allows direct comparison of new tests with
the reference standard without this potentially
flawed assumption), and a comparative measure
can incorporate all information provided by a test
(including that which is not readily defined). 
Several potential barriers to carrying out an RCT
require consideration. There may be ethical
objections; despite the lack of good-quality
accuracy data, withholding a particular test may be
deemed unethical. This may be a more persuasive
argument for some tests, where diagnostic
accuracy data are stronger. The same could be said
for institutions where certain technologies are
used as part of the routine assessment of PAD.
The feasibility of carrying out an RCT may also be
questioned, primarily regarding the refinements in
the technology over time and the logistic problems
associated with the availability of the technologies
and concerning the potentially large sample size
required for such an RCT. Where resources are too
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judgement as to when a technology is sufficiently
refined to warrant investigation in an RCT is
required. 
Results of the review of economic
evaluations
There exists some discrepancy in the literature
regarding the most cost-effective imaging
technique for PAD patients, according to the
results observed in the economic evaluations
included in the systematic review. One of the
studies126 found that DUS was not cost-effective as
a preoperative imaging technique because of its
low sensitivity. Two studies128,129 compared MRA,
DUS and CA followed by treatment among PAD
patients with intermittent claudication, and
concluded that differences in costs and
effectiveness were slight and either MRA or DUS
could replace CA without a substantial reduction
in effectiveness and with a minor cost reduction.
Yin and colleagues131 compared MRA with CA as a
preoperative diagnostic test for patients with limb-
threatening peripheral vascular disease and
concluded that MRA was cost-effective, either
alone or in combination with selective use of CA.
CTA was compared with MRA in a further study130
for the evaluation of patients with intermittent
claudication, the conclusion being that CTA has
the potential to be cost-effective. (See Appendix 7
for more details of these studies.) What seems
clear from these results is that non-invasive
imaging techniques appear to have a place in the
preoperative diagnosis of PAD patients.
Results of the economic modelling 
When the short-term model was considered, the
most cost-effective imaging modality appeared to
be DUS, which presented a cost of £2617 per
CDPwATP and an incremental cost per additional
CDPwATP obtained, compared with 2D TOF
MRA, equal to £2260. One year after initial
treatment, DUS remained the dominant strategy,
incurring a cost per QALY of £13,646. The
assumption about whether endarterectomy was
included as a bypass or as a PTA procedure did
not have an impact on the cost-effectiveness
results. The adjustments performed to overcome
the problem of zero counts for some of the events
considered in the decision model also had no
impact. 
However, when test performance was related to a
specific area of the leg (i.e. either above- or below-
the-knee comparisons), the preoperative
diagnostic strategy that appeared to be more cost-
effective was 2D TOF MRA, with a cost per QALY
equal to £8628 for above-the-knee comparisons,
and an incremental cost per additional QALY
equal to £37,024, when 2D TOF MRA was
compared with DUS.
It seems relevant to highlight that these cost-
effectiveness results do not depend exclusively on
the accuracy of the tests, but also on the accuracy
of the clinician’s decision about the best treatment
to formulate for each patient according to type
and severity of stenosis and other relevant factors. 
In conclusion, these results suggest that for PAD
patients for whom the whole leg is evaluated by a
preoperative diagnostic test, in order to identify
the type and level of stenosis and subsequently
formulate a treatment plan, DUS dominates the
other alternatives by presenting higher
effectiveness at a lower cost per QALY. However,
when analysis of stenosis is limited to a section of
the leg, either above the knee or below the knee,
2D TOF MRA appears to be the most cost-
effective preoperative diagnostic strategy.
Discussion
86Implications for clinical
practitioners and decision-makers
The results of the review suggest that CE MRA has
the best overall diagnostic accuracy of the three
index tests evaluated. Where available, CE MRA
may be a viable alternative to CA.
CE MRA was generally preferred by patients over
CA. Where reported, there was a greater number
of adverse events associated with CE MRA than
with CA. However, these were mild and do not
appear to affect patient preferences. The most
severe adverse events were more common in
patients undergoing CA. It should be noted that
reporting of adverse event data and patient
attitudes was poor.
The only controlled trial of the effectiveness of
imaging procedures suggested that the results of
DUS were comparable to those of CA, in terms of
surgical planning and outcome. This finding
conflicts with the results of diagnostic accuracy
studies, which reported poor estimates of accuracy
for DUS in comparison with CA.
The overall diagnostic performance of CTA in
detecting stenoses of 50% or more was inferior to
CE MRA. However, the results for the
performance of CTA to image arteries of the foot
appear promising. As the assessment of PAD is a
relatively new application for this technology,
there was insufficient evidence to evaluate the
usefulness of CTA in this area.
The results of the economic modelling suggest
that once the accuracy and effectiveness of the
tests (in terms of surgical planning and outcome)
are combined with their associated costs, DUS
dominates the other alternatives, presenting
higher effectiveness at a lower cost per QALY. 
This outcome is in line with the results shown 
by the only trial included in the systematic 
review assessing the effectiveness of imaging
procedures.
However, when analysis of stenosis was limited to a
section of the leg, either above the knee or below
the knee, the findings show 2D TOF MRA to be
the most cost-effective preoperative diagnostic
strategy. This result was in accordance with the
overall findings of the systematic review.
Implications for research
Quality assessment highlighted limitations in the
methodological and reporting quality of many
studies included in this review. Future evaluations
of diagnostic tests should follow the STARD
guidelines for reporting of diagnostic accuracy
studies.684,685 The following specific questions
require further research.
What is the relative clinical
effectiveness of the available imaging
tests, in terms of surgical planning and
postoperative outcome?
Diagnostic accuracy studies will not provide
information on effectiveness or cost-effectiveness.
The diagnostic accuracy study is designed to
compare the results obtained from new tests 
with those of the reference standard of diagnosis
(which are assumed always to be correct); it is
therefore inherently not capable of comparing
tests in terms of their ultimate impact upon
patient outcomes. The diagnostic accuracy studies
included in this review compare imaging tests with
the reference standard purely in terms of their
ability to detect a predefined level of stenosis at a
given point in the vasculature. They do not
provide an overall picture of the relative
contributions of the images obtained to
therapeutic decision-making, or of any consequent
impact upon patient outcomes. To address these
issues, a large, multicentre RCT is required.
Ideally, those imaging modalities that are of
primary interest for surgical planning (CT 
and CE MRA) would be evaluated in more than
one centre included in the RCT, in an attempt to
avoid performance bias. Such a trial would
provide direct and robust information on the
influence of a test on treatment planning and
patient outcome.
Health economic data could be collected
simultaneously, allowing an examination of cost-
effectiveness. The availability of data on the
management of patients after testing currently
restricts the scope of economic modelling.
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Chapter 9
ConclusionsRecognising that the establishment of large-scale
RCTs is particularly problematic in rapidly
evolving fields such as vascular imaging, a
compromise approach may be to establish a
multicentre tracker study. Such a study should
enable the collection of data comparing the
numbers of misdiagnoses, and the relative health
status and health-related quality of life resulting
from alternative imaging strategies.
What adverse events occur as a
consequence of testing, and what is the
relative incidence for the available
tests?
Future studies should consider methods
appropriate for the collection of adverse event
data.
Which testing options do patients
prefer?
Further research, which is well designed,
conducted and reported, is required in this area.
Future studies should consider collection of data
on patient attitudes.
What is the true diagnostic accuracy of
DUS in comparison with CA, for the
detection of stenoses of 50% or greater
and occlusions?
Existing diagnostic accuracy studies on DUS have
a number of methodological weaknesses, which
are highlighted in this report. Further well-
designed diagnostic accuracy studies may provide
additional useful information. Particular
consideration should be given to the time between
the index test and reference standard, and
assessment of the influence of operator
skill/experience on accuracy.
What are the effects of operator
skill/training/experience on measures of
test accuracy for all the imaging
modalities of interest?
Future studies should report details of observers
and allow collection of data on inter-observer
variability.
What is the diagnostic accuracy and
clinical effectiveness of tests to image
arteries in different areas of the lower
limbs, particularly the foot?
Future studies should allow collection of data on
effectiveness and diagnostic performance of tests,
which is specific to their application in the foot.
What is the diagnostic accuracy and
clinical effectiveness of tests in clinically
important patient subgroups, such as
diabetes mellitus?
Future studies should allow collection of data on
effectiveness and diagnostic performance of tests,
which is specific to clinically important patient
subgroups.
In addition, the available literature showed a lack
of data about how patients are managed after the
results of diagnostic tests are obtained; these were
required to populate the economic model. It is not
clear from the literature whether the prognosis
and quality of life of patients who had an
inaccurately formulated treatment plan and
underwent a change of procedure would be
significantly different from those of patients who
were correctly diagnosed and managed from the
outset. Further research on these topics is
required, which could take the form of an
observational study of patients with PAD
presenting different levels of severity, over the
long term.
If the allocation of treatment pathway were to be
modelled, further research in this area would also
be required to allow these decisions to be captured
and accurately represented. Such a model would
reflect different treatment plans to be performed
according to the specific clinical characteristics of
patients obtained by means of the preoperative
diagnostic testing. Therefore, the model should
consider:
● choice of treatments available (for patients with
the same characteristics, which is the most cost-
effective treatment to choose for the patient?)
● the treatment chosen by the clinicians according
to the test results.
Both options could be taken into account to
develop alternative treatment scenarios for
patients according to the patient characteristics
reflected by the test results. A model of this nature
was outside the scope of this project owing to time
constraints and the lack of available data that
would have made such a model a viable option.
However, it is recommended that a patient
simulation model, considering the above issues, be
performed to assess the long-term cost-
effectiveness of preoperative imaging diagnostic
tests for PAD patients.
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Appendix 1
Advisory panel membersInclusion criteria
Studies with fewer than 20 participants were
excluded, other than for adverse events.
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Appendix 2
Protocol changesT
he core search strategy used for this review
was as follows:
(iliac adj (arter$ or vein$ or vessel$))
(femoral adj (arter$ or vein$ or vessel)
(popliteal adj (arter$ or vein$ or vessel)
(tibial adj (arter$ or vein$ or vessel)
(peroneal adj (arter$ or vein$ or vessel$))
(genicular adj (arter$ or vein$ or vessel$))
(saphenous adj (vein$ or vessel$))
femoropopliteal
iliofemoral
aortoiliac
infrapopliteal
(tibial runoff adj (arter$ or vein$ or vessel$)) 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12 
(lower limb$ adj2 (ischaemi$ or ischemi$ or arter$
or vein$ or vessel$ or vascular or occlusive)) 
(lower extremit$ adj2 (ischaemi$ or ischemi$ or
arter$ or vein$ or vessel$ or vascular or
occlusive)) 
(leg adj2 (ischaemi$ or ischemi$ or arter$ or vein$
or vessel$ or vascular or occlusive)) 
peripheral vascular
peripheral arter$ 
14 or 15 or 16 or 17 or 18 
exp ultrasonography, doppler, duplex/
exp ultrasonography, doppler, color/
exp magnetic resonance angiography/
exp tomography, x-ray computed/
duplex ultrasound
echography 
ct angiography 
mr angiography 
mra.ab,ti.
(mr adj2 angiograph$) 
(mri adj2 angiograph$) 
cta.ti,ab.
(duplex adj2 ultrasound) 
20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31 or 32 
19 and 33
Animals/
Human/
35 not (35 and 36)
33 not 37
This strategy was designed for searching the
MEDLINE electronic database (on Ovid), and was
adapted, as appropriate, for all other databases
searched, taking into account differences in
indexing terms and search syntax for each
database. Search strategies were not designed to
restrict the retrieved results by study type. Full
details of all the databases searched and search
strategies used are provided below.
MEDLINE: Ovid
The MEDLINE database was searched from 1996
to April week 4 2004 on 10 May 2004 and the
following strategy was used. An update search was
undertaken on 11 May 2005 covering the period
May 2004 to 2005 April week 4.
(iliac adj (arter$ or vein$ or vessel$))
(femoral adj (arter$ or vein$ or vessel)
(popliteal adj (arter$ or vein$ or vessel)
(tibial adj (arter$ or vein$ or vessel)
(peroneal adj (arter$ or vein$ or vessel$))
(genicular adj (arter$ or vein$ or vessel$))
(saphenous adj (vein$ or vessel$))
femoropopliteal
iliofemoral
aortoiliac
infrapopliteal
(tibial runoff adj (arter$ or vein$ or vessel$)) 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12 
(lower limb$ adj2 (ischaemi$ or ischemi$ or arter$
or vein$ or vessel$ or vascular or occlusive)) 
(lower extremit$ adj2 (ischaemi$ or ischemi$ or
arter$ or vein$ or vessel$ or vascular or
occlusive)) 
(leg adj2 (ischaemi$ or ischemi$ or arter$ or vein$
or vessel$ or vascular or occlusive)) 
peripheral vascular
peripheral arter$ 
14 or 15 or 16 or 17 or 18 
exp ultrasonography, doppler, duplex/
exp ultrasonography, doppler, color/
exp magnetic resonance angiography/
exp tomography, x-ray computed/
duplex ultrasound
echography 
ct angiography 
mr angiography 
mra.ab,ti.
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Appendix 3
Detailed search strategies(mr adj2 angiograph$) 
(mri adj2 angiograph$) 
cta.ti,ab.
(duplex adj2 ultrasound) 
20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31 or 32 
19 and 33
Animals/
Human/
35 not (35 and 36)
33 not 37
EMBASE: Ovid
The EMBASE database was searched from 1980 to
week 19 2004 on 10 May 2004 and the following
strategy was used. An update search was
undertaken on 11 May 2005 covering the period
2004 week 20 to 2005 week 19.
(iliac adj (arter$ or vein$ or vessel$))
(femoral adj (arter$ or vein$ or vessel$)) 
(popliteal adj (arter$ or vein$ or vessel$)) 
(tibial adj (arter$ or vein$ or vessel$)) 
(peroneal adj (arter$ or vein$ or vessel$)) 
(genicular adj (arter$ or vein$ or vessel$)) 
(saphenous adj (vein$ or vessel$)) 
femoropopliteal 
iliofemoral 
aortoiliac 
infrapopliteal 
(tibial runoff adj (arter$ or vein$ or vessel$)) 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12 
(lower limb$ adj2 (ischaemi$ or ischemi$ or arter$
or vein$ or vessel$ or vascular or occlusive)) 
(lower extremit$ adj2 (ischaemi$ or ischemi$ or
arter$ or vein$ or vessel$ or vascular or
occlusive)) 
(leg adj2 (ischaemi$ or ischemi$ or arter$ or vein$
or vessel$ or vascular or occlusive)) 
peripheral vascular
peripheral arter
13 or 14 or 15 or 16 or 17 or 18
duplex ultrasound 
echography 
ct angiography
mr angiography 
mra.ab,ti.
(mr adj2 angiograph$) 
(mri adj2 angiograph$)
cta.ti,ab.
(duplex adj2 ultrasound
exp echography/
exp computer assisted tomography/
((duplex or doppler) adj2 ultrasonograph$)
20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28
or 29 or 30 or 31
19 and 32
human/
nonhuman/
34 not (34 and 35)
33 not 36
BIOSIS Previews: Dialog
The Biosis Previews database was searched from
1969 to May week 2 2004 on 14 May 2004 and the
following strategy was used. An update search was
undertaken on 12 May 2005 covering the period
May 2004 to May 2005.
S1 iliac(w)(arter? Or vein? Or vessel?)/ti,ab,de
s2 femoral(w)(arter? Or vein? Or vessel?)/ti,ab,de
s3 popliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s4 tibial(w)(arter? Or vein? Or vessel?)/ti,ab,de
s5 peroneal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s6 genicular(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s7 saphenous(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s8 femoropopliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s9 iliofemoral/ti,ab,de
s10 aortoiliac/ti,ab,de
s11 infrapopliteal/ti,ab,de
s12 (tibial(w)runoff)(2w)(vein? Or arter? Or
vessel?)/ti,ab,de
s13 (lower(w)limb?)(2w)(ischaemi? Or ischemi? Or
arter? Or vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s14 (lower(w)extremit?)(2w)(ischaemi? Or
ischemi? Or arter? Or vein? Or vessel? Or
vascular or occlusive)/ti,ab,de
s15 leg(2w)(ischaemi? Or ischemi? Or arter? Or
vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s16 peripheral(w)vascular/ti,ab,de
s17 peripheral(w)arter?/ti,ab,de
s18 s1:s17
s19 doppler(2w)ultrasonograph?/ti,ab,de
s20 magnetic(w)resonance(w)angiograph?/ti,ab,de
s21 computed(2w)tomography/ti,ab,de
s22 duplex(w)ultrasound/ti,ab,de
s23 echography/ti,ab,de
s24 ct(w)angiograph?/ti,ab,de
s25 mra/ti,ab
s26 mr(w)angiograph?/ti,ab,de
s27 mri(w)angiograph?/ti,ab,de
s28 cta/ti,ab
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s30 s18 and s29
Science Citation Index: 
ISI Web of Knowledge
The Science Citation Index database was searched
from 1981 to May 2004 on 10 May 2004 and the
following strategy was used. An update search was
undertaken on 11 May 2005 covering the period
1981 to 11 May 2005.
TS=((iliac or femoral or popliteal or tibial or
peroneal or genicular or saphenous) same
(arter* or vein* or vessel*))
TS=(femoropopliteal or iliofemoral or aortoiliac
or infrapopliteal)
TS=(tibial same runoff same (arter* or vein* or
vessel*))
TS=(((lower limb*) or (lower extremit*) or leg)
same (iscaehi* or ischemi* or arter* or vein* or
vessel* or vascular or occlusive))
TS=((peripheral vascular) or (peripheral arter*))
#1 OR #2 OR #3 OR #4 OR #5
TS=(ultrasonograph* same doppler)
TS=(magnetic resonance angiograph*)
TS=(computed same tomograph*)
TS=((duplex ultrasound) or echography )
TS=(ct same angiograph*)
TS=((mr or mri) same angiograph*)
#7 or #8 or #9 or #10 or #11 or #12
#6 and #13
NTIS: Dialog
The NTIS database was searched from 1964 to
week 2 May 2004 on 14 May 2004 and the
following strategy was used. An update search was
undertaken on 12 May 2005 covering the period
May 2004 to April 2005.
S1 iliac(w)(arter? Or vein? Or vessel?)/ti,ab,de
s2 femoral(w)(arter? Or vein? Or vessel?)/ti,ab,de
s3 popliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s4 tibial(w)(arter? Or vein? Or vessel?)/ti,ab,de
s5 peroneal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s6 genicular(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s7 saphenous(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s8 femoropopliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s9 iliofemoral/ti,ab,de
s10 aortoiliac/ti,ab,de
s11 infrapopliteal/ti,ab,de
s12 (tibial(w)runoff)(2w)(vein? Or arter? Or
vessel?)/ti,ab,de
s13 (lower(w)limb?)(2w)(ischaemi? Or ischemi? Or
arter? Or vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s14 (lower(w)extremit?)(2w)(ischaemi? Or
ischemi? Or arter? Or vein? Or vessel? Or
vascular or occlusive)/ti,ab,de
s15 leg(2w)(ischaemi? Or ischemi? Or arter? Or
vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s16 peripheral(w)vascular/ti,ab,de
s17 peripheral(w)arter?/ti,ab,de
s18 s1:s17
s19 doppler(2w)ultrasonograph?/ti,ab,de
s20 magnetic(w)resonance(w)angiograph?/ti,ab,de
s21 computed(2w)tomography/ti,ab,de
s22 duplex(w)ultrasound/ti,ab,de
s23 echography/ti,ab,de
s24 ct(w)angiograph?/ti,ab,de
s25 mra/ti,ab
s26 mr(w)angiograph?/ti,ab,de
s27 mri(w)angiograph?/ti,ab,de
s28 cta/ti,ab
s29 s19:s28
s30 s18 and s29
LILACS: via
http://bases.bireme.br/
cgi-bin/wxislind.exe/iah/online/
The LILACS database was searched from 1982 to
May 2004 on 14 May 2004 and the following
strategy was used. An update search was
undertaken on 13 May 2005 covering the period
1982 to 13 May 2005.
((iliac AND arter$) OR (iliac AND vein$) OR (iliac
AND vessel$) OR (femoral AND arter$) OR
(femoral AND vein$) OR (femoral AND vessel$)
OR (popliteal AND arter$) OR (popliteal AND
vein$) OR (poplitealL AND vessel$) OR (tibial
AND arter$) OR (tibial AND vein$) OR (tibial
AND vessel$) OR (peroneal AND arter$) OR
(peroneal AND vein$) OR (peroneal AND vessel$)
OR (genicular AND arter$) OR (genicular and
vein$) OR (genicular AND vessel$) OR
(saphenous AND arter$) OR (saphenous AND
vein$) OR (saphenous AND vessel$) OR
(femoropoliteal AND arter$) OR (femoropopliteal
AND vein$) OR (femoropopliteal AND vessel$)
OR (iliofemoral) OR (aortoiliac) OR
(infrapopliteal) OR (lower AND limb$ AND
ischaemi$) OR (lower AND limb$ AND ischemi$)
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AND limb$ AND vein$) OR (lower AND limb$
AND vessel$) OR (lower AND limb$ AND
vascular) OR (lower AND limb$ AND occlusive)
OR (lower AND extremit$ AND ischaemi$) OR
(lower AN! D extremit$ AND ischemi$) OR (lower
AND extremit$ AND arter$) OR (lower AND
extremit$ AND vein$) OR (lower AND extremit$
AND vessel$) OR (lower AND extremit$ and
vascular) OR (lower AND extremit$ and occlusive)
OR (leg AND limb$ AND ischaemi$) OR (leg
AND limb$ AND ischemi$) OR (leg AND limb$
AND arter$) OR (leg AND limb$ AND vein$) OR
(leg AND limb$ AND vessel$) OR (leg AND limb$
and vascular) OR (leg AND limb$ and occlusive)
OR (peripheral AND vascular) OR (peripheral
AND arter$)) and ((doppler AND
ultrasonograph$) OR (magnetic AND resonance
AND angiograph$) OR (computed AND
tomograph$) OR (duplex AND ultrasound) OR
(echocography) OR (ct AND angiograph$) OR
(MR AND angiograph$) OR (MRI AND
angiograph$)) 
SIGLE: WebSPIRS
The SIGLE database was searched from 1980 to
May 2004 on 19 May 2004 and the following
strategy was used. 
#1 iliac adj (arter* or vein* or vessel*)
#2 femoral adj (arter* or vein* or vessel*)
#3 popliteal adj (arter* or vein* or vessel*)
#4 tibial adj (arter* or vein* or vessel*)
#5 peroneal adj (arter* or vein* or vessel*)
#6 genicular adj (arter* or vein* or vessel*)
#7 saphenous adj (arter* or vein* or vessel*)
#8 femoropopliteal
#9 iliofemoral
#10 aortoiliac
#11 infrapopliteal
#12 (tibial runoff) adj (arter* or vein* or vessel*)
#13 (lower limb*) adj (ischaemia or ischemia or
arter* or vein* or vessel* or vascular or
occlusive)
#14 (lower extremit*) adj (ischaemia or ischemia
or arter* or vein* or vessel* or vascular or
occlusive)
#15 leg adj (ischaemia or ischemia or arter* or
vein* or vessel* or vascular or occlusive)
#16 peripheral vascular
#17 peripheral arter*
#18 (aortoiliac) or (iliofemoral) or
(femoropopliteal) or (saphenous adj (arter*
or vein* or vessel*)) or (genicular adj (arter*
or vein* or vessel*)) or (peroneal adj (arter*
or vein* or vessel*)) or (tibial adj (arter* or
vein* or vessel*)) or (popliteal adj (arter* or
vein* or vessel*)) or (femoral adj (arter* or
vein* or vessel*)) or (iliac adj (arter* or vein*
or vessel*)) or (peripheral arter*) or
(peripheral vascular) or (leg adj (ischaemia
or ischemia or arter* or vein* or vessel* or
vascular or occlusive)) or ((lower extremit*)
adj (ischaemia or ischemia or arter* or vein*
or vessel* or vascular or occlusive)) or ((lower
limb*) adj (ischaemia or ischemia or arter*
or vein* or vessel* or vascular or occlusive))
or ((tibial runoff) adj (arter* or vein* or
vessel*)) or (infrapopliteal)
#19 doppler ultrasonography
#20 duplex ultrasonography
#21 magnetic resonance angiograph*
#22 computed tomography
#23 echography
#24 duplex ultrasound
#25 ct angiography
#26 mr angiography
#27 mra in ti,ab(3 records)
#28 mr adj angiograph*
#29 mri angiograph*
#30 cta in ti,ab
#31 duplex ultrasound
#32 duplex ultrasound
#33 (cta in ti,ab) or (duplex ultrasound) or (mri
angiograph*) or (duplex ultrasound) or (mr
adj angiograph*) or (mra in ti,ab) or (mr
angiography) or (ct angiography) or (duplex
ultrasound) or (echography) or (duplex
ultrasonography) or (computed tomography)
or (doppler ultrasonography) or (magnetic
resonance angiograph*)
#34 ((cta in ti,ab) or (duplex ultrasound) or (mri
angiograph*) or (duplex ultrasound) or (mr
adj angiograph*) or (mra in ti,ab) or (mr
angiography) or (ct angiography) or (duplex
ultrasound) or (echography) or (duplex
ultrasonography) or (computed tomography)
or (doppler ultrasonography) or (magnetic
resonance angiograph*)) and ((aortoiliac) or
(iliofemoral) or (femoropopliteal) or
(saphenous adj (arter* or vein* or vessel*))
or (genicular adj (arter* or vein* or vessel*))
or (peroneal adj (arter* or vein* or vessel*))
or (tibial adj (arter* or vein* or vessel*)) or
(popliteal adj (arter* or vein* or vessel*)) or
(femoral adj (arter* or vein* or vessel*)) or
(iliac adj (arter* or vein* or vessel*)) or
(peripheral arter*) or (peripheral vascular)
or (leg adj (ischaemia or ischemia or arter*
or vein* or vessel* or vascular or occlusive))
or ((lower extremit*) adj (ischaemia or
ischemia or arter* or vein* or vessel* or
Appendix 3
128vascular or occlusive)) or ((lower limb*) adj
(ischaemia or ischemia or arter* or vein* or
vessel* or vascular or occlusive)) or ((tibial
runoff) adj (arter* or vein* or vessel*)) or
(infrapopliteal))
Dissertation Abstracts: Dialog
The Dissertation Abstracts database was searched
from 1861 to April 2004 on 17 May 2004 and the
following strategy was used. An update search was
undertaken on 12 May 2005 covering the period
April 2004 to May 2005.
S1 iliac(w)(arter? Or vein? Or vessel?)/ti,ab,de
s2 femoral(w)(arter? Or vein? Or vessel?)/ti,ab,de
s3 popliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s4 tibial(w)(arter? Or vein? Or vessel?)/ti,ab,de
s5 peroneal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s6 genicular(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s7 saphenous(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s8 femoropopliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s9 iliofemoral/ti,ab,de
s10 aortoiliac/ti,ab,de
s11 infrapopliteal/ti,ab,de
s12 (tibial(w)runoff)(2w)(vein? Or arter? Or
vessel?)/ti,ab,de
s13 (lower(w)limb?)(2w)(ischaemi? Or ischemi? Or
arter? Or vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s14 (lower(w)extremit?)(2w)(ischaemi? Or
ischemi? Or arter? Or vein? Or vessel? Or
vascular or occlusive)/ti,ab,de
s15 leg(2w)(ischaemi? Or ischemi? Or arter? Or
vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s16 peripheral(w)vascular/ti,ab,de
s17 peripheral(w)arter?/ti,ab,de
s18 s1:s17
s19 doppler(2w)ultrasonograph?/ti,ab,de
s20 magnetic(w)resonance(w)angiograph?/ti,ab,de
s21 computed(2w)tomography/ti,ab,de
s22 duplex(w)ultrasound/ti,ab,de
s23 echography/ti,ab,de
s24 ct(w)angiograph?/ti,ab,de
s25 mra/ti,ab
s26 mr(w)angiograph?/ti,ab,de
s27 mri(w)angiograph?/ti,ab,de
s28 cta/ti,ab
s29 s19:s28
s30 s18 and s29
Inside Conferences: Dialog
The Inside Conferences database was searched
from 1861 to April 2004 on 17 May 2004 and the
following strategy was used. An update search was
undertaken on 12 May 2005 covering the period
May 2004 to May 2005.
S1 iliac(w)(arter? Or vein? Or vessel?)/ti,ab,de
s2 femoral(w)(arter? Or vein? Or vessel?)/ti,ab,de
s3 popliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s4 tibial(w)(arter? Or vein? Or vessel?)/ti,ab,de
s5 peroneal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s6 genicular(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s7 saphenous(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s8 femoropopliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s9 iliofemoral/ti,ab,de
s10 aortoiliac/ti,ab,de
s11 infrapopliteal/ti,ab,de
s12 (tibial(w)runoff)(2w)(vein? Or arter? Or
vessel?)/ti,ab,de
s13 (lower(w)limb?)(2w)(ischaemi? Or ischemi? Or
arter? Or vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s14 (lower(w)extremit?)(2w)(ischaemi? Or
ischemi? Or arter? Or vein? Or vessel? Or
vascular or occlusive)/ti,ab,de
s15 leg(2w)(ischaemi? Or ischemi? Or arter? Or
vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s16 peripheral(w)vascular/ti,ab,de
s17 peripheral(w)arter?/ti,ab,de
s18 s1:s17
s19 doppler(2w)ultrasonograph?/ti,ab,de
s20 magnetic(w)resonance(w)angiograph?/ti,ab,de
s21 computed(2w)tomography/ti,ab,de
s22 duplex(w)ultrasound/ti,ab,de
s23 echography/ti,ab,de
s24 ct(w)angiograph?/ti,ab,de
s25 mra/ti,ab
s26 mr(w)angiograph?/ti,ab,de
s27 mri(w)angiograph?/ti,ab,de
s28 cta/ti,ab
s29 s19:s28
s30 s18 and s29
Pascal: Dialog
The Pascal database was searched from 1973 to
2004 July week 4 on 3 August 2004 and the
following strategy was used. An update search was
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May 2004 to August 2005.
S1 iliac(w)(arter? Or vein? Or vessel?)/ti,ab,de
s2 femoral(w)(arter? Or vein? Or vessel?)/ti,ab,de
s3 popliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s4 tibial(w)(arter? Or vein? Or vessel?)/ti,ab,de
s5 peroneal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s6 genicular(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s7 saphenous(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s8 femoropopliteal(w)(arter? Or vein? Or
vessel?)/ti,ab,de
s9 iliofemoral/ti,ab,de
s10 aortoiliac/ti,ab,de
s11 infrapopliteal/ti,ab,de
s12 (tibial(w)runoff)(2w)(vein? Or arter? Or
vessel?)/ti,ab,de
s13 (lower(w)limb?)(2w)(ischaemi? Or ischemi? Or
arter? Or vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s14 (lower(w)extremit?)(2w)(ischaemi? Or
ischemi? Or arter? Or vein? Or vessel? Or
vascular or occlusive)/ti,ab,de
s15 leg(2w)(ischaemi? Or ischemi? Or arter? Or
vein? Or vessel? Or vascular or
occlusive)/ti,ab,de
s16 peripheral(w)vascular/ti,ab,de
s17 peripheral(w)arter?/ti,ab,de
s18 s1:s17
s19 doppler(2w)ultrasonograph?/ti,ab,de
s20 magnetic(w)resonance(w)angiograph?/ti,ab,de
s21 computed(2w)tomography/ti,ab,de
s22 duplex(w)ultrasound/ti,ab,de
s23 echography/ti,ab,de
s24 ct(w)angiograph?/ti,ab,de
s25 mra/ti,ab
s26 mr(w)angiograph?/ti,ab,de
s27 mri(w)angiograph?/ti,ab,de
s28 cta/ti,ab
s29 s19:s28
s30 s18 and s29
In addition to the literature searches to identify
studies of effectiveness, searches were undertaken
to inform the economic modelling. These are
detailed below.
Cochrane Database of Systematic
Reviews
Issue 3 2005 was searched on 1 August 2005 using
the Wiley Interscience interface to identify reviews
of effectiveness. The following search strategy was
used.
"(lower limb*) near/2 (ischaem* or ischem*) in
Record Title or (lower extremit*) near/2 
(ischaem* or ischem*) in Record Title or leg*
near/2 (ischaem* or ischem*) in Record Title or
Peripheral arter* in Record Title or peripheral
vascular disease* in Keywords in The Cochrane
Database of Systematic Reviews" 
MEDLINE: Ovid
The MEDLINE database was searched from 1993
to 2005 on 27 July 2005 to identify quality of life
studies using the strategy below.
1. (utilit$ approach$ or health gain or hui or
hui2 or hui3).ti,ab.
2. (health measurement$ scale$ or health
measurement$ questionnaire$).ti,ab.
3. (standard gamble$ or categor$ scal$ or linear
scal$ or linear analog$ or visual scal$ or
magnitude estimat$).ti,ab.
4. (time trade off$ or rosser$ classif$ or 
rosser$ matrix or rosser$ distress$ or
hrqol).ti,ab.
5. (index of wellbeing or quality of wellbeing or
qwb).ti,ab.
6. (multiattribute$ health ind$ or multi
attribute$ health ind$).ti,ab.
7. (health utilit$ index or health utilit$
indices).ti,ab.
8. (multiattribute$ theor$ or multi attribute$
theor$ or multiattribute$ analys$ or multi
attribute$ analys$).ti,ab.
9. (health utilit$ scale$ or classification of illness
state$).ti,ab.
10. health state$ utilit$.ti,ab.
11. well year$.ti,ab.
12. (multiattribute$ utilit$ or multi attribute$
utilit$).ti,ab.
13. health utilit$ scale$.ti,ab.
14. (euro qual or euro qol or eq-5d or eq5d or eq
5d or euroqual or euroqol).ti,ab.
15. (qualy or qaly or qualys or qalys or quality
adjusted life year$).ti,ab.
16. willingness to pay.ti,ab.
17. (hye or hyes or health$ year$
equivalent$).ti,ab.
18. (person trade off$ or persn tradeoff$ or time
tradeoff$ or time trade off$).ti,ab.
19. theory utilit$.ti,ab.
20. (sf36 or sf 36).ti,ab.
21. (short form 36 or shortform 36 or sf thirtysix
or sf thirty six or shortform thirtysix or
Appendix 3
130shortform thirty six or short form thirtysix or
short form thirty six).ti,ab.
22. (sf 6d or sf6d or short form 6d or shortform
6d or sf six$ or shortform six$ or short form
six$).ti,ab.
23. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10
or 11 or 12 or 13 or 14 or 15 or 16 or 17 or
18 or 19 or 20 or 21 or 22
24. (iliac adj (arter$ or vein$ or vessel$)).mp. 
25. (femoral adj (arter$ or vein$ or vessel$)).mp. 
26. (popliteal adj (arter$ or vein$ or vessel$)).mp.
27. (tibial adj (arter$ or vein$ or vessel$)).mp. 
28. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
29. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
30. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
31. (genicular adj (arter$ or vein$ or
vessel$)).mp. 
32. (saphenous adj (vein$ or vessel$)).mp. 
33. femoropopliteal.mp. 
34. iliofemoral.mp. 
35. aortoiliac.mp. 
36. infrapopliteal.mp. 
37. (tibial runoff adj (arter$ or vein$ or
vessel$)).mp. 
38. 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
or 32 or 33 or 34 or 35 or 36 or 37
39. (lower limb$ adj2 (ischaemi$ or ischemi$ or
arter$ or vein$ or vessel$ or vascular or
occlusive)).mp. 
40. (lower extremit$ adj2 (ischaemi$ or ischemi$
or arter$ or vein$ or vessel$ or vascular or
occlusive)).mp. 
41. (leg adj2 (ischaemi$ or ischemi$ or arter$ or
vein$ or vessel$ or vascular or occlusive)).mp
42. peripheral vascular.mp. 
43. peripheral arter$.mp. 
44. 38 or 39 or 40 or 41 or 42 or 43
45. 23 and 44
PREMEDLINE: Ovid
The PREMEDLINE database was searched on 
27 July 2005 to identify quality of life studies
using the strategy below.
1. (utilit$ approach$ or health gain or hui or
hui1 or hui2 or hui3).ti,ab.
2. (health measurement$ scale$ or health
measurement$ questionnaire$).ti,ab.
3. (standard gamble$ or categor$ scal$ or linear
scal$ or linear analog$ or visual scal$ or
magnitude estimat$).ti,ab.
4. (time trade off$ or rosser$ classif$ or rosser$
matrix or rosser$ distress$ or hrqol).ti,ab.
5. (index of welbeing or quality of wellbeing or
qwb).ti,ab.
6. (multiattribute$ health ind$ or multi
attribute$ health ind$).ti,ab.
7. (health utilit$ index or health utilit$
indices).ti,ab.
8. (multiattribute$ theor$ or multi attribute$
theor$ or multiattribute$ analys$ or multi
attribute$ analys$).ti,ab.
9. (health utilit$ scale$ or classification of illness
state$).ti,ab.
10. health state$ utilit$.ti,ab.
11. well year$.ti,ab.
12. (multiattribute$ utilit$ or multi attribute$
utilit$).ti,ab.
13. health utilit$ scale$.ti,ab.
14. (euro qual or euro qol or eq-5d or eq5d or eq
5d or euroqual or euroqol).ti,ab.
15. (qualy or qaly or qualys or qalys or quality
adusted life year$).ti,ab.
16. willingness to pay.ti,ab.
17. (hye or hyes or health$ year$
equivalent$).ti,ab.
18. (person trade off$ or person tradeoff$ or time
tradeoff$ or time trade off$).ti,ab.
19. theory utilit$.ti,ab.
20. (sf36 or sf 36).ti,ab.
21. (short form 36 or shortform 36 or sf thirtysix
or sf thirty six or shortform thirtysix or
shortform thirty six or short form thirtysix or
short form thirty six).ti,ab.
22. (sf 6d or sf6d or short form 6d or shortform
6d or sf six$ or shortform six$ or short form
six$).ti,ab.
23. or/1-22
24. (iliac adj (arter$ or vein$ or vessel$)).mp. 
25. (femoral adj (arter$ or vein$ or vessel$)).mp. 
26. (popliteal adj (arter$ or vein$ or vessel$)).mp. 
27. (tibial adj (arter$ or vein$ or vessel$)).mp. 
28. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
29. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
30. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
31. (genicular adj (arter$ or vein$ or
vessel$)).mp. 
32. (saphenous adj (vein$ or vessel$)).mp. 
33. femoropopliteal.mp. 
34. iliofemoral.mp. 
35. aortoiliac.mp. 
36. infrapopliteal.mp. 
37. (tibial runoff adj (arter$ or vein$ or
vessel$)).mp. 
38. 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
or 32 or 33 or 34 or 35 or 36 or 37
39. (lower limb$ adj2 (ischaemi$ or ischemi$ or
arter$ or vein$ or vessel$ or vascular or
occlusive)).mp. 
40. (lower extremit$ adj2 (ischaemi$ or ischemi$
or arter$ or vein$ or vessel$ or vascular or
occlusive)).mp. 
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vein$ or vessel$ or vascular or occlusive)).mp. 
42. peripheral vascular.mp. 
43. peripheral arter$.mp. 
44. 38 or 39 or 40 or 41 or 42 or 43
45. 23 and 44
EMBASE: Ovid
The EMBASE database was searched from 1993 to
2005 on 27 July 2005 to identify quality of life
studies using the strategy below.
1. (utilit$ approach$ or health gain or hui or
hui1 or hui2 or hui3).ti,ab.
2. (health measurement$ scale$ or health
measurement$ questionnaire$).ti,ab.
3. (standard gamble$ or categor$ scal$ or linear
scal$ or linear analog$ or visual scal$ or
magnitude estimat$).ti,ab.
4. (time trade off$ or rosser$ classif$ or rosser$
matrix or rosser$ distress$ or hrqol).ti,ab.
5. (index of wellbeing or quality of wellbeing or
qwb).ti,ab.
6. (multiattribute$ health ind$ or multi
attribute$ health ind$).ti,ab.
7. (health utilit$ index or health utilit$
indices).ti,ab.
8. (multattribute$ theor$ or multi attribute$
theor$ or multiattribute$ analys$ or multi
attribute$ analys$).ti,ab.
9. (health utilit$ scale$ or classification of illness
state$).ti,ab.
10. health state$ utilit$.ti,ab.
11. well year$.ti,ab.
12. (multiattribute$ utilit$ or multi attribute$
utilit$).ti,ab.
13. health utilit$ scale$.ti,ab.
14. (euro qual or euro qol or eq-5d or eq5d or eq
5d or euroqual or euroqol).ti,ab.
15. (qualy or qaly or qualys or qalys or quality
adjusted life year$).ti,ab.
16. willingness to pay.ti,ab.
17. (hye or hyes or health$ year$
equaivalent$).ti,ab.
18. (person trade off$ or person tradeoff$ or time
tradeoff$ or time trade off$).ti,ab.
19. theory utilit$.ti,ab.
20. (sf36 or sf 36).ti,ab.
21. (short form 36 or shortform 36 or sf thirtysix
or sf thirty six or shortform thirtysix or
shortform thirty six or shrt form thirtysix or
short form thirty six).ti,ab.
22. (sf 6d or sf6d or short form 6d or shortform
6d or sf six$ or shortform six$ or short form
six$).ti,ab.
23. or/1-22
24. (iliac adj (arter$ or vein$ or vessel$)).mp.
25. (femoral adj (arter$ or vein$ or vessel$)).mp. 
26. (popliteal adj (arter$ or vein$ or vessel$)).mp. 
27. (tibial adj (arter$ or vein$ or vessel$)).mp. 
28. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
29. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
30. (peroneal adj (arter$ or vein$ or vessel$)).mp. 
31. (genicular adj (arter$ or vein$ or vessel$)).mp
32. (saphenous adj (vein$ or vessel$)).mp
33. femoropopliteal.mp. 
34. iliofemoral.mp.
35. aortoiliac.mp.
36. infrapopliteal.mp.
37. (tibial runoff adj (arter$ or vein$ or
vessel$)).mp.
38. 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
or 32 or 33 or 34 or 35 or 36 or 37
39. (lower limb$ adj2 (ischaemi$ or ischemi$ or
arter$ or vein$ or vessel$ or vascular or
occlusive)).mp. 
40. (lower extremit$ adj2 (ischaemi$ or ischemi$
or arter$ or vein$ or vessel$ or vascular or
occlusive)).mp.
41. (leg adj2 (ischaemi$ or ischemi$ or arter$ or
vein$ or vessel$ or vascular or occlusive)).mp. 
42. peripheral vascular.mp. 
43. peripheral arter$.mp. 
44. 38 or 39 or 40 or 41 or 42 or 43
45. 23 and 44
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Appendix 4
QUADAS and details of criteria for scoring studies
TABLE 34 The QUADAS tool
1. Was the spectrum of patients representative of the patients who will receive the test in practice?
Yes Unselected, prospective, adult patients with symptoms suggestive of lower limb PAD
No All other patient spectra including retrospectively selected patient spectra
Unclear If insufficient details were provided to make a judgement as to whether the patient spectrum would be scored
as ‘yes’
2. Were selection criteria clearly described?
Yes Enough details were provided of how patients were selected so that the selection process could be replicated
No Insufficient details were presented
Unclear Not applicable
3. Was the reference standard likely to correctly classify the target condition?
NA Only studies with an appropriate reference standard were included
4. Was the time period between reference standard and index test short enough to be reasonably sure
that the target condition did not change between the two tests?
Yes The time between index test and reference standard was 1 month
No If greater than above
Unclear If details of the time elapsed between tests were not reported
5. Did the whole sample or a random selection of the sample receive verification using a reference
standard of diagnosis?
Yes If the whole sample or a random selection of the sample received the same reference standard
No If only a selected sample received the reference standard
Unclear If it was not clear whether all the patients received the reference standard
6. Did patients receive the same reference standard regardless of the index test result?
Yes If all patients received the same reference standard
No If some patients received a different reference standard
Unclear If it was not clear whether all patients received the same reference standard
7. Was the reference standard independent of the index test (i.e. the index test did not form part of
the reference standard)?
Yes If the index test and reference standard were independent
No If the index test formed part of the reference standard
Unclear If it was not clear whether the index test and reference standard were independent
8a. Was the execution of the index test described in sufficient detail to permit replication of the test?
8b. Was the execution of the reference standard described in sufficient detail to permit its replication?
Yes If sufficient details of test/reference standard execution were reported so that the test/reference standard could
reasonably be replicated
No If sufficient details were not reported
Unclear Not applicable
9a. Were the index test results interpreted without knowledge of the results of the reference standard?
9b. Were the reference standard results interpreted without knowledge of the results of the index test?
Yes If the index test was interpreted without knowledge of the results of the reference standard and vice versa
If one test was clearly interpreted before the results of the other test were available then this should be scored
as ‘yes’
No If the person interpreting the index test was aware of the results of the reference standard or vice versa
Unclear If no information is provided regarding whether tests were interpreted blindly 
continuedAppendix 4
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TABLE 34 The QUADAS tool (cont’d)
10. Were the same clinical data available when test results were interpreted as would be available when
the test is used in practice?
Yes If the article states that the following information was available: description (including side) of symptoms, site of
any ulceration or gangrene, presence of peripheral pulses, surgical history
No If not as above
Unclear If details on the availability of clinical data were not reported
11. Were uninterpretable/intermediate test results reported?
Yes If details were provided on uninterpretable/intermediate test results
No If there appear to be some uninterpretable/intermediate test results but the results of these were not reported
Unclear If it was not clear whether there were any uninterpretable/intermediate test results
12. Were withdrawals from the study explained?
Yes If all patients recruited into the study were accounted for
No If there appear to be patients who were recruited into the study who were not accounted for
Unclear If it is not clear whether any withdrawals occurredHealth Technology Assessment 2007; Vol. 11: No. 20
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Appendix 5
Quality checklist for the included economic 
evaluationsAppendix 5
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T
ABLE 35
Quality checklist
Question
Visser
, 2003
128
Visser
, 2003
130
Geitung, 1996
126
Visser
, 2003
129
Yin, 1995
131
1.
The research question is stated
YYYY
Y
2.
The economic importance of the research question is stated
Y
Y
N
Y
Y
3.
The viewpoint(s) of the analysis are stated and justified
Unclear
Unclear
N
N
Y
4.
The rationale for choosing the alternative programmes or interventions is stated
YYYY
Y
5.
The alternatives being compared are clearly described
YYYY
Y
6.
The form of economic evaluation is stated
N
N
Y
N
Y
7.
The choice of form of economic evaluation is justified in relation to the questions 
addressed
NNNN
N
8.
The source(s) of effectiveness estimates are stated
YYYY
Y
9.
Details of the design and results of effectiveness study are given (if based on a 
single study)
NA
NA
Y
NA
NA
10.
Details of methods of synthesis or meta-analysis of estimates are given 
(if based on an overview of a number of effectiveness studies)
N
N
NA
N
N
11.
The primary outcome measure(s) for the economic evaluation are clearly stated
YYYY
Y
12.
Methods to value health states and other benefits are stated
NA
Y
N
A
Y
Y
13.
Details of the subjects from whom valuations are obtained are given
Unclear
Unclear
Unclear
N
N
14.
P
roductivity changes (if included) are reported separately
NA
NA
NA
N
Unclear
15.
The relevance of productivity changes to the study question is discussed
Y
N
N
N
N
16.
Quantities of resources are reported separately from their unit costs
N
N
Unclear
N
N
17.
Methods for the estimation of quantities and unit costs are described
Unclear
Unclear
Y
Unclear
Unclear
18.
Currency and price data are recorded
YYYY
Unclear
19.
Details of currency of price adjustments for inflation or currency conversion 
are given
YY
N
Y
N
20.
Details of any model used are given
Y
Y
NA
Y
Y
21.
The choice of model used and key parameters on which it is based are justified
N
Unclear
NA
Unclear
Unclear
22.
The horizon of costs and benefits is stated
Y
Y
N
Y
N
23.
The discount rate is stated
Y
Y
NA
Y
Y
24.
The choice of rate is justified
Unclear
Unclear
NA
Unclear
N
25.
An explanation is given if costs or benefits are not discounted
NA
NA
NA
NA
NA
26.
Details of statistical test and confidence intervals are given for stochastic data
N
N
A
N
NA
NA
27.
The approach to sensitivity analysis is given
N
Y
Y
Y
Y
28.
The choice of variables for sensitivity analysis is justified
Y
Y
N
Y
Y
29.
The ranges over which the variables are varied is stated
Y
Y
N
Y
Y
30.
R
elevant alternatives are compared
YYYY
Y
31.
Incremental analysis is reported
Y
N
N
Y
Y
32.
Major outcomes are reported in a disaggregated as well as an aggregated form
NNNN
N
33.
The answer to the study question is given
YYYY
Y
34.
Conclusions follow from the data reported
YYYY
Y
35.
Conclusions are accompanied by the appropriate caveats
Y
Y
N
Y
Y
36.
Generalisability issues are addressed
Y
N
N
Unclear
N
Y
, yes; N, no.Health Technology Assessment 2007; Vol. 11: No. 20
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Appendix 6
Included studies evaluating tests to diagnose 
stenosis/occlusion
TABLE 36 Studies evaluating tests to diagnose stenosis/occlusion
Study Participants Index test Reference standard
Aly, 199820 Aim of the study:
Assessment of primary stenosis
Number of patients: 90 (proportion male:
66%)
Median age (years): 68 (range NR)
Fontaine stage II: 90%
Fontaine stage III: 9%
Fontaine stage IV: 1%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
2.5- and 7-MHz linear array
probes
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details: 
Uniplanar
Common femoral artery
puncture
Ashleigh, 199321 Aim of the study:
Assessment of primary stenosis
Number of patients: 60 (proportion male:
63%)
Mean age (years): 67 (range 34–89)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
5-MHz linear array
transducer
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details:
None reported
Baum, 199522 Aim of the study:
Assessment of primary stenosis and graft
stenosis
Number of patients: 155 (proportion male:
63%)
Mean age (years): 66 (range 27–88)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: Extremity
Field strength: 1.5
Reference standard:
Angiography
Reference standard details:
Intraoperative
Hand injection directly into
bypass graft
Postprocedure arteriograms
in patients having
subcutaneous procedures
Baxter, 199323
continued
Aim of the study:
Assessment of primary stenosis
Number of patients: 20 (proportion male:
60%)
Mean age (years): 62 (range 21–86)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
5-MHz linear array probe
PSVR of >1.8 indicated 
50% stenosis
Reference standard:
Angiography
Reference standard details: 
4 station cut filmAppendix 6
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TABLE 36 Studies evaluating tests to diagnose stenosis/occlusion (cont’d)
Study Participants Index test Reference standard
Bergamini,
199524
Aim of the study:
Assessment of primary stenosis
Number of patients: 44 (proportion male:
NR)
Mean/median age (years): NR (range NR)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
5-MHz Doppler transducer
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography
Reference standard details:
Uniplanar 
Bostrom,
200125
Aim of the study:
Assessment of primary stenosis
Number of patients: 183 (proportion male:
54%)
Median age (years): 69 (range 43–88)
Fontaine stage II: 52%
Fontaine stage III: 27%
Fontaine stage IV: 21%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
4–6-MHz linear, 2.5–5-MHz
curved and 2–4-MHz vector
array
PSVR of 2.5 indicated 50%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details: 
Uniplanar
Femoral artery
catheterisation
Catalano,
200426
Aim of the study:
Assessment of primary stenosis
Number of patients: 50 (proportion male:
78%)
Mean age (years): 67 (range 43–89)
Fontaine stage II: 6%
Fontaine stage III: 48%
Fontaine stage IV: 46%
Are the data from a patient subgroup? No
Index test: CTA
Instrument: Volume Zoom,
Siemens
Reference standard:
Angiography (with DSA)
Reference standard details:
Transfemoral in 43 patients
Left transaxillary in 7 patients
Cronberg,
200328
Aim of the study:
Assessment of primary stenosis
Number of patients: 35 (proportion male:
46%)
Mean age (years): 78 (range 50–98)
Fontaine stage II: 9%
Fontaine stage III: 3%
Fontaine stage IV: 89%
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
1.7-mm straight or pigtail
catheter 
Superficial femoral or
common iliac artery
Cortell, 199627 Aim of the study:
Assessment of primary stenosis
Number of patients: 31 (proportion male:
65%)
Mean age (years): 69 (range 42–85)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: Head
Field strength: 1.5
Above-knee and pelvic
vessels were also imaged
using 3D TOF MRA (with
contrast when deemed
appropriate); however, these
results were not reported
Reference standard:
Angiography (with DSA in 
13 patients)
Reference standard details:
Common femoral artery
puncture in 30 patients
Axillary artery puncture in 
1 patient
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TABLE 36 Studies evaluating tests to diagnose stenosis/occlusion (cont’d)
Study Participants Index test Reference standard
Currie, 199529 Aim of the study:
Assessment of primary stenosis
Number of patients: 92 (proportion male:
74%)
Median age (years): 64 (range 43–83)
Fontaine stage II: 97%
Fontaine stage III: 0%
Fontaine stage IV: 3%
Are the data from a patient subgroup? No
Index test 1: 2D TOF MRA
Coil: NR
Field strength: 1
Index test 2: Colour DUS
Instrument/probe type: 
5-MHz linear and 2.25- and
3.5-MHz phased array
PSVR of 2.5 indicated 50%
stenosis
Reference standard:
Angiography
Reference standard details: 
Biplanar
Transfemoral or transbrachial
routes
Davies, 199230 Aim of the study:
Assessment of primary stenosis
Number of patients: 52 (proportion male:
75%)
Median age (years): 64 (range 56–80)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type:
Linear 5-MHz, phased array
2.25-MHz
PSVR: NR
Reference standard:
Angiography
Reference standard details:
Biplanar
Eiberg, 200131 Aim of the study:
Assessment of primary stenosis
Number of patients: 94 (proportion male:
55%)
Median age (years): 72 (range 42–90)
Fontaine stage II: 22%
Fontaine stage III: 33%
Fontaine stage IV: 45%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
7.5-MHz
PSVR: NR
Reference standard:
Angiography
Reference standard details:
Transfemoral arteriography
Eklof, 199832 Aim of the study:
Assessment of primary stenosis
Number of patients: 24 (proportion male:
50%)
Median age (years): 72 (range 37–97)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: Knee
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Femoral artery puncture
El-Kayali,
200433
Aim of the study:
Assessment of primary stenosis
Number of patients: 44 (proportion male:
66%)
Mean age (years): 55 (range NR)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: DUS
Instrument/probe type: 
4-MHz probe (iliac
segments), 7-MHz
(infrainguinal segments)
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details:
Uniplanar or biplanar
continuedAppendix 6
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TABLE 36 Studies evaluating tests to diagnose stenosis/occlusion (cont’d)
Study Participants Index test Reference standard
Fletcher, 199034 Aim of the study:
Assessment of primary stenosis
Number of patients: 28 (proportion male:
61%)
Mean age (years): 65 (range 48–88)
Fontaine stage II: 68%
Fontaine stage III: 21%
Fontaine stage IV: 11%
Are the data from a patient subgroup? No
Index test: DUS
Instrument/probe type: NR
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography
Reference standard details:
None reported
Grassbaugh,
200335
Aim of the study:
Assessment of primary stenosis
Number of patients: 38 (proportion male:
53%)
Mean age (years): 72 (range 44–82)
Fontaine stage II: 0%
Fontaine stage III: 34%
Fontaine stage IV: 66%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
4–7-MHz linear array probe
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography
Reference standard details: 
Preoperative or
intraoperative
Aorta, iliac or femoral artery
injection
Hatsukami,
199237
Aim of the study:
Assessment of primary stenosis
Number of patients: 29 (proportion male:
100%)
Mean age (years): 63 (range 43–86)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
5-MHz transducer
PSVR: NR
Reference standard:
Angiography
Reference standard details:
None reported
Heuschmid,
200338
Aim of the study:
Assessment of primary stenosis
Number of patients: 23 (proportion male:
65%)
Mean age (years): 66 (range NR)
Fontaine stage II: 78%
Fontaine stage III: 13%
Fontaine stage IV: 9%
Are the data from a patient subgroup? No
Index test: CTA
Instrument: Somatom
Volume Zoom (Siemens)
Reference standard:
Angiography (with DSA)
Reference standard details:
Femoral artery puncture
Hany, 199736 Aim of the study:
Assessment of primary stenosis
Number of patients: 39 (proportion male:
72%)
Mean age (years): 62 (range 34–81)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Transfemorally inserted 5-F
pigtail catheter 
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TABLE 36 Studies evaluating tests to diagnose stenosis/occlusion (cont’d)
Study Participants Index test Reference standard
Hirai, 199839 Aim of the study:
Assessment of primary stenosis
Number of patients: 52 (proportion male:
NR)
Mean/median age (years): NR (range NR)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 5- or
3.5-MHz convex array (iliac),
7.5-MHz linear array
(femoropopliteal)
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography
Reference standard details:
None reported
Hoch, 199640 Aim of the study:
Assessment of primary stenosis
Number of patients: 45 (proportion male:
76%)
Mean age (years): 65 (range NR)
Fontaine stage II: 18%
Fontaine stage III: 20%
Fontaine stage IV: 62%
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: body (above knee),
head or leg (below knee)
Field strength: 1 or 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Femoral artery puncture
Hofmann,
200442
Aim of the study:
Assessment of primary stenosis
Number of patients: 33 (proportion male:
85%)
Median age (years): 70 (range 48–86)
Fontaine stage II: 0%
Fontaine stage III: 0%
Fontaine stage IV: 100%
Are the data from a patient subgroup?
Diabetes mellitus
Index test: Colour DUS
Instrument/probe type: 
13-MHz linear array
transducer
PSVR: NR
Reference standard:
Angiography (with DSA)
and/or CE MRAa
Reference standard details: 
Biplanar
Ipsilateral common femoral
artery puncture
Karacagil,
199643
Aim of the study:
Assessment of primary stenosis
Number of patients: 38 (proportion male:
45%)
Mean age (years): 71 (range 43–87)
Fontaine stage II: 16%
Fontaine stage III: 34%
Fontaine stage IV: 50%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
5-MHz linear array probe
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details: 
Uniplanar
Femoral artery puncture
Hoch, 199941 Aim of the study:
Assessment of primary stenosis
Number of patients: 20 (proportion male:
100%)
Mean/median age (years): NR (range NR)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: body (above knee),
head (below knee)
Field strength: 1
Reference standard:
Angiography (with DSA)
Reference standard details:
None reported
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Study Participants Index test Reference standard
Koelemay,
199744
Aim of the study:
Assessment of primary stenosis
Number of patients: 23 (proportion male:
39%)
Median age (years): 71 (range 29–85)
Fontaine stage II: 9%
Fontaine stage III: 52%
Fontaine stage IV: 39%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 3.7-
and 5.5-MHz probe
PSVR: NR
Reference standard:
Angiography (with DSA)
Reference standard details: 
Biplanar
Femoral artery puncture
Koelemay,
199845
Aim of the study:
Assessment of primary stenosis
Number of patients: 120 (proportion male:
61%)
Median age (years): 72 (range 27–95)
Fontaine stage II: 16%
Fontaine stage III: 34%
Fontaine stage IV: 50%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 3.7-
and 5.5-MHz
PSVR: NR
Reference standard:
Angiography (with DSA)
Reference standard details: 
Biplanar
Common femoral artery
puncture
Lai, 199547 Aim of the study:
Assessment of primary stenosis
Number of patients: 50 (proportion male:
0%)
Mean/median age (years): NR (range NR)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 3.5-
and/or 2.25-MHz and 5-MHz
probe
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details:
None reported
Lai, 199648 Aim of the study:
Assessment of primary stenosis
Number of patients: 50 (proportion male:
not reported)
Mean/median age (years): NR (range NR)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 2.25-
and/or 3.5-MHz (aortoiliac),
5-MHz (femoropopliteal)
PSVR of 2.1 indicated 50%
stenosis
PSVR of 4.1 indicated 76%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details:
Transfemoral catheterisation
Kreitner, 200046 Aim of the study:
Unclear whether assessment of primary
stenosis or graft stenosis
Number of patients: 24 (proportion male:
71%)
Mean age (years): 69 (range 53–84)
Fontaine stage II: 0%
Fontaine stage III: 0%
Fontaine stage IV: 100%
Are the data from a patient subgroup?
Diabetes mellitus
Index test: CE MRA
Coil: Head
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details: 
5-F pigtail catheter in distal
aorta in 8 patients
Femoral artery puncture in
6 patients
Retrograde cross-over
antegrade catheterisation of
the common femoral,
superficial femoral or
popliteal artery in 10 patients
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TABLE 36 Studies evaluating tests to diagnose stenosis/occlusion (cont’d)
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Laissy, 199849 Aim of the study:
Assessment of primary stenosis
Number of patients: 20 (proportion male:
85%)
Mean age (years): 53 (range 42–62)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1
Reference standard:
Angiography
Reference standard details:
Femoral or brachial artery
puncture
5-F pigtail catheter in the
distal aorta
Linke, 199452 Aim of the study:
Assessment of primary stenosis
Number of patients: 25 (proportion male:
60%)
Mean age (years): 68 (range 48–87)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 5-
and 7.5-MHz transducer
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography
Reference standard details:
Femoral artery puncture
Lenhart, 200051 Aim of the study:
Assessment of primary stenosis
Number of patients: 45 (proportion male:
80%)
Median age (years): 63 (range 44–77)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Leg
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Aortic catheterisation
Legemate,
199150
Aim of the study:
Assessment of primary stenosis
Number of patients: 61 (proportion male:
NR)
Mean/median age (years): NR (range NR)
Fontaine stage II: 80%
Fontaine stage III: 16%
Fontaine stage IV: 3%
Are the data from a patient subgroup? No
Index test: DUS
Instrument/probe type: 
3-MHz (abdominal), 5- or
7.5-MHz (femoropopliteal)
imaging or 3-MHz
(abdominal), 5-MHz
(femoropopliteal) single-gate
pulsed-Doppler probes
PSVR of 1.5 indicated
25–50% stenosis
PSVR of 2.5 indicated
50–99% stenosis
Reference standard:
Angiography (with DSA)
Reference standard details:
Common femoral artery
puncture using the Seldinger
technique Uniplanar
recordings for superficial
femoral and popliteal arteries
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Lundin, 200053 Aim of the study:
Assessment of primary stenosis
Number of patients: 39 (proportion male:
54%)
Mean age (years): 67 (range 51–87)
Fontaine stage II: 87%
Fontaine stage III: 10%
Fontaine stage IV: 3%
Are the data from a patient subgroup? No
Index test 1: DUS
Instrument/probe type: 
2.5-MHz curved array/3.5-
or 5-MHz linear array
PSVR of 2.5 indicated 50%
stenosis
Index test 2: 2D TOF MRA
Coil: Body
Field strength: 1
Index test 3: CE MRA
Coil: Body
Field strength: 1
Reference standard:
Angiography (with DSA)
Reference standard details:
Transfemoral puncture, with
contrast agent injected via
pigtail catheter into distal
aorta in 37 patients
External iliac artery approach
in 2 patients
Martin, 200354 Aim of the study:
Assessment of primary stenosis
Number of patients: 41 (proportion male:
68%)
Mean age (years): 67 (range 45–84)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: CTA
Instrument: Astein VR four-
channel MDCT scanner
Reference standard:
Angiography (with DSA)
Reference standard details:
Right common femoral artery
approach in 25 patients
Left common femoral artery
approach in 15 patients
Right brachial artery
approach in 1 patient
McDermott,
199555
Aim of the study:
Assessment of primary stenosis
Number of patients: 31 (proportion male:
48%)
Mean/median age (years): NR (range 50–87)
Fontaine stage II: 13%
Fontaine stage III: 19%
Fontaine stage IV: 68%
Are the data from a patient subgroup?
Diabetes mellitus
Index test: 2D TOF MRA
Coil: Leg
Field strength: 1.5
Reference standard:
Angiography (with DSA in
12 patients)
Reference standard details:
Pigtail catheter in the distal
abdominal aorta
Intraoperative angiography
performed in 10 patients
Meaney, 19999 Aim of the study:
Assessment of primary stenosis
Number of patients: 20 (proportion male:
60%)
Mean age (years): 65 (range 47–83)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Pigtail catheter placed in
distal aorta
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Mergelsberg,
198656
Aim of the study:
Assessment of primary stenosis
Number of patients: 32 (proportion male:
75%)
Mean/median age (years): NR (range 45–84)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: DUS
Instrument/probe type: 
5-MHz linear probe
PSVR: NR
Reference standard:
Angiography (with DSA)
Reference standard details:
None reported
Portugaller,
200457
Aim of the study:
Assessment of primary stenosis
Number of patients: 50 (proportion male:
84%)
Mean age (years): 68 (range 45–86)
Fontaine stage II: 62%
Fontaine stage III: 4%
Fontaine stage IV: 34%
Are the data from a patient subgroup? No
Index test: CTA
Instrument: Lightspeed 
four-detector spiral scanner
(General Electrics)
Reference standard:
Angiography (with DSA)
Reference standard details:
Femoral puncture route in
48 patients
Transbrachial approach in
2 patients
Puls, 200258 Aim of the study:
Assessment of primary stenosis
Number of patients: 31 (proportion male:
55%)
Mean age (years): 53 (range 38–75)
Fontaine stage II: 97%
Fontaine stage III: 3%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: CTA
Instrument: Somatom Plus 4
Volume Zoom
Reference standard:
Angiography (with DSA)
Reference standard details:
Femoral artery puncture
Rieker, 199659 Aim of the study:
Assessment of primary stenosis and graft
stenosis
Number of patients: 50 (proportion male:
NR)
Mean age (years): 65 (range 45–83)
Fontaine stage II: 74%
Fontaine stage III: 12%
Fontaine stage IV: 14%
Are the data from a patient subgroup? No
Index test: CTA
Instrument: PQ 2000 (Picker
International)
Reference standard:
Angiography (with DSA)
Reference standard details:
Common femoral artery
puncture 
Pigtail catheter in the
infrarenal aorta or superficial
femoral artery
Rieker, 199760 Aim of the study:
Assessment of primary stenosis
Number of patients: 30 (proportion male:
NR)
Mean age (years): 62 (range 42–85)
Fontaine stage II: 87%
Fontaine stage III: 10%
Fontaine stage IV: 3%
Are the data from a patient subgroup? No
Index test: CTA
Instrument: PQ 5000 scanner
(Picker International)
Reference standard:
Angiography (with DSA)
Reference standard details: 
5-F pigtail catheters 
Femoral artery route in 28
patients
Transbrachial route in two
patients with weak or absent
femoral pulses
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Schafer, 200361 Aim of the study:
Assessment of primary stenosis
Number of patients: 30 (proportion male:
60%)
Median age (years): 68 (range 46–89)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Catheter at aortic bifurcation
Sensier, 199662 Aim of the study:
Assessment of primary stenosis
Number of patients: 76 (proportion male:
58%)
Median age (years): 71 (range 46–84)
Fontaine stage II: 88%
Fontaine stage III: 0%
Fontaine stage IV: 12%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 3.5-
or 5-MHz probe
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography (with DSA)
Reference standard details:
Uniplanar, with biplanar in
some aortoiliac arteries
Shaalan, 200363 Aim of the study:
Assessment of primary stenosis
Number of patients: 132 (proportion male:
47%)
Mean age (years): 65 (range NR)
Fontaine stage II: 65%
Fontaine stage III: 0%
Fontaine stage IV: 35%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
4–7-MHz linear array
transducer and probe
PSVR: NR
Reference standard:
Angiography
Reference standard details:
None reported
Snidow, 199564 Aim of the study:
Unclear whether assessment of primary
stenosis or graft stenosis
Number of patients: 42 (proportion male:
95%)
Mean/median age (years): NR (range NR)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography
Reference standard details:
None reported
Snidow, 199665 Aim of the study:
Assessment of primary stenosis and graft
stenosis
Number of patients: 32 (proportion male:
97%)
Mean age (years): 63 (range 43–75)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details: 
5-F pigtail catheter positioned
at or above the level of the
renal arteries, or at the aortic
bifurcation
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TABLE 36 Studies evaluating tests to diagnose stenosis/occlusion (cont’d)
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Steffens, 199766 Aim of the study:
Assessment of primary stenosis
Number of patients: 115 (proportion male:
NR)
Mean age (years): 62 (range 32–81)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: 2D PC MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details: 
5-F catheter positioned at 
the level of the first lumbar
vertebra
Steffens, 200367 Aim of the study:
Assessment of primary stenosis
Number of patients: 50 (proportion male:
58%)
Mean age (years): 65 (range 35–86)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Pigtail catheter positioned at
the aortic bifurcation
Sueyoshi,
199968
Aim of the study:
Assessment of primary stenosis and graft
stenosis
Number of patients: 23 (proportion male:
87%)
Mean age (years): 68 (range 52–85)
Fontaine stage II: 83%
Fontaine stage III: 17%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details:
Femoral puncture in 20
patients
Brachial puncture in 3
patients
Pigtail catheter positioned in
the distal aorta
Timonina,
199969
Aim of the study:
Assessment of primary stenosis
Number of patients: 36 (proportion male:
100%)
Mean age (years): 54 (range 32–64)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography
Reference standard details:
Femoral artery
catheterisation
Vavrik, 200470 Aim of the study:
Assessment of primary stenosis
Number of patients: 48 (proportion male:
52%)
Mean age (years): 66 (range NR)
Fontaine stage II: 92%
Fontaine stage III: 2%
Fontaine stage IV: 6%
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details: 
4-F catheter positioned
above the aortic bifurcation
Common femoral artery
puncture
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Whyman,
199271
Aim of the study:
Assessment of primary stenosis
Number of patients: 30 (proportion male:
NR)
Median age (years): 65 (range 45–85)
Fontaine stage II: 100%
Fontaine stage III: 0%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
5-MHz transducer
PSVR of 2.0 indicated 50%
stenosis 
Reference standard:
Angiography
Reference standard details:
None reported
Wilson, 199772 Aim of the study:
Assessment of primary stenosis
Number of patients: 43 (proportion male:
77%)
Mean age (years): 78 (range 53–95)
Fontaine stage II: 0%
Fontaine stage III: 28%
Fontaine stage IV: 72%
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
4–7 or 5–10-MHz linear
array transducers
PSVR: Not reported
Reference standard:
Angiography
Reference standard details:
None reported 
Winterer,
199973
Aim of the study:
Assessment of primary stenosis
Number of patients: 76 (proportion male:
57%)
Mean age (years): 66 (range 36–96)
Fontaine stage II: 87%
Fontaine stage III: 13%
Fontaine stage IV: 0%
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Body
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details: 
5-F pigtail catheter in the
bifurcation of the distal aorta
Yucel, 199374 Aim of the study:
Assessment of primary stenosis and graft
stenosis
Number of patients: 25 (proportion male:
60%)
Mean age (years): 68 (range 37–80)
Fontaine stage II: 0%
Fontaine stage III: 84%
Fontaine stage IV: 16%
Are the data from a patient subgroup? No
Index test: 2D TOF MRA
Coil: NR
Field strength: 1.5
Reference standard:
Angiography
Reference standard details:
Multistation digital or cut-film
run-off studies
Zeuchner,
199475
Aim of the study:
Assessment of primary stenosis and graft
stenosis
Number of patients: 54 (proportion male:
56%)
Mean age (years): 70 (range 42–86)
Fontaine stage: NR
Are the data from a patient subgroup? No
Index test: Colour DUS
Instrument/probe type: 
3.5-MHz convex, 7.5-MHz
linear
PSVR of 2.0 indicated 50%
stenosis
Reference standard:
Angiography
Reference standard details:
None reported
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Zhang, 200576 Aim of the study:
Assessment of primary stenosis
Number of patients: 52 (proportion male:
54%)
Mean age (years): 68 (range 38–92)
Fontaine stage II: 46%
Fontaine stage III: 12%
Fontaine stage IV: 42%
Are the data from a patient subgroup? No
Index test: CE MRA
Coil: Head
Field strength: 1.5
Reference standard:
Angiography (with DSA)
Reference standard details: 
4- or 5-F catheter
Femoral artery puncture
a CE MRA results are not included in this review, as the inclusion criteria specified CA as the reference standard.
NR, not reported.I
n order to facilitate data extraction the NHS
EED abstract template has been used to provide
critical structured abstracts. The abstracts are
intended to provide users with comprehensive
information about the original papers and their
quality. Structured NHS EED abstracts are
presented below for all economic evaluations that
met the inclusion criteria of the review.
Visser and colleagues (2003)129
Visser K, Kuntz KM, Donaldson MC, Gazelle GS,
Hunink MG. Pretreatment imaging workup for
patients with intermittent claudication: a cost-
effectiveness analysis. J Vasc Interv Radiol 2003;
14:53–62.
This record was compiled by CRD commissioned
reviewers according to a set of guidelines
developed in collaboration with a group of leading
health economists.
Health technology
Alternative pretreatment imaging work-up
procedures were studied. These were magnetic
resonance angiography (MRA), duplex
ultrasonography (DUS) and intra-arterial digital
subtraction angiography (DSA), followed by
treatment. Two alternative treatment scenarios
were analysed. One was a minimally invasive
scenario in which treatment was limited to
angioplasty and patients with non-suitable lesions
entered a supervised exercise programme. The
other was a more invasive treatment scenario in
which angioplasty was performed, if feasible,
otherwise bypass surgery was carried out.
Disease
Cardiovascular diseases.
Type of intervention
Diagnosis and treatment.
Hypothesis/study question
The objective of this study was to assess the cost-
effectiveness of MRA, DUS and intra-arterial DSA
for the pretreatment imaging work-up of patients
with lifestyle-limiting intermittent claudication.
The comparator chosen was exercise therapy
without imaging work-up. A societal perspective
was adopted in the economic analysis (although
this was only stated in the abstract of the study). 
Economic study type
Cost–utility analysis. 
Study population
The study population comprised a hypothetical
cohort of 60-year-old men with a 1-year history of
severe unilateral claudication, an initial ankle
brachial index of 0.70 and no history of coronary
artery disease. 
Setting
The study setting was secondary care. It was
unclear where the economic study was carried out. 
Dates to which data relate
The effectiveness data were derived from studies
published between 1981 and 2002. The resource-
use and cost data appear to have been collected
from studies published between 1998 and 2002.
The price year was 1998. 
Source of effectiveness data
The effectiveness data were derived from a review
and synthesis of published studies and several
authors’ assumptions.
Modelling
A decision-analytic model was developed to
evaluate the cost-effectiveness of MRA, DUS and
DSA. The outcomes and lifetime costs for
treatment and follow-up of all possible diagnostic
outcomes were calculated using a Markov model
with first order Monte Carlo simulations of
100,000 hypothetical patients, and were combined
with the cost and effectiveness of the pretreatment
work-up. The cycle length used for the Markov
model was not identified. The health states
considered were severe intermittent claudication,
mild intermittent claudication, critical limb
ischaemia, history of angina pectoris, systemic
long-term complications after intervention and
death.
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Data extraction of included economic evaluationsOutcomes assessed in the review
The outcomes assessed were: 
● the sensitivity and specificity of MRA and 
DUS for the detection of stenosis of more than
50% 
● the probabilities with MRA and DUS of
uninterpretable test results and indeterminate
test results 
● the probabilities with MRA and DUS of results
suggesting angioplasty given that the lesion is
suitable for angioplasty, angioplasty given that
the lesion is suitable for bypass surgery, and
angioplasty given that the lesion is not suitable
for invasive treatment 
● the probabilities with MRA and DUS of results
suggesting bypass surgery given that the lesion
is suitable for bypass surgery, and bypass
surgery given that the lesion is not suitable for
invasive treatment 
● the probability of suprainguinal disease 
● the probability that a suprainguinal lesion is
suitable for angioplasty 
● the probability that an infrainguinal lesion is
suitable for angioplasty 
● the probability that lesions are suitable for
invasive treatment 
● the annual rate of progression of invasively
untreated disease 
● the annual rate of changing disease location 
● the 2-year patency in patients with intermittent
claudication who underwent either angioplasty
or bypass surgery 
● the quality of life associated with the health
states mild and severe intermittent claudication,
critical limb ischaemia, history of angina
pectoris and systemic long-term complications
after intervention. 
Study designs and other criteria for
inclusion in the review
The authors did not explicitly report the study
designs included in the review, although they 
did report that several meta-analyses were
included. 
Sources searched to identify primary
studies
Not reported.
Criteria used to ensure the validity of
primary studies
Not reported. 
Methods used to judge relevance,
validity, extracting data
Not reported. 
Number of primary studies included
Approximately 19 published studies were included
in the review. 
Method of combination of primary
studies
Not reported. 
Investigation of differences between
primary studies
Not reported. 
Results of the review
The sensitivities and specificities for MRA versus
DUS to detect a stenosis of more than 50% were,
respectively, 0.96 (range 0.91–0.97) and 0.96
(range 0.94–0.98) versus 0.90 (range 0.89–0.90)
and 0.95 (range 0.93–0.96).
The probability of an uninterpretable result was
0.07 (range 0.05–0.10) with MRA and 0.11 (range
0.0–0.23) with DUS.
The probability of an indeterminate result was 0
with MRA and 0.089 (range 0.036–0.14) with DUS.
The probability that the results suggested
angioplasty given that the lesion was suitable for
angioplasty was 0.79 with MRA and 0.60 with DUS.
The probability that the results suggested
angioplasty given that the lesion was suitable for
bypass surgery was 0.03 with MRA and 0.08 with
DUS.
The probability that the results suggested
angioplasty given that the lesion was not suitable
for invasive treatment was 0 with MRA and 0.09
with DUS.
The probability that the results suggested bypass
surgery given that the lesion was suitable for
bypass surgery was 0.97 with MRA and 0.87 with
DUS.
The probability that the results suggested bypass
surgery given that the lesion was suitable for
angioplasty was 0.14 with MRA and 0.36 with
DUS.
The probability that the results suggested bypass
surgery given that the lesion was not suitable for
invasive treatment was 0 with MRA and 0.09 with
DUS.
The probability of suprainguinal disease was 0.56
(range 0.12–0.85).
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suitable for angioplasty was 0.51 (range
0.43–0.59).
The probability that an infrainguinal lesion was
suitable for angioplasty was 0.18 (range
0.11–0.25).
The probability that lesions were suitable for
invasive treatment was 0.95.
The annual rate of progression of invasively
untreated disease was 0.20.
The annual rate of changing disease location was
0.15.
The 2-year patency in patients with intermittent
claudication ranged from 0.46 for angioplasty of
infrainguinal lesions occlusion to 0.95 when aortic
bifurcation grafts were performed. 
The health-related quality of life was:
● 0.71 in patients with severe intermittent
claudication 
● 0.79 in patients with mild intermittent
claudication 
● 0.35 in patients with critical limb ischaemia 
● 0.90 in patients with history of angina pectoris 
● 0.72 in patients with systemic long-term
complications after intervention. 
Methods used to derive estimates of
effectiveness
The authors made assumptions to derive some of
the effectiveness estimators.
Estimates of effectiveness and key
assumptions
The authors assumed that after diagnosis with
DSA, an additional angioplasty session would be
required in 10% of cases, owing to incorrect
referral. Moreover, 95% of patients undergoing
diagnostic work-up for peripheral arterial disease
would be eligible for invasive treatment after
work-up.
Measure of benefits used in the
economic analysis
The health benefit measure used in the economic
analysis was the quality-adjusted life-years
(QALYs). The health values used were obtained
from the review of the literature (see the section
‘Results of the review’, p. 152). The time-horizon
adopted was the patient’s lifetime. The health
benefits were discounted at a rate of 3%.
Direct costs
The direct costs included in the analysis were
those of the health service and the patient.
Medical costs included the costs of diagnostic tests,
treatment and follow-up. The authors also
included the extra costs for inefficient use of
personnel, equipment and housing in the case of
an incorrectly scheduled angioplasty procedure.
The non-medical costs included transportation
costs and patient time spent on diagnostic testing,
interventions and follow-up visits. The unit costs
and the resource quantities were not reported
separately. The authors used Medicare
reimbursement rates, which included technical
and professional fees, for the costs of MRA, DUS
and DSA. All other costs were derived from the
literature. Discounting was necessary since the
costs were incurred during the lifetime of the
patient, and was undertaken at a rate of 3% per
annum. All of the costs were converted to 1998
prices using the Consumer Price Index. The
average costs were reported. 
Indirect costs
The indirect costs were not included in the analysis.
Currency
US dollars ($).
Statistical analysis of costs
The costs were treated as point estimates (i.e. the
data were deterministic). 
Sensitivity analysis
All parameters were varied in a one-way sensitivity
analysis within a range of plausible values. The
authors also reported the cost-effectiveness of two
additional diagnostic strategies in order to plan
bypass surgery within the more invasive treatment
scenario. One strategy was MRA in all patients
followed by DSA, while the other was DUS with
DSA. Two other patient cohorts were also
considered. One was 40-year-old men (all other
characteristics similar to the base case), while the
other was 70-year-old men with a history of
coronary artery disease. 
Estimated benefits used in the
economic analysis
The QALYs gained in the minimally invasive
(more invasive) treatment scenario were:
● with no diagnostic work-up, 6.0606 (6.0606)
QALYs 
● with DUS, 6.1465 (6.2002) QALYs 
● with MRA, 6.1487 (6.2136) QALYs 
● with DSA, 6.1498 (6.2254) QALYs.
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The costs in the minimally invasive (more invasive)
treatment scenario were:
● with no diagnostic work-up, $18,912 ($18,912) 
● with DUS, $22,042 ($50,178) 
● with MRA, $21,959 ($48,980) 
● with DSA, $22,497 ($48,411).
Synthesis of costs and benefits
The cost-effectiveness was determined by
excluding dominated and extended dominated
strategies and then calculating the incremental
cost–utility ratio (ICUR). A strategy was
considered to be dominated by another strategy 
if the latter yielded higher QALYs at a lower cost.
A strategy was considered to be extended
dominated by another if the latter yielded higher
QALYs at a lower ICUR. The ICUR of a strategy
was calculated as the difference in QALYs
compared with the next best strategy, which
represented the additional costs per additional
QALY gained for a strategy compared with the
next best strategy. 
In the minimally invasive treatment scenario for
the base-case analysis, the ICUR for MRA yielded
$35,000 per QALY compared with no diagnostic
work-up. DSA had an ICUR of $471,000 per
QALY compared with MRA. DUS was dominated
by MRA. 
In the more invasive treatment scenario, DSA had
an ICUR of $179,000 per QALY compared with
no diagnostic work-up. MRA and DUS were both
dominated by DSA. 
For 40-year-old men, the ICURs decreased:
minimally invasive treatment scenario, $18,000
per QALY for MRA; more invasive treatment
scenario, $119,000 per QALY for DSA. For 
70-year-old men with a history of coronary artery
disease, only the minimally invasive treatment
scenario was considered and MRA had an ICUR of
$95,000 per QALY. 
The results from the sensitivity analyses were not
sensitive to changes in the diagnostic test
characteristics. If angioplasty was assumed to
follow DSA immediately, it was found that the
QALYs increased and costs decreased for DSA, but
only the ICUR for DSA in the minimally invasive
scenario changed to $195,000 per QALY. When
the criteria of suitability for angioplasty were
broadened for patients with intermittent
claudication, the results changed in favour of DSA.
When severe intermittent claudication was defined
as a walking distance of less than 175 m (base case
250 m), the effectiveness increased and the costs
decreased. The authors found that when they
explored the cost-effectiveness of MRA and DUS
in combination with DSA for planning bypass
surgery, the strategy with DUS was the optimal
strategy, with an ICUR of $179,000 per QALY
compared with no diagnostic work-up strategy. 
Authors’ conclusions
The differences in costs and effectiveness among
diagnostic imaging strategies for patients with
intermittent claudication were slight. MRA or DUS
could replace intra-arterial DSA without
substantial loss in effectiveness and with a slight
cost reduction. 
CRD commentary
Selection of comparators
The authors evaluated MRA, DUS and DSA
because they were three imaging modalities that
were being widely used for the diagnostic work-up
of peripheral arterial disease. You should decide
whether these are widely used health technologies
in your own setting. 
Validity of estimate of measure of effectiveness
The authors did not report that a systematic
review of the literature had been undertaken to
identify relevant research and minimise biases.
The authors also did not report the methods used
in the review, such as the study designs to be
included, the criteria used to ensure the validity of
the studies, the methods used to judge relevance,
and the sources searched or the search strategy to
identify relevant studies. The authors did not
report how estimates of effectiveness from the
primary studies were combined, nor did they
report whether differences between the primary
studies were investigated. 
The authors reported ranges for most of the
model probabilities, which were then used in the
sensitivity analysis. As the authors reported, the
use of secondary data has its own limitations and
is not always applicable to the question under
study. A further limitation, as stated by the
authors, was that several assumptions had to be
made to keep the model tractable. However, an
extensive sensitivity analysis was performed to
assess the uncertainty surrounding the
effectiveness parameters.
Validity of estimate of measure of benefit
The estimation of benefits was modelled. The
instrument used to derive a measure of health
benefit, a decision-analytic model with an
Appendix 7
154embedded Markov model, appears to have been
appropriate. QALYs were used as the summary
measure of benefit, which will enable comparisons
of the study findings with those from different
interventions. Since a lifetime horizon was
considered for the estimation of health benefits,
these were discounted at a rate of 3%. However,
there is controversy in the health economics
literature about whether health benefits should be
discounted.
Validity of estimate of costs
Although the authors reported that a societal
perspective was adopted, the indirect costs were
not included. All of the direct costs appear to have
been included in the analysis. The costs and the
quantities were not reported separately, which will
limit reflation exercises in other settings. The costs
were derived from published sources and
Medicare reimbursement rates. Hence, charges
were used to proxy prices, which may not reflect
the true opportunity cost of the assessed
interventions. Appropriate sensitivity analyses of
the costs were undertaken, and the ranges used
appear to have been appropriate. The authors
used the Consumer Price Index to inflate costs to
1998 prices. However, it would have been more
appropriate if the authors had used healthcare
inflation instead, as it is generally the case that
healthcare prices rise more quickly than average
prices. Since all of the costs were incurred during
the lifetime of the patient, the costs were
appropriately discounted. The price year was
reported, which will assist any possible inflation
exercises. 
Other issues
The authors made appropriate comparisons with
two other studies evaluating the cost-effectiveness
of the pretreatment work-up for peripheral
arterial disease. DUS and DSA were compared in
one study, and it was concluded that DUS was not
a cost-effective alternative because of its low
sensitivity. The other study reported that MRA
alone, or in combination with selective use of
DSA, might be a cost-effective alternative
compared with DSA. The issue of generalisability
to other settings was partially addressed in the
sensitivity analysis. The authors do not appear to
have presented their results selectively. However,
in their conclusions they reported that DUS could
replace DSA without substantial loss in
effectiveness and with a slight cost reduction.
Albeit this is true, DUS was found to be
dominated by MRA in both treatment scenarios
and, therefore, its use is not cost-effective and
hence inefficient. 
The authors reported a number of further
limitations. For example, DSA and a subsequent
angioplasty procedure were assumed to be
scheduled in separate sessions. However, in
clinical practice, DSA and angioplasty may be
planned as a single session. The authors also
commented that not every centre has all three
diagnostic modalities at its disposal and, therefore,
the comparisons considered in this study might be
irrelevant in some settings. 
Implications of the study
The authors suggested further research in the
form of a clinical study, which should focus on the
decision-making process and workflow in clinical
practice. They also stated that an appropriate
design for such a comparison would be a
pragmatic randomised controlled trial in which
patients are randomised among available imaging
modalities. 
Other publications of related interest
Yin D, Baum RA, Carpenter JP, Langlotz CP,
Pentecost, MJ. Cost-effectiveness of MR
angiography in cases of limb-threatening
peripheral vascular disease. Radiology
1995;194:757–64.
Geitung JT, Wikstrom T, Zeuchner J, Gothlin JH.
Cost-effectiveness of colour duplex sonography
compared with angiography of the pelvis and
lower limb. Eur Radiol 1996;6:481–4. 
Subject index terms
Subject indexing assigned by NLM
Angiography, Digital Subtraction/ec (economics);
Cost Benefit Analysis; Decision Support
Techniques; Human; Intermittent Claudication/di
(diagnosis); Intermittent Claudication/ec
(economics); Intermittent Claudication/th
(therapy); Magnetic Resonance Angiography/ec
(economics); Models, Economic; Quality Adjusted
Life Years; Sensitivity and Specificity; Support,
Non US Gov’t; Ultrasonography, Doppler,
Color/ec (economics).
Country codes
The Netherlands.
Source of funding
Supported in part by the Foundation ‘Vereniging
Trustfolds Erasmus Universiteit Rotterdam’ and by
the Netherlands Organization for Scientific
Research.
Copyright comments
Copyright: University of York, 2005.
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Visser K, de Vries SO, Kitslaar PJ, 
van Engelshoven JM, Hunink MG. Cost-
effectiveness of diagnostic imaging work-up and
treatment for patients with intermittent
claudication in the Netherlands. Eur J Vasc
Endovasc Surg 2003;25:213–23.
This record was compiled by CRD commissioned
reviewers according to a set of guidelines
developed in collaboration with a group of leading
health economists.
Health technology
The following alternative management strategies
for patients with intermittent claudication were
investigated.
Magnetic resonance angiography (MRA) in all
patients and subsequent angioplasty for all
patients with suitable lesions, otherwise patients
entered a supervised exercise programme
(MRA+PTA/EX).
MRA in all patients and subsequent angioplasty
for patients with suitable lesions, bypass surgery
for the remainder of patients, except for those
non-suitable who entered a supervised exercise
programme (MRA+PTA/BS/EX).
Colour-guided duplex ultrasound (DUS) in all
patients and subsequent angioplasty for patients
with suitable lesions, otherwise patients entered a
supervised exercise programme (DUS+PTA/EX).
Colour-guided DUS in all patients and 
subsequent angioplasty for patients with suitable
lesions and bypass surgery for the remainder of
patients, except for those non-suitable who
entered a supervised exercise programme
(DUS+PTA/BS/EX).
Intra-arterial digital subtraction angiography
(DSA) in all patients and subsequent angioplasty
for patients with suitable lesions, otherwise
patients entered a supervised exercise programme
(DSA+PTA/EX).
DSA in all patients and subsequent angioplasty for
patients with suitable lesions and bypass surgery
for the remainder of patients, except for those
non-suitable who entered a supervised exercise
programme (DSA + PTA/BS/EX).
A conservative strategy in which all patients
entered a supervised exercise programme
(Notest+EX) and were only evaluated further if
critical limb ischaemia developed. 
Disease
Cardiovascular diseases.
Type of intervention
Diagnosis and treatment. 
Hypothesis/study question
The main objective of this study was to evaluate
the cost-effectiveness of management strategies,
including imaging work-up and treatment, for
patients with intermittent claudication in The
Netherlands. A second objective was to determine
whether the results from cost-effectiveness analyses
performed in the USA were generalisable to
The Netherlands. The comparator chosen would
appear to be the conservative strategy (since the
authors stated that this was the reference strategy).
A societal perspective was adopted in the
economic analysis. 
Economic study type
Cost–utility analysis. 
Study population
The study population comprised a hypothetical
cohort of previously untreated 60-year-old patients
presenting with severe unilateral claudication of at
least 1 year in duration, who had at least one
significant lesion (>50% arterial diameter reduction)
that was located predominantly suprainguinal or
infrainguinal, an ankle brachial index pressure of
0.70 and no history of coronary artery disease. 
Setting
The study setting was secondary care. The economic
study was carried out in The Netherlands. 
Dates to which data relate
The effectiveness data were derived from studies
published between 1960 and 2002. The cost data
would appear to relate to data published between
1995 and 2002. The price year was 1999. 
Source of effectiveness data
The effectiveness data were derived from a review
and synthesis of published studies. 
Modelling
The authors used a model that had been developed
already, which consisted of a Markov Monte Carlo
model embedded in a larger decision-analytic
model. The health states considered were
asymptomatic or mild claudication, severe
claudication, critical limb ischaemia and amputation
Appendix 7
156of the limb. Hypothetical patients were followed
lifelong from the time that the initial diagnostic
work-up was performed. The cycle length used in
the Markov model was not clearly identified.
Outcomes assessed in the review
The outcomes assessed in the review were: 
● the sensitivities for MRA and DUS to detect a
stenosis of more than 50% 
● the test characteristics of MRA and DUS to
assess the treatment option (i.e. percentage of
patients undergoing angioplasty versus bypass
surgery versus lesions not suitable for invasive
treatment given the test results) 
● data on equivocal MRA and DUS results 
● the mortality and morbidity of DSA 
● the excess mortality for peripheral arterial
disease (PAD) 
● the mortality from vascular interventions for
those patients at high and low risk 
● the risk of systemic complications 
● the 2-year patency in patients with intermittent
claudication 
● the probability of suprainguinal disease 
● the suitability for angioplasty 
● the rate of critical limb ischaemia 
● the risk of amputation 
● the relative risk of severe intermittent
claudication after stopping exercise and after
graft failure 
● the mean annual rate of contralateral symptoms. 
Study designs and other criteria for
inclusion in the review
Not reported. 
Sources searched to identify primary
studies
Not reported. 
Criteria used to ensure the validity of
primary studies
Not reported. 
Methods used to judge relevance,
validity, extracting data
Not reported. 
Number of primary studies included
Approximately 28 primary studies were included
in the review (at least three of them were meta-
analyses and one was a case series). 
Method of combination of primary
studies
Not reported. 
Investigation of differences between
primary studies
Not reported. 
Results of the review
The sensitivities for MRA and DUS to detect a
stenosis of more than 50% were, respectively, 0.98
(range 0.96–0.99) and 0.88 (range 0.84–0.91).
The probabilities that MRA and DUS results
suggested angioplasty given that the lesion was
suitable for angioplasty were, respectively, 0.79
and 0.60.
The probabilities that MRA and DUS results
suggested angioplasty given that the lesion was
suitable for bypass surgery were, respectively, 0.03
and 0.08.
The probabilities that MRA and DUS results
suggested angioplasty given that the lesion was not
suitable for invasive treatment were, respectively, 
0 and 0.09.
The probabilities that MRA and DUS results
suggested bypass surgery given that the lesion was
suitable for bypass surgery were, respectively, 0.97
and 0.87.
The probabilities that MRA and DUS results
suggested bypass surgery given that the lesion was
suitable for angioplasty were, respectively, 0.14
and 0.36.
The probabilities that MRA and DUS results
suggested bypass surgery given that the lesion was
not suitable for invasive treatment were,
respectively, 0 and 0.09.
The probabilities of additional work-up with DSA
for equivocal MRA and DUS results were,
respectively, 0.09 (range 0.06–0.14) and 0.23
(range 0.08–0.37).
The risks of major complications or death with
DSA were 0.03 (range 0.02–0.05) and 3.33 × 104
(range 2.9 × 104–16.2 × 104), respectively.
The excess mortality for PAD was 3.14 (range
2.74–3.54).
The mortality from vascular interventions in high-
versus low-risk patients ranged from 0.013 (range
0–0.037) versus 0.001 (range 0–0.029) when
suprainguinal angioplasty with selective stent
placement was performed to 0.098 (range
0.077–0.119) versus 0.147 (range 0.113–0.181)
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less than 75 years old versus those aged 75 or
older. 
The rate of systemic complications ranged from
0.013 (range 0–0.035) when suprainguinal
angioplasty with selective stent placement was
performed to 0.38 (range 0.377–0.383) when
amputation was performed. 
The 2-year patency in patients with intermittent
claudication ranged from 0.67 when
suprainguinal angioplasty with selective stent
placement was performed in case of occlusion to
0.95 when aortic bifurcation grafts were
performed. 
The probability of suprainguinal disease ranged
from 0.17 (range 0.09–0.25) for subsequent
interventions with prior infrainguinal disease to
0.56 (range 0.12–0.85) for the first intervention. 
The suitability for angioplasty in case of
claudication ranged from 0.18 for a first
intervention in a patient with infrainguinal disease
to 0.51 for a first intervention in a patient with
suprainguinal disease.
The annual incidence rates of critical limb
ischaemia for patients aged less than 65 years old
and for those aged 65 or older were, respectively,
0.017 (range 0–0.039) and 0.036 (range 0–0.075).
The 5-week probabilities following graft failure of
pretreatment symptoms/claudication and critical
limb ischaemia were, respectively, 0.062 (range
0–0.014) and 0.242 (range 0.14–0.36).
The proportion of above-knee amputations was
0.08 (range 0.03–0.13).
The annual incidence rate of progression below-
knee to above-knee amputation was 0.015 (range
0–0.07).
The relative risks of severe intermittent
claudication after stopping exercise and after graft
failure were, respectively, 5.81 (range 1.8–18.5)
and 1.36 (range 0.96–1.92).
The mean annual rate of contralateral symptoms
was 0.149.
The health-related quality of life ranged from 
0.20 (range 0–0.40) in patients with above-knee
amputation to 0.90 (range 0.60–1.00) in patients
with angina pectoris. 
Measure of benefits used in the
economic analysis
The summary measure of benefit used was the
number of quality-adjusted life-years (QALYs).
The health values for intermittent claudication
were available from patients who participated in a
supervised exercise programme, with the
responses to the EuroQol being transformed into
time trade-off values. For all other health states,
time trade-off values were used from the literature.
The time-horizon considered for the estimation of
health benefits was a lifetime. The health benefits
were discounted at a rate of 3%.
Direct costs
The direct costs considered appear to have been
those incurred by the health system and the patients.
The direct medical costs were for personnel,
materials, equipment, hospital admission,
inpatient services and overheads. The direct non-
medical costs included patient time spent on
interventions and travel expenses. The costs were
derived from the University Hospital Maastricht,
data collected from the literature and authors’
assumptions. Resource use and the costs were not
reported separately. Discounting was necessary, as
the costs were incurred over the lifetime of the
patient, and was appropriately performed at an
annual rate of 3%. The study reported the average
costs. All of the costs were updated with the
Consumer Price Index to 1999 prices. 
Indirect costs
Friction costs (i.e. costs for productivity losses,
calculated as the costs of replacement of an
employee) were not included in the analysis as
most patients with PAD are retired. 
Currency
Euros (€). The exchange rate used was Dutch
guilders 2.20 = €1.00 = US $1.06 (1999).
Statistical analysis of costs
The costs were treated as point estimates (i.e. the
data were deterministic). 
Sensitivity analysis
Sensitivity analyses were performed for diagnostic
work-up parameters and also for the most
influential parameters of treatment and follow-up,
based on another analysis [de Vries et al., 2002,
see the section ‘Other publications of related
interest’ (p. 160) for bibliographic details]. The
authors also considered a cohort of 40-year-old
men and one of 70-year-old men with a history of
coronary artery disease in order to assess the
results for alternative populations. 
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economic analysis
The QALYs gained per patient with each
management strategy were:
● 6.0606 with Notest+EX 
● 6.1465 with DUS+PTA/EX 
● 6.1487 with MRA+PTA/EX 
● 6.1498 with DSA+PTA/EX 
● 6.2002 with DUS+PTA/BS/EX 
● 6.2136 with MRA+PTA/BS/EX 
● 6.2254 with DSA+PTA/BS/EX.
Cost results
The cost of each management strategy was: 
● Notest+EX, €6793 
● DUS+PTA/EX, €8546 
● MRA+PTA/EX, €8566 
● DSA+PTA/EX, €8997 
● DUS+PTA/BS/EX, €18,720 
● MRA+PTA/BS/EX, €18,440 
● DSA+PTA/BS/EX, €18,583.
Synthesis of costs and benefits
The cost-effectiveness was determined by
excluding (extended) dominated strategies and
then calculating the incremental cost–utility ratio
(ICUR). A strategy was considered to be
dominated by another strategy if the latter yielded
higher QALYs at a lower cost. A strategy was
considered to be extended dominated by another
if the latter yielded higher QALYs at a lower
ICUR. The ICUR of a strategy was calculated as
the difference in QALYs compared with the next
best strategy, which represented the additional
costs per additional QALY gained for a strategy
compared with the next best strategy. 
The strategy MRA+PTA/EX had an ICUR of
€20,138 per QALY compared with the Notest+EX
strategy. 
The strategy DSA+PTA/BS/EX had an ICUR of
€130,557 per QALY compared with the
MRA+PTA/EX strategy. 
All other management strategies were inferior by
either dominance or extended dominance. 
For 40-year-old male patients, the ICURs of
MRA+PTA/EX (compared with Notest+EX) and
DSA+PTA/BS/EX (compared with MRA+PTA/EX)
decreased (€13,000 per QALY and €98,000 per
QALY, respectively). For 70-year-old patients with
a history of coronary artery disease it was found
that the DUS+PTA/EX strategy had an ICUR of
€48,000 per QALY compared with the Notest+EX
strategy, while MRA+PTA/EX had an ICUR of
€75,000 per QALY compared with DUS+PTA/EX.
The results were found to be sensitive to an
increase in the costs of MRA. When the number of
patients with intermittent claudication having
lesions suitable for angioplasty was increased, the
effectiveness of all strategies increased. In
addition, the costs increased for management
strategies with angioplasty as the only invasive
treatment option, but decreased for management
strategies with both angioplasty and bypass
surgery. 
Authors’ conclusions
For patients with severe unilateral intermittent
claudication of at least 1 year in duration, non-
invasive imaging modalities could replace intra-
arterial DSA without an important loss in
effectiveness and at a minimal cost reduction.
Management strategies including angioplasty were
cost-effective in The Netherlands and, although
strategies including bypass surgery were more
effective, their incremental costs were very high. 
CRD commentary
Selection of comparators
The authors compared seven different management
strategies for patients with intermittent claudication
in The Netherlands and chose Notest+EX as the
comparator (although no explicit justification was
given for this choice). As the authors stated,
medical therapy and smoking cessation were not
considered as separate treatment options, but
rather as a part of the general management of all
patients. All these strategies appear to have
covered the available diagnostic and treatment
options for this group of patients. You should
decide whether these are widely used health
technologies in your own setting. 
Validity of estimate of measure of effectiveness
The authors did not report that a systematic
review of the literature had been undertaken to
identify relevant research and minimise bias. They
also failed to report any methodology of their
review, such as the sources searched, study designs
for inclusion and synthesis of the results from
different studies, and whether they investigated
any differences between the primary studies.
Despite this, the authors included approximately
28 studies in their review, and a range of values
(or an alternative value) was given for each point
estimate to allow sensitivity analyses. Further,
sensitivity analyses were performed for diagnostic
parameters and for the most influential
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the results from a prior analysis. 
Validity of estimate of measure of benefit
The estimation of benefit was modelled. The
decision-analytic model used to derive the health
benefits appears to have been appropriate. The fact
that QALYs were used as the measure of benefit
enables comparisons of the study results with results
from different interventions. The estimated benefits
were discounted, although there is controversy in
the health economics literature about whether
health benefits should or should not be discounted.
Validity of estimate of costs
All the categories of cost relevant to the perspective
adopted appear to have been included in the
analysis, although some relevant costs were omitted.
Downstream induced medical costs were not
considered since the treatment of PAD did not
prolong life but improved the quality of life of the
patient. In addition, although the stated
perspective was societal, friction costs were not
considered since most patients with PAD are retired.
The costs and the quantities were not reported
separately, which will limit reflation exercises to
other settings. The costs were derived from the
authors’ setting, published sources and from several
assumptions. Appropriate sensitivity analyses of the
costs were performed. Discounting was necessary, as
the costs were incurred over the lifetime of the
patient, and was appropriately performed at 3% per
annum. The price year was reported, which will aid
any possible inflation exercises. 
Other issues
The authors made appropriate comparisons of
their findings with those from other US studies,
finding that the ICURs for the USA were higher
than those for The Netherlands. Despite this, the
authors reported that the implications for both
countries were the same. The issue of
generalisability to other settings was addressed in
the sensitivity analysis, and by the fact that the
authors explicitly compared their results with
those from other studies with US settings. The
authors do not appear to have presented their
results selectively and their conclusions reflected
the scope of the analysis. 
The authors reported a number of limitations to
the study. First, they assumed that DSA would be
performed for recurrent or contralateral
symptoms instead of MRA or colour-guided DUS,
which may not be the case in current clinical
practice. However, they commented that the
results would only change minimally and that the
conclusions would not change. Secondly, several
secondary data sources were used as input data for
the parameters, with limiting assumptions having
to be made. 
The authors do not appear to have recommended
strategies with bypass surgery, compared with
angioplasty, as their additional gain in effectiveness
does not justify the additional expense.
Other publications of related interest
De Vries SO, Visser K, de Vries JA, Wong JB,
Donaldson MC, Hunick MGM. Intermittent
claudication: cost-effectiveness of revascularisation
versus exercise therapy. Radiology 2002;222:25–36.
Visser K, Kuntz KM, Donaldson MC, Gazelle GS,
Hunink MG. Pretreatment imaging workup for
patients with intermittent claudication: a cost-
effectiveness analysis. J Vasc Interv Radiol 2003;
14:53–62.
Sculpher M, Michaels J, McKenna M, Minor J. 
A cost–utility analysis of laser-assisted angioplasty
for peripheral arterial occlusions. Int J Technol
Assess Health Care 1996;12:104–25.
Subject index terms
Subject indexing assigned by NLM
Adult; Aged; Angiography, Digital Subtraction/ec
(economics); Cost of Illness; Cost Benefit Analysis;
Diagnostic Imaging/ec (economics); Health Care
Costs; Human; Intermittent Claudication/ec
(economics); Intermittent Claudication/ra
(radiography); Intermittent Claudication/su
(surgery); Magnetic Resonance Angiography/ec
(economics); Male; Markov Chains; Models,
Economic; Netherlands; Quality of Life; Support,
Non U.S. Gov’t; Ultrasonography, Doppler,
Color/ec (economics); Vascular Surgical
Procedures/ec (economics).
Country codes
The Netherlands.
Source of funding
Supported by the Netherlands Organization for
Scientific Research.
Copyright comments
Copyright: University of York, 2005.
Visser and colleagues (2003)130
Visser K, Kock MC, Kuntz KM, Donaldson MC,
Gazelle GS, Hunink MG. Cost-effectiveness targets
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160for multi-detector row CT angiography in the
work-up of patients with intermittent claudication.
Radiology 2003;227:647–56.
This record was compiled by CRD commissioned
reviewers according to a set of guidelines
developed in collaboration with a group of leading
health economists.
Health technology
The study investigated the use of multidetector row
computed tomographic angiography (CTA)
compared with gadolinium-enhanced magnetic
resonance angiography (MRA) in the work-up of
patients with intermittent claudication. To reflect
clinical practice, the authors evaluated two
treatment scenarios after initial imaging work-up.
In the first scenario (minimally invasive treatment),
percutaneous treatment was performed on patients
in whom a lesion suitable for percutaneous
treatment had been detected at imaging work-up;
otherwise, patients started a supervised exercise
programme. In the second scenario (more invasive
treatment), bypass surgery was performed on those
patients who did not have lesions that were suitable
for angiography. Intra-arterial digital subtraction
angiography (DSA) would be used in cases where
additional work-up was required.
Disease
Cardiovascular diseases.
Type of intervention
Diagnosis and treatment. 
Hypothesis/study question
The objective of the study was to determine the
costs, sensitivity for the detection of significant
stenoses, and proportion of equivocal
multidetector row CTA results in the work-up of
patients with intermittent claudication that would
make this imaging examination cost-effective in
comparison with gadolinium-enhanced MRA.
Gadolinium-enhanced MRA was used as the
comparator as it represented current practice in
the authors’ settings. A societal perspective was
adopted in the economic analysis. 
Economic study type
Cost–utility analysis. 
Study population
The study population comprised hypothetical
cohorts of 60-year-old men with symptoms of
severe unilateral claudication for 1 year, an ankle
brachial index of 0.70 and no history of coronary
artery disease. All of the patients had at least one
significant stenosis in the suprainguinal or
infrainguinal arterial tract. Patients were excluded
if they had isolated infrapopliteal disease.
Setting
The setting was secondary care. The economic
study was carried out in The Netherlands. 
Dates to which data relate
The effectiveness data were derived from studies
published between 1961 and 2002. The healthcare
use data appear to have been mainly collected
from studies published between 1998 and 2000.
The price year was 1998. 
Source of effectiveness data
The effectiveness data were derived from a review
of published studies, supplemented with authors’
assumptions. 
Modelling
The authors used a decision-analytic model to
evaluate the societal cost-effectiveness of diagnostic
imaging strategies for the work-up of patients with
intermittent claudication. An embedded Monte
Carlo Markov model was used to include data on
treatment and follow-up. A total of 100,000
patients was considered for the simulation.
Outcomes assessed in the review
The outcomes assessed were: 
● the sensitivity of MRA for the detection of
stenoses of more than 50% 
● the probability that MRA would facilitate
recommendation of angioplasty given that the
lesion was suitable, the lesion was suitable for
bypass surgery and the lesion was not suitable
for invasive treatment 
● the probability that MRA would facilitate
recommendation of bypass surgery given that
the lesion was suitable, the lesion was suitable
for angioplasty and the lesion was not suitable
for invasive treatment 
● the mortality and morbidity of DSA 
● the probability that additional diagnostic work-
up is required after MRA 
● the health-related quality of life for several
health states (i.e. no or mild intermittent
claudication, severe intermittent claudication,
critical limb ischaemia, amputation below knee
and amputation above knee) 
● the proportions of suprainguinal and
infrainguinal lesions that were suitable for
percutaneous treatment 
● the annual rate of critical limb ischaemia in
patients with intermittent claudication. 
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inclusion in the review
The authors did not report the study designs
included in the review. However, they did report
that several published meta-analyses were
included. 
Sources searched to identify primary
studies
Not reported. 
Criteria used to ensure the validity of
primary studies
Not reported. 
Methods used to judge relevance,
validity, extracting data
Not reported. 
Number of primary studies included
Approximately 15 primary studies were included
in the review. 
Method of combination of primary
studies
Not relevant. 
Investigation of differences between
primary studies
Not relevant. 
Results of the review
The sensitivity of MRA for the detection of
stenoses of more than 50% was 0.96.
The probabilities that MR would facilitate
recommendation of angioplasty given that the
lesion was suitable, the lesion was suitable for
bypass surgery and the lesion was not suitable for
invasive treatment were, respectively, 0.79, 0.03
and 0.
The probabilities that MR would facilitate
recommendation of bypass surgery given that the
lesion was suitable, the lesion was suitable for
angioplasty and the lesion was not suitable for
invasive treatment were, respectively, 0.97, 0.14
and 0. 
The morbidity of DSA was 0.03 and the mortality
was 3.3 × 104.
The probability that additional diagnostic work-up
was required after MRA was 0.07.
The health-related quality of life for the different
health states was: 
● 0.79 for no or mild intermittent claudication 
● 0.71 for severe intermittent claudication 
● 0.35 for critical limb ischaemia 
● 0.61 for amputation below the knee 
● 0.20 for amputation above the knee. 
The proportions of suprainguinal and infrainguinal
lesions that were suitable for percutaneous
treatment were 51% and 18%, respectively.
The annual rate of critical limb ischaemia in
patients with intermittent claudication was 0.017
for patients younger than 65 years and 0.036 for
patients aged 65 years and older. 
Methods used to derive estimates of
effectiveness
The authors supplemented the results obtained
from the review of the literature with their own
assumptions. 
Estimates of effectiveness and key
assumptions
The authors assumed the following:
● The sensitivity of DSA for the detection of
stenoses of more than 50% was 1.
● The probabilities that DSA would facilitate
recommendation of angioplasty given that the
lesion was suitable, the lesion was suitable for
bypass surgery and the lesion was not suitable
for invasive treatment were, respectively, 1, 0
and 0.
● The probabilities that DSA would facilitate
recommendation of bypass surgery given that
the lesion was suitable, the lesion was suitable
for angioplasty and the lesion was not suitable
for invasive treatment were, respectively, 1, 0
and 0. 
● The mortality and morbidity related risks
associated with angiography were assumed to
be, respectively, 0 and 0. The respective values
associated with CTA were assumed to be 
9.0 × 106 and 3.1 × 104.
● The probabilities of each given treatment 
being recommended on the basis of CTA
findings were assumed to be the same as those
for MRA.
Measure of benefits used in the
economic analysis
The summary measure of benefits used was the
number of quality-adjusted life-years (QALYs).
Estimated health values were obtained from the
review. The estimated health values for patients
with intermittent claudication were available 
from a study performed with participants from
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responses to the EuroQol 5D and converted them
to time trade-off values. The estimated health
values for patients with critical limb ischaemia
and amputation were derived from a study
conducted among the general public. The
estimated health benefits were discounted at a
rate of 3%.
Direct costs
The direct costs considered were those of the
healthcare system. These included the costs of
MRA and DSA, surgery, amputation, 1 year of
supervised exercise, and the costs of planned 
but not performed angioplasty (e.g. the 
inefficient use of personnel, room and
equipment). The unit costs of MRA, DSA and
amputations were derived from Medicare
reimbursement rates. All of the other unit costs
were derived from the literature. In addition, the
authors made several assumptions in the
estimation of healthcare resource use. Resource
use and the costs were not reported separately.
Discounting was relevant, as the costs were
incurred through the lifetime of the patient, and
was appropriately applied at a rate of 3% per
annum. The study reported the average costs. 
All of the costs were converted to 1998 prices
using the Consumer Price Index. 
Indirect costs
The indirect costs were not included in the
analysis. 
Currency
US dollars ($). 
Statistical analysis of costs
The costs were treated as point estimates (i.e. the
data were deterministic). 
Sensitivity analysis
Sensitivity analyses were performed. In these
analyses:
● the thresholds (i.e. the willingness to pay for an
extra QALY) were varied 
● two different patient cohorts (40-year-old men
with characteristics similar to those in the base
case and 70-year-old men with a history of
coronary artery disease and other 
characteristics similar to those in the base case)
were considered 
● quality of life with no or mild intermittent
claudication was varied 
● the costs of revascularisation were varied (by
50% and 150% of the baseline estimates). 
Estimated benefits used in the
economic analysis
In the minimally invasive treatment scenario,
MRA yielded 6.1487 QALYs and CTA yielded
6.1490 QALYs. 
In the more invasive treatment scenario, MRA
yielded 6.2137 QALYs and CTA yielded 6.2151
QALYs. 
Cost results
In the minimally invasive treatment scenario,
MRA cost $21,942 and CTA cost $21,965.
In the more invasive treatment scenario, MRA cost
$48,965 and CTA cost $49,102. 
Synthesis of costs and benefits
In the minimally invasive treatment scenario,
using a societal willingness to pay of $100,000 per
QALY, CTA was equivalent to MRA in terms of
cost-effectiveness if the cost of the modality was
$420, the sensitivity for the detection of significant
stenoses was 90%, and 20% of the patients
required additional work-up because of equivocal
CTA results. 
In the more invasive treatment scenario, using a
societal willingness to pay of $100,000 per QALY,
CTA was equivalent to MRA in terms of cost-
effectiveness if the cost of the modality was $673,
the sensitivity for the detection of significant
stenoses was 95%, and 20% of the patients
required additional work-up because of equivocal
CTA results.
These target values did not change substantially
when the societal willingness to pay was varied.
For the younger cohort the target criterion for the
cost of CTA was more lenient, whereas for the
older cohort the target criterion was stricter. 
There was an inverse relationship between health-
related quality of life and the estimated costs of CTA. 
Authors’ conclusions
Multidetector row CTA, compared with currently
used imaging modalities such as MRA, has the
potential to be cost-effective in the evaluation of
patients with intermittent claudication. 
CRD commentary
Selection of comparators
Gadolinium-enhanced MRA was used as the
comparator as it represented current practice in the
authors’ settings. You should decide whether this is
a widely used health technology in your own setting. 
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The authors did not state that a systematic review
of the literature had been undertaken to identify
relevant research and minimise biases. The
authors also failed to describe much of the
methodology used in their review, such as the
sources searched, the study designs for inclusion
and the methods used to judge the validity of the
studies. The authors also supplemented the
results from the review of the literature with their
own assumptions. The authors did not report
whether these had been derived from expert
opinion or were based on the literature. However,
they did perform sensitivity analyses on the
effectiveness parameters used in the model. 
Validity of estimate of measure of benefit
The estimation of benefits was modelled using a
decision-analytic model, which appears to have
been appropriate for the research question posed.
The fact that QALYs were used as the summary
measure of benefit enables comparisons with the
findings from other interventions. The benefits
were discounted at a rate of 3%. However, there is
controversy in the health economics literature
about the discounting of health benefits. 
Validity of estimate of costs
Although the authors reported that the costs were
estimated from a societal perspective, the indirect
costs were not included. It was also unclear
whether all the relevant costs were included in the
analysis, as the authors did not report what
resources were included for each treatment
modality. The costs and the quantities were not
reported separately, which will limit the
transferability of the authors’ results to other
settings. The costs were derived from Medicare
reimbursement rates and from published sources.
Appropriate sensitivity analyses of the costs, using
ranges that appear to have been appropriate, were
performed. Although all of the costs were
converted to 1998 prices using the Consumer
Price Index, it would have been more appropriate
had these been converted using the health section
of the Consumer Price Index as, generally,
healthcare cost inflation is higher than for the
economy in general. Medicare reimbursement
rates were used to proxy prices, consequently
these cost estimates might not represent the actual
costs of the treatment provided. The price year
was reported, which will aid any possible inflation
exercises. 
Other issues
The authors did not make appropriate
comparisons of their findings with those from
other studies, although they did point out that the
cost of a contrast material-enhanced CTA
examination was estimated to be $237, which was
below the target cost they found. The issue of
generalisability to other settings was partially
addressed in the sensitivity analysis since different
age groups were evaluated. The authors do not
appear to have presented their results selectively
and their conclusions reflected the scope of the
analysis. 
The authors reported a number of further
limitations. First, they used several data sources
and made a number of assumptions to keep the
model tractable. Secondly, they assumed that MRA
and CTA were clinically interchangeable, an
assumption that may not be realistic. Thirdly, the
model did not consider regional healthcare
circumstances such as the expertise of the
radiologists and the availability of the equipment.
Fourthly, to determine the cost-effectiveness of
CTA it might have been better had these
comparisons been made through a randomised
controlled trial. Finally, the authors based the
societal willingness to pay for one additional
QALY on an assumption. 
Implications of the study
The authors reported that the role of new 
imaging modalities that have shown fairly good
preliminary results could be assessed by
performing a pragmatic randomised controlled
trial in which the new modality is compared with
the imaging modality currently in use. 
Other publications of related interest
Visser K, Hunink MG. Peripheral arterial disease:
gadolinium enhanced MR angiography versus
colour guided duplex US – a meta-analysis.
Radiology 2000;216:67–77.
Visser K, Kuntz KM, Donaldson MC, Gazelle GS,
Hunick MGM. Pretreatment imaging workup for
patients with intermittent claudication: a cost-
effectiveness analysis. J Vasc Interv Radiol
2003;14:53–62.
De Vries SO, Visser K, de Vries JA, Wong JB,
Donaldson MC, Hunick MGM. Intermittent
claudication: cost-effectiveness of revascularisation
versus exercise therapy. Radiology 2002;
222:25–36. 
Subject index terms
Subject indexing assigned by NLM
Angiography, Digital Subtraction/ec (economics);
Angiography, Digital Subtraction/mt (methods);
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164Contrast Media; Cost Benefit Analysis; Costs and
Cost Analysis; Decision Trees; Gadolinium;
Human; Intermittent Claudication/ec 
(economics); Intermittent Claudication/ra
(radiography); Intermittent Claudication/th
(therapy); Magnetic Resonance Angiography/ec
(economics); Quality Adjusted Life Years;
Sensitivity and Specificity; Support, Non US 
Gov’t; Tomography, X Ray Computed/ec
(economics); Tomography, X Ray Computed/mt
(methods).
Country codes
The Netherlands.
Source of funding
Supported in part by the Netherlands
Organization for Scientific Research.
Copyright comments
Copyright: University of York, 2005.
Geitung and colleagues (1996)126
Geitung JT, Wikstrom T, Zeuchner J, Gothlin JH.
Cost-effectiveness of colour duplex sonography
compared with angiography of the pelvis and
lower limb. Eur Radiol 1996;6:481–4.
This record was compiled by CRD commissioned
reviewers according to a set of guidelines
developed in collaboration with a group of leading
health economists.
Health technology
Use of colour duplex sonography (CDS) as a
preoperative examination in aorta, pelvis and
lower limb. The CDS examinations were
performed with a Toshiba SSA 270A ultrasound
scanner, with 7.5-MHz linear, or 3.5-MHz convex,
scanner probes (3.5 MHz for most of the pelvic
arteries). Documentation of CDS was performed
on colour prints. 
Disease
Techniques and equipment; cardiovascular
diseases.
Type of intervention
Diagnosis and treatment. 
Hypothesis/study question
The aim of the study was to assess the cost-
effectiveness of the use of CDS compared with
angiography as a preoperative examination in
aorta, pelvis and lower limb. The strategy of 
using angiography, as the gold standard, was
regarded as the comparator. Angiography was
performed with a conventional technique in a
standardised manner, comprising images of the
distal abdominal aorta, pelvic and peripheral
vessels down to ankle level. Documentation of 
the angiograms was performed on conventional
films.
Economic study type
Cost-effectiveness analysis. 
Study population
Patients referred for preoperative angiography of
the lower limb. 
Setting
Hospital. The economic analysis was carried out in
Sweden.
Dates to which data relate
Effectiveness and resource-use data corresponded
to patients examined between January and
September 1991. The price year was 1993. 
Source of effectiveness data
The evidence for the final outcomes was based on
a single study. 
Link between effectiveness and cost
data
Costing was performed on the patient sample
(n = 122) in 1993 at the study hospital. It was
reported as having been conducted both
retrospectively and prospectively.
Study sample
Power calculations were not used to determine the
sample size. The study sample consisted of a total
of 53 patients with a mean age of 69.4 (range
42–86) years.
Study design
This was a diagnostic cohort study, carried out in a
single centre. The duration of the follow-up was
not reported. Regarding the loss to follow-up, it
was reported that the records of four patients were
not available when the review was performed (they
could not be retrieved from the archive). The
results were confirmed at surgery. Both
angiograms and CDS were either performed by, or
controlled by, experienced radiologists (consultant
level). An experienced vascular surgeon and an
experienced vascular radiologist reviewed all
clinical and radiological data. They reviewed the
records together and reached complete consensus
in all cases. 
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The principle used in the analysis of effectiveness
was treatment completers only. The form for
recording the clinical efficacy and radiological
results included: 
● comparisons of the methods’ efficacy in
detecting occlusions and stenoses 
● evaluation of possible discrepancies between the
two methods 
● a clinical evaluation of whether or not the
methods were adequate for planning surgery. 
Effectiveness results
The effectiveness results were as follows:
● If surgery had been performed solely on the
basis of the ultrasonographic diagnosis, repeat
surgery would have been necessary in nine
patients.
● In a further three patients, necessary surgery
would not have been performed.
● Two patients would have been overtreated
(unnecessary surgery instead of percutaneous
transluminal balloon angioplasty).
● There were discrepancies between the findings
at angiography and CDS in 33 of 49 patients.
● CDS overlooked ten occlusions, 14 stenoses
greater then 50% and 22 stenoses less than 50%.
● The clinical review showed neither of the two
diagnostic methods to be sufficient for
preoperative planning in 32 of the patients.
● Angiography alone was adequate in 15 cases. 
Clinical conclusions
CDS as a preoperative investigation for aorta,
pelvic and lower limb vascular diseases had low
sensitivity for aortic aneurysms and for occlusions
and stenoses in the pelvic region. This has been
reported elsewhere in studies on the efficacy and
accuracy of ultrasonography.
Measure of benefits used in the
economic analysis
No summary benefit measure was identified in the
economic analysis, and only individual clinical
outcomes were reported, as shown in the
effectiveness results.
Direct costs
Costs were not discounted owing to the short time-
frame of the cost analysis. Some quantities were
reported separately from the costs. Cost items
were reported separately. Cost analysis covered the
costs of CDS and angiographic examinations
(wages, material and contrast medium, overheads,
capital costs, patient preparation and idle time),
surgical procedures (hospital stay, surgery,
anaesthesiology, intensive care, and services from
the departments of clinical physiology, clinical
chemistry and radiology). The costs of the two
diagnostic methods and the consequences of
inappropriate treatment were assessed. The
perspective adopted in the cost analysis appears to
have been that of the hospital (Department of
Surgery). The cost analysis appears to have been
conducted both retrospectively (based on the
hospital’s price list) and prospectively. The source
of the cost data for the two methods was the prices
at the radiology department of the study hospital.
The cost of hospitalisation with surgery was based
upon the diagnosis related group (DRG) prices
and the hospital’s accounting. The cost analysis
was based on true costs. The price year was 1993.
Indirect costs
Indirect costs were not considered.
Currency
Swedish kroner (Sek). 
Statistical analysis of costs
Sensitivity analysis
The result of a threshold analysis was reported,
but the parameters modified and the areas of
uncertainty investigated were not identified. 
Estimated benefits used in the
economic analysis
See effectiveness results above. 
Cost results
The total cost savings from performing CDS
instead of angiography in 122 patients would total
Sek 514,000. The additional costs from utilising
only CDS would total Sek 1,303,000, resulting in
net costs of Sek 789,000. It was reported that, on
the basis of 49 patients, the boundary of the
sensitivity analysis was at 2.7 reoperations.
Synthesis of costs and benefits
Costs and benefits were not combined. 
Authors’ conclusions
The present investigation concludes that, with
current techniques, CDS of the aorta and arteries
of the pelvis and lower limb is not cost-effective as
a preoperative examination because of its low
sensitivity in the pelvic region. 
CRD commentary
Selection of comparators
A justification was given for the choice of the
comparator. It was the gold standard in the
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as a database user, should consider whether this is
a widely used health technology in your own
setting. 
Validity of estimate of measure of effectiveness 
The study design was appropriate in answering
the question, but had a number of limitations
associated with the retrospective analysis, the lack
of power calculations to determine sample size
and the fact that the effectiveness analysis was
based on treatment completers only. The study
sample is likely to have been representative of the
study population, but more information could
have been provided regarding the inclusion and
exclusion criteria adopted in the study. 
Validity of estimate of measure of benefit 
The authors did not derive a summary measure of
health benefit. The analysis was therefore one of
cost–consequences design. 
Validity of estimate of costs
The validity of the cost results was enhanced by
the following features of the cost analysis: some
quantities were reported separately from the costs;
adequate details of methods of cost estimation
were given; the price year was specified; the
perspective adopted in the cost analysis was
explicitly reported; and the cost analysis was based
on actual costs. However, the following limitations
exist: statistical analysis was not performed on
resource-use and cost data; the variables modified
and ranges used for the threshold sensitivity
analysis were not identified in the paper; the
effects of the two diagnostic procedures on
indirect costs (productivity loss) were not
addressed; and the cost results may not be
generalisable outside the study setting.
Other issues 
Given the limitations of the study design and the
lack of extensive sensitivity analysis and statistical
analysis of costs, some degree of caution should be
exercised in interpreting the study results. The
issue of generalisability to other settings or
countries was not addressed, although appropriate
comparisons were made with other studies. The
issue of whether the study sample was
representative of the study population was not
fully addressed; it was only reported that all the
patients studied had severe vascular disease with
atherosclerosis and tortuous pelvic arteries. 
Implications of the study
The results of the study suggest that, at present,
angiography must be regarded as the most cost-
effective preoperative examination. Awareness of
this may stimulate technical improvements in CDS
that may make angiography unnecessary in the
future.
Subject index terms
Subject indexing assigned by NLM
Adult; Aged; Aged,-80-and-over; Angioplasty,-
Balloon/ec (economics); Aorta/us (ultrasonography);
Aortography/ec (economics); Arterial-Occlusive-
Diseases/su (surgery); Arterial-Occlusive-Diseases/th
(therapy); Cost-Benefit-Analysis; Diagnostic-Errors;
Health-Care-Costs; Middle-Age; Preoperative-Care;
Prospective-Studies; Reoperation/ec (economics);
Sweden; Angiography/ec (economics); Arterial-
Occlusive-Diseases/ra (radiography); Arterial-
Occlusive-Diseases/us (ultrasonography); Leg/bs
(blood-supply); Pelvis/bs (blood-supply);
Ultrasonography,-Doppler,-Color/ec (economics);
Comparative-Study; Female; Human; Male.
Country codes
Sweden.
Source of funding
None stated.
Copyright comments
Copyright: University of York, 2001.
Yin and colleagues (1995)131
Yin D, Baum RA, Carpenter JP, Langlotz CP,
Pentecost MJ. Cost-effectiveness of MR angiography
in cases of limb-threatening peripheral vascular
disease. Radiology 1995;194:757–64
This record was compiled by CRD commissioned
reviewers according to a set of guidelines
developed in collaboration with a group of leading
health economists.
Health technology
The health intervention examined in the study
was magnetic resonance angiography (MRA), used
as the diagnostic imaging procedure in the
preoperative evaluation of patients with limb-
threatening peripheral vascular disease (PVD). 
Disease
Type of intervention
Diagnosis. 
Hypothesis/study question
The main objective of the study was to examine
the cost-effectiveness of MRA in comparison with
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management of patients with limb-threatening
PVD. A secondary aim of the analysis was to
determine the threshold of diagnostic accuracy
that MRA should reach for it to be a cost-effective
option relative to conventional angiography. MRA
had several advantages over standard
angiography, but its economic implications were
unclear. A combined approach based on MRA
used as the primary imaging modality plus
conventional angiography performed only in
patients with contraindication to resonance was
also evaluated in comparison with conventional
angiography alone. A societal perspective was
adopted in the study. 
Economic study type
Cost–utility analysis. 
Study population
The study population comprised a hypothetical
cohort of patients undergoing angiography for the
preoperative evaluation of limb-threatening PVD. 
Setting
The setting was hospital. The economic study was
carried out in the USA. 
Dates to which data relate
The effectiveness data were derived from studies
published between 1981 and 1994. No dates were
reported for resource-use data. The price year
might have been 1992. 
Source of effectiveness data
The effectiveness evidence came from a synthesis
of previously completed studies and authors’
assumptions. 
Modelling
A decision-tree model was constructed to
determine the costs and benefits of conventional
versus MRA in a cohort of patients undergoing the
preoperative work-up before surgical treatment for
limb-threatening PVD. The structure of the tree
was reported. Patients initially could receive MRA
or conventional angiography and, based on the
results of the tests (positive inflow lesion, negative
inflow lesion or non-informative), could undergo
another test. Then an outflow angiographic (MRA
or CA) evaluation was performed in order to find
a suitable target vessel. Again the test could be
positive (suitable target vessel present), negative
(suitable target vessel absent) or non-informative
(in this case another test was performed). If a
target vessel was identified patients underwent
surgical bypass grafting. Bypass graft could be
successful or unsuccessful (in this case patients
returned to undergo re-evaluation and surgical
procedures). Patients without a suitable target
vessel underwent amputation. All patients
underwent at least two tests, an inflow and outflow
evaluation. However, it is not clear from the model
whether these two evaluations were undertaken at
the same time (i.e. one appointment). The time-
horizon was not explicitly reported. 
Outcomes assessed in the review
The outcomes estimated from the literature were
as follows: sensitivity and specificity of MRA and
conventional angiography in inflow evaluation,
sensitivity of MRA and conventional angiography
in outflow evaluation, percentage of patients with
suitable target vessels, percentages of non-
diagnostic MR angiograms in inflow and outflow
evaluations, and quality of life values (derived
using the Quality of Well-Being Scale) after
amputation and after bypass graft. 
Study designs and other criteria for
inclusion in the review
It was not stated whether a systematic review of
the literature had been undertaken. The design of
the primary studies was not reported. However,
the results in terms of sensitivity and specificity of
MRA and conventional angiography were reported
for all the included studies, together with the
number of patients and the number of segments
(when available).
Sources searched to identify primary
studies
Not stated. 
Criteria used to ensure the validity of
primary studies
Not stated. 
Methods used to judge relevance,
validity, extracting data
Not stated. 
Number of primary studies included
The effectiveness evidence came from 14 studies. 
Method of combination of primary
studies
Primary estimates appear to have been combined
using narrative methods. In some cases, the
authors selected the best estimate. 
Investigation of differences between
primary studies
Not stated. 
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The sensitivity and specificity of MRA in inflow
evaluation were 92% (range 92–95%) and 88%
(range 88–92%), respectively. 
The sensitivity and specificity of conventional
angiography in inflow evaluation were both 97%
(range 95–99%). 
The sensitivity in outflow evaluation was 98%
(range 95–100%) for MRA and 83% (range
75–88%) for conventional angiography. 
The percentage of patients with suitable target
vessels was 86% (range 70–100%). 
The percentage of non-diagnostic MR angiograms
was 2% (range 0–10%) in both inflow and outflow
evaluations. 
The values of quality of life were 0.484 (range
0.3–0.7) after amputation and 0.939 (range 0.9–1)
after bypass graft.
Methods used to derive estimates of
effectiveness
The authors made some assumptions in order to
derive some estimators. 
Estimates of effectiveness and key
assumptions
The percentage of patients with clinically important
stenosis was 80% (range 50–100%). The disutility
value associated with conventional angiography
relative to MRA was 0.0015 owing to a higher risk
of complications. Other disutility values were 0.005
for blind surgical exploration and 0.02 for repeated
surgical procedures. The rate of graft failure if a
substantial stenosis was missed was 100% (range
90–100%). The rate of graft failure if an artificial
stenosis was assumed was 30% (range 10–60%). 
Measure of benefits used in the
economic analysis
The summary benefit measure used in the
economic evaluation was the number of quality-
adjusted life-years (QALYs), which were derived
from the decision model. Utility weights were
based on authors’ assumptions, as reported above.
An annual 5% discount rate was applied to QALYs. 
Direct costs
Discounting was relevant as costs were incurred
over a long time-frame and, appropriately, a 5%
annual rate was applied. Unit costs were not
presented separately from quantities of resources
used and a detailed breakdown of cost items was
not provided. The health services included in the
economic evaluation were professional fees
(surgeon, radiologist and anaesthesiologist) and
hospital costs associated with angiography, bypass
grafting and amputation. The cost/resource
boundary of the third party payer was adopted in
the analysis of direct costs. Costs were derived
from Medicare sources, while resource-use data
were mainly based on authors’ assumptions. The
price year appears to have been 1992. 
Indirect costs
Indirect costs in the form of productivity losses
were included in the analysis as the perspective of
society was adopted. Lost income was based on US
national average daily earnings and the number of
workdays lost due to the diagnostic and surgical
procedures. Resource-use data were mainly based
on authors’ assumptions. Unit costs were not
reported. Discounting was relevant and a 5%
annual rate was applied as costs were incurred
over a long time-frame. The price year was 1992. 
Currency
US dollars ($). 
Statistical analysis of costs
Costs were treated deterministically in the base case. 
Sensitivity analysis
Univariate sensitivity analyses were carried out on
each major model input to investigate the impact
of data variability on the estimated cost–utility
ratios. A threshold analysis was also performed to
identify the sensitivity/specificity values of MRA
that would produce a cost per QALY below the
threshold value of $30,000. 
Estimated benefits used in the
economic analysis
The estimated quality of life value was 0.8680 with
MRA and 0.8636 with conventional angiography. 
Assuming that the benefits lasted for 2 years, in a
cohort of 1000 patients, the estimated QALYs
saved with MRA over conventional angiography
would be 8.5 (or 0.0085 per patient).
Cost results
The estimated costs of patient management were
$19,671 with MRA and $19,451 with conventional
angiography. 
In a cohort of 1000 subjects, the additional costs
associated with MRA relative to conventional
angiography would be $220,000 (or $220 per
patient). 
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An incremental cost–utility ratio was calculated to
combine costs and QALYs of the two diagnostic
strategies. Under base-case assumptions, the
incremental cost per QALY saved with MRA over
conventional angiography was $25,895. 
The results of the univariate sensitivity analysis
showed that the cost–utility ratio was sensitive to
variations in the sensitivity of MRA for inflow
lesions, sensitivity of conventional angiography for
inflow lesions and sensitivity of conventional
angiography for target vessels. 
The cost–utility ratio varied from a negative value
(which suggested that MRA saved QALYs and costs)
to a maximum of $78,166 per QALY. However, in
the vast majority of cases the incremental cost per
QALY for MRA compared with conventional
angiography was lower than $50,000. 
The threshold analysis showed that, when the
sensitivity and specificity of conventional therapy
were 95%, MRA would have to have at least 90%
sensitivity and 85% specificity for it to be cost-
effective (cost per QALY below the threshold of
$30,000) in comparison with conventional
angiography; when the sensitivity and specificity of
conventional therapy were 100%, MRA would have
to have at least 95% sensitivity and 86% specificity
to be cost-effective. 
Under base-case assumptions, the incremental cost
per additional QALY saved with the combined
approach (MRA plus conventional angiography)
relative to conventional angiography alone was
$29,305. 
Authors’ conclusions
The authors concluded that MRA proved to be a
cost-effective alternative to conventional
angiography as a preoperative diagnostic tool in
patients undergoing surgery for limb-threatening
PVD. 
CRD commentary
Selection of comparators
The choice of comparator was appropriate as
conventional angiography represented the
traditional diagnostic procedure in the authors’
setting. You should decide whether this is a valid
comparator in your own setting. 
Validity of estimate of measure of effectiveness
The effectiveness evidence was mainly derived
from published studies, but it was unclear whether
a systematic review of the literature had been
undertaken. No information on the design of the
primary studies was provided. Therefore, it is not
possible to comment on the validity of the sources
used. Primary estimates were combined using
narrative methods and the authors did not
investigate possible differences among the
published studies. Some assumptions were also
made and the issue of uncertainty was investigated
in the sensitivity analysis. The authors
acknowledged that some key estimates were
derived from a limited number of studies. In
addition, some data were obtained from studies
with short-term follow-up, which led to some
uncertainty in the long-term results of the analysis. 
Validity of estimate of measure of benefit
The use of QALYs as a summary benefit measure
was appropriate as it captured the impact of the
interventions on quality of life and survival.
Discounting was applied, as recommended in US
guidelines. The method used to derive utility
values was reported. The impact of variations in
quality of life values was investigated in the
sensitivity analysis. QALYs can be readily compared
with the benefits of other healthcare interventions. 
Validity of estimate of costs
The authors explicitly reported the perspective
adopted in the study and all relevant costs were
included in the economic evaluation. The source
of data was reported, but a detailed breakdown of
cost categories was not provided. Therefore, it
could be difficult to replicate the cost analysis.
Costs were treated deterministically in the base
case, but sensitivity analyses were conducted to
examine the issue of variability in economic data.
The price year was reported, which will simplify
reflation exercises in other settings. The authors
noted some limitations of using Medicare charges
as source of cost data. 
Other issues
The authors compared their findings with those
from other studies and reported that similar
results were observed. The authors noted that the
cost-effectiveness of MRA might have been
underestimated owing to the use of conservative
assumptions. The issue of the generalisability of
the study results to other settings was not explicitly
addressed. However, several sensitivity analyses
were carried out on key model inputs, which had a
positive impact on the external validity of the
analysis. The authors acknowledged some
limitations to the validity of their analysis, such as
the use of assumptions and the fact that the
decision model did not consider angioplasty as an
alternative reconstructive procedure. 
Appendix 7
170Implications of the study
The authors stress that further research should be
carried out in order better to determine the
quality of life associated with patients undergoing
amputation and bypass procedures. The availability
of data based on prospective trials could provide
an opportunity to replicate the analysis in order to
corroborate the current findings. 
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Appendix 8
Parameter distributions used in the probabilistic 
sensitivity analysis for baseline analysis 
(1-year time-horizon model)
TABLE 37 Parameter distributions used in PSA for baseline analysis (1-year time-horizon model)
Description of the parameters used Distributions
Probability of inaccurate amputation with CA Beta, integer parameters only, n = 5, r = 3; expected value: 0.6
Probability of inaccurate amputation with MRA Beta, integer parameters only, n = 3, r = 1; expected value: 0.333333333
Probability of inaccurate amputation with DUS Beta, integer parameters only, n = 4001, r = 1; 
expected value: 0.000249938
Probability of having amputation after CA Dirichlet, alphas list = list(5;61;33); 
expected value: 0.050505051; 0.616161616; 0.333333333
Probability of having amputation after MRA Dirichlet, alphas list = list(3;67;29); 
expected value: 0.03030303; 0.676767677; 0.292929293
Probability of having amputation after DUS Dirichlet, alphas list = list(4;18;15); 
expected value: 0.108108108; 0.486486486; 0.405405405
Probability of having bypass after CA Dirichlet, alphas list = list(61;5;33); 
expected value: 0.616161616; 0.050505051; 0.333333333
Probability of having bypass after MRA Dirichlet, alphas list = list(67;3;29); 
expected value: 0.676767677; 0.03030303; 0.292929293
Probability of having bypass after DUS Dirichlet, alphas list = list(18;4;15); 
expected value: 0.486486486; 0.108108108; 0.405405405
Probability of having PTA after CA Dirichlet, alphas list = list(33;5;61); 
expected value: 0.333333333; 0.050505051; 0.616161616
Probability of having PTA after MRA Dirichlet, alphas list = list(29;3;67); 
expected value: 0.292929293; 0.03030303; 0.676767677
Probability of having PTA after DUS Dirichlet, alphas list = list(15;4;18); 
expected value: 0.405405405; 0.108108108; 0.486486486
Probability of modifying incorrect amputation  Dirichlet, alphas list = list(1001;2001;1;1); 
after CA expected value: 0.33322237; 0.666111851; 0.000332889; 0.000332889
Probability of modifying incorrect amputation  Dirichlet, alphas list = list(1001;1;1;1); 
after MRA expected value: 0.997011952; 0.000996016; 0.000996016; 0.000996016
Probability of modifying incorrect amputation  Dirichlet, alphas list = list(1001;1;1;1); 
with DUS expected value: 0.997011952; 0.000996016; 0.000996016; 0.000996016
Probability of changing from incorrect  Dirichlet, alphas list = list(2001;1001;1;1); 
amputation to bypass with CA expected value: 0.666111851; 0.33322237; 0.000332889; 0.000332889
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;1;1); 
amputation to bypass with MRA expected value: 0.000996016; 0.997011952; 0.000996016; 0.000996016
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;1;1); 
amputation to bypass after DUS expected value: 0.000996016; 0.997011952; 0.000996016; 0.000996016
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;2001;1); 
amputation to PTA after CA expected value: 0.000332889; 0.33322237; 0.666111851; 0.000332889
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;1;1); 
amputation to PTA after MRA expected value: 0.000996016; 0.997011952; 0.000996016; 0.000996016
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;1;1); 
amputation to PTA after DUS expected value: 0.000996016; 0.997011952; 0.000996016; 0.000996016
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TABLE 37 Parameter distributions used in PSA for baseline analysis (1-year time-horizon model) (cont’d)
Description of the parameters used Distributions
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;2001;1); 
amputation to medical management after CA expected value: 0.000332889; 0.33322237; 0.666111851; 0.000332889
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;1;1); 
amputation to medical management after MRA expected value: 0.000996016; 0.997011952; 0.000996016; 0.000996016
Probability of changing from incorrect  Dirichlet, alphas list = list(1;1001;1;1); 
amputation to medical management after DUS expected value: 0.000996016; 0.997011952; 0.000996016; 0.000996016
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(1;2001;1;1); 
to amputation after CA expected value: 0.000499002; 0.998502994; 0.000499002; 0.000499002
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(1;2001;5001;1); 
to amputation after MRA expected value: 0.000142776; 0.285693889; 0.71402056; 0.000142776
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(1;11001;2001;1); 
to amputation after DUS expected value: 0.000076899; 0.845970471; 0.153875731; 0.000076899
Probability of modifying incorrect bypass after  Dirichlet, alphas list = list(2001;1;1;1); 
CA expected value: 0.998502994; 0.000499002; 0.000499002; 0.000499002
Probability of modifying incorrect bypass after  Dirichlet, alphas list = list(2001;1;5001;1); 
MRA expected value: 0.285693889; 0.000142776; 0.71402056; 0.000142776
Probability of modifying incorrect bypass after  Dirichlet, alphas list = list(11001;1;2001;1); 
DUS expected value: 0.845970471; 0.000076899; 0.153875731; 0.000076899
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(1;1;2001;1); 
to PTA after CA expected value: 0.000499002; 0.000499002; 0.998502994; 0.000499002
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(5001;1;2001;1); 
to PTA after MRA expected value: 0.71402056; 0.000142776; 0.285693889; 0.000142776
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(2001;1;11001;1); 
to PTA after DUS expected value: 0.153875731; 0.000076899; 0.845970471; 0.000076899
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(1;1;2001;1); 
to medical management after CA expected value: 0.000499002; 0.000499002; 0.998502994; 0.000499002
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(1;1;2001;5001); 
to medical management after MRA expected value: 0.000142776; 0.000142776; 0.285693889; 0.71402056
Probability of changing from incorrect bypass  Dirichlet, alphas list = list(1;1;11001;2001); 
to medical management after DUS expected value: 0.000076899; 0.000076899; 0.845970471; 0.153875731
Probability of changing from incorrect PTA to  Dirichlet, alphas list = list(1;1001;2001;1); 
amputation after CA expected value: 0.000332889; 0.33322237; 0.666111851; 0.000332889
Probability of changing from incorrect PTA to  Dirichlet, alphas list = list(1;1001;1001;1); 
amputation after MRA expected value: 0.000499002; 0.499500998; 0.499500998; 0.000499002
Probability of changing from incorrect PTA to  Dirichlet, alphas list = list(1;3001;1;1001); 
amputation after DUS expected value: 0.00024975; 0.7495005; 0.00024975; 0.25
Probability of changing from incorrect PTA to  Dirichlet, alphas list = list(1001;1;2001;1); 
bypass after CA expected value: 0.33322237; 0.000332889; 0.666111851; 0.000332889
Probability of changing from incorrect PTA to  Dirichlet, alphas list = list(1001;1;1001;1); 
bypass after MRA expected value: 0.499500998; 0.000499002; 0.499500998; 0.000499002
Probability of changing from incorrect PTA to  Dirichlet, alphas list = list(3001;1;1;1001); 
bypass after DUS expected value: 0.7495005; 0.00024975; 0.00024975; 0.25
Probability of modifying incorrect PTA after CA Dirichlet, alphas list = list(2001;1;1001;1); 
expected value: 0.666111851; 0.000332889; 0.33322237; 0.000332889
Probability of modifying incorrect PTA after  Dirichlet, alphas list = list(1001;1;1001;1); 
MRA expected value: 0.499500998; 0.000499002; 0.499500998; 0.000499002
Probability of modifying incorrect PTA after  Dirichlet, alphas list = list(1;1;3001;1001); 
DUS expected value: 0.00024975; 0.00024975; 0.7495005; 0.25
Probability of changing from PTA to medical  Dirichlet, alphas list = list(1;1;1001;2001); 
management after CA expected value: 0.000332889; 0.000332889; 0.33322237; 0.666111851
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TABLE 37 Parameter distributions used in PSA for baseline analysis (1-year time-horizon model) (cont’d)
Description of the parameters used Distributions
Probability of changing from PTA to medical  Dirichlet, alphas list = list(1;1;1001;1001); 
management after MRA expected value: 0.000499002; 0.000499002; 0.499500998; 0.499500998
Probability of modifying from PTA to medical  Dirichlet, alphas list = list(1001;1;3001;1); 
management after DUS expected value: 0.25; 0.00024975; 0.7495005; 0.00024975
Probability of inaccurate bypass with CA Beta, integer parameters only, n = 61, r = 2; 
expected value: 0.032786885
Probability of inaccurate bypass with MRA Beta, integer parameters only, n = 67, r = 7; 
expected value: 0.104477612
Probability of inaccurate bypass with DUS Beta, integer parameters only, n = 18, r = 2; 
expected value: 0.111111111
Probability of inaccurate PTA with CA Beta, integer parameters only, n = 33, r = 3; 
expected value: 0.090909091
Probability of inaccurate PTA with MRA Beta, integer parameters only, n = 29, r = 2; 
expected value: 0.068965517
Probability of inaccurate PTA with DUS Beta, integer parameters only, n = 15, r = 1; 
expected value: 0.066666667
Probability of having positive test (i.e. 50%  Beta, real-numbered parameters, alpha = (0.468^2)*(1-0.468)/
or more of stenosis) with 2D TOF MRA (0.0097^2), beta = 0.468*(1-0.468)/(0.0097^2)-(0.468^2)*(1-0.468)/
(0.0097^2); expected value: 0.468
Probability of having positive test (i.e. 50%  Beta, real-numbered parameters, alpha = 0.271^2*(1-0.271)/
or more of stenosis) with CE MRA (0.0064^2), beta = 0.271*(1-0.271)/(0.0064^2)-0.271^2*(1-0.271)/
(0.0064^2); expected value: 0.271
Probability of having positive test (i.e. 50%  Beta, real-numbered parameters, alpha = 0.222^2*(1-0.222)/
or more of stenosis) with DUS (0.0055^2), beta = 0.222*(1-0.222)/(0.0055^2)-0.222^2*(1-0.222)/
(0.0055^2); expected value: 0.222
Probability of having positive test (i.e. 50%  Beta, real-numbered parameters, alpha = 0.279^2*(1-0.279)/
or more of stenosis) with CA (0.0039^2), beta = 0.279*(1-0.279)/(0.0039^2)-0.279^2*(1-0.279)/
(0.0039^2); expected value: 0.279
Negative predictive value after 2D TOF MRA Beta, real-numbered parameters, alpha = 0.881^2*(1-0.881)/
(0.0087^2), beta = 0.881*(1-0.881)/(0.0087^2)-0.881^2*(1-0.881)/
(0.0087^2); expected value: 0.881
Negative predictive value after CE MRA Beta, real-numbered parameters, alpha = 0.983^2*(1-0.983)/
(0.0023^2), beta = 0.983*(1-0.983)/(0.0023^2)-0.983^2*(1-0.983)/
(0.0023^2); expected value: 0.983
Negative predictive value after DUS Beta, real-numbered parameters, alpha = 0.969^2*(1-0.969)/
(0.0028^2), beta = 0.969*(1-0.969)/(0.0028^2)-0.969^2*(1-0.969)/
(0.0028^2); expected value: 0.969
Cost of CA (includes capital equipment) Gamma, alpha = (536.80^2)/(178.1814^2), 
lambda = 536.80/(178.1814^2); expected value: 536.8
Costs of complications with CA Gamma, alpha = (5740.35^2)/(1305.3197^2), 
lambda = 5740.35/(1305.3197^2); expected value: 5740.35
Costs of MRA (includes capital equipment) Gamma, alpha = (462^2)/(13.2487^2), lambda = 462/(13.2487^2);
expected value: 462
Cost of DUS Gamma, alpha = (92.49^2)/(15.6747^2), lambda = 92.49/(15.6747^2);
expected value: 92.49
Cost of primary amputation Gamma, alpha = (6435.36^2)/(230.334^2), 
lambda = 6435.36/(230.334^2); expected value: 6435.36
Costs of changing from incorrect amputation  Gamma, alpha = (5943.65^2)/(245.7685^2), 
to bypass lambda = 5943.65/(245.7685^2); expected value: 5943.65
Cost of amputation revision, readmission Gamma, alpha = (6232.81^2)/(2219.6125^2), 
lambda = 6232.81/(2219.6125^2); expected value: 6232.81
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TABLE 37 Parameter distributions used in PSA for baseline analysis (1-year time-horizon model) (cont’d)
Description of the parameters used Distributions
Cost of primary bypass Gamma, alpha = (4965.55^2)/(193.9938^2), 
lambda = 4965.55/(193.9938^2); expected value: 4965.55
Cost of changing from incorrect bypass to  Gamma, alpha = (4965.55^2)/(193.9938^2), 
amputation lambda = 4965.55/(193.9938^2); expected value: 4965.55
Cost of changing from incorrect bypass to PTA Gamma, alpha = (2355.46^2)/(11.0515^2), 
lambda = 2355.46/(11.0515^2); expected value: 2355.46
Cost of bypass revision, readmission Gamma, alpha = (4965.55^2)/(193.9938^2), 
lambda = 4965.55/(193.9938^2); expected value: 4965.55
Costs of primary PTA Gamma, alpha = (1178.27^2)/(48.7386^2), 
lambda = 1178.27/(48.7386^2); expected value: 1178.27
Cost of changing from incorrect PTA to bypass Gamma, alpha = (5502.21^2)/(222.4012^2), 
lambda = 5502.21/(222.4012^2); expected value: 5502.21
Cost of changing from incorrect PTA to  Gamma, alpha = (7141.67^2)/(267.7218^2), 
amputation lambda = 7141.67/(267.7218^2); expected value: 7141.67
Cost of changing from incorrect PTA to MM Gamma, alpha = (245.36^2)/(62.592^2), lambda = 245.36/(62.592^2);
expected value: 245.36
Cost of PTA revision, readmission Gamma, alpha = (1178.27^2)/(48.7386^2), 
lambda = 1178.27/(48.7386^2); expected value: 1178.27
Cost of mortality from vascular interventions Gamma, alpha = (9906.04^2)/(3567.3456^2), 
lambda = 9906.04/(3567.3456^2); expected value: 9906.04
Long term costs of limited mobility  Gamma, alpha = (771.45^2)/(393.3202^2), 
independent patient lambda = 771.45/(393.3202^2); expected value: 771.45
Long term costs of limited mobility  Gamma, alpha = (7290.35^2)/(2932.9266^2), 
dependent patient lambda = 7290.35/(2932.9266^2); expected value: 7290.35
Long term costs of being in a wheelchair Gamma, alpha = (13169.81^2)/(908.9147^2), 
lambda = 13169.81/(908.9147^2); expected value: 13169.81
Long term costs of being bedridden Gamma, alpha = (22150.2^2)/(3672.9206^2), 
lambda = 22150.2/(3672.9206^2); expected value: 22150.2
Probability of complications with CA Triangular, Min = 0.2, Likeliest = 0.3, Max = 0.5; 
expected value: 0.333333333
Cost per outpatient visit (i.e. to the vascular  Gamma, alpha = (144^2)/(15.3265^2), lambda = 144/(15.3265^2); 
surgeon) expected value: 144
Cost of medical management per year Gamma, alpha = (14.66^2)/(4.2699^2), lambda = 14.66/(4.2699^2);
expected value: 14.66Health Technology Assessment 2007; Vol. 11: No. 20
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Appendix 9
Cumulative probabilities for the distributions of 
costs, effectiveness and cost-effectivenessAppendix 9
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FIGURES 32–35
Cumulative probabilities for distribution of costs (10/50/90%) (base case, 1-year time-horizon)Health Technology Assessment 2007; Vol. 11: No. 20
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FIGURES 36–39
Cumulative probabilities for the distribution of effectiveness (10/50/90%) (base case, 1-year time-horizon)Appendix 9
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FIGURES 40–43
Cumulative probabilities for the cost-effectiveness ratios (10/50/90%) (base case, 1-year time-horizon)Health Technology Assessment 2007; Vol. 11: No. 20
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Appendix 10
Cost-effectiveness analysis for 1-year time-horizon 
model: endarterectomy considered as a 
PTA procedure
TABLE 38 Cost-effectiveness results for endarterectomy as a PTA procedure (1-year time-horizon model) 
Mean SD Minimum Median Maximum
2D TOF MRA Cost (£ 2004) 10,690 1145 8393 10552 15075
QALYs 0.609 0.002 0.601 0.609 0.614
CER 17,559 1,886 13,756 17,331 24,840
CE MRA Cost (£ 2004) 9,039 1,163 6,662 8,899 13,486
QALYs 0.64 0.001 0.634 0.64 0.642
CER 14,134 1,819 10,409 13,913 21,093
DUS Cost (£ 2004) 8,724 1,170 6,366 8,610 13,426
QALYs 0.64 0.002 0.632 0.64 0.645
CER 13,629 1,833 9,892 13,463 21,025
CA Cost (£ 2004) 11,459 1,358 8,456 11,354 16,824
QALYs 0.64 0.001 0.635 0.64 0.643
CER 17,901 2,122 13,242 17,739 26,386
TABLE 39 Incremental cost-effectiveness results for endarterectomy as a PTA procedure (1-year time-horizon model)
Strategy Cost Incremental Effectiveness Incremental  C/E Incremental 
cost effectiveness C/E (ICER)
DUS 8,723.75 – 0.640124 – 13,628.22 –
CE MRA 9,039.433 315.6833 0.639564 –0.00056 14,133.74 Dominated
2D TOF MRA 10,689.74 1,965.99 0.608814 –0.03131 17,558.31 Dominated
CA 11,458.95 2,735.203 0.640113 –1.1E-05 17,901.46 Dominated
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FIGURE 44 Cost-effectiveness plane for endarterectomy as a PTA procedure (1-year time-horizon model)Appendix 10
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FIGURE 45 Scatterplot for PSA for endarterectomy as a PTA procedure (1-year time-horizon model)
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FIGURE 46 CEACs of the alternative diagnostic preoperative tests for endarterectomy as a PTA procedure (1-year time-horizon
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Appendix 11
Cost-effectiveness analysis for adjustment of 
Dirichlet distribution-10 
(1-year time-horizon model)
TABLE 40 Cost-effectiveness results for adjustment of Dirichlet distribution-10 (1-year time-horizon model)
Mean SD Minimum Median Maximum
2D TOF MRA Cost (£ 2004) 10,715 1,160 8,317 10,581 16,377
QALYs 0.609 0.001 0.604 0.609 0.613
CER 17,588 1,910 13,612 17,364 26,994
CE MRA Cost (£ 2004) 9,125 1,182 6,807 8,977 14,856
QALYs 0.639 0.001 0.635 0.639 0.642
CER 14,274 1,850 10,668 14,053 23,248
DUS Cost (£ 2004) 8,755 1,197 6,222 8,612 14,715
QALYs 0.64 0.002 0.631 0.64 0.644
CER 13,679 1,874 9,687 13,444 23,033
CA Cost (£ 2004) 11,501 1,437 7,976 11,357 19,208
QALYs 0.64 0.001 0.634 0.64 0.642
CER 17,977 2,245 12,465 17,738 29,990
TABLE 41 Incremental cost-effectiveness results for adjustment of Dirichlet distribution-10 (1-year time-horizon model)
Strategy Cost Incremental Effectiveness Incremental  C/E Incremental 
cost effectiveness C/E (ICER)
DUS 8,755.34 – 0.64007 – 13,678.72 –
CE MRA 9,125.48 370.1395 0.639307 –0.00076 14,274.01 Dominated
2D TOF MRA 10,715.27 1,959.932 0.609275 –0.0308 17,586.91 Dominated
CA 11,500.98 2,745.643 0.639772 –0.0003 17,976.7 Dominated
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